<SEC-DOCUMENT>0001140361-23-024499.txt : 20230515
<SEC-HEADER>0001140361-23-024499.hdr.sgml : 20230515
<ACCEPTANCE-DATETIME>20230515075040
ACCESSION NUMBER:		0001140361-23-024499
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230515
DATE AS OF CHANGE:		20230515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		23918451

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>brhc20051581_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:galt="http://galectintherapeutics.com/20230331" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_b5c6b10bb3b04e32a8ba29c18b62c100" contextRef="c20230101to20230331" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_05210424cb2a497c9ee9e2e3e6885795" contextRef="c20230101to20230331" format="ixt:date-month-day">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_89db6ac3bea245e2987aee853eb229e5" contextRef="c20230101to20230331">2023</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_5d58903a20da445abe4743e2328c16cc" contextRef="c20230101to20230331">Q1</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_d394eed4075c43e6883c52aaa31f9083" contextRef="c20230101to20230331">0001133416</ix:nonNumeric><ix:nonNumeric name="galt:FreeRentPeriod" id="Fact_3257fbc22511431091132ea0cf902d08" contextRef="c20230101to20230331">P6M15D</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Fact_ca7b3631a1474b9799fb873ed35a3567" contextRef="c20230331">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Fact_26a5d647f0b84359bcf1207a54ef8756" contextRef="c20230331">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Fact_8c9f7ebb1d3c4996a11d58878cfc0b06" contextRef="c20230331">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_81cc316c68af4b039a5f536f55cc0be6" contextRef="c20230331" unitRef="U002" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_286f6ac5954e459db05211ea9b77408f" contextRef="c20221231" unitRef="U002" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="galt-20230331.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230101to20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_LongtermDebtTypeAxis_LoansPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_LongtermDebtTypeAxis_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210416to20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250416to20250416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-16</xbrli:startDate><xbrli:endDate>2025-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20251230to20251230_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-30</xbrli:startDate><xbrli:endDate>2025-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250917to20250917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-17</xbrli:startDate><xbrli:endDate>2025-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230131_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230331_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230331_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230331_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandTwentyMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementClassOfStockAxis_SeriesAAndSeriesCPreferredStockMember_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandTwentyMarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesAAndSeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementClassOfStockAxis_SeriesAAndSeriesCPreferredStockMember_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandTwentyMarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesAAndSeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221219to20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-19</xbrli:startDate><xbrli:endDate>2022-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220725to20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_FinancialInstrumentAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221219_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FinancialInstrumentAxis_WarrantTwoMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725to20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230331_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725to20220725_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221219to20221219_FinancialInstrumentAxis_WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-19</xbrli:startDate><xbrli:endDate>2022-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20140101to20140131_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_InProcessResearchAndDevelopmentMember_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20141001to20141231_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20140101to20220331_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>galt:PromissoryNote</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>galt:Lease</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
      <div>
        <div style="text-align: center; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">UNITED STATES</div>

        <div style="text-align: center; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">SECURITIES AND EXCHANGE COMMISSION</div>

        <div style="text-align: center; font-size: 12pt; font-weight: bold; font-family: 'Times New Roman';">Washington, D.C. 20549</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <div style="text-align: center;">
          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; margin-left: auto; margin-right: auto;" />
<div>&#160;</div>
</div>

        <div style="text-align: center; font-size: 18pt; font-weight: bold; font-family: 'Times New Roman';">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_5416128e21c2421bb8a3e92830e5e206" contextRef="c20230101to20230331">10-Q</ix:nonNumeric></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <div style="text-align: center;">
          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; margin-left: auto; margin-right: auto;" />
<div>&#160;</div>
</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" id="Fact_e27edeace03f40c0815f4046fb23c697" contextRef="c20230101to20230331" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric><br />
              </td>

    <td style="width: 96%; vertical-align: top;">
                <div style="font-weight: bold;">Quarterly report pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</div>
              </td>

  </tr>


</table>
        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_414ca40c28be4a0ebb20d5255bb75dfe" contextRef="c20230101to20230331" format="ixt:date-monthname-day-year-en">March 31, 2023</ix:nonNumeric></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_404a2187bc734a44981313dcaea48599" contextRef="c20230101to20230331" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
              </td>

    <td style="width: 96%; vertical-align: top;">
                <div style="font-weight: bold;">Transition report pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</div>
              </td>

  </tr>


</table>
        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">For the transition period from<span style="text-decoration: underline;">&#160; &#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160;&#160;</span> to <span style="text-decoration: underline;">&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; <br />
          </span></div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Commission File No. <ix:nonNumeric name="dei:EntityFileNumber" id="Fact_15203ffc74d849c1b7c4d855ecab106c" contextRef="c20230101to20230331">001-31791</ix:nonNumeric></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <div style="text-align: center;">
          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; margin-left: auto; margin-right: auto;" /></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <div style="text-align: center; font-size: 24pt; font-weight: bold; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_cae960854d514a5e8546447138a154c5" contextRef="c20230101to20230331">GALECTIN THERAPEUTICS INC.</ix:nonNumeric><br />
        </div>

        <div style="text-align: center;">
<div>&#160;
          </div>
<hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; margin-left: auto; margin-right: auto;" /></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_79fb6e6cc15248449415a97252d59e02" contextRef="c20230101to20230331" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric><br />
                </div>
              </td>

    <td style="width: 50%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_da3dc7722e374ea2a9fbdf9a6287fd83" contextRef="c20230101to20230331">04-3562325</ix:nonNumeric><br />
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of incorporation)</div>
              </td>

    <td style="width: 50%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">(I.R.S. Employer Identification No.)</div>
              </td>

  </tr>


</table>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_ae79b549e17447dd89492bff8ab8c740" contextRef="c20230101to20230331">4960 Peachtree Industrial Blvd.</ix:nonNumeric>,</div>
                <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_467e3efc462e419fb9fec4ec39e6bf71" contextRef="c20230101to20230331">Suite 240</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_1ab10db30f11449e834553990dfe0490" contextRef="c20230101to20230331">Norcross</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_968efe8504a844988a4bc76c877c5079" contextRef="c20230101to20230331">GA</ix:nonNumeric></div>
              </td>

    <td style="width: 50%; vertical-align: bottom;">
                <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_4a7ee412e41c40969993d5df971a9955" contextRef="c20230101to20230331">30071</ix:nonNumeric><br />
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">(Address of Principal Executive Offices)</div>
              </td>

    <td style="width: 50%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">(Zip Code)</div>
              </td>

  </tr>


</table>
        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_fabc0378f443497b87c54834ad07079c" contextRef="c20230101to20230331">678</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_8938cb6c47094d32b0c92c67f928b152" contextRef="c20230101to20230331">620 -3186</ix:nonNumeric></div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(Registrant&#8217;s Telephone Number, Including Area Code)</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <div style="text-align: center;">
          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; margin-left: auto; margin-right: auto;" />
<div>&#160;</div>
</div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered or to be registered pursuant to Section&#160;12(b) of the Act.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33.26%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Title of each class</div>
              </td>

    <td style="width: 33.26%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">Trading</div>
                <div style="text-align: center; font-weight: bold;">Symbol(s)</div>
              </td>

    <td style="width: 33.26%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">Name&#160;of&#160;each&#160;exchange</div>
                <div style="text-align: center; font-weight: bold;">on&#160;which&#160;registered</div>
              </td>

  </tr>

  <tr>

    <td style="width: 33.26%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_726d4b94c2724053bc0e6a0c071f4b3a" contextRef="c20230101to20230331">Common Stock</ix:nonNumeric><br />
                </div>
              </td>

    <td style="width: 33.26%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_f318bd771be54ab18b747223180990dd" contextRef="c20230101to20230331">GALT</ix:nonNumeric><br />
                </div>
              </td>

    <td style="width: 33.26%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_1337bfc3368f4e3aaecea0fe785e1e6a" contextRef="c20230101to20230331" format="ixt-sec:exchnameen">The Nasdaq Stock Market</ix:nonNumeric><br />
                </div>
              </td>

  </tr>


</table>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
          (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160; &#9746; <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_02ff16d30a944144a979b12668087078" contextRef="c20230101to20230331">Yes</ix:nonNumeric> &#160;&#160;&#160; <span style="font-family: 'Segoe UI Symbol',sans-serif;">&#9744;</span>&#160;&#160;No</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this
          chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160; &#9746;&#160; <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_7642f982732d4badae7a6e5932ea2035" contextRef="c20230101to20230331">Yes</ix:nonNumeric>
          &#160;&#160;&#160; <span style="font-family: 'Segoe UI Symbol',sans-serif;">&#9744;</span>&#160;&#160;No</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company.
          See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 20%; vertical-align: bottom;">
                <div>Large&#160;Accelerated&#160;Filer</div>
              </td>

    <td style="width: 58%; vertical-align: bottom;">&#9744;</td>

    <td style="width: 20%; vertical-align: bottom;">
                <div>Accelerated&#160;Filer</div>
              </td>

    <td style="width: 2.4%; vertical-align: bottom;">&#9744;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: middle;">&#160;</td>

    <td style="width: 58%; vertical-align: middle;">&#160;</td>

    <td style="width: 20%; vertical-align: middle;">&#160;</td>

    <td style="width: 2.4%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: bottom;">
                <div><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_143a99f0849f45b4b2a1583ed46f85c9" contextRef="c20230101to20230331" format="ixt-sec:entityfilercategoryen">Non-Accelerated Filer</ix:nonNumeric><br />
                </div>
              </td>

    <td style="width: 58%; vertical-align: bottom;">&#9746;</td>

    <td style="width: 20%; vertical-align: bottom;">
                <div>Smaller&#160;reporting&#160;company</div>
              </td>

    <td style="width: 2.4%; vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_19f811eb251045be95c94a91cdb77818" contextRef="c20230101to20230331" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric><br />
              </td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: middle;">&#160;</td>

    <td style="width: 58%; vertical-align: middle;">&#160;</td>

    <td style="width: 20%; vertical-align: middle;">&#160;</td>

    <td style="width: 2.4%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: bottom;">
                <div>Emerging&#160;growth&#160;company</div>
              </td>

    <td style="width: 58%; vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_deb5c908c090445fabde5e3b252d2248" contextRef="c20230101to20230331" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
              </td>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 2.4%; vertical-align: bottom;">&#160;</td>

  </tr>


</table>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
          standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160; &#9744;</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160; <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_0b69dcf1c42940f8ad57c9b72e177a8e" contextRef="c20230101to20230331" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160; Yes &#160;&#160;&#160; &#9746;&#160; No</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">The number of shares outstanding of the registrant&#8217;s common stock as of May 8, 2023 was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_f1ceed76e7404d39acf65581f718cf35" contextRef="c20230508" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">59,582,253</ix:nonFraction>.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <div>
          <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">GALECTIN THERAPEUTICS INC.</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">INDEX TO FORM 10-Q<a id="INDEXTOFORM10-Q"><!--Anchor--></a></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">FOR THE QUARTER ENDED MARCH 31, 2023</div>

      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <br />
      </div>

    </div>

    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0); margin-left: auto; margin-right: auto;">


  <tr>

    <td rowspan="1" style="width: 7.79%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td rowspan="1" style="width: 86.23%; vertical-align: bottom; text-align: center; padding-bottom: 2px;">PART I &#8212; FINANCIAL INFORMATION</td>

    <td rowspan="1" style="width: 5.87%; vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);"><span style="font-weight: bold;">PAGE</span><br />
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ITEM 1.</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unaudited Condensed Consolidated Financial Statements (unaudited)</div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom;" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom;" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#BALANCESHEETS">Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">3</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#STATEMENTSOFOPERATIONS">Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2023 and
                  2022</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">4</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#STATEMENTSOFCASHFLOWS">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and
                  2022</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">5</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#STATEMENTSOFCHANGES">Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and
                  Stockholders&#8217; Equity (Deficit) for the three months ended March 31, 2023 and 2022</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;6</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br />
              </div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom;">
              <div style="text-align: right; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#NOTESTOUNAUDITED">Notes to Unaudited Condensed Consolidated Financial Statements</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">7</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ITEM 2.</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#Item2.">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">14</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ITEM 3.</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#Item3.">Quantitative and Qualitative Disclosures about Market Risk</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">21</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ITEM 4.</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#Item4.">Controls and Procedures</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">22</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0);">&#160;</td>

    <td rowspan="1" style="width: 86.23%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0);">PART II &#8212; OTHER INFORMATION</td>

    <td rowspan="1" style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);">&#160;</td>

    <td rowspan="1" style="width: 86.23%; vertical-align: bottom; text-align: center; color: rgb(0, 0, 0);">&#160;</td>

    <td rowspan="1" style="width: 5.87%; vertical-align: bottom; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ITEM 1.</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#Item1.">Legal Proceedings</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">22</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ITEM 1A.</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#Item1A.">Risk Factors</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">22</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ITEM 2.</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#UnregisteredSalesofEquity">Unregistered Sales of Equity Securities and Use of Proceeds</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">22</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ITEM 3.</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#DefaultsUponSeniorSecurit">Defaults Upon Senior Securities</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">22</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ITEM 4.</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#MineSafetyDisclosures">Mine Safety Disclosures</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">22</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ITEM 5.</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#OtherInformation">Other Information</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">22</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ITEM 6.</div>
            </td>

    <td style="width: 86.23%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#Exhibits">Exhibits</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">22</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.79%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 86.23%; vertical-align: bottom; color: rgb(0, 0, 0);" rowspan="1">&#160;</td>

    <td style="width: 5.87%; vertical-align: bottom; text-align: center;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td colspan="2" style="width: 94.03%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><a href="#SIGNATURES">SIGNATURES</a></div>
            </td>

    <td style="width: 5.87%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">24</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS INC.</div>

        <!--Anchor-->
        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONDENSED CONSOLIDATED<!--Anchor-->
          <!--Anchor--><!--Anchor--><a id="BALANCESHEETS"><!--Anchor--></a>BALANCE SHEETS (UNAUDITED)</div>

        <div> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">March 31,<br />
                  2023</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">December 31,<br />
                  2022</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">ASSETS</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Current assets:</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Cash and cash equivalents</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_048390694a224842af7ead63ca0520f3" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,799</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_7b08fd2fdf08411bbab4bbd80800804c" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,592</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Prepaid expenses and other current assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_95e7a73ce3df46a9b240df0b9d38e041" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,753</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_5a5c52185a4c49f38b19b567612a6d2b" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,960</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Total current assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_b4299004a4c94f78982968383d152410" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,552</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_481d78605dc84683a1b5c6c92551753d" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,552</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Other assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_67c33afa06f64e8195bf7fc4793bd8b2" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">673</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_d4bcf7aa9894439f8e66de1ad520938e" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">733</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Total assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:Assets" id="Fact_28b0eff6345b4537adee904ce32990d6" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,225</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:Assets" id="Fact_2b7ad816704b40f89c79d2e5ddbfca8b" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,285</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)<br />
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Current liabilities:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Accounts payable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_ac620a4e6de046a7bf8b1cc033220611" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,553</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_5c3cfe2373c04786804d3351d2917c50" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,890</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Accrued expenses and other</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_fc92e46c13fc454490966bb81ae99d58" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,980</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_9f93a80fecca434ab53b40a8163c600a" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,058</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Accrued dividends payable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DividendsPayableCurrent" id="Fact_6ffb726881b84b088488721408f7717d" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DividendsPayableCurrent" id="Fact_f28eaa8bdbf34d9786e5087f79d4aaf8" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">64</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Total current liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_974c3c633c1044888966158e6766110a" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,533</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_a3c808d9f2154c8aae345e24c2cde12d" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,012</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Convertible notes payable and accrued interest, net of discounts &#8211; related party (Note 3) <br />
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" id="Fact_5785c1d950e34918b7cbe16cccd7c45d" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,200</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" id="Fact_22c2e40bc25a4598a361d29d45886966" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,964</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">Derivative liabilities (Note 4)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_41296a2760d64e7ebf680e986da820fa" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,342</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_7504870ed1bc409888e96b9b4d2242de" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">573</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Borrowing and accrued interest under convertible line of credit, net of debt discount &#8211; related party (Note 9)<br />
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" id="Fact_d23e229317c74450ae2397116e1a5f81" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,741</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" id="Fact_7af49d1b324545638c01930c61bfc1ca" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,864</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Other liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_5cf985e3956d4bdeb75f078682ed793a" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">55</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_5dee13a731c8470a9f89120857ed8426" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">66</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Total liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_c1ae96c4e3d646f0bd594a7b1fafc358" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,871</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_bdb934c0c5c64bbc80533ce2b8a95f69" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,479</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Commitments and contingencies (Note 10)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><span style="-sec-ix-hidden:Fact_81cc316c68af4b039a5f536f55cc0be6"> </span></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><span style="-sec-ix-hidden:Fact_286f6ac5954e459db05211ea9b77408f"> </span></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Series C super dividend redeemable convertible preferred stock; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" id="Fact_3adf82f0d55c482893d996e0b3511720" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" id="Fact_c155b67dd88e4ed8b3bc65418c950c0a" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000</ix:nonFraction></ix:nonFraction></span>
                  shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" id="Fact_f227ac5925104148896b3c7bea6d447c" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" id="Fact_4823bc712c8c4f9ebfc4dca37b503b0e" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" id="Fact_c94ccf29245e4886adb92b3ede1ce558" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" id="Fact_1865c60374f44284a76bcf91933c9852" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">176</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at <span style="text-indent: 0pt;">March 31, 2023</span> and <span style="text-indent: 0pt;">December 31, 2022</span>, redemption
                  value: $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement" id="Fact_55be00149c554c43910d80c81d1403ef" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,256,000</ix:nonFraction></span>, liquidation value: $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" id="Fact_c4ec59ebcde14d6ea37a2239d688c7db" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,760,000</ix:nonFraction></span> at <span style="text-indent: 0pt;">March 31, 2023</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Fact_8fc45eb45a7c4f2784b724873c995461" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Fact_a8a2adcae1d847039380f7b465591edb" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Stockholders&#8217; equity (deficit):</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Undesignated stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:UndesignatedCapitalStockParValue" id="Fact_1ff215f7983d4886b5d91084e3cae7c7" contextRef="c20221231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="galt:UndesignatedCapitalStockParValue" id="Fact_45c698f9da9a46e0944545df4dffb359" contextRef="c20230331" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></span> par value; <span style="text-indent: 0pt;"><ix:nonFraction name="galt:UndesignatedCapitalStockSharesAuthorized" id="Fact_39e68ef9f0e34b1ba83fe4128462b921" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="galt:UndesignatedCapitalStockSharesAuthorized" id="Fact_e47de5bff8d3455195b6e8066a582e5e" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="galt:UndesignatedCapitalStockSharesDesignated" id="Fact_4b6cc646002042c3b563f484767dd4fb" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="galt:UndesignatedCapitalStockSharesDesignated" id="Fact_f5346b636a4d47eeb3efcb9f3d3c4941" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction></span>
                  designated at <span style="text-indent: 0pt;">March 31, 2023</span> and <span style="text-indent: 0pt;">December 31, 2022</span>, respectively</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="galt:UndesignatedCapitalStockValue" id="Fact_db397f7c2e7648419aa6ae641adf97d1" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="galt:UndesignatedCapitalStockValue" id="Fact_ebce82607ae04fbe8be20f9f679ffcfb" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Series A 12% convertible preferred stock; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_e7a0af64b22b4b03a983094ce4f70418" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_7fb556f95513454cb38e944cdb330297" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,742,500</ix:nonFraction></ix:nonFraction></span> shares authorized,&#160;<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_ea7edb4f96fd420380997e88882523c9" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_e3677fee33f04843a51596b70020ab1c" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_d7787b946a9e40d6bdb558611e6bcfaa" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_215c2b1e35cc4c93a9fab96ab439b13d" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,260,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span> issued and outstanding at <span style="text-indent: 0pt;">March 31, 2023</span> and <span style="text-indent: 0pt;">December 31, 2022</span>, liquidation value $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" id="Fact_ab1368a6db964eb39d77462d7adc3001" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,260,500</ix:nonFraction></span> at <span style="text-indent: 0pt;">March 31, 2023</span><br />
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_10c4337e634342c3ae90aa73baae5b84" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">510</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_f40e85d17a6c49ca9ab1b6a4c55b23cc" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">510</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Common stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_a9df48d8259c46d89ee1a799cffa37ac" contextRef="c20221231" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_e9f2a954bf12463dba75995ae4e95478" contextRef="c20230331" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span> par value; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_1da61028e8134559a69fc746134a6ecc" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_013f93bd39d841cb9a69c9721a127225" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized at <span style="text-indent: 0pt;">March 31, 2023</span>
                  and <span style="text-indent: 0pt;">December 31, 2022</span>, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_fde9bb43f79847768742806e2b17d764" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_01db0080873f4b61ad2fc19068f102ac" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">59,582,253</ix:nonFraction></ix:nonFraction></span>
                  and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_e1eb627f570647e3a346e1607d93552a" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_5635979cfb334598baa66ef34f07b99f" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">59,426,005</ix:nonFraction></ix:nonFraction></span> issued and outstanding at <span style="text-indent: 0pt;">March 31, 2023</span> and <span style="text-indent: 0pt;">December 31, 2022</span>, respectively</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_02b6c803d2484223a69ce00dc62f2f1e" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">59</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_3b6dbf6d6dcb418289fa35f1d7446a64" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">59</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Additional paid-in capital</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_0a33e91948ae492e9a30664804d13942" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">276,156</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_7308101c5ed4456e855f36805516b0a2" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">275,081</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Retained deficit</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_c17eff7fbf124577a8baedfadbe4eecb" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">321,094</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_cab00d1fa98a426eb49538a56ceac1a9" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">309,567</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 36pt;">Total stockholders&#8217; equity (deficit)<br />
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d04ef4259619420d96654775a50c1bc4" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44,369</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_923dad082ca64f379c1f2a7c6871d0b7" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">33,917</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_2bc5b1b60c88471d9c819e3fbdf44b91" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,225</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_0ccca35e90474617adfd39a00e4c417b" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,285</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-style: italic; font-size: 8pt;"><br />
          </span></div>

        <div><span style="font-style: italic; font-size: 8pt;"> </span></div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">See notes to unaudited condensed consolidated financial statements.</div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"> <br />
        </div>

        <div><span style="font-style: italic; font-size: 8pt;"> </span></div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS INC.</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONDENSED CONSOLIDATED <a id="STATEMENTSOFOPERATIONS"><!--Anchor--></a><!--Anchor-->STATEMENTS OF OPERATIONS (UNAUDITED)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-weight: bold;">Three Months Ended<br />
                March 31,</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">2023<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">2022<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
              <div>&#160;</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="6">
              <div style="text-align: center; font-weight: bold;">(in thousands, except per share data)</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Operating expenses:</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 18pt;">Research and development</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_bf72f95a0c3c454895f6a83940492c89" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,799</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_1ba5c475c97f401a87ff0c2af0461af5" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,058</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -9pt; margin-left: 18pt;">General and administrative</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_8c58c0163b3d490a83e8efe398b8b5b5" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,543</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_de4e4f4257ee43868aa61c8e6cead624" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,877</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 27pt;">Total operating expenses</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_23aab4c9aa1f482ea8ca2e51e308d1c4" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,342</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_0d92307596a942259f87efaaa87d09c8" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,935</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -9pt; margin-left: 27pt;">Total operating loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_0307830d95bc412a85d46150d94beaa3" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,342</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_463676cc0b60485fa3a8866efdbcd8d6" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,935</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Other income (expense):</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -9pt; margin-left: 18pt;">Interest income</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_fa6a412b0b7b4850b8e3d86063875f48" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">44</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_895840ba930c4767b199d17b1a95add8" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 18pt;">Change in fair value of derivatives</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_ebaabe365c3f46a98ddb5018df310d23" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">769</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_ac39b8dcd7654e3e99b83593ce36a448" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">229</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -9pt; margin-left: 18pt;">Interest expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_1805cdff81784e2eb47debebc2f43067" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">460</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_4777fa2602ed4fe9947d3b58e39e3b37" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">227</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 27pt;">Total other income (expense)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_2986330ec2224221a50a0c77eacd79b9" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,185</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_95216f74bba24b4ca7e8d652ff33bdee" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_0545a3fad7c5421784263f7243965381" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,527</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_1f5e71a253d9499d93c25dfe85cd2d4c" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,932</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Preferred stock dividends</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_56cbdf6d54bc40cd92bc75de5e295dfd" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_58f13404940548b890c85cb079dc0d08" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Net loss applicable to common stockholders</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_116747b254d24618bfbbb2cb1ca803b9" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,527</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_e9cc04f4d716477cb84a36c1db53305f" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,916</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Net loss per common share &#8212; basic and diluted</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_e69a89510e5348299add8113cb8a10e8" contextRef="c20230101to20230331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_154a66e1a175401096ae6706327e2374" contextRef="c20230101to20230331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.19</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_cc6c840abe07436e9e0a1e0af54bef7d" contextRef="c20220101to20220331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_2be1c25f45294fb387c369cedad06ff1" contextRef="c20220101to20220331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.17</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Weighted average common shares outstanding &#8212; basic and diluted</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_c3ddcedc3ca94fbbb41baa5916ab0d24" contextRef="c20230101to20230331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_312d48a7b66147668c561cca3c5a19ef" contextRef="c20230101to20230331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,480</ix:nonFraction></ix:nonFraction><br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_eeeeb967115a4ae28a50ef9f4e3a2c6d" contextRef="c20220101to20220331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_9c9c152a51e14e5180b6cb828f7a81ca" contextRef="c20220101to20220331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,354</ix:nonFraction></ix:nonFraction><br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">See notes to unaudited condensed consolidated financial statements.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS INC.</div>

        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONDENSED CONSOLIDATED
          <!--Anchor--><a id="STATEMENTSOFCASHFLOWS"><!--Anchor--></a>STATEMENTS OF<!--Anchor-->
          <!--Anchor-->CASH FLOWS (UNAUDITED)<!--Anchor--></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">Three Months Ended<br />
                  March 31,</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2023<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2022<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom;">
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                <div style="text-indent: -9pt; margin-left: 9pt;">CASH FLOWS FROM OPERATING ACTIVITIES:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Net loss</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_18e78584b5454f1da65532a5e4a67074" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,527</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_419ebe65401644b3941e8f8b14bbca93" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,932</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Adjustments to reconcile net loss to net cash flows from operating activities:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Stock-based compensation expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_973e0e5e588f4d77939ce2ed1c1beecd" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">662</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_465b2a3547f74a12842bbf4f835ab075" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">858</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Amortization of right to use lease asset</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_3cc7eebc3ab5415b965f410554efafe8" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">32</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_02c9b2f22c544df58a5ba4bb0c23cf80" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Non-cash interest expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_a9db1d4cc4054fb891559d4815afcf0f" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">144</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_1e00a2aa52dd4345b59eaa026218bdeb" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">80</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Change in fair value of derivative liabilities<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_6abc72b7ecfb49abaf06de7c29dbc109" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">769</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_c790fb4fba2f49789ab202a3a35f171c" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">229</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Changes in operating assets and liabilities:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 36pt;">Prepaid expenses and other assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_239de87574954b03b1e0be0545c12630" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">183</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_ef6252ab03904a8191b9bec176ffb471" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">160</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 36pt;">Accounts payable, accrued expenses and other liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" id="Fact_7906d66885f04d63aa6cc22097ce62da" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,372</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" id="Fact_a4522627f6b6494a9f71090b519846b7" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">864</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div>
                  <div>
                    <div style="text-indent: -9pt; margin-left: 36pt;">Accrued interest on convertible debt - related party</div>
                  </div>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" id="Fact_3d1641f3b3a1498aa0cce8c8c2c1eb3b" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">316</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" id="Fact_c79e7d38581c43c0acfb633d10a7a050" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">147</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 45pt;">Net cash from operating activities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_3b6e688b22654bb7a0eb4208bf705c28" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,793</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_d7414eb79aec4b37939091493e2c3346" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,042</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 9pt;">CASH FLOWS FROM FINANCING ACTIVITIES:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
                <div style="margin-left: 18pt; text-indent: -9pt;">Net proceeds from convertible line of credit &#8211; related party<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_f8bfb43dbfd54e67abe1cb04c484d2a6" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_03f02b206b8847d388ad75786f76f03c" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Net cash flows from financing activities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_a66e527a48984c72b34c0412ddd19cc9" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_c86e1ea78a774c2a910cb35365642a57" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 9pt;">NET DECREASE IN CASH AND CASH EQUIVALENTS</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_cb5b49cf304546e68e5a65655e18521c" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">793</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_a064cf171f3a446ab81a2aa76f83c547" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,042</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -9pt; margin-left: 9pt;">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_de2da9b686cf4aeabca66ba4b7e4d80e" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,592</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_e9539b6347fa4991b114699e17c10b40" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,648</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 9pt;">CASH AND CASH EQUIVALENTS, END OF PERIOD</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_f4b73644fa3e4a108b54cf9b8fe77294" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,999</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_7d22327c8389401583cefa2d72e05e01" contextRef="c20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,606</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 9pt;">NONCASH FINANCING ACTIVITIES:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Payment of preferred stock dividends in common stock</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssued1" id="Fact_c2a5c710e3e24badb340f51050724527" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">62</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssued1" id="Fact_2cf1bdca9cda4c5b92ccb3d2d7d607a3" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">49</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Reclassification of accrued bonus to additional paid in capital</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital" id="Fact_19008fdf19664140990be12b7e47254c" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">210</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital" id="Fact_73e12b5508684244b1cfc3aac65a04c2" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">200</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: 0pt; margin-left: 9pt;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Common stock purchase warrants issued in connection with related party line of credit</span></div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" id="Fact_f63b67df6315479eba298ce1db7edf49" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">297</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" id="Fact_f12b5fb7eff842dbb96f3015b8b38191" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 9pt; width: 76%;">
                <div>Noncash right to use lease asset</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" id="Fact_c8afd37641894454a0c2ee8cb65e9d7d" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" id="Fact_378eb3b33cd54fccabbc53b4c14aa0de" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">111</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">See notes to unaudited condensed consolidated financial statements.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS INC.</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONDENSED CONSOLIDATED <a id="STATEMENTSOFCHANGES"><!--Anchor--></a>STATEMENTS OF CHA<!--Anchor-->NGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217;
        EQUITY (DEFICIT) (UNAUDITED)</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(amounts in thousands except share data)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-weight: bold;">Series C Super<br />
                Dividend Redeemable<br />
                Convertible<br />
                Preferred Stock</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; font-weight: bold;">Number of<br />
                Shares</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; font-weight: bold;">Amount</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
              <div style="font-weight: bold;">Balance at December 31, 2021</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" id="Fact_3a7c96e460d141c3bbd8eb2d27265f41" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">176</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Fact_13cf6e1bcb6843f29ca72bcde6f1b570" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="font-weight: bold;">Balance at March 31, 2022</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" id="Fact_2a7f8f2c93db4926bd544ea67047d606" contextRef="c20220331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">176</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Fact_8370b9a4e6ba4dcc95077d8b6619cb3e" contextRef="c20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
              <div style="font-weight: bold;">Balance at December 31, 2022</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" id="Fact_922d027a686a4c51b532f61e8b945a92" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">176</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Fact_39904421b53c4095b42a0793cb2b8c26" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
              <div style="font-weight: bold;">Balance at March 31, 2023</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" id="Fact_6f5dfabf1af945c487f27962feff0fb1" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">176</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Fact_38e5a0a728fd4f78bd86ad5fcfec2c87" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      <div><br /></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-weight: bold;">Series A 12%<br />
                Convertible<br />
                Preferred Stock</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-weight: bold;">Common Stock</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="2"><br />
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Number<br />
                of<br />
                Shares</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Amount</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Number<br />
                of<br />
                Shares</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Amount</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="2">
              <div style="text-align: center; font-weight: bold;">Additional</div>
              <div style="text-align: center; font-weight: bold;">Paid-In<br />
                Capital</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="2">
              <div style="text-align: center; font-weight: bold;">Retained<br />
                Deficit</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="2">
              <div style="text-align: center; font-weight: bold;">Total<br />
                Stockholders&#8217;<br />
                Equity<br />
                (Deficit)</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;">
              <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance at December 31, 2021</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_311f05cc06124e61b4d3b760b4287b6c" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,302,500</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_b8a82d7ad653459cb60dc42ffe42faab" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">527</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_21f567c5f52846059fe80fe18408d1d1" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">59,341,305</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_52fea6fa9b8246e6ab75f411c4728048" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">59</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_fecb1d0b9f0e4d93a2a4055c21255887" contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">271,001</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2e56a59ef91c4cdb88e6dce621baaef4" contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">270,694</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_bac80c3c7ab9435ab9204818217d3a44" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">893</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Series A 12% convertible preferred stock dividend</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="galt:ConvertiblePreferredStockDividendsShares" id="Fact_9ba03e3c79d947c8b9f74a714fb0349e" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">13,025</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="galt:ConvertiblePreferredStockDividends" id="Fact_13aa72b998d9421aaa246b98e5b7b9f3" contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:ConvertiblePreferredStockDividends" id="Fact_aed8127e18d64e0ba44197541465e34c" contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:ConvertiblePreferredStockDividends" id="Fact_2d09b66379cc40fb86e6f8ee56604f64" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">38</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Series C super dividend redeemable convertible preferred stock dividend</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="galt:TemporaryEquityDividendsShares" id="Fact_2bed236b15b846d4b5463ea0365e0234" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">17,600</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="galt:TemporaryEquityDividends" id="Fact_7e1585a4359e49c695ab6df66b6e752e" contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="galt:TemporaryEquityDividends" id="Fact_6f04bf8ac268450a89f7ebc2525145fb" contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:TemporaryEquityDividends" id="Fact_b636ec147f6d4dfb84ea4341a4752b1b" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Stock-based compensation expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" id="Fact_438a169a0e934f38b45e315228643fdf" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">16,588</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_ca3053ceadc748e2858595230351f178" contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,058</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_7cf7d113da3b45f28d23443cb1e5ab58" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,058</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_49a27127e4fc450492127046b5ebd747" contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,932</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_da998332a8e14c8ab3ee051cc7ab32c2" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,932</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; padding-bottom: 4px;">
              <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2022</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_79eba817db224d31aa64fd6b1978f645" contextRef="c20220331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,302,500</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_9fb580fd37d74fd0a66508cc0fee2f45" contextRef="c20220331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">527</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_12059f081504430184e3d121c33d49f9" contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">59,388,518</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_9d0a9a7705894032b2b877944d54c4f3" contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">59</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2a57b495a8db40a695f4691732e34b92" contextRef="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">272,108</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_dce0c9d83b4e4f21953e654330e504a9" contextRef="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">280,610</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_96e0654a320148e58c9290e72462e0a4" contextRef="c20220331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,916</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;">
              <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance at December 31, <span style="text-indent: 0pt;">2022</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_3b506f6021574825b5877e85fc062df0" contextRef="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,260,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6c0ca1becf244969a0e232ddeafa3f16" contextRef="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">510</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_e880803a32e14acab761f7031b14e3dd" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">59,426,005</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d98bc72a0a86450a8f077609f1aa23ab" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">59</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_0187ab9474d743b89e5862742261cfdc" contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">275,081</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d536101d36b04032b6861829c9e75f1d" contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">309,567</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_b145318a8a144871896b88cad11d63c2" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">33,917</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Series A 12% convertible preferred stock dividend</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="galt:ConvertiblePreferredStockDividendsShares" id="Fact_cd7d7b572b3b4530a3e1140a9db7b7b0" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">12,600</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="galt:ConvertiblePreferredStockDividends" id="Fact_e42abda7d204496196725af337cb618d" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">26</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="galt:ConvertiblePreferredStockDividends" id="Fact_3295a101549e4cc28d9b39b17613476f" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:ConvertiblePreferredStockDividends" id="Fact_5a3b636e8fdc4d20894bf86b9555a781" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Series C super dividend redeemable convertible preferred stock dividend</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="galt:TemporaryEquityDividendsShares" id="Fact_f85c8f6773714e83ae226535e785384b" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">17,600</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="galt:TemporaryEquityDividends" id="Fact_3f68130f931445b4ac4bbf25884ebd9d" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:TemporaryEquityDividends" id="Fact_a302ff3be2e94027aa901c94acf8eadd" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:TemporaryEquityDividends" id="Fact_317c242461874cb38cdd5790f7cc4d01" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">C<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ommon








                stock purchase warrants issued in connection with related party line of credit</span> <br />
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_86ab1cf408ce4fd58fc87a4cd9fd188a" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">297</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_0156a06b9a32484aab6d696d6b192063" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">297</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Stock-based compensation expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" id="Fact_6430fea247174267ae98b310c7ca23fe" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">126,048</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_d6d927cbc5d9499eb69eabfc931df86e" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">716</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_624003e1bc2441f29aa3e910e1acf3f4" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">716</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 2px;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e067a89aff2e416cbcaad997fe9be1d0" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,527</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c0d2096c0aba4491b4caca682a723098" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,527</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2023</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_e8c1257f6884443090b1830aa7c58090" contextRef="c20230331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,260,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_36ad5b29ae394792ac41fc49549fc148" contextRef="c20230331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">510</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_e81de51a0aaa47428e6eaf35188a6557" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">59,582,253</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6e362ec4848d4313a562ffaea5fb0664" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">59</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_57533dd62f52417f9c5e720b8ffa93c2" contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">276,156</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e6452ebfab00402dbe9b84401a45f40d" contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">321,094</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_857432e4fc3a42feabc57140c95c975d" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44,369</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br />
        </span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">See notes to unaudited condensed consolidated financial statements.</span></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

          </div>

        </div>

      </div>

      <!--PROfilePageNumberReset%Num%7%%%--> </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS INC.</div>

        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor--><a id="NOTESTOUNAUDITED"><!--Anchor--></a>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>


        <ix:nonNumeric name="us-gaap:BasisOfAccounting" id="Text_ec4126679081413a9c2641eed9147e57" contextRef="c20230101to20230331" escape="true" continuedAt="Text_09dfe7a671224d35bb045fe0a0f85bdb1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">1. Basis of Presentation and Liquidity<br />
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_09dfe7a671224d35bb045fe0a0f85bdb1" continuedAt="Text_09dfe7a671224d35bb045fe0a0f85bdb2">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_09dfe7a671224d35bb045fe0a0f85bdb2" continuedAt="Text_09dfe7a671224d35bb045fe0a0f85bdb3">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Galectin Therapeutics Inc. and subsidiaries (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and
          drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company&#8217;s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have
          application for drugs to treat other diseases and chronic health conditions.</div>
</ix:continuation>
        <ix:continuation id="Text_09dfe7a671224d35bb045fe0a0f85bdb3" continuedAt="Text_09dfe7a671224d35bb045fe0a0f85bdb4">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_09dfe7a671224d35bb045fe0a0f85bdb4" continuedAt="Text_09dfe7a671224d35bb045fe0a0f85bdb5">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of
          management, necessary to present fairly the financial position of the Company as of March 31, 2023 and the results of its operations for the three months ended March 31, 2023 and 2022 and its cash flows for the three months ended March 31, 2023
          and 2022. All adjustments made to the interim financial statements include all those of a normal and recurring nature. Amounts presented in the condensed consolidated balance sheet as of December 31, 2022 are derived from the Company&#8217;s audited
          consolidated financial statements as of that date, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The Company
          considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.
          Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the
          full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2022.</div>
</ix:continuation>
        <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_09dfe7a671224d35bb045fe0a0f85bdb5" continuedAt="Text_09dfe7a671224d35bb045fe0a0f85bdb6">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; margin-top: 8pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The







            Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At March 31, 2023, the company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_b63276500f0e409b95e3c574fda4aadc" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,799</ix:nonFraction>,000 of unrestricted cash and cash equivalents available to fund future operations.&#160; In July 2022, the Company entered into a $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_b7dfd5dc38324d868d9e7b712d1ed9f0" contextRef="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction> million unsecured line of credit financing with its chairman, Richard E. Uihlein (See Note 10). The Company believes there is sufficient cash,
            including availability of the line of credit, to fund currently planned operations at least through December 31, 2024. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other
              strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when
              needed could have a material adverse effect on the Company&#8217;s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity
              concerns until a date when those concerns are relieved.</span></div>
</ix:continuation>
          <ix:continuation id="Text_09dfe7a671224d35bb045fe0a0f85bdb6" continuedAt="Text_09dfe7a671224d35bb045fe0a0f85bdb7">
<div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>

        <ix:continuation id="Text_09dfe7a671224d35bb045fe0a0f85bdb7" continuedAt="Text_09dfe7a671224d35bb045fe0a0f85bdb8">
<div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_09dfe7a671224d35bb045fe0a0f85bdb8" continuedAt="Text_09dfe7a671224d35bb045fe0a0f85bdb9">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_09dfe7a671224d35bb045fe0a0f85bdb9" continuedAt="Text_09dfe7a671224d35bb045fe0a0f85bdb10">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_09dfe7a671224d35bb045fe0a0f85bdb10">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Company was
          founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name &#8220;Pro-Pharmaceuticals, Inc.,&#8221; and changed its name to &#8220;Galectin Therapeutics Inc.&#8221; on May&#160;26, 2011.</div>
</ix:continuation>

        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Text_58eb7977e7d046628a599c133f135850" contextRef="c20230101to20230331" escape="true" continuedAt="Text_bd42a19972f043d092e8aee375a830fd1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2. Accrued Expenses and Other</div>
</ix:nonNumeric>
        <ix:continuation id="Text_bd42a19972f043d092e8aee375a830fd1" continuedAt="Text_bd42a19972f043d092e8aee375a830fd2">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>

        <ix:continuation id="Text_bd42a19972f043d092e8aee375a830fd2" continuedAt="Text_bd42a19972f043d092e8aee375a830fd3"><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_a58dce520b5a4eb99d760a06cd017f08" contextRef="c20230101to20230331" escape="true" continuedAt="Text_ef48ed2a25574a338c987942ea7fd9e41">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued expenses consist of the following:</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_bd42a19972f043d092e8aee375a830fd3" continuedAt="Text_bd42a19972f043d092e8aee375a830fd4"><ix:continuation id="Text_ef48ed2a25574a338c987942ea7fd9e41" continuedAt="Text_ef48ed2a25574a338c987942ea7fd9e42">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_bd42a19972f043d092e8aee375a830fd4" continuedAt="Text_bd42a19972f043d092e8aee375a830fd5"><ix:continuation id="Text_ef48ed2a25574a338c987942ea7fd9e42">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="width: 100%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;"> <span style="font-weight: bold;">March 31,<br />
                    2023</span></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;"><span style="font-weight: bold;">December 31,<br />
                  </span> <span style="font-weight: bold;">2022</span></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom;">
                <div style="text-align: center;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -27pt; margin-left: 27pt;">Legal and accounting fees</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_cb33e893f3aa4861a353d1dfe5139050" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">142</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_2b65ac529b5c4979bb419d128bd01830" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">65</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -27pt; margin-left: 27pt;">Accrued compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_a8a5951d6086494fb73d9cf589584b33" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">386</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_eb8895a82cd64f36962fa12545b64585" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">973</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -27pt; margin-left: 27pt;">Lease liability</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_ca684e33620e4ff9bc0881c53815c7ec" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">42</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_72ad09eb584c48f4982ea540397224c6" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -27pt; margin-left: 27pt;">Accrued research and development costs and other</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent" id="Fact_88eaab65ce7c4f66a4a670d95cd1a620" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,410</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent" id="Fact_b2cabe0a533f45ec95d7c356e6cd785f" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,980</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <div style="text-indent: -27pt; margin-left: 27pt;">Total</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_803311fc2a2e46238ca364ffe6953ee0" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,980</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_932446db74a04b44a04380264a052e87" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,058</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_bd42a19972f043d092e8aee375a830fd5" continuedAt="Text_bd42a19972f043d092e8aee375a830fd6">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_bd42a19972f043d092e8aee375a830fd6">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 24.5pt;">Research and development expenses, including personnel costs, allocated facility costs, lab supplies, outside services, contract laboratory costs related to
          manufacturing drug product, clinical trials and preclinical studies are charged to research and development expense as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research
          and development activities as expense when the service has been performed or when the goods have been received. Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors. We
          accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses and related expenses associated with the conduct of clinical trials, the significant
          factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients have been enrolled in the trial. We monitor patient enrollment levels and related activities
          to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We base our estimates on the best information available at the time. We monitor patient enrollment levels and related activities to the
          extent possible through discussions with CRO personnel and based our estimates of clinical trial costs on the best information available at the time. However, additional information may become available to us which will allow us to make a more
          accurate estimate in future periods. In that event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.</div>
</ix:continuation>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

    <div>
      <div>
        <ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" id="Text_daff77bcc5784263b876e49cd149b3d8" contextRef="c20230101to20230331_LongtermDebtTypeAxis_LoansPayableMember" escape="true" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd51">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">3. Convertible Notes Payable &#8211; Related Party</div>
</ix:nonNumeric>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd51" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd52">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd52" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd53">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd53" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd54">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd54" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd55">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;">On April&#160;16, 2021, the Company and
          Richard E. Uihlein entered into a debt financing arrangement whereby Mr.&#160;Uihlein loaned $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_14a116e3061e44908a4e6c22288a730c" contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> to Company. In consideration for
          the loan, the Company issued a convertible promissory note (the &#8220;April 2021 Note&#8221;) in the principal amount of <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" id="Fact_35b13f39c45c4be59bc2179e4a7a4abb" contextRef="c20210416to20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">ten million</ix:nonFraction> dollars.</div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd55" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd56">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd56" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd57">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd57" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd58">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd58" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd59">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;">The April 2021 Note has a maturity date
          of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_0b91cb6851824360b6b9d57a726cd44d" contextRef="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">April 16, 2025</ix:nonNumeric>, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#8217;s
          common stock at a conversion price equal to $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" id="Fact_47d259e2e11b451ab520a8300ce28783" contextRef="c20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction> per share at the option of the noteholder. The April 2021 Note bears interest at the
          rate of two percent (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_13d3ff2c9ded45f0b3b63142fcf789f9" contextRef="c20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%) per annum, compounded annually with an effective interest rate of approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_7cd3466342b943f2b3f9cf4d07095f16" contextRef="c20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%. For the three months ended March 31, 2023 and 2022, approximately $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_52315b5e710f43caae8dbad4a8d6dac4" contextRef="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_4bd2da8be0374ed3aa303bc40f29ad41" contextRef="c20220101to20220331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction>, respectively, of interest expense was accrued and
          included with the principal in the financial statements.<br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd59" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd510">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd510" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd511">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd511" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd512">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd512" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd513">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;">The April 2021 Note also includes a
          contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (<ix:nonFraction name="galt:QuarterlyInterestRate" id="Fact_2d80bce2ba934f54b9dfb9fe0b8af3e9" contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>%) per
          quarter (<ix:nonFraction name="galt:AnnualInterestRate" id="Fact_3d16b54aabf041a4bfc71ae367a09cde" contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% per annum) (the &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date,
          provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the April 2021 Note into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on
          creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the April 2021 Note at its inception. The fair value of
          the contingent interest derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_513eb784f4264cd68cbda02565907647" contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">420,000</ix:nonFraction> at note inception (April 16, 2021). The fair value of the contingent interest
          derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_50d1d85a9d66440cb1cb27f67c3aa139" contextRef="c20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">587,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_15c562d8192443138c655c8782502544" contextRef="c20221231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">249,000</ix:nonFraction>
          at March 31, 2023 and December 31, 2022, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability for the three months ended March 31, 2023 and 2022 of $<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_f30d49e8268a4180a384eceb8c17adf2" contextRef="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">338,000</ix:nonFraction> and $(<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_1dc3e760ece44cd9a7996bf41f126ae4" contextRef="c20220101to20220331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">104,000</ix:nonFraction>), respectively,
          was charged to other expense/(income) for the three months ended March 31, 2023 and 2022. The amortization of the original $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" id="Fact_883e844578d64d73baaf0a289dfa1c41" contextRef="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">420,000</ix:nonFraction>
          debt discount of $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_6466a3ac9afe4fe6b91316985be8a581" contextRef="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_e6cfd25d67354ce0a528a75e1641ffa9" contextRef="c20220101to20220331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,000</ix:nonFraction>
          was recorded as additional interest expense for the three months ended March 31, 2023 and 2022, respectively<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.</span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd513" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd514">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd514" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd515">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal; background-color: rgb(255, 255, 255);"><br />
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd515" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd516">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd516" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd517">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;">The September 2021 Note has a maturity
          date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_1873ba1b171b4e42b5c17da7e64dc9a9" contextRef="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">September 17, 2025</ix:nonNumeric>, is prepayable at the option of the Company in whole or in part at any time and is convertible into the
          Company&#8217;s common stock at a conversion price equal to $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" id="Fact_38e7fc764d394ee39ba7aa53fad0018a" contextRef="c20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">8.64</ix:nonFraction> per share at the option of the noteholder. The September 2021 Note bears
          interest at the rate of two percent (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_6d98aac880a14e09a14132dc052449bf" contextRef="c20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%) per annum, compounded annually with an effective interest rate of approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_f43ee19911a84dd1bc5090abf06bb33a" contextRef="c20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%. For the three months ended March 31, 2023 and 2022, approximately $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_025112e9e1c4407b94216e32a96d5cb0" contextRef="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_a6cdf50e959f4ad78a24bb1c053c7319" contextRef="c20220101to20220331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction>, respectively, of interest expense was accrued and
          included with the principal in the financial statements. </div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd517" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd518">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br />
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd518" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd519">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt;"><span style="letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>The September 2021 Note
          also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (<ix:nonFraction name="galt:QuarterlyInterestRate" id="Fact_321596370b0445359548a8fb430b4856" contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>%)
          per quarter (<ix:nonFraction name="galt:AnnualInterestRate" id="Fact_2d67b634995040f7b1de9359c77384fa" contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% per annum) (the &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date,
          provided however, that such payment is only required if and only if the noteholder elects&#160;&#160; to convert the entire balance of the September 2021 Note into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on
          creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the September Note at its inception. The fair value of the
          contingent interest derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_397b74c232744ef087048e65ff2d531a" contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">433,000</ix:nonFraction> at note inception (September 17, 2021). The fair value of the contingent interest
          derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_60439042d1ed458da9dfd1d0c5f08716" contextRef="c20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">276,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_6a3103a7157c4494a03822939bc01233" contextRef="c20221231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">109,000</ix:nonFraction>
          and March 31, 2023 and December 31, 2022, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability three months ended March 31, 2023 and 2022 of $<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_414a8f654e9c4a848f1a83249d5b1532" contextRef="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">167,000</ix:nonFraction> and ($<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_1ea6e7412e694f5ab6a6852f2082c3b0" contextRef="c20220101to20220331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">62,000</ix:nonFraction>), respectively,
          was recorded to other expense/(income) for three months ended March 31, 2023 and 2022. The amortization of the original $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" id="Fact_44f2081cc6d14ef2a7e72a1fd7c50659" contextRef="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">433,000</ix:nonFraction> debt
          discount of $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_69e4bc4336ba420392d38923506eb874" contextRef="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">27,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_8de61bd7bd4d497b8819baa420148df8" contextRef="c20220101to20220331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">27,000</ix:nonFraction>
          was recorded as additional interest expense for the three months ended March 31, 2023 and 2022<span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;">.</span><span style="width: 9pt; font-size: 10pt; display: inline-block; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" class="HorizontalTab">&#160; </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd519" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd520">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> <br />
          </span></div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd520" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd521">
<div style="display:none;"><br /></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: left; text-indent: 24.5pt; text-transform: none;"><span style="font-weight: normal;">On</span> December 20, 2021, the
          second of the <ix:nonFraction name="galt:NumberOfPromissoryNotesEvidencedByLoansAgreement" id="Fact_2e358460dba84b699bc466561a414f9e" contextRef="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> promissory notes under the Loan Agreement was executed and delivered, (the &#8220;December 2021 Note&#8221;) to evidence the
          second loan in the principal amount of $<ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" id="Fact_00a4fd5b8a8d43599bcee7482d75f7e9" contextRef="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction>. The December 2021 Note has a maturity date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_db83ca325d9d4023bc91fce3dac12ec2" contextRef="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" format="ixt:date-monthname-day-year-en">December 20, 2025</ix:nonNumeric>, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#8217;s common stock at a
          conversion price equal to $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" id="Fact_7e829753d06446d4a4bbc34d9fce4c7d" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.43</ix:nonFraction> per share at the option of the noteholder. The December Note bears interest at the rate of two percent
          (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_922fc5a4f7924e77bba022248fc579ff" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%) per annum, compounded annually with an effective interest rate of approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_d62c5efe1129464482fab099d27b0a7c" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%. For three months ended March 31, 2023 and 2022, approximately $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_103ccc24369c47299f8ff5b761b875d0" contextRef="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction>
          and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_3c4765043eb04e38a6915bac31d46867" contextRef="c20220101to20220331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction>, respectively, of interest expense was accrued and included with the principal in the financial statements.</div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd521" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd522">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> <br />
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd522" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd523">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">The </span>December 2021
          Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (<ix:nonFraction name="galt:QuarterlyInterestRate" id="Fact_d2d2636f8f81438aaac3596ee8eac95d" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>%)
          per quarter (<ix:nonFraction name="galt:AnnualInterestRate" id="Fact_f41ef027e69d49969e66c971a2cb92ee" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% per annum) (the &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date,
          provided however, that such payment is only required if and only if the noteholder elects&#160;&#160; to convert the entire balance of the December 2021 Note into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on
          creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the December Note at its inception. The fair value of the
          contingent interest derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_7968ddfa3a834190a1cccc0e24cb7232" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">415,000</ix:nonFraction> at note inception (December 20, 2021). The fair value of the contingent interest
          derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_fdd53a1e09994413a64202dd08fb473e" contextRef="c20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">479,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_e93131c413524c1498aaf9bcc39a4db4" contextRef="c20221231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">215,000</ix:nonFraction>
          at March 31, 2023 and December 31, 2022, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability for three months ended March 31, 2023 and 2022.of $<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_12c294cf534b4c9c88f28d2f3af0696a" contextRef="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">264,000</ix:nonFraction> and ($<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_b75621a59df64d968e196d051de78c53" contextRef="c20220101to20220331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">63,000</ix:nonFraction>), respectively was
          recorded to other expense/(income) for three months ended March 31, 2023 and 2022.. The amortization of the original $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" id="Fact_ec5f2725cf1a481090559d8c058e05cc" contextRef="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">415,000</ix:nonFraction> debt
          discount of $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_f681710a74794b398fa98f9443e2bfb4" contextRef="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_c7b11a80020a4ecba0e2d9a8fde22eb4" contextRef="c20220101to20220331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,000</ix:nonFraction>
          was recorded as additional interest expense for three months ended March 31, 2023 and 2022, respectively<span style="font-weight: normal;">. </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd523" continuedAt="Text_aa4112233c07499ebe64fc1bbe0a7fd524">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> <br />
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_aa4112233c07499ebe64fc1bbe0a7fd524">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company&#8217;s contractual cash obligations related to the outstanding
              convertible notes payable is a repayment of the April 2021 Note of the $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" id="Fact_067ab0804cb844ad918c4fb87c0e5600" contextRef="c20250416to20250416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> plus accrued interest on April&#160;16, 2025 and a
              repayment of the September 2021 Note of the $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" id="Fact_f1003953679641568e0d776a314aba97" contextRef="c20250917to20250917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">plus accrued interest on September 17, 2025 and a
                repayment of the December 2021 Note of the $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" id="Fact_fe4d6cd317c447b1bf434bfb410c3298" contextRef="c20251230to20251230_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> plus accrued interest on December 30, 2025, unless converted at the option
                of the noteholder.</span></span> </span> </div>
</ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

      </div>

    </div>

    <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;"> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

    <div>
      <div>
        <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" id="Text_25979fe1fc7f493298783fb9c5e9efaa" contextRef="c20230101to20230331" escape="true" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">4. Fair Value of Financial Instruments</div>
</ix:nonNumeric>
        <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c1" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c2">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span> </div>
</ix:continuation>
        <div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">
          <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c2" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c3">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">The Company has
            certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than
            quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to
            develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximate their carrying value due to their short-term nature. There were <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_ed929c584ec541ac9fc92b0abd98701b" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_bd84f3d9838b4f768206e55ba40252b0" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_76365f60bead4f0db8e098eff3b670e2" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_613dec05f24a49bf847b89c3ea0fae6f" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_52684fcafd004618a162a1ebabcd4029" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_248de12f43804583b53c8190eb5a5971" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_1fa7ae58e1ef47e3bad681197dc832b9" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_1c9b29ebf08843498473942e1a39552b" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> level 1 or 2 assets or liabilities at March 31, 2023 or December 31, 2022. See below for Fair Value of Derivatives related to Convertible
            Notes Payable at March 31, 2023 and December 31, 2022, which are level 3 liabilities.</div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c3" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c4">
<div><br />
            </div>
</ix:continuation>

            <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c4" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c5"><ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Text_ff5d2961b06540fda0733d4919c91a0c" contextRef="c20230101to20230331" escape="true" continuedAt="Text_d9f60690153241068043d638465d7c721">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">Level 3 assets
              and liabilities measured and recorded at fair value on a recurring basis at March 31, 2023 and December 31, 2022 were as follows:</div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c5" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c6"><ix:continuation id="Text_d9f60690153241068043d638465d7c721" continuedAt="Text_d9f60690153241068043d638465d7c722">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br />
            </div>
</ix:continuation></ix:continuation>
          </div>

        </div>

        <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c6" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c7"><ix:continuation id="Text_d9f60690153241068043d638465d7c722">
<table cellspacing="0" cellpadding="0" border="0" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-left: 23%; padding-bottom: 2px;" colspan="1"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span> </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                <div style="text-align: center; font-weight: bold;">
                  <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                  </div>
                  <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2022</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div><span style="font-family: 'Times New Roman'; font-size: 10pt;">Derivative Liability &#8211; Contingent Interest April Note </span> </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_8d62ac7305274dcfbbbf590af5e821a9" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">587,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_efcc20fb1ef7415c9d2a6a2b778f1da6" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">249,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Derivative Liability &#8211; Contingent Interest September Note </span> </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_2c46bc0eb3fa4f259b6a78bacf0ecda3" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">276,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_6a04870b55dd476fa0bdf7417fdd2f4b" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">109,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">Derivative Liability &#8211; Contingent Interest December Note</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_1a843d3b8b374804ac17bcae56181e56" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">479,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_6f7c1e0bd3844c43bdfad7e6a6f11566" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">215,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
      </div>

      <div><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Text_71a49c3b39dc4f25b3b0d738831877a3" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" escape="true" continuedAt="Text_bdb56844f95a44d1af2f1fd0f26afd7f1"><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c7" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c8">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span> </div>
</ix:continuation></ix:nonNumeric>
        <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;">
          <ix:continuation id="Text_bdb56844f95a44d1af2f1fd0f26afd7f1" continuedAt="Text_bdb56844f95a44d1af2f1fd0f26afd7f2"><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c8" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c9">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.3pt; margin-right: 41pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The April Note derivative liability &#8211;
            contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bdb56844f95a44d1af2f1fd0f26afd7f2" continuedAt="Text_bdb56844f95a44d1af2f1fd0f26afd7f3"><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c9" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c10">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation></div>

        <ix:continuation id="Text_bdb56844f95a44d1af2f1fd0f26afd7f3" continuedAt="Text_bdb56844f95a44d1af2f1fd0f26afd7f4"><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c10" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c11">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_bdb56844f95a44d1af2f1fd0f26afd7f4" continuedAt="Text_bdb56844f95a44d1af2f1fd0f26afd7f5"><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c11" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c12">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_bdb56844f95a44d1af2f1fd0f26afd7f5"><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c12" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c13">
<table cellspacing="0" cellpadding="0" border="0" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">
                  <div style="text-align: center; font-weight: bold;">
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                    </div>
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                  </div>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="2">
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2022</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Stock Price</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_28b37c8ac90145e9ac272c74474b4c2b" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U005" decimals="2" scale="0" format="ixt:num-dot-decimal">2.10</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_3d91d0f255f04c1d98c9f4b1c5f4945b" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U005" decimals="2" scale="0" format="ixt:num-dot-decimal">1.13</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Conversion Price of conversion feature</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_4fe2ef302d984153aaf98cc8fbfaf019" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U005" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_27f4299b80b04c57b5a6e8f66be59d33" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U005" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Term</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" colspan="2">
                <div style="text-align: right;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160; <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_82057babbdf94652a489de269b486f92" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">2.04</ix:nonNumeric> years<br />
                  </span> </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" colspan="2">
                <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_584d3cec687f46e19a6ef6a209e95fcb" contextRef="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">2.29</ix:nonNumeric> years</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Risk Free Interest Rate</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_519ffb766b0f4c77a460e57d8604d069" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.06</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_701aa842fe684c5380c4f1cece4e3947" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.41</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_bea351d585e84e9a9506651d566ec551" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">14.04</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_8cb06bc1a431417fa4f48f4f3c87a6fc" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">14.76</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Volatility</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_c8b0bb4e0f1541cf8dd76cb2473ee9ae" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_95bc2cdd69c0468a85791d973e8a14de" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">81</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Dividend Rate</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_40119d080ff3447eaae3076bfc74e009" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%<br />
                </span> </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_c89b16f6d2494aa7956b316afe83de01" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%<br />
                </span> </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c13" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c14">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br /></div>
</ix:continuation>
        <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c14" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c15">
<div><br />
        </div>
</ix:continuation>

        <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;">
          <div style="margin-left: 3pt;">
            <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c15" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c16"><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Text_88c1952d6b0f4acb987d4f94377f3270" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" escape="true" continuedAt="Text_8e24ff5845174fae8a0edb38840ead641">
<div style="display:none;"><br /></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt; margin-left: 9pt;">The roll forward of the April Note derivative liability &#8211; contingent interest is as follows for the three months ended March 31, 2023 and 2022:</div>
</ix:nonNumeric></ix:continuation>
          </div>

        </div>

        <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c16" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c17"><ix:continuation id="Text_8e24ff5845174fae8a0edb38840ead641" continuedAt="Text_8e24ff5845174fae8a0edb38840ead642">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c17" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c18"><ix:continuation id="Text_8e24ff5845174fae8a0edb38840ead642">
<table cellspacing="0" cellpadding="0" border="0" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2022</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_90b889ea631544209d761f5f7fa8ee65" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">249,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_99506e06e9d2477782e6c6fa43e1814e" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">338,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2023</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_d24dfecd5da44800b9cd2359a5e81f57" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">587,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%;">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" rowspan="1"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2021<br />
                </span> </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$ <br />
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_53fcead1aa3f4abda44a5d9b9563ceec" contextRef="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">495,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">Fair Value Adjustment</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_26a7c701920f49e199393639596487ea" contextRef="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">104,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2022</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_cbfd0a8e8f9345aab3bea70143d03632" contextRef="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">391,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <div>
          <div><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c18" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c19">
<div><br /></div>
</ix:continuation>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div>
                  <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

                </div>

              </div>

            </div>

          </div>


          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 27pt; text-transform: none;">
            <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c19" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c20"><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Text_4cc7676293e04353aca15577dedcadc9" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" escape="true" continuedAt="Text_7d183dcd253446d5a2f686f3404103dc1">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">The September
              Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:</div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c20" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c21"><ix:continuation id="Text_7d183dcd253446d5a2f686f3404103dc1" continuedAt="Text_7d183dcd253446d5a2f686f3404103dc2">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation></div>

          <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c21" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c22"><ix:continuation id="Text_7d183dcd253446d5a2f686f3404103dc2" continuedAt="Text_7d183dcd253446d5a2f686f3404103dc3">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c22" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c23"><ix:continuation id="Text_7d183dcd253446d5a2f686f3404103dc3" continuedAt="Text_7d183dcd253446d5a2f686f3404103dc4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c23" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c24"><ix:continuation id="Text_7d183dcd253446d5a2f686f3404103dc4">
<table cellspacing="0" cellpadding="0" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="2">
                  <div style="text-align: center; font-weight: bold;">
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                    </div>
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="2">
                  <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold;">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">2022</span></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Stock Price</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_d785533d436049ad985894b1cf46400e" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U005" decimals="2" scale="0" format="ixt:num-dot-decimal">2.10</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_edfea0f792824775a519b10dc1f32daf" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U005" decimals="2" scale="0" format="ixt:num-dot-decimal">1.13</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Conversion Price of conversion feature</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_b2b4012924cd44a48c9f7e4dcfc7c8e5" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U005" decimals="2" scale="0" format="ixt:num-dot-decimal">8.64</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_d9a1e9b83be74a2491e025b20623ea61" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U005" decimals="2" scale="0" format="ixt:num-dot-decimal">8.64</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF;">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Term</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;" colspan="2">
                  <div style="text-align: right; text-indent: -18pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_2335d44520224816888de71c8e471756" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">2.47</ix:nonNumeric></span> years
                      <br />
                    </span> </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;" colspan="2">
                  <div style="text-indent: 6pt; text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_ea28aefacd9a4daba5f92629eef9d3a1" contextRef="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">2.72</ix:nonNumeric></span> years</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Risk Free Interest Rate</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_2dac7004572f438fb0e82b83f78bf9ba" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.94</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_2fde38a786434ee5926f901ba941ebaa" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.22</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Credit Adjusted Discount Rate</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_d8404b89cee34cc09bb88ab285649c82" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">14.04</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_098afd0c6f204f73a16db0315a05fb88" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">14.76</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Volatility</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_3d9f5b00b9c748a2a0c952590660af0e" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_341ba63eadaa4d668dc3455a3132b469" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">81</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Dividend Rate</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_5410e056fc9748feb241e977d88d8522" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">%</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_4464d6e2d64d4f49bc821bbee11e6f50" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">%</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c24" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c25">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </span> </div>
</ix:continuation>

          <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c25" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c26"><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Text_63a1ce19f8c0480caf772ae2e622a4ff" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" escape="true" continuedAt="Text_e2b91fbe9ed6496eb4cd9776ed92aeb91">
<div style="display:none;"><br /></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 27pt; text-transform: none;">The roll forward of the September
            Note derivative liability &#8211; contingent interest is as follows: </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c26" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c27"><ix:continuation id="Text_e2b91fbe9ed6496eb4cd9776ed92aeb91" continuedAt="Text_e2b91fbe9ed6496eb4cd9776ed92aeb92">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c27" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c28"><ix:continuation id="Text_e2b91fbe9ed6496eb4cd9776ed92aeb92">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2022</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_79356b0a05d040aabdac5b8a7a7f8522" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">109,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: left; width: 88%; padding-bottom: 2px;" rowspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_230e6307dd01401f99d9eb0c318059bf" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">167,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2023</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_e174be3285ae4a7cbb6909f3f58c6120" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">276,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%;">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" rowspan="1">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2021</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_0348ab9cbcc644a982a736f3406ef66c" contextRef="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">Fair Value Adjustment</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_9c0cf2eae69a454ea3b89e8c5d90e491" contextRef="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">62,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" rowspan="1">Balance &#8211; March 31, 2022</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_8c0ab58a8d3b4fad97ae2d6d1f40e043" contextRef="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">188,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c28" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c29">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>
</ix:continuation>
          <div>
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 27pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
              <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c29" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c30"><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Text_c005da4a81184f22aaea744c41a61011" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" escape="true" continuedAt="Text_d0a81db54a4d4323818ca411e7c0a6591">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.3pt; margin-right: 23pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The December Note derivative
                liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c30" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c31"><ix:continuation id="Text_d0a81db54a4d4323818ca411e7c0a6591" continuedAt="Text_d0a81db54a4d4323818ca411e7c0a6592">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
              <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
              </span></div>
</ix:continuation></ix:continuation> </div>

            <ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c31" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c32"><ix:continuation id="Text_d0a81db54a4d4323818ca411e7c0a6592">
<table cellspacing="0" cellpadding="0" border="0" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                      <div style="text-align: center; font-weight: bold;">
                        <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                        </div>
                        <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                      </div>
                    </div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2022</div>
                    </div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock Price</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_5d2c538b609b435fb0a9fbf946b3588f" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U001" decimals="2" scale="0" format="ixt:num-dot-decimal">2.10</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_6341985977234b0a9c957b53c2ddceb2" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U001" decimals="2" scale="0" format="ixt:num-dot-decimal">1.13</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Conversion Price of conversion feature</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_d1da775388274b07919d4864c4ca4482" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U001" decimals="2" scale="0" format="ixt:num-dot-decimal">5.43</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_031b1c530e1e4ce7aab27b853a6738b4" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U001" decimals="2" scale="0" format="ixt:num-dot-decimal">5.43</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Term</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="2"><span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_66306581f19c452a8612be7d5b1e4760" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">2.73</ix:nonNumeric> years<br />
                    </span></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;" colspan="2">
                    <div style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_b67069ef080e4451b5225fa158adf34d" contextRef="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">2.97</ix:nonNumeric> years</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Risk Free Interest Rate</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_dd1340170e5f49a596940c5fb3a15bdb" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U001" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.81</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_2cb026185ddd4815bd5d3581d6d457c2" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U001" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.22</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Credit Adjusted Discount Rate</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_5fe3f2065df5403ba567db2a618916d3" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U001" decimals="4" scale="-2" format="ixt:num-dot-decimal">14.04</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_3e892bafb74b4ec1b16536b987732ccb" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U001" decimals="4" scale="-2" format="ixt:num-dot-decimal">14.76</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Volatility</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_1a05b4d99390419796892046bf03a8e6" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U001" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_29e82476119b41ef96c9c55df1babf45" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U001" decimals="2" scale="-2" format="ixt:num-dot-decimal">83</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Dividend Rate</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_8efa115e0c1842608bfd5ee538d48d95" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U001" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1"><span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</span></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_916b427eca62408eae18a05518489182" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1"><span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</span></td>

  </tr>


</table>
</ix:continuation></ix:continuation>

            <div><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Text_ee0173543a324ac591423b0e77c656d7" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" escape="true" continuedAt="Text_a97dd27a1dea4291bb72f886adac99181"><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c32" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c33">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
              </span> </div>
</ix:continuation></ix:nonNumeric>
              <ix:continuation id="Text_a97dd27a1dea4291bb72f886adac99181" continuedAt="Text_a97dd27a1dea4291bb72f886adac99182"><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c33" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c34">
<div style="display:none;"><br /></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;">The roll forward
                of the December Note derivative liability &#8211; contingent interest is as follows: </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_a97dd27a1dea4291bb72f886adac99182" continuedAt="Text_a97dd27a1dea4291bb72f886adac99183"><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c34" continuedAt="Text_b8aaffae300840dd872b12f22a06ac2c35">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
              </span></div>
</ix:continuation></ix:continuation> </div>

            <ix:continuation id="Text_a97dd27a1dea4291bb72f886adac99183"><ix:continuation id="Text_b8aaffae300840dd872b12f22a06ac2c35">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2022</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_0f5fc27da1a04d80b880fd71dc5bb0a8" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">215,000</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_418fede2267d4d9b93b38453fa9b3f2a" contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">264,000</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2023</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_2926570b101f45c484c8a3f2b0c70262" contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">479,000</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 88%;">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255);" rowspan="1"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2021<br />
                    </span> </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_a3d3eb498a874aeba0dc359276a49bad" contextRef="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">109,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_8f62bc77f6fb4b7489c27b1832333076" contextRef="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">167,000</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2022</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_33460354015042b390e6b11ceea25aac" contextRef="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">276,000</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
            </div>

          </div>

      </div>

    </div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  </div>


  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div>
          <div><br />
          </div>


          <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Text_05c0875528b141e0953a9a16053997aa" contextRef="c20230101to20230331" escape="true" continuedAt="Text_6554ca62d28345848a90d67e40a940041">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">5. Stock-Based Compensation</div>
</ix:nonNumeric>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a940041" continuedAt="Text_6554ca62d28345848a90d67e40a940042">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>
</ix:continuation>

          <ix:continuation id="Text_6554ca62d28345848a90d67e40a940042" continuedAt="Text_6554ca62d28345848a90d67e40a940043"><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Text_9011ea0c898a4c6f9241e95bcb9bc839" contextRef="c20230101to20230331" escape="true" continuedAt="Text_c7efa67b853f469fb386412b7cd47a881">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:</div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a940043" continuedAt="Text_6554ca62d28345848a90d67e40a940044"><ix:continuation id="Text_c7efa67b853f469fb386412b7cd47a881" continuedAt="Text_c7efa67b853f469fb386412b7cd47a882">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a940044" continuedAt="Text_6554ca62d28345848a90d67e40a940045"><ix:continuation id="Text_c7efa67b853f469fb386412b7cd47a882">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">Three Months Ended<br />
                    March 31,</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">2023<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">2022<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div>Research and development</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_d7b6824e8aa2443882c0014c399a0c16" contextRef="c20230101to20230331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">270</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_ca299e72048546ccb4e89961336d0a0a" contextRef="c20220101to20220331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">225</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div>General and administrative</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_ccfaeea94e734fa3872c7e65e029a26f" contextRef="c20230101to20230331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">392</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_f381947dd48f4bd4aa948b8317f7bb45" contextRef="c20220101to20220331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">633</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="margin-left: 9pt;">Total stock-based compensation expense</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_00d5992cc92447c8b2f3a98039042f1c" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">662</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_bbb82c9690074a86bf01cdd1005b983d" contextRef="c20220101to20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">858</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_6554ca62d28345848a90d67e40a940045" continuedAt="Text_6554ca62d28345848a90d67e40a940046">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div>
                <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

              </div>

            </div>

          </div>


          <ix:continuation id="Text_6554ca62d28345848a90d67e40a940046" continuedAt="Text_6554ca62d28345848a90d67e40a940047"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_9d9c277515224ec0b9771a85dca8d706" contextRef="c20230101to20230331" escape="true" continuedAt="Text_e16f5d505cb14bf0bf1289638da6f5741">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the stock option activity in the Company&#8217;s equity incentive plans, including non-plan grants to Company executives, from
            December&#160;31, 2022 through March 31, 2023:</div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a940047" continuedAt="Text_6554ca62d28345848a90d67e40a940048"><ix:continuation id="Text_e16f5d505cb14bf0bf1289638da6f5741" continuedAt="Text_e16f5d505cb14bf0bf1289638da6f5742">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a940048" continuedAt="Text_6554ca62d28345848a90d67e40a940049"><ix:continuation id="Text_e16f5d505cb14bf0bf1289638da6f5742">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">Shares</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">Weighted Average<br />
                    Exercise Price</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div>Outstanding, December 31, 2022</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_ea7dd9c9e6764230860bc44948226997" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,745,561</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_ae0cc01126ca482eb4c0a22af53b5e50" contextRef="c20221231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.90</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="margin-left: 9pt;">Granted</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_26c1cf14771d4f0384976db02c584b58" contextRef="c20230101to20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">800,000</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_311d3f2540b145aea3d1618845d6f356" contextRef="c20230101to20230331" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.11</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="margin-left: 9pt;">Exercised</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_145d86e1fad44d74a91b218790b886cf" contextRef="c20230101to20230331" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_69dd3fe4ae5346f1bf8993878d882140" contextRef="c20230101to20230331" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div style="margin-left: 9pt;">Options forfeited/cancelled</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" id="Fact_84148206ffc6414d9480d7ec5001e25e" contextRef="c20230101to20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">18,803</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div>)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="Fact_27f7e374b56b46dab1410be17ba2cc91" contextRef="c20230101to20230331" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.59</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div>Outstanding, March 31, 2023</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_58b44c444064492eb911300a57ae8ce9" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,526,758</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_92d3df653b804204a09bdb773096f156" contextRef="c20230331" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.67</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a940049" continuedAt="Text_6554ca62d28345848a90d67e40a9400410">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400410" continuedAt="Text_6554ca62d28345848a90d67e40a9400411">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">As of March 31, 2023, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" id="Fact_b158ab53432a4724b5f37c9fbce04415" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,268,000</ix:nonFraction> of
            unrecognized compensation related to <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" id="Fact_43ee3b627bfa48bea8d8026ec0d4ef44" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,850,833</ix:nonFraction> unvested options, which is expected to be recognized over a weighted&#8211;average period
            of approximately <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_6cb167ce40a84105b3a2e2dc18dff3b6" contextRef="c20230101to20230331" format="ixt-sec:duryear">1.29</ix:nonNumeric> years. The weighted-average grant date fair value for options granted during the three months ended March 31,
            2022 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_48331ab24b0f4ad18ce272c125881566" contextRef="c20230101to20230331" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.80</ix:nonFraction>. The Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_56ec89f1597240c385e01d65ab66b745" contextRef="c20230101to20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">800,000</ix:nonFraction>
            stock options during the three months ended March 31, 2023.<br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400411" continuedAt="Text_6554ca62d28345848a90d67e40a9400412">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>
</ix:continuation>

          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400412" continuedAt="Text_6554ca62d28345848a90d67e40a9400413"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_582ace65091b4b42a8c3336a8eae29e7" contextRef="c20230101to20230331" escape="true" continuedAt="Text_c826cd51c371464c8e5e80235a66a3801">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:</div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400413" continuedAt="Text_6554ca62d28345848a90d67e40a9400414"><ix:continuation id="Text_c826cd51c371464c8e5e80235a66a3801" continuedAt="Text_c826cd51c371464c8e5e80235a66a3802">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400414" continuedAt="Text_6554ca62d28345848a90d67e40a9400415"><ix:continuation id="Text_c826cd51c371464c8e5e80235a66a3802">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">Three<br />
                    Months Ended<br />
                    March 31,</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">Three<br />
                    Months Ended<br />
                    March 31,</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">2023<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">2022<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div>Risk-free interest rate</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_538c8594b3004eefa79272d86ffde775" contextRef="c20230101to20230331" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.76</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>%</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_03583d38ca3d42a6a01f839f840fdb6a" contextRef="c20220101to20220331" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.23</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>%</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                  <div>Expected life of the options</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_2f769be158fc4fb8a6084c1b32108514" contextRef="c20230101to20230331" format="ixt-sec:duryear">5.5</ix:nonNumeric> years </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_5672c992ac8c4c2ca64c285f935881fa" contextRef="c20220101to20220331" format="ixt-sec:duryear">5.5</ix:nonNumeric> years <br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div>Expected volatility of the underlying stock</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_7626d3df4cac4167a9a91a127645fb73" contextRef="c20230101to20230331" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">86</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>%</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_fc64d1600933426da564082766d47753" contextRef="c20220101to20220331" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">95</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>%</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div>Expected dividend rate</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_9cb6e846f2044f7aad6d81184c4e0c30" contextRef="c20230101to20230331" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">%</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_d5a820fd201046d5b28775776be10d4d" contextRef="c20220101to20220331" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">%</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400415" continuedAt="Text_6554ca62d28345848a90d67e40a9400416">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400416" continuedAt="Text_6554ca62d28345848a90d67e40a9400417">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">In January 2023, the Company&#8217;s board chairman elected to take restricted stock grants in lieu of cash retainers for 2023. A total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_5ee97d5c0e6747df8b66f8216dcaa833" contextRef="c20230101to20230131_AwardTypeAxis_RestrictedStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">36,036</ix:nonFraction> shares of restricted stock valued at approximately $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_8f256336a3f24b0ebff993f4463393da" contextRef="c20230101to20230131_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">40,000</ix:nonFraction> is being amortized to expense on a straight-line basis until December 31, 2023 when the stock vests in full. In January 2022, the Company&#8217;s board chairman elected to take restricted stock grants in lieu
            of cash retainers for 2022. A total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_8a66b848e27f47bb833e2931ae7197eb" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">17,677</ix:nonFraction> shares of restricted stock valued at approximately $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_5084b10e9385458ca990fd874d1862a9" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">35,000</ix:nonFraction> is being amortized to expense on a straight-line basis until December 31, 2022 when the stock vested in full.</div>
</ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400417" continuedAt="Text_6554ca62d28345848a90d67e40a9400418">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400418" continuedAt="Text_6554ca62d28345848a90d67e40a9400419">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">In September 2020, the Company entered into an employment agreement with its new Chief Executive Officer whereby <ix:nonFraction name="galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" id="Fact_bf1c35fd875c4466af1968364790d092" contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of his base salary and performance bonuses will be paid in cash, and <ix:nonFraction name="galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" id="Fact_adb81f26837041a5a11b4c1b0acd8d70" contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction>%
            will be paid in the form of deferred stock units (&#8220;DSUs&#8221;) in accordance with the terms and subject to the provisions set forth in the DSU Agreement. DSUs credited to Mr. Lewis as of any date shall be fully vested and nonforfeitable at all
            times. Pursuant to an amendment to the DSU Agreement in July 2022, the Company shall issue the shares underlying the outstanding whole number of DSUs credited to Mr. Lewis as follows: <ix:nonFraction name="galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" id="Fact_40693188436147cb8fa33e826f09f312" contextRef="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U005" decimals="2" scale="-2" format="ixt-sec:numwordsen">twenty five </ix:nonFraction>percent shall be issued on March 1, 2023, <ix:nonFraction name="galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" id="Fact_b00cba5586d1451289aea97373c911bf" contextRef="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U005" decimals="2" scale="-2" format="ixt-sec:numwordsen">fifty </ix:nonFraction>percent
            shall be issued on March 1, 2024 and <ix:nonFraction name="galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" id="Fact_f6fd0a639b9d458ea34abe9f04071867" contextRef="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U005" decimals="2" scale="-2" format="ixt-sec:numwordsen">twenty five </ix:nonFraction>percent shall be issued on September 1, 2028.&#160; On March 1, 2023, <ix:nonFraction name="galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" id="Fact_4907daf555b54f74ae8e0a21c0fc63e3" contextRef="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U005" decimals="2" scale="-2" format="ixt-sec:numwordsen">twenty five </ix:nonFraction>percent of the DSU&#8217;s were issued to Mr. Lewis in accordance with the DSU Agreement.&#160;&#160; A total of <ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" id="Fact_47c2b8ed1da5469790ef42ceafaf811b" contextRef="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">183,900</ix:nonFraction> shares were due to be issued; however, <ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" id="Fact_9896ee18d85047de8cf8b82bfadd6138" contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">75,529</ix:nonFraction>
            shares were withheld to cover income tax withholding of $<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" id="Fact_acddf4c1dea54b62954b79182c4ccda4" contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">156,345</ix:nonFraction> resulting in <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" id="Fact_9732f880dac54156a49329c012d16255" contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">108,371</ix:nonFraction> shares actually issued.<br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400419" continuedAt="Text_6554ca62d28345848a90d67e40a9400420">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400420" continuedAt="Text_6554ca62d28345848a90d67e40a9400421">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">For the three months ended March 31, 2023, approximately $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" id="Fact_1e806bb70d0c42a8b9cc1093f1133758" contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">112,000</ix:nonFraction>
            of his compensation was recorded as stock compensation expense representing <ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" id="Fact_39b0aa5de6494fb184611af57cdcea99" contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">72,440</ix:nonFraction> shares of common stock to be issued under the DSU
            agreement with a weighted average grant date fair value of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice" id="Fact_164c9e8aa5c043efb6f79135ed2270fd" contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.55</ix:nonFraction> per share.&#160; For the three months ended March 31, 2022, approximately
            $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" id="Fact_960fcfb5302f4139b756eac6f39eb672" contextRef="c20220101to20220331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">103,000</ix:nonFraction> of his compensation was recorded as stock compensation expense representing <ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" id="Fact_79add5ba61b84c1e99f4716cc5abb984" contextRef="c20220101to20220331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">55,626</ix:nonFraction> shares of common stock to be issued under the DSU agreement with a weighted average grant date fair value of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice" id="Fact_ae8f227ebd9b4ceea7797dcee5fea340" contextRef="c20220101to20220331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.86</ix:nonFraction> per share.</div>
</ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400421" continuedAt="Text_6554ca62d28345848a90d67e40a9400422">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_6554ca62d28345848a90d67e40a9400422">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Also, Mr. Lewis&#8217; bonus for the year ended December 31, 2022 of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" id="Fact_21d1691ae87b4c068b0eb681bff749a2" contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">210,000</ix:nonFraction>
            (which was included in accrued compensation at December 31, 2022) was approved in January 2023 and represents <ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" id="Fact_86828f61790a4602915129c0d65b147a" contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">143,836</ix:nonFraction> shares of
            common stock to be issued under the DSU agreement with a grant date fair value of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice" id="Fact_bd49f57fefac45248d8f28a83acfe2ce" contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.46</ix:nonFraction> per share. The $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_ed963e0ec57d4dcc90bc0c9df9ad0b8f" contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">210,000</ix:nonFraction> was reclassified from accrued compensation to additional paid in capital in January 2023. There is <ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" id="Fact_94ed2ece97ba427f8cbb5fd5b750ad9a" contextRef="c20230331_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> unrecognized compensation expense related to the DSUs.</div>
</ix:continuation>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div>
                <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

              </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="galt:CommonStockWarrantsDisclosureTextBlock" id="Text_cb469a68106c4223b8be9a79a50c410a" contextRef="c20230101to20230331" escape="true" continuedAt="Text_34ddc876fc4549e8a1d8d226edb2db221">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">6. Common Stock Warrants</div>
</ix:nonNumeric>
        <ix:continuation id="Text_34ddc876fc4549e8a1d8d226edb2db221" continuedAt="Text_34ddc876fc4549e8a1d8d226edb2db222">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>

        <ix:continuation id="Text_34ddc876fc4549e8a1d8d226edb2db222" continuedAt="Text_34ddc876fc4549e8a1d8d226edb2db223"><ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Text_cc3a2ef89d4a4c63a639c940b07f21a7" contextRef="c20230101to20230331" escape="true" continuedAt="Text_0d83824017db4999a353ac6fa46deeb81">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the common stock warrant activity from December 31, 2022 through March 31, 2023:</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_34ddc876fc4549e8a1d8d226edb2db223" continuedAt="Text_34ddc876fc4549e8a1d8d226edb2db224"><ix:continuation id="Text_0d83824017db4999a353ac6fa46deeb81" continuedAt="Text_0d83824017db4999a353ac6fa46deeb82">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_34ddc876fc4549e8a1d8d226edb2db224" continuedAt="Text_34ddc876fc4549e8a1d8d226edb2db225"><ix:continuation id="Text_0d83824017db4999a353ac6fa46deeb82">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Weighted Average<br />
                  Exercise Price</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Outstanding, December 31, 2022</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_80611eeabdee4889b5860de2401c349b" contextRef="c20221231_FinancialInstrumentAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">11,557,964</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" id="Fact_9b8a82abd4ec4799922cc58edfba216d" contextRef="c20221231_FinancialInstrumentAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.37</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="margin-left: 9pt;">Granted</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_39355c2fbb0c422eb9933f5c8d0e7576" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_67326353f2404bb09ef71332e73a737e" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.26</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="margin-left: 9pt;">Exercised</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" id="Fact_6ffe0727189843cca0567f6decb7d908" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_987d9c3807a44d5cbf9513967587e987" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="margin-left: 9pt;">Forfeited/cancelled</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_d63c9e05cd434c499f9cd48cfc0bbcc9" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;">
                <div><ix:nonFraction name="galt:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="Fact_84652e37cc0f48fc81e3f74e28ef890c" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div>Outstanding, March 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_5fa19e2cdccc4effb02246e8e282ffc6" contextRef="c20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">11,757,964</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" id="Fact_7fd173a26f3747d6825220e261aa5c9a" contextRef="c20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.35</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_34ddc876fc4549e8a1d8d226edb2db225" continuedAt="Text_34ddc876fc4549e8a1d8d226edb2db226">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_34ddc876fc4549e8a1d8d226edb2db226">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The weighted average expiration of the warrants outstanding as of March 31, 2023 is <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Fact_a0c81e861cae4cf98a7345ded32f7bb0" contextRef="c20230331" format="ixt-sec:duryear">1.8</ix:nonNumeric> years.</div>
</ix:continuation>

        <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" id="Text_70f50e9e8d5a491a839ddd22c6db5b52" contextRef="c20230101to20230331" escape="true" continuedAt="Text_bf0dd0fd606e41ebb271466899d5334c1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">7. Loss Per Share</div>
</ix:nonNumeric>
        <ix:continuation id="Text_bf0dd0fd606e41ebb271466899d5334c1" continuedAt="Text_bf0dd0fd606e41ebb271466899d5334c2">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_bf0dd0fd606e41ebb271466899d5334c2" continuedAt="Text_bf0dd0fd606e41ebb271466899d5334c3">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding
          during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares
          consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the
          issuance of common shares that have an anti-dilutive effect on net loss per share. </div>
</ix:continuation>
        <ix:continuation id="Text_bf0dd0fd606e41ebb271466899d5334c3" continuedAt="Text_bf0dd0fd606e41ebb271466899d5334c4">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>

        <ix:continuation id="Text_bf0dd0fd606e41ebb271466899d5334c4" continuedAt="Text_bf0dd0fd606e41ebb271466899d5334c5"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_10f05d5c6af74e8eb70b6f2658f631a0" contextRef="c20230101to20230331" escape="true" continuedAt="Text_9a5308b31f5f4cb6ba0a71dabdf3762d1">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would
          have been anti-dilutive are as follows:</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_bf0dd0fd606e41ebb271466899d5334c5" continuedAt="Text_bf0dd0fd606e41ebb271466899d5334c6"><ix:continuation id="Text_9a5308b31f5f4cb6ba0a71dabdf3762d1" continuedAt="Text_9a5308b31f5f4cb6ba0a71dabdf3762d2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_bf0dd0fd606e41ebb271466899d5334c6"><ix:continuation id="Text_9a5308b31f5f4cb6ba0a71dabdf3762d2">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">March 31,</div>
                <div style="text-align: center; font-weight: bold;">2023<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">March 31,</div>
                <div style="text-align: center; font-weight: bold;">2022<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;">(shares) <br />
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;">(shares) <br />
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Warrants to purchase shares of common stock</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_8ee69841c61c423caaca6da5c5437ce5" contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">11,757,964</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_b61f5e5f5e7d418da5e297a4e7559897" contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,857,964</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div>Options to purchase shares of common stock</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_4dbc264a794f40659e7f2315a6f5f2ae" contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,526,758</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_ed27ad9ab58f427ba20800fe8a4adf4a" contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,630,561</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Shares of common stock issuable upon conversion of convertible notes payable &#8211; related party</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_51f4d2487da24cb6836fdca8984f2bdc" contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,966,437</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_026bbdc453dc4be09db12aa7e25da518" contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,365,259</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%;">Shares of common stock issuable upon conversion of convertible line of credit &#8211; related party<br />
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_101f884cccb046e09e785a529057f667" contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,727,849</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_9895351692274d1fad229e6a3f6ceb6b" contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Shares of common stock issuable upon conversion of preferred stock</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_98ddf7fd466e4654b6e20c691914361e" contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">503,340</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_9ab090f499d840c0a812f7bbd95eb571" contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">510,424</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_320d49c400d2401e85e58e48ca2d2a72" contextRef="c20230101to20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">31,482,348</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_d2c1aebaaf254ba5b60ebe699121aed3" contextRef="c20220101to20220331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">22,364,208</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_fe79eb8bb40d4eecb286764802f0cf9a" contextRef="c20230101to20230331" escape="true" continuedAt="Text_c754f8478bb54e03a0364aae225759a61">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">8. Common Stock</div>
</ix:nonNumeric>
        <ix:continuation id="Text_c754f8478bb54e03a0364aae225759a61" continuedAt="Text_c754f8478bb54e03a0364aae225759a62">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_c754f8478bb54e03a0364aae225759a62" continuedAt="Text_c754f8478bb54e03a0364aae225759a63">
<div style="font-style: italic; margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">2020 At Market Issuance of Common Stock</div>
</ix:continuation>
        <ix:continuation id="Text_c754f8478bb54e03a0364aae225759a63" continuedAt="Text_c754f8478bb54e03a0364aae225759a64">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_c754f8478bb54e03a0364aae225759a64" continuedAt="Text_c754f8478bb54e03a0364aae225759a65">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 21.5pt; margin-top: 3pt; margin-bottom: 3pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 11, 2020, the Company entered into an At Market Issuance Sales Agreement (the
          &#8220;2020 At Market Agreement&#8221;) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $<ix:nonFraction name="galt:AggregateOfferingPrice" id="Fact_2c82746a23d6434a9ac88ce9a0395ad7" contextRef="c20230331_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction> million from time to time through the sales agent. Sales of the Company&#8217;s common stock through the sales agent, if any, will be made by any method that is deemed an &#8220;at the market&#8221; offering as defined by the
          U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to <ix:nonFraction name="galt:CommissionRate" id="Fact_422b62ae021d49c3967b6e2a170ac5b3" contextRef="c20230331_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.0</ix:nonFraction>% of the gross proceeds
          from the sale of any shares of common stock sold through the sales agent under the 2020 At Market Agreement. During the quarter ended March 31, 2023, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_c867370700a04c0eaa5eb0aeed5bbaf8" contextRef="c20230331_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> issuances of shares of common stock under the 2020 At Market Agreement.</div>
</ix:continuation>
        <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_c754f8478bb54e03a0364aae225759a65" continuedAt="Text_c754f8478bb54e03a0364aae225759a66">
<div style="margin-top: 3pt; margin-bottom: 3pt; font-family: 'Times New Roman';"><br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_c754f8478bb54e03a0364aae225759a66">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">For each of the three months ended March 31, 2023 and 2022, the Company issued a total of <ix:nonFraction name="us-gaap:CommonStockDividendsShares" id="Fact_c8ba1352c6ad4072af285780a6faf3bb" contextRef="c20230101to20230331_StatementClassOfStockAxis_SeriesAAndSeriesCPreferredStockMember_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,200</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockDividendsShares" id="Fact_3aa2d152831a43fdab4b8f31e7228ad2" contextRef="c20220101to20220331_StatementClassOfStockAxis_SeriesAAndSeriesCPreferredStockMember_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,625</ix:nonFraction> shares of common stock, respectively, for
            dividends on Series A and Series C Preferred Stock.</div>
</ix:continuation>
           </div>

        <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;"> <div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

    <div>
      <ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" id="Text_59159bc46d974297a6e5dd5e3871aa13" contextRef="c20230101to20230331_LongtermDebtTypeAxis_LineOfCreditMember" escape="true" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc8341">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-right: 11pt; font-weight: bold;">9. Convertible Line of Credit &#8211; Related Party</div>
</ix:nonNumeric>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc8341" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc8342">
<div><span style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc8342" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc8343">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc8343" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc8344">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc8344" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc8345">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">On July 25, 2022, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into a Line of Credit Letter Agreement (the &#8220;Credit Agreement&#8221;),
        pursuant to which the Lender shall provide the Company a line of credit of up to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_d4e741de393c4bbba01be91267ca536a" contextRef="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">60.0</ix:nonFraction> million (the &#8220;Line of Credit&#8221;) to finance the
        Company&#8217;s working capital needs. The Company may draw upon the Line of Credit through July 31, 2024.</div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc8345" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc8346">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc8346" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc8347">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc8347" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc8348">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc8348" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc8349">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">Each advance made pursuant to the Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a
        &#8220;Promissory Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at the Applicable Federal Rate for short term loans, plus two (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_481f955a563f4da6bd2c6aa44348a1a5" contextRef="c20220725to20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%)
        percent. Principal and interest on the Promissory Notes are due on or before <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_6610b622ae8f4631b5b28290803eb3a0" contextRef="c20220725to20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">January 31, 2026</ix:nonNumeric>. Only with the consent of the Lender, may
        the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid.</div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc8349" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83410">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83410" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83411">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83411" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83412">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83412" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83413">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the
        Company&#8217;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_8d363a1a39da41688da57d0f1aef2a5d" contextRef="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share.</div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83413" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83414">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83414" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83415">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83415" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83416">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83416" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83417">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">In connection with the Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_b47d8c016ccf400a99da864e47748d84" contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,700,000</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_aba99699f8964f7db703ae2eaf3b45f0" contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction>
        per share (collectively, the &#8220;Warrants&#8221;). Upon execution of the Credit Agreement, the Company issued the Lender a Warrant to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_9e209327449d4517844b054925a4967b" contextRef="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>
        shares of Company&#8217;s Common Stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_f0774d15fbee4aa58eb203bb7edcc0ec" contextRef="c20220725_FinancialInstrumentAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction> per share, which Warrant is exercisable upon issuance. Further, pursuant
        to the Credit Agreement, the Company shall issue to the Lender additional Warrants to purchase up to the remaining <ix:nonFraction name="galt:ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_d4d5bd30c90041548d4fb78ca6433e88" contextRef="c20220725to20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,200,000</ix:nonFraction> shares of
        the Company&#8217;s common stock, ratably, upon borrowings under the Credit Agreement, with exercise prices equal to <ix:nonFraction name="galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" id="Fact_e218fe87b5b9486b84ec3a57b94862ef" contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">150</ix:nonFraction>% of the closing price
        of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_3495431564c84d0b83fd0cd0e206f645" contextRef="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per share nor
        less than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_34e1c455b4dc4b7db7e5063d1b9f04ff" contextRef="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. The Warrants expire on <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="Fact_dc5a64b7b3f04e5bbf2acc028ea91cac" contextRef="c20230331_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">July 31, 2029</ix:nonNumeric>.</div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83417" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83418">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83418" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83419">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83419" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83420">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83420" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83421">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">The fair value of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_d02279202074444f871fe418fecefde1" contextRef="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>
        warrants vested at closing on July 25, 2022 was $<ix:nonFraction name="galt:IssuanceOfWarrantsValue" id="Fact_d87dea8e83d24b1893b885fad9005dca" contextRef="c20220725to20220725_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">738,000</ix:nonFraction> at the date of issuance based on the following assumptions: an expected life of
        <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_17340297b99c4201929f281ad1fc4c32" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember" format="ixt-sec:durwordsen">7 years</ix:nonNumeric>, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_f7e7294e8e8744f6a262b965313ea257" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">92</ix:nonFraction>%,
        risk free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_3be4aa9a7def4f2ca1f4cb50107ba9d2" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.19</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_f654edd32beb4fc58ba13b8e17833bfd" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U005" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction>
        dividends. The fair value of the vested warrants was recorded in other assets (non-current) as a deferred financing cost and will be amortized on a straight-line basis from July 25, 2022 through January 31, 2026. Amortization for the three months
        ended March 31, 2023 of $<ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" id="Fact_8250218113a948968b6666bff3951bee" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">52,000</ix:nonFraction> was recorded as interest expense.</div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83421" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83422">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83422" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83423">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83423" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83424">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83424" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83425">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">On December 19, 2022, the Company executed a $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_5ed892abf47d49a1a4f0707e56680f09" contextRef="c20221219to20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>
        million Promissory Note under the Line of Credit. The interest rate on this draw is <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" id="Fact_cf68dd6a845b4280ab207f1074cf955a" contextRef="c20221219to20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.46</ix:nonFraction>% (Applicable Federal Rate for short term loans
        on date of draw of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_6c35b055836e413fb31b7a1cbfeb661e" contextRef="c20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.46</ix:nonFraction>% plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_37e90b0662fe4b138d07fc40cb8c0713" contextRef="c20221219to20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%).









        The effective interest rate is approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_7b506e3fc9f34e2dab42ddb15a02b87e" contextRef="c20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.1</ix:nonFraction>%. Accrued interest on this draw was $<ix:nonFraction name="galt:DebtInstrumentAccruedInterest" id="Fact_c412a6372d7040169ba16326d2a735e9" contextRef="c20221231_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">23,000</ix:nonFraction> at December 31, 2022. The principal and accrued interest is convertible at the option of the Lender at $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_ff660f1f8cb44578ab7d220ef42a90d5" contextRef="c20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_faa71843e0f3453596a98a74fc1e4630" contextRef="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> shares of Company&#8217;s Common Stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_7b337cde9f484885a2a03b2e6aeadc5e" contextRef="c20221219_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction>
        per share, which Warrant is exercisable upon issuance.</div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83425" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83426">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83426" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83427">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83427" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83428">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83428" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83429">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">The fair value of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_62ef045a39374fe191dbd127dcf9b171" contextRef="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction>
        warrants vested at closing on December 19, 2022 was $<ix:nonFraction name="galt:IssuanceOfWarrantsValue" id="Fact_8e847481ae97487db2612cab0c2f4dcd" contextRef="c20221219to20221219_FinancialInstrumentAxis_WarrantOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">160,780</ix:nonFraction> at the date of issuance based on the following assumptions: an expected life
        of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_72d03402cb9e4ed68b1ca2ce49e4380e" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember" format="ixt-sec:durwordsen">7 years</ix:nonNumeric>, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_b9af8daf2fd94287ab0a988f48ffad0d" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">91</ix:nonFraction>%,
        risk free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_c7c8178ed13c400a846e19c0955ba07f" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.06</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_48bf9a3a50b542338b4b22b68b431dde" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember" unitRef="U005" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction>
        dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal to be amortized on a straight-line basis, which is not
        materially different than the effective interest method, from December 19, 2022 through January 31, 2026. Amortization for the three months ended March 31, 2023 of $<ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" id="Fact_a5eeb7e4d42449629dae49de34f55cc8" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,000</ix:nonFraction> was recorded as interest expense. The fair value of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the remaining period through January
        31, 2026.</div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83429" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83430">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83430" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83431">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83431" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83432">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83432" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83433">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">On March 31, 2023, the Company executed an additional $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_dc32105a50824fea9ad980232659c6b7" contextRef="c20230101to20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction> million Promissory Note under the Line of Credit. The interest rate on this draw is <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" id="Fact_c1eb18f7f8cc4f538119e87b65aadfa4" contextRef="c20230101to20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.41</ix:nonFraction>%
        (Applicable Federal Rate for short term loans on date of draw of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_203dea1e2c4f4ca49ee86e23dbc0d80f" contextRef="c20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.41</ix:nonFraction>% plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_a91c530959e14d00aebd6b50b774f8ac" contextRef="c20230101to20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%). The effective interest rate is approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_6d9687379c1d4950889e586cc78c4f8e" contextRef="c20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.1</ix:nonFraction>%.&#160; The
        principal and accrued interest is convertible at the option of the Lender at $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_0e8cff3cae2840469e5fa929a22c16be" contextRef="c20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. In accordance with the Credit Agreement,
        the Company issued the Lender a Warrant to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_237f7613f32a4483865db4d0e421119f" contextRef="c20230331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> shares of Company&#8217;s Common Stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_fa98249d2a534b689dca92ed89e7d7b3" contextRef="c20230331_FinancialInstrumentAxis_WarrantTwoMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.26</ix:nonFraction> per share, which Warrant is exercisable upon issuance.</div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83433" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83434">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83434" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83435">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83435" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83436">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83436" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83437">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">The fair value of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_207785f2908b417ca0195d18ed6a33b2" contextRef="c20230331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction>
        warrants vested at closing on March 31, 2023 was $<ix:nonFraction name="galt:IssuanceOfWarrantsValue" id="Fact_b111c105be574df984a62abfa9c30012" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">296,680</ix:nonFraction> at the date of issuance based on the following assumptions: an expected life of
        <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_77d712b8ee26417aa2593a6c4232cab1" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember" format="ixt-sec:duryear">6.33</ix:nonNumeric> years, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_5d256ebe81924e47b42ee4172f5b2649" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">88</ix:nonFraction>%,
        risk free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_9eea12dbfc1047b88f79bfc20b7a636e" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.94</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_c3fc2065c7834a9eb5f73de28d18c4e0" contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U005" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction>
        dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal to be amortized on a straight-line basis, which is not
        materially different than the effective interest method, from March 31, 2023 through January 31, 2026.</div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83437" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83438">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83438" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83439">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83439" continuedAt="Text_d71912d47d7b42fd97bf858a30bbc83440">
<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d71912d47d7b42fd97bf858a30bbc83440">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">The fair value of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the
        remaining period through January 31, 2026.</div>
</ix:continuation>

      <div><br />
      </div>

    </div>

    <div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_53cdaeb5abb840608a6e2bae192f5e97" contextRef="c20230101to20230331" escape="true" continuedAt="Text_e0bb1c31014c4b26bcc5f9043ac144c11">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">10. Commitments and Contingencies</div>
</ix:nonNumeric>
        <ix:continuation id="Text_e0bb1c31014c4b26bcc5f9043ac144c11" continuedAt="Text_e0bb1c31014c4b26bcc5f9043ac144c12">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_e0bb1c31014c4b26bcc5f9043ac144c12" continuedAt="Text_e0bb1c31014c4b26bcc5f9043ac144c13">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Other Legal Proceedings</div>
</ix:continuation>
        <ix:continuation id="Text_e0bb1c31014c4b26bcc5f9043ac144c13" continuedAt="Text_e0bb1c31014c4b26bcc5f9043ac144c14">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_e0bb1c31014c4b26bcc5f9043ac144c14" continuedAt="Text_e0bb1c31014c4b26bcc5f9043ac144c15">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable, and the related damages are
          estimable. There are no significant pending legal proceedings.</div>
</ix:continuation>
        <ix:continuation id="Text_e0bb1c31014c4b26bcc5f9043ac144c15" continuedAt="Text_e0bb1c31014c4b26bcc5f9043ac144c16">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_e0bb1c31014c4b26bcc5f9043ac144c16" continuedAt="Text_e0bb1c31014c4b26bcc5f9043ac144c17">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Clinical Trial and Research Commitments</div>
</ix:continuation>
        <ix:continuation id="Text_e0bb1c31014c4b26bcc5f9043ac144c17" continuedAt="Text_e0bb1c31014c4b26bcc5f9043ac144c18">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_e0bb1c31014c4b26bcc5f9043ac144c18">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company has entered into agreements with contractors for research and development activities to further its product candidates. The contracts generally may be
          canceled at any time by providing <ix:nonNumeric name="galt:ContractCancelationNoticePeriod" id="Fact_ee080835a3e14e7e9a0afaf101fab543" contextRef="c20230101to20230331" format="ixt-sec:durwordsen">thirty days</ix:nonNumeric>&#8217; notice.</div>
</ix:continuation>

        <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%13%%%--> </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" id="Text_6e591e11b032468d8268ec4e00d962ab" contextRef="c20230101to20230331" escape="true" continuedAt="Text_62a74449c5c64ad7ada892d31e08d9541">
<div><br />
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_62a74449c5c64ad7ada892d31e08d9541" continuedAt="Text_62a74449c5c64ad7ada892d31e08d9542">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">11. Leases</div>
</ix:continuation>
        <ix:continuation id="Text_62a74449c5c64ad7ada892d31e08d9542" continuedAt="Text_62a74449c5c64ad7ada892d31e08d9543">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_62a74449c5c64ad7ada892d31e08d9543" continuedAt="Text_62a74449c5c64ad7ada892d31e08d9544">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company has <ix:nonFraction name="galt:NumberOfOperatingLeases" id="Fact_675fec9b57ee4167b7f53c72a13bda26" contextRef="c20230101to20230331" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> operating lease for its office
          space which was amended effective March 1, 2022 for a term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Fact_286d6e0129084259a1180fc375dc174a" contextRef="c20230331" format="ixt-sec:durwordsen">38 months</ix:nonNumeric> with no residual value guarantees or material restrictive
          covenants. The amended lease provided for free rent for the first <span style="-sec-ix-hidden:Fact_3257fbc22511431091132ea0cf902d08">six and a half months</span> of the lease and continues the security
          deposit of $<ix:nonFraction name="us-gaap:SecurityDeposit" id="Fact_8cb8a6ec24354735ba61641435dd30e3" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,000</ix:nonFraction>. In addition to base rental payments included in the contractual obligations table above, the Company is responsible
          for our pro-rata share of the operating expenses for the building. Our lease cost for the three-month periods ended March 31, 2023 and 2022 was approximately $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_bc25b5bae4c541a9a6b5b0baa3eca571" contextRef="c20220101to20220331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_1ac1b1769f47488da954c961dd8d125c" contextRef="c20230101to20230331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,000</ix:nonFraction></ix:nonFraction> for each period and is included in general and administrative expenses. As of March 31, 2023, the right to use lease asset consisted of $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_7a4f03d6dd884259a8864090a507771a" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">78,000</ix:nonFraction> and is included in <span style="-sec-ix-hidden:Fact_ca7b3631a1474b9799fb873ed35a3567">other assets</span>. Also, at March 31,
          2023, current lease liability of $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_76b82fcfa2b347b3818811361eaae660" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">42,000</ix:nonFraction> is included in <span style="-sec-ix-hidden:Fact_26a5d647f0b84359bcf1207a54ef8756">accrued expenses</span> and long term lease liability was $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_cc852b6bf7e446c68ee738c90508558f" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">55,000</ix:nonFraction> and included in <span style="-sec-ix-hidden:Fact_8c9f7ebb1d3c4996a11d58878cfc0b06">other liabilities</span>.<br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_62a74449c5c64ad7ada892d31e08d9544" continuedAt="Text_62a74449c5c64ad7ada892d31e08d9545">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>

        <ix:continuation id="Text_62a74449c5c64ad7ada892d31e08d9545" continuedAt="Text_62a74449c5c64ad7ada892d31e08d9546"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_cdb1e7194c3b41d78d8af2d85111e30a" contextRef="c20230101to20230331" escape="true" continuedAt="Text_1c6c0878c7e540278fa2f5787e525b0b1">
<div style="display:none;"><br /></div>
<div style="text-indent: 27pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Maturity of operating lease as of March 31, 2023 in thousands:</span></div>
</ix:nonNumeric></ix:continuation>
        <div>
          <div style="margin-left: 9pt;">
            <ix:continuation id="Text_62a74449c5c64ad7ada892d31e08d9546" continuedAt="Text_62a74449c5c64ad7ada892d31e08d9547"><ix:continuation id="Text_1c6c0878c7e540278fa2f5787e525b0b1" continuedAt="Text_1c6c0878c7e540278fa2f5787e525b0b2">
<div style="margin-left: 9pt;"> <br />
            </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_62a74449c5c64ad7ada892d31e08d9547" continuedAt="Text_62a74449c5c64ad7ada892d31e08d9548"><ix:continuation id="Text_1c6c0878c7e540278fa2f5787e525b0b2" continuedAt="Text_1c6c0878c7e540278fa2f5787e525b0b3">
<div style="margin-left: 9pt;"> <br />
            </div>
</ix:continuation></ix:continuation>
          </div>

        </div>

        <ix:continuation id="Text_62a74449c5c64ad7ada892d31e08d9548" continuedAt="Text_62a74449c5c64ad7ada892d31e08d9549"><ix:continuation id="Text_1c6c0878c7e540278fa2f5787e525b0b3">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);">
                <div>2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" id="Fact_b57e964bf75e4b719e044ef4cc175097" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">38</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
                <div>2024</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_7ae77091d27c4d8bad5b3b0f2f392059" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">51</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">2025</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_a8696612bae548cdb27a1c8e2706460e" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
                <div>Total</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_0975167fd3d0403fb39a060bb356cebc" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">107</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                <div>Less imputed interest</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_f0990472ca3042b5a6c601a12857e452" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px;">
                <div>Present value of lease liability</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_99e0c72e20b344168cb84e79e6d8629b" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">97</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_62a74449c5c64ad7ada892d31e08d9549" continuedAt="Text_62a74449c5c64ad7ada892d31e08d95410">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 24.5pt;"> <br />
        </div>
</ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_62a74449c5c64ad7ada892d31e08d95410">
<div style="display:none;"><br /></div>
<div style="text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The
              discount rate used in calculating the present value of the lease payments was <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" id="Fact_a190bc0b96094bd9a6d694f16c71f776" contextRef="c20230331" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">11</ix:nonFraction>%</span>.  </div>
</ix:continuation>
          <div><br />
          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" id="Text_35069dec59d94ffe8cbda9e93b94156e" contextRef="c20230101to20230331" escape="true" continuedAt="Text_30bdb0d2270a470b94a4f525261aa1a71">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">12. Galectin Sciences LLC</div>
</ix:nonNumeric>
        <ix:continuation id="Text_30bdb0d2270a470b94a4f525261aa1a71" continuedAt="Text_30bdb0d2270a470b94a4f525261aa1a72">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_30bdb0d2270a470b94a4f525261aa1a72">
<div style="display:none;"><br /></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">In January 2014, we created Galectin Sciences, LLC (the &#8220;LLC&#8221; or &#8220;Investee&#8221;), a collaborative joint venture co-owned by SBH Sciences, Inc. (&#8220;SBH&#8221;),
          to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $<ix:nonFraction name="us-gaap:PaymentsToAcquireEquityMethodInvestments" id="Fact_1faba6d199064d8286f1b37875c8c2fd" contextRef="c20140101to20140131_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">400,000</ix:nonFraction>
          cash investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (&#8220;IPR&amp;D&#8221;) contributed by SBH.&#160;The estimated fair value of the IPR&amp;D contributed by
          SBH, on the date of contribution, was $<ix:nonFraction name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" id="Fact_7f70b2f1b7f04cb8907bdf75b533501b" contextRef="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_InProcessResearchAndDevelopmentMember_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">400,000</ix:nonFraction>.&#160;Initially, the Company and SBH each had a <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_a45588565c634b05947d7d1d0fbd160b" contextRef="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% equity ownership interest in the LLC, with neither party having control over the LLC.&#160;Accordingly, from inception through the fourth quarter of 2014, the Company
          accounted for its investment in the LLC using the equity method of accounting.&#160;Under the equity method of accounting, the Company&#8217;s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize
          additional investments in or distributions from the Investee, as well as the Company&#8217;s share of the Investee&#8217;s earnings, losses and/or changes in capital. The estimated fair value of the IPR&amp;D contributed to the LLC was immediately expensed
          upon contribution as there was no alternative future use available at the point of contribution.&#160;The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial
          capitalization, then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_102eac83c15e4ad5b0b1faecc892bc88" contextRef="c20141001to20141231_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">400,000</ix:nonFraction> in cash, SBH decided not to contribute its share of the funding required. Cumulatively, the Company has contributed a total of $<ix:nonFraction name="galt:CapitalContributionExpense" id="Fact_2ae0ea1ff4514aa6a41cdb71cf5f256f" contextRef="c20140101to20220331_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,364,000</ix:nonFraction>, including $<ix:nonFraction name="galt:CapitalContributionExpense" id="Fact_61eb59d85b544464a1d0983baad2ca6a" contextRef="c20230101to20230331_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">126,000</ix:nonFraction> for the
          three months ended March 31, 2023, for expenses of the LLC. Since the end of 2014, SBH has contributed $<ix:nonFraction name="galt:CapitalContributionExpense" id="Fact_9063a0ce9fb44130addcf80b60c2f7bf" contextRef="c20220101to20220331_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">158,000</ix:nonFraction> for expenses in the
          LLC. As of March 31, 2023, the Company&#8217;s ownership percentage in the LLC was <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_b082526be1b34595abc84ea7303f86a3" contextRef="c20230331_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">85.8</ix:nonFraction>%. The Company accounts for the interest in the LLC
          as a consolidated, less than wholly owned subsidiary. Because the LLC&#8217;s equity is immaterial, the value of the non-controlling interest is also deemed to be immaterial.</div>
</ix:continuation>

        <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageFooter" style="width: 100%;"></div>

      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">13</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div>
          <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

        </div>

      </div>

    </div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div> <a id="Item2."><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-indent: 21.5pt; margin-right: 1pt;">In addition to historical information, the following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements as defined under
          Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created therein for forward-looking statements. Such statements include, but are not limited to, statements concerning our anticipated operating
          results, research and development, clinical trials, regulatory proceedings, and financial resources, and can be identified by use of words such as, for example, &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe&#8221; and
          &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could&#8221; or &#8220;may.&#8221; All statements, other than statements of historical facts, included herein that address activities, events, or developments that the Company expects or anticipates will or may occur in the future, are
          forward-looking statements, including statements regarding: plans and expectations regarding clinical trials; plans and expectations regarding regulatory approvals; our strategy and expectations for clinical development and commercialization of
          our products; potential strategic partnerships; expectations regarding the effectiveness of our products; plans for research and development and related costs; statements about accounting assumptions and estimates; expectations regarding
          liquidity and the sufficiency of cash to fund currently planned operations through at least December 31, 2024; our commitments and contingencies; and our market risk exposure. Forward-looking statements are based on current expectations,
          estimates and projections about the industry and markets in which Galectin Therapeutics operates, and management&#8217;s beliefs and assumptions. These statements are not guarantees of future performance and involve certain known and unknown risks and
          uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties are related to and include, without limitation,</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>our early stage of development,</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>we have incurred significant operating losses since our inception and cannot assure you that we will generate revenue or profit,</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>our dependence on additional outside capital,</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>we may be unable to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates,</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>uncertainties related to any litigation,</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>uncertainties related to our technology and clinical trials, including expected dates of availability of clinical data,</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>we may be unable to demonstrate the efficacy and safety of our developmental product candidates in human trials,</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>we may be unable to improve upon, protect and/or enforce our intellectual property,</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>we are subject to extensive and costly regulation by the U.S. Food and Drug Administration (FDA) and by foreign regulatory authorities, which must approve our product candidates in development and could restrict the sales and marketing
                  and pricing of such products,</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>competition and stock price volatility in the biotechnology industry,</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>limited trading volume for our stock, concentration of ownership of our stock, and other risks detailed herein and from time to time in our SEC reports,</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-size: 8pt;"><span style="font-size: 10pt;">the impact resulting from the outbreak of COVID-19, which has delayed and may continue to delay our clinical trial and development efforts, as well as the impact that COVID-19 has
                    on the volatility of the capital market and our ability to access the capital market and,</span></div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 47.7pt;"><br />
              </td>

    <td style="width: 23.3pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>other risks detailed herein and from time to time in our SEC reports, including our Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2022, and our subsequent SEC filings.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-indent: 21.5pt; margin-right: 37pt;">The following discussion should be read in conjunction with the accompanying consolidated financial statements and notes thereto of Galectin Therapeutics appearing elsewhere herein.</div>

        <div><br />
        </div>

        <div style="font-weight: bold;">Overview</div>

        <div><br />
        </div>

        <div style="text-indent: 19.35pt; margin-right: 1pt;">We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates
          are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily available plant products as starting material in manufacturing processes to create
          proprietary, patented complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique
          carbohydrate-based candidate compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectin proteins have a demonstrated role in the
          pathogenesis of a given disease. We focus on diseases with serious, life-threatening consequences and those where current treatment options are limited specifically in NASH (non-alcoholic steatohepatitis) with cirrhosis and certain cancer
          indications. Our strategy is to establish and implement clinical development programs that add value to our business in the shortest period of time possible and to seek strategic partners when one of our programs becomes advanced and requires
          significant additional resources.</div>

        <div><br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">14</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <div style="text-indent: 19.35pt;">Our lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent
          its complication: the development of esophageal varices. Belapectin has the potential to treat many diseases due to galectin-3&#8217;s involvement in multiple key biological pathways such as fibrosis, immune cell function and immunity, cell
          differentiation, cell growth, and apoptosis (cell death). The importance of galectin-3 in the fibrotic process is supported by experimental evidence. Animals with the galectin-3 gene &#8220;knocked-out&#8221; can no longer develop fibrosis in response to
          experimental stimuli compared to animals with an intact galectin-3 gene. We are using our galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in NASH patients. We have completed two Phase 1 clinical studies, a Phase 2
          clinical study in NASH patients with advanced fibrosis (NASH-FX) and a second Phase 2b clinical trial in NASH patients with compensated cirrhosis and portal hypertension (NASH-CX).</div>

        <div><br />
        </div>

        <div style="text-indent: 19.35pt;">In February 2023, we completed randomizations totaling 357 patients in a large, global Phase 2b/3 clinical trial. Our study protocol was filed with the FDA on April 30, 2020, for a seamless adaptively-designed
          Phase 2b/3 clinical study, the NAVIGATE trial, evaluating the safety and efficacy of our galectin-3 inhibitor, belapectin, for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis (Further details
          are available at <span style="text-decoration: underline;">www.clinicaltrials.gov</span> under study NCT04365868); this study began enrolling patients in Q2-2020. In September 2020, the Company received a letter from the FDA providing comments, asking questions and providing guidance on
          various aspects of the ongoing NAVIGATE trial. These comments were addressed, and the study proceeded accordingly.</div>

        <div><br />
        </div>

        <div style="text-indent: 19.35pt;">Additionally, a study protocol entitled &#8220;A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment&#8221;
          has been filed with the FDA to examine the effects of the drug in subjects with normal hepatic function and subjects with varying degrees of hepatic impairment (study details are listed under study NCT04332432 on <span style="text-decoration: underline;">www.clinicaltrials.gov</span>);
          this study became fully enrolled in February 2022.</div>

        <div><br />
        </div>

        <div style="text-indent: 19.35pt;">We endeavor to leverage our scientific and product development expertise as well as established relationships with outside sources to achieve cost-effective and efficient drug development. These outside sources,
          amongst others, provide us with expertise in preclinical models, pharmaceutical development, toxicology, clinical trial operations, pharmaceutical manufacturing, including physical and chemical drug characterization, and commercial development.
          We also have established through our majority-owned joint venture subsidiary, Galectin Sciences LLC, a discovery program developing small molecules that inhibit galectin-3 and may afford alternative drug delivery (e.g., oral) and as a result
          expand the potential uses of galectin-3 inhibitor beyond belapectin. Three chemical series of composition of matter patents have been filed.</div>

        <div><br />
        </div>

        <div style="text-indent: 19.35pt;">We are also pursuing a development pathway to clinical enhancement and commercialization for our lead compounds in immuno-oncology following our previous successful collaboration with Providence Portland Cancer
          Center. In 2022, we filed a new IND with FDA for advanced or metastatic head and neck cancer using belapectin in combination with a checkpoint (PD-1) inhibitor and received a Study May Proceed letter. The proposed phase 2 trial commencement is
          dependent on timing of financing.</div>

        <div><br />
        </div>

        <div style="text-indent: 19.35pt;">All of our proposed products are presently in development, including pre-clinical and clinical trials.</div>

        <div><br />
        </div>

        <div style="font-weight: bold;">Our Drug Development Programs</div>

        <div><br />
        </div>

        <div style="text-indent: 21.35pt; margin-right: 18pt;">Galectins are a class of proteins that are made by many cells in the body, but predominantly in cells of the immune system. As a group, these proteins are able to bind to sugar molecules that
          are attached to other proteins, called glycoproteins that are responsible for various functions within the body, most notably inflammation and fibrosis. Galectins, in particular galectin-3,act as a molecular glue, bringing together molecules that
          have sugars on them. Galectin-3, is known to be markedly increased in a number of significant diseases including inflammatory diseases leading to organs scarring (e.g. liver, lung, kidney, and heart) and cancers. The increase in galectin-3, by
          creating the so-called galectin-3 fibrosome, promotes the progression of multiple diseases. Published data substantiating the importance of galectin-3 in the fibrotic process arises from gene knockout experiments in animal studies. For instance,
          mice genetically altered to eliminate the galectin-3 gene, and thus unable to produce galectin-3, do not develop liver fibrosis in response to toxic insult to the liver.</div>

        <div><br />
        </div>

        <div style="text-indent: 21.35pt; margin-right: 18pt;">We have one new proprietary chemical entity (NCE) in development, belapectin, which has shown promise in preclinical and clinical studies for the treatment of liver fibrosis, severe skin
          disease, and cancer (melanoma and head and neck squamous cell carcinoma). Currently, we are focusing on development of belapectin for the treatment of NASH cirrhosis and head and neck cancer. Belapectin is a proprietary, patented compound derived
          from natural, plant-based, starting materials, which following chemical processing, exhibits the properties of binding to and inhibiting galectin.</div>

        <div><br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">15</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <div>Our product pipeline is shown below:</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 20%; vertical-align: bottom;">
                <div style="font-weight: bold;">Indication</div>
                <div style="font-weight: bold;">Prevention of esophageal varices</div>
                <div style="font-weight: bold;"> in</div>
                <div style="font-weight: bold;">NASH cirrhosis</div>
              </td>

    <td style="width: 20%; vertical-align: top;">
                <div style="font-weight: bold;">Drug</div>
              </td>

    <td style="width: 60%; vertical-align: top;">
                <div style="font-weight: bold;">Status</div>
              </td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 60%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: top;">
                <div>Phase 1 interaction trial:</div>
                <div>NASH-CX trial and</div>
                <div>NASH-FX trial</div>
              </td>

    <td style="width: 20%; vertical-align: bottom;">
                <div>belapectin</div>
                <div> &#160;</div>
                <div> &#160;</div>
                <div> &#160;</div>
                <div> &#160;</div>
              </td>

    <td style="width: 60%; vertical-align: top;">
                <div>IND submitted January 2013. Results from the Phase 1 interaction trial were reported</div>
                <div>in 2014, with final results reported in January 2015. The Phase 2 NASH FX trial</div>
                <div>was conducted in patients with advanced fibrosis but not cirrhosis. Its principal</div>
                <div>purpose was to evaluate various imaging modalities. The NASH FX trial top line</div>
                <div>data was reported in September 2016 and published in Alimentary Pharmacology</div>
                <div>and Therapeutics in 2016.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 60%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 60%; vertical-align: bottom;">
                <div>The Phase 2 NASH CX trial was conducted in patients with compensated cirrhosis</div>
                <div>and portal hypertension. The NASH CX trial top line data was reported in</div>
                <div>December 2017 and was published in <span style="font-style: italic;">Gastroenterology</span> in 2020.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 60%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: top;">
                <div>NASH NAVIGATE</div>
                <div> &#160;</div>
                <div> &#160;</div>
              </td>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 60%; vertical-align: bottom;">
                <div>Following FDA feedback, the NAVIGATE trial is an adaptive Phase 2b/3 trial for</div>
                <div>the prevention of esophageal varices in NASH patients with compensated cirrhosis</div>
                <div>and clinical signs of portal hypertension. A Phase 2b interim efficacy analysis will be</div>
                <div>incorporated to confirm previous Phase 2 data, select an optimal dose and reaffirm</div>
                <div>the risk/benefit of belapectin. The Phase 3 end of study analysis will evaluate the</div>
                <div>development of esophageal varices as the same primary outcome of efficacy and</div>
                <div>a composite clinical endpoint including progression to varices requiring treatment</div>
                <div>as a key secondary outcome of efficacy ( www.clinicaltrials.gov NCT04365868).</div>
                <div>The final patient was randomized in February 2023.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 60%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: top;">
                <div>Phase 1 study: hepatic insufficiency</div>
              </td>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 60%; vertical-align: bottom;">
                <div>A hepatic impairment study is being conducted in subjects with normal hepatic</div>
                <div>function and subjects with varying degrees of hepatic impairment</div>
                <div>(www.clinicaltrials.gov NCT04332432) and began enrolling patients in the</div>
                <div>second quarter of 2020. The study completed enrollment in February 2022.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 20%; vertical-align: bottom;">
                <div style="font-weight: bold;">Cancer Immunotherapy</div>
              </td>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 60%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 20%; vertical-align: bottom;">&#160;</td>

    <td style="width: 60%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: top;">
                <div>Melanoma, Head, Neck Squamous Cell</div>
                <div>Carcinoma (HNSCC)</div>
              </td>

    <td style="width: 20%; vertical-align: top;">
                <div>belapectin</div>
              </td>

    <td style="width: 60%; vertical-align: bottom;">
                <div>Investigator IND study was completed. A Phase 1B study began in Q-1 2016.</div>
                <div>Early data was reported in February 2017 and additional data were reported</div>
                <div>in September 2018. Data from an extension trial was reported in July 2021</div>
                <div>for additional melanoma and HNSCC patients which provided a rational basis</div>
                <div>for additional trials which the Company is exploring.&#160;&#160; In the third quarter of 2022,</div>
                <div>the Company announced its IND application for belapectin in combination with</div>
                <div>a checkpoint inhibitor for the treatment of HNSCC was filed and a Study May</div>
                <div>Proceed letter was received from FDA.&#160;&#160; The Company is reviewing options</div>
                <div>for financing this trial which will determine when such trial could commence.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-indent: 19.35pt; margin-right: 3pt;"><span style="font-style: italic;">Liver cirrhosis. </span>Belapectin is our lead product candidate for treatment of compensated NASH cirrhosis in patients with portal hypertension. Our
          preclinical data show that belapectin has a significant therapeutic effect on liver fibrosis as shown in several relevant animal models. In addition, in NASH animal models, belapectin has been shown to reduce liver fat, inflammation, portal
          pressure, and ballooning degeneration (death of liver cells). Therefore, we chose belapectin as the lead candidate in a development program targeted initially at fibrotic liver disease associated with non-alcoholic steatohepatitis (NASH). In
          January 2013, an Investigational New Drug (&#8220;IND&#8221;) was submitted to the FDA with the goal of initiating a Phase 1 study in patients with NASH and advanced liver fibrosis to evaluate the safety of belapectin and pharmacodynamics biomarkers of
          disease. On March 1, 2013, the FDA indicated we could proceed with a US Phase 1 clinical trial for belapectin with a development program aimed at obtaining support for a proposed indication of belapectin for treatment of NASH with advanced
          fibrosis. The Phase 1 trial was completed and demonstrated that belapectin up to 8 mg/kg Lean Body Mass (LBM), i.v. was safe and well tolerated.</div>

        <div><br />
        </div>

        <div style="text-indent: 19.35pt; margin-right: 3pt;">Additionally, an open label drug-drug phase 1 interaction study was completed in healthy volunteers during the second quarter of 2015 with belapectin and it showed that with 8 mg/kg LBM dose of
          belapectin and 2 mg/kg LBM dose of midazolam there was no drug-drug interaction, and no serious adverse events or drug-related adverse events were observed. The secondary objective was to assess the safety and tolerability of belapectin when
          administered concomitantly with midazolam.</div>

        <div><br />
        </div>

        <div style="text-indent: 19.35pt; margin-right: 3pt;">Our Phase 2 program in fibrotic disease consisted of two separate human clinical trials. The main clinical trial was the Phase 2b NASH-CX study for one year for patients with NASH with
          compensated cirrhosis and portal hypertension, which began enrolling patients in June 2015. This study was a randomized, placebo-controlled, double-blind, parallel-group Phase 2b trial to evaluate the safety and efficacy of belapectin for
          treatment of liver fibrosis and resultant portal hypertension in NASH patients with compensated cirrhosis. A smaller, exploratory NASH-FX trial was conducted to explore potential use of various non-invasive imaging techniques in NASH patients
          with advanced fibrosis but not cirrhosis.</div>

        <div><br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">16</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: #000000;"><span style="font-weight: bold;">NASH-FX Trial: </span>The NASH-FX trial was a Phase 2a pilot trial for patients with NASH and advanced fibrosis that explored use of three non-invasive imaging
            technologies. It was a short, single site, four-month trial in 30 NASH patients with advanced fibrosis (F3) randomized 1:1 to either 9 bi-weekly doses of 8 mg/kg LBM of belapectin or placebo. The trial did not meet its primary endpoint as
            measured using multi-parametric magnetic resonance imaging (LiverMultiScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(R)</sup>, Perspectum Diagnostics). The trial also did not meet secondary endpoints that
            measure liver stiffness as a surrogate for fibrosis using, magnetic resonance-elastography and FibroScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> score. With a four-month treatment period and a small
            number of patients per arm the study was not powered to demonstrate efficacy results in established advanced liver fibrosis. In the trial however, belapectin was found to be safe and well tolerated with no serious adverse events and showing
            evidence of a pharmacodynamic effect. These results provided support for further development in NASH.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: #000000;"><span style="font-weight: bold;">NASH-CX Trial: </span>The NASH-CX trial was a larger multi-center clinical trial that explored the use of belapectin for the treatment of patients with<span style="font-weight: bold;">&#160;</span>well-compensated NASH cirrhosis and portal hypertension. Enrollment was completed in September 2016, and a total of 162 patients at 36 sites in the United States were randomized to receive either 2 mg/kg LBM
            of belapectin, 8 mg/kg LBM of belapectin or placebo. Approximately 50% of patients at baseline had esophageal varices (a complication of portal hypertension). The primary endpoint was a reduction in hepatic venous pressure gradient (HVPG), a
            hemodynamic measure that estimates portal hypertension. Patients received an infusion of belapectin or placebo every other week for one year and were evaluated to determine the change in HVPG as compared with placebo. Secondary or exploratory
            endpoints included evaluation of fibrosis on liver biopsy, measurement of liver stiffness (FibroScan) and assessment of liver metabolism (<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">13</sup>C-methacetin breath
            test). Top line data readout was reported in December 2017. The study demonstrated a favorable safety profile and clinically meaningful efficacy results in patients without esophageal varices at baseline as demonstrated by a decrease in portal
            pressure associated with the prevention of development of varices when compared to placebo.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">In the total patient population, the primary endpoint HVPG showed a trend toward benefit with belapectin treatment, but the difference from placebo was not statistically significant. The mean
            change in HVPG of placebo from baseline to week 54 was 0.3 mm Hg. The mean change in HVPG from baseline was -0.37 and -0.42 for the 2 mg/kg LBM dose and 8 mg/kg LBM dose of belapectin, respectively.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">In those NASH cirrhosis patients with portal hypertension who have not yet developed esophageal varices at baseline (about 50% of the total population), there was a statistically significant
            effect of the 2 mg/kg LBM dose of belapectin on the absolute change in HVPG (-1.08 mm Hg, p&lt;0.01). The effect of the 8 mg/Kg LBM dose of belapectin on absolute or percent change in HVPG from baseline to week 54 was not significant.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">Also because of the clinical relevance of this population, a responder analysis was performed on those patients without esophageal varices at baseline. Analysis was performed looking at two
            groups: those with an equal to or greater than 2 mm Hg decrease in HVPG from baseline or those with an equal to or greater than 2 mm Hg and a greater than or equal to 20% decrease in HVPG from baseline. In both cases, the change observed in the
            belapectin 2 mg/kg LBM group was statistically significant (p&lt;0.01) while that of the 8 mg/kg LBM group was not.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">Over the 54-week treatment period, in patients without varices at baseline there were also a statistically significantly fewer new varices that developed in the belapectin treatment groups (0%
            and 4% in the 2 mg/kg LBM and the 8 mg/kg LBM, respectively) vs placebo (18%). This meant that the decrease seen in portal pressure was associated with a decreased incidence of esophageal varices. The results were noticeable in the belapectin 2
            mg/Kg LBM group as statistical significance against placebo was achieved for both parameters. As esophageal varices can lead to hemorrhagic complication, which can be fatal, and are a severe complication of liver cirrhosis, we believe the
            prevention of esophageal varices may represent a clinically relevant measure of clinical efficacy in patients with NASH cirrhosis.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">The major conclusions from the NASH-CX trial results were that: (i) belapectin had a statistically significant and clinically meaningful effect in improving HVPG vs placebo in patients with
            NASH cirrhosis who did not have esophageal varices at baseline, (ii) Belapectin in the total patient population was associated with a statistically significant improvement in hepatocyte ballooning (ie cell death), (iii) There was a
            statistically significant reduction (p=0.02) in the development of new esophageal varices in drug-treated patients compared to placebo. We believe that the prevention of esophageal varices is a clinically relevant endpoint related to patient
            outcomes, (iv) While there was a drug effect in both the 2 mg/kg LBM and 8 mg/kg LBM groups on the development of varices and liver biopsy there was a consistently greater and statistically significant effect of the 2 mg/kg LBM dose of
            belapectin, (v) belapectin appears to be safe and well tolerated in this one year clinical trial, a feature that is of prime importance for a cirrhotic population and (vi) This is the first large, randomized clinical trial to demonstrate a
            clinically meaningful improvement in portal hypertension in patients with compensated NASH cirrhosis who have not yet developed esophageal varices.</div>

        </div>

        <div><br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">17</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">Further information and details on the NASH-CX results is available in public presentations posted to our website and filed with the SEC and in a peer reviewed publication in <span style="font-style: italic;">Gastroenterology</span> 2020;158:1334&#8211;1345.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: #000000;"><span style="font-weight: bold;">NASH NAVIGATE Trial: </span>Building on the experience of the NASH-CX trial, the NAVIGATE Trial is a seamless adaptively-designed Phase 2b/3<span style="font-weight: bold;">&#160;</span>clinical study evaluating the safety and efficacy of our galectin-3 inhibitor, belapectin, for the prevention of esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis. The major
            features of this innovative Phase 2b/3 study design are: i) In patients with NASH cirrhosis and clinical signs of portal hypertension but without esophageal varices at baseline, this trial will assess the effect of belapectin on the incidence
            of new varices (the primary endpoint) &#8211; as well as assessing the effect of belapectin on the incidence of additional clinically significant cirrhosis-related outcomes (a key secondary efficacy endpoint), (ii) The study targets NASH patients
            with a clearly identified unmet medical need: patients with compensated cirrhosis who have clinical signs of portal hypertension and, thus, are at risk of developing esophageal varices, a potentially life-threatening complication of cirrhosis
            (bleeding varices are a cause of death in about one-third of cirrhotic patients). There is currently no approved treatment for preventing varices in these patients. In addition, the development of esophageal varices reflects the progression of
            hepatic cirrhosis and thus portends the development of other cirrhosis complications such as ascites, hepatic encephalopathy, and liver failure, and (iii) During the first 18 months, two belapectin dose levels (2 mg/kg LBM and 4 mg/kg LBM) will
            be compared to placebo (phase 2b). Then, at the interim analysis (IA), the best belapectin dose will be selected, based on efficacy and safety, for continued evaluation (Phase 3). The belapectin dose selected for the phase 2b/3 were based on
            the analysis of the NASH-CX trial. Prior belapectin clinical studies have also indicated the good tolerance and safety profile of belapectin with doses of up to 8 mg/kg LBM for up to 52 weeks, an important feature to inform the future risk
            benefit analysis in patients with NASH cirrhosis.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">The study design provides for a pre-specified interim analysis (IA). The IA of efficacy and safety data will be conducted after all planned subjects in Phase 2b component have completed at
            least 78 weeks (18 months) of treatment and a second esophago-gastro-duodeno endoscopic assessment. The purpose of the IA is to allow potential seamless adaptive modifications of the study, including: (1) the selection of the optimal dose of
            belapectin for Phase 3, (2) the re-estimation of the study sample size for Phase 3 portion of the trial, (3) the re-evaluation of the randomization ratio for the Phase 3 portion of the trial, (4) the refinement of the inclusion and exclusion
            criteria for the Phase 3 portion of the trial, including the cirrhosis status, (5) and/or termination of the study for overwhelming efficacy or for futility.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">The trial design also includes a blinded sample size re-estimation (&#8220;SSR&#8221;) during the Phase 2b, prior to the IA, to allow for potential sample size readjustment. The SSR will be conducted when
            50% of the patients have completed 18 months of therapy. This will allow us to confirm the underlying assumption regarding the rate of varices development, currently estimated from our prior Phase 2b trial (NASH-CX). The study design also
            minimizes invasive testing requirements, such as the measurement of HVPG or repeated liver biopsies, which we believe are particularly risky in patients with portal hypertension and will facilitate enrollment and retention of patients. It also
            provides for a seamless transition of patients from the Phase 2b component into the phase 3 stage, including the potential addition of new patients. The trial design preserves the surrogate end-point concepts (development of new varices versus
            variceal hemorrhage) previously discussed with FDA.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">We believe that these adaptations taken together are innovative and optimize conduct of the NAVIGATE trial with a clinically relevant primary outcome giving belapectin the best opportunity to
            show a positive therapeutic effect to address an unmet medical need. As a testimony of this innovation, the NAVIGATE trial design was presented to the hepatology community and featured during the last meeting of the American Association for the
            Study of Liver Diseases, in November 2021. If the IA results of the NAVIGATE trial are compelling, there could be the potential for accelerated FDA approval and/or partnership opportunity with a pharmaceutical company.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">In the Phase 3 component of this trial, as proposed in the protocol, the primary endpoint remains the development of varices. Secondary endpoints include a composite clinical outcomes endpoint,
            including varices requiring treatment (development of large varices or varices with a red wale), decompensating events, all-cause mortality, MELD score increase, liver transplant. Also, NASH non-invasive biomarkers will be evaluated. To target
            a population at risk of developing esophageal varices, patient selection will be based on clinical signs of portal hypertension, including, but not limited to, a low platelet count, an increased spleen size and/or evidence of abdominal
            collaterals circulation.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">The focus and goal of the therapeutic program is to stop the progression of and/or reverse portal hypertension and thereby prevent the development of varices, potentially one of the most
            immediately life-threatening complications of cirrhosis. Based on the results of the NASH-CX trial and subject to confirmation in later stage clinical trials, we believe that this goal is achievable in a significant portion of the NASH
            cirrhosis patient population i.e. those NASH cirrhosis patients with clinical signs of portal hypertension for whom, currently no specific, liver targeted, treatment are available.</div>

        </div>

        <div><br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">18</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">The COVID-19 pandemic has delayed and may continue to delay our regulatory and ethics approvals, recruitment of sites, and enrollment of patients for our Phase 2b/3 NAVIGATE trial despite a
            recent uptick in screening activities. Many investigational centers in the United States and Europe have experienced shut-downs, and while some have loosened or removed restrictions, there may be a risk of experiencing new shut-downs and
            restrictions. In some countries, shutdown orders have also affected the regulatory process to authorize study starts. Governments and medical facilities focused their resources for battling the COVID-19 pandemic. For several reasons, the
            pandemic made enrolling patients for the NAVIGATE trial more challenging, including because patients eligible for the NAVIGATE trial have liver cirrhosis and, as such, are at a greater health risk of complications from COVID-19. It is also
            important to consider the safety of our candidate participants first, as cirrhotic patients with portal hypertension are immune compromised. As we emerged from the COVID-19 pandemic, site recruitment and patient enrollment accelerated and we
            experienced increases in enrollment, particularly in the United States.&#160; However, we did not see the enrollment in Europe that we anticipated, and conditions there remain uncertain. Consequently, we activated multiple sites in Latin America.&#160;
            The final patient was randomized in February 2023, and we expect topline results from the IA in Fall of 2024.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">We have activated more than 150 clinical trial sites in 14 countries for the NAVIGATE trial.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">Further details on the NAVIGATE trial can be found on <span style="text-decoration: underline;">www.clinicaltrials.gov</span> under study NCT04365868 and on our NAVIGATE website (navigatenash.com).</div>

        </div>

        <div><br />
        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">The Company also has commenced a Hepatic Impairment Study, which will run in parallel with the phase 2b/3 trial as part of the development program. The Hepatic Impairment Study is being
            conducted at three sites and involves approximately 40 patients (divided amongst normal healthy volunteers, and patients with hepatic impairment categorized as Child-Turcotte-Pugh (CTP) classes A (mild), B (moderate), and C (severe). Each
            subject will receive a single infusion of belapectin (4 mg/kg LBM) and their serum belapectin levels will be monitored for up to approximately two weeks to define the effects of various stages of cirrhosis on serum belapectin levels. The
            tolerance and safety of belapectin will be evaluated. Enrollment in this study was completed in February 2022, and the results will be announced when available. Based on the results from this hepatic impairment study, the Company may consider
            including patients with more advanced cirrhosis in the Phase 3 portion of its NAVIGATE trial. Until dosing and safety profile is further informed in CTP Class B and/or Class C patients, the NAVIGATE trial will enroll only CTP Class A patients.
            Further details on this hepatic impairment study can be found on <span style="text-decoration: underline;">www.clinicaltrials.gov</span> study NCT04332432.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: #000000;"><span style="font-style: italic;">Cancer Immunotherapy. </span>We believe there is potential for galectin inhibition to play a key role in the innovative area of cancer immunotherapy. For<span style="font-style: italic;">&#160;</span>example, there have been several recent approvals of drugs that enhance a patient&#8217;s immune system to fight cancer. It is our goal to use ourgalectin-3 inhibitor to further enhance the immune system function
            to help the body to fight cancer in a way that complements other approaches to this type of therapy. This hypothesis is supported by the fact that galectin-3 is expressed at high levels in multiple types of tumors and their micro-environment,
            where it fosters the malignant nature of the tumors, and protects the tumors from immune attack by the patient&#8217;s own defense mechanism. Our drug candidates provide a promising new therapeutic approach to enhance the activity of the immune
            system against cancer cells. Preclinical studies have indicated that belapectin enhances the immune response to cancer cells, increased tumor shrinkage and enhanced survival in immune competent mice with prostate, breast, melanoma and sarcoma
            cancers when combined with one of the immune checkpoint inhibitors, anti-CTLA-4 or anti-PD-1, or with the immune cell activator anti-OX40. These preclinical data led to the filing of two Investigator-sponsored INDs and the initiation of Phase
            1B studies of belapectin in combination with Yervoy<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (ipilimumab) in metastatic melanoma and another phase 1B study in combination with KEYTRUDA (pembrolizumab) in
            patients with metastatic melanoma and head and neck squamous cell carcinoma. These studies were conducted under the sponsorship of Providence Portland Medical Center&#8217;s Earle A. Chiles Research Institute (EACRI).</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">The phase IB study in combination with Yervoy was rapidly discontinued after the first patients were recruited because of the availability of new treatment in the selected population.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">Promising results were reported in the Phase 1b trial combining belapectin with pembrolizumab (KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>). When
            aggregated cohorts are combined, in advanced melanoma, a 50% objective response rate with belapectin in combination with KEYTRUDA, was documented. In addition, a 33% response rate was documented in patients with head and neck cancer. The
            results have been published in 2021 in a highly rated peer reviewed journal (Curti et al. Journal of Immunotherapy of cancer 2021;9:e002371). There was also a suggestion that the combination of belapectin with pembrolizumab could decrease the
            auto-immune side-effect induced by pembrolizumab. These side-effects, which are directly linked to the mechanism of action of pembrolizumab, can be poorly tolerated and even severe enough to lead to treatment interruption, even if the effect on
            the cancer was encouraging. This is, a very frustrating situation for patients who have to discontinue an active treatment but have no other options available to them. We believe these data, taken together with the observed favorable safety and
            tolerability of the combination, provide a rationale to move the belapectin program in oncology forward.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-indent: 27pt; color: rgb(0, 0, 0);">Late in 2021, we engaged three noted physicians &#8211; Dr. Chetan Bettegowda, from Johns Hopkins, and Dr. Nishant Agrawal and Dr. Ari Rosenberg, both from University of Chicago Medical Center &#8211; as
            consultants to help define the path forward in oncology. In consultation with our oncology experts, we have now selected the treatment of recurrent or metastatic head and neck cancer as the lead indication to pursue for belapectin in
            combination with an immune checkpoint inhibitor. The decision is notably based on the lack of available treatments for these patients, the limited number of therapies in development, and the resulting very high medical need. We filed an IND
            with FDA and are planning a phase 2 trial to be filed with the FDA oncology division.</div>

        </div>

        <div><br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">19</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <div style="margin-left: 22pt; font-weight: bold;">Results of Operations</div>

        <div><br />
        </div>

        <div style="font-weight: bold;">Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022</div>

        <div><br />
        </div>

        <div>
          <div style="font-style: italic;">Research and Development Expense.</div>

        </div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="2" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="2" colspan="6">
                <div style="text-align: center;">Three Months</div>
                <div style="text-align: center;">Ended March 31,</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="2" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="2" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="2" colspan="6">
                <div style="text-align: center;">2023 as Compared to 2022</div>
                <div style="text-align: center;">Three Months</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="2" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center;"> 2023</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center;"> 2022</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center;">$ Change</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center;">% Change</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
                <div style="text-align: center;">(In thousands, except %)</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
                <div>Research and development</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>8,799</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>8,058</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>741</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>9</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div>We generally categorize research and development expenses as either direct external expenses, comprised of amounts paid to third party vendors for services, or all other research and development expenses, comprised of employee payroll and
          general overhead allocable to research and development. We consider a clinical program to have begun upon acceptance by the FDA, or similar agency outside of the United States, to commence a clinical trial in humans, at which time we begin
          tracking expenditures by the product candidate. Clinical program expenses comprise payments to vendors related to preparation for, and conduct of, all phases of the clinical trial, including costs for drug manufacture, patient dosing and
          monitoring, data collection and management, oversight of the trials and reports of results. Pre-clinical expenses comprise all research and development amounts incurred before human trials begin, including payments to vendors for services related
          to product experiments and discovery, toxicology, pharmacology, metabolism, and efficacy studies, as well as manufacturing process development for a drug candidate.</div>

        <div> <br />
        </div>

        <div style="margin-left: 27pt;">Our research and development expenses were as follows:</div>

        <div> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                <div style="text-align: center;">Three Months</div>
                <div style="text-align: center;">Ended</div>
                <div style="text-align: center;">March 31,</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-left: 23%;" colspan="1">
                <div style="text-align: right;">&#160;</div>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center;" colspan="2"> 2023</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center;" rowspan="1" colspan="2">2022 <br />
              </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="2" colspan="1">
                <div>Direct external expenses:</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="6">
                <div style="text-align: center;">(in thousands)</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="margin-left: 9pt;">Clinical activities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>6,820</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>6,869</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="margin-left: 9pt;">Pre-clinical activities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>772</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>359</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>All other research and development expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                <div>1,207</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                <div>830</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                <div>8,799</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                <div>8,058</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; margin-left: 27pt;">Other research and development expenses increased primarily due to additional employees hired after the first quarter of 2022.</div>

        <div><br />
        </div>

        <div style="text-indent: 21.5pt;">Both the time required and costs we may incur in order to commercialize a drug candidate that would result in material net cash inflow are subject to numerous variables, and therefore we are unable at this stage of
          our development to forecast useful estimates. Variables that make estimates difficult include the number of clinical trials we may undertake, the number of patients needed to participate in the clinical trial, patient recruitment uncertainties,
          trial results as to the safety and efficacy of our product, and uncertainties as to the regulatory agency response to our trial data prior to receipt of marketing approval. Moreover, the FDA or other regulatory agencies may suspend clinical
          trials if we or an agency believes patients in the trial are subject to unacceptable risks or find deficiencies in the conduct of the clinical trial. Delays or rejections may also occur if governmental regulation or policy changes during our
          clinical trials or in the course of review of our clinical data. Due to these uncertainties, accurate and meaningful estimates of the ultimate cost to bring a product to market, the timing of costs and completion of our program and the period
          during which material net cash inflows will commence are unavailable at this time.</div>

        <div><br /></div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">20</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <div>
          <div style="font-style: italic;">General and Administrative Expense.</div>

        </div>

        <div> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-left: 18pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="2" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="2" colspan="6">
                <div style="text-align: center;">Three Months</div>
                <div style="text-align: center;">Ended March 31,</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="2" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="2" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="2" colspan="6">
                <div style="text-align: center;">2023 as Compared to 2022</div>
                <div style="text-align: center;">Three Months</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="2" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-left: 18pt; padding-bottom: 2px;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-left: 18pt; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center;"> 2023</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center;">2022</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center;">$ Change</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center;">% Change</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-left: 18pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
                <div>(In thousands, except %)</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" colspan="1">
                <div>General and administrative</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>1,543</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>1,877</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>(334</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>(18</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)%</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 21.5pt; margin-right: 11pt;">General and administrative expenses consist primarily of salaries including stock-based compensation, legal and accounting fees, insurance, investor relations, business
          development and other office related expenses. The primary reasons for the decrease in general and administrative expenses for the three-months ended March 31, 2023 as compared to the same period in 2022 is due to a decrease insurance expense of
          67,000 and decrease in non-cash stock based compensation expenses of approximately $241,000.</div>

        <div><br />
        </div>

        <div style="font-weight: bold;">Liquidity and Capital Resources</div>

        <div><br />
        </div>

        <div style="text-indent: 21.5pt; color: #000000;">Since our inception on July 10, 2000, we have financed our operations from proceeds of public and private offerings of debt and equity. As of December 31, 2022, we raised a net total of $254.5
          million from these offerings. At March 31, 2023, the Company had $17.8 million of unrestricted cash and cash equivalents in addition to $40 million remaining available under a line of credit provided by our chairman available to fund future
          operations. The Company believes there is sufficient cash to fund currently planned operations at least through December 31, 2024. We will require more cash to fund our operations after December 31, 2024 and believe we will be able to obtain
          additional financing. The currently planned operations include costs related to our adaptively designed NAVIGATE Phase 2b/3 clinical trial. However, there can be no assurance that we will be successful in obtaining such new financing or, if
          available, that such financing will be on terms favorable to us.</div>

        <div><br />
        </div>

        <div style="text-indent: 21.5pt;">Net cash used in operations increased by $2,751,000 to $10,793,000 for the three months ended March 31, 2032, as compared to $8,042,000 for the three months ended March 31, 2022. Cash operating expenses increased
          principally due to the preparations and expenses related to our NAVIGATE clinical trial with belapectin.</div>

        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">Off-Balance Sheet Arrangements</div>

        <div><br />
        </div>

        <div style="text-indent: 21.5pt; margin-right: 1pt;">We have not created, and are not a party to, any special-purpose or off-balance sheet entities for the purpose of raising capital, incurring debt or operating parts of our business that are not
          consolidated into our financial statements. We do not have any arrangements or relationships with entities that are not consolidated into our financial statements that are reasonably likely to materially affect our liquidity or the availability
          of capital resources.</div>

        <div><br />
        </div>

        <div style="font-weight: bold;">Application of Critical Accounting Policies and Estimates</div>

        <div><br />
        </div>

        <div style="text-indent: 21.5pt; margin-right: 9pt;">The preparation of condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and related
          disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to accrued expenses, stock-based compensation, contingencies and litigation. We base our estimates on historical experience,
          terms of existing contracts, our observance of trends in the industry, information available from other outside sources and on various other factors that we believe to be appropriate under the circumstances. Actual results may differ from these
          estimates under different assumptions or conditions.</div>

        <div><br />
        </div>

        <div style="text-indent: 21.5pt; margin-right: 9pt;">Critical accounting policies are those policies that affect our more significant judgments and estimates used in preparation of our consolidated financial statements. We believe our critical
          accounting policies include our policies regarding stock-based compensation, accrued expenses and income taxes. For a more detailed discussion of our critical accounting policies, please refer to our 2022 Annual Report on Form 10-K.</div>

        <div><br />
        </div>

        <a id="Item3."><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 3.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Quantitative and Qualitative Disclosures about Market Risk</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-indent: 21.5pt; margin-right: 1pt;">Market risk represents the risk of loss that may impact our financial position, operating results or cash flows due to changes in the U.S. interest rates. The primary objective of our investment
          activities is to preserve cash until it is required to fund operations. To minimize risk, we maintain our portfolio of cash and cash equivalents in operating bank accounts and money market funds. Since our investments are short-term in duration,
          we believe that we are not subject to any material market risk exposure.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">21</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <a id="Item4."><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 4.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Controls and Procedures</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">Evaluation of Disclosure Controls and Procedures</div>

        <div><br />
        </div>

        <div style="text-indent: 21.5pt; margin-right: 2pt;">Our management, with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule
          13a-15(e) promulgated under the Securities Exchange Act of 1934) and concluded that, as of March 31, 2023, our disclosure controls and procedures were effective.</div>

        <div><br />
        </div>

        <div style="text-indent: 21.5pt; margin-right: 8pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and
          all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that
          there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues
          and instances of fraud, if any, within the Company have been detected.</div>

        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">Changes in Internal Control Over Financial Reporting</div>

        <div><br />
        </div>

        <div style="text-indent: 21.5pt; margin-right: 17pt;">During the quarter ended March 31, 2023, no change in our internal control over financial reporting has materially affected, or is reasonably likely to materially affect, our internal control
          over financial reporting.</div>

        <div><br />
        </div>

        <div style="text-align: center; font-weight: bold;">PART II &#8212; OTHER INFORMATION</div>

        <div><br />
        </div>

        <a id="Item1."><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 1.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Legal Proceedings</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="margin-left: 22pt;">None.</div>

        <div><br />
        </div>

        <div>
          <a id="Item1A."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 45pt;">
                  <div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">Item 1A.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">Risk Factors</div>
                </td>

  </tr>


</table>
        </div>

        <div><br />
        </div>

        <div style="text-indent: 21.5pt; margin-right: 14pt;">The information set forth in this report should be read in conjunction with the risk factors set forth in Item 1A, &#8220;Risk Factors,&#8221; of Part I of our Annual Report on Form 10-K for the year ended
          December 31, 2022, which could materially impact our business, financial condition or future results.</div>

        <div><br />
        </div>

        <a id="UnregisteredSalesofEquity"><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Unregistered Sales of Equity Securities and Use of Proceeds</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="margin-left: 22pt;">None</div>

        <div><br />
        </div>

        <a id="DefaultsUponSeniorSecurit"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 3.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Defaults Upon Senior Securities</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="margin-left: 22pt;">None</div>

        <div><br />
        </div>

        <a id="MineSafetyDisclosures"><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 4.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Mine Safety Disclosures</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="margin-left: 22pt;">Not Applicable</div>

        <div><br />
        </div>

        <a id="OtherInformation"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 5.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Other Information</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="margin-left: 22pt;">Not Applicable</div>

        <div><br />
        </div>

        <a id="Exhibits"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 6.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Exhibits</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="3" rowspan="2">
                <div style="text-align: center; margin-left: 18pt; font-weight: bold; text-indent: -18pt;">Exhibit</div>
                <div style="text-align: center; margin-left: 18pt; font-weight: bold; text-indent: -18pt;">Number</div>
              </td>

    <td style="width: 1.25%; vertical-align: bottom;">&#160;</td>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="2" colspan="2">
                <div style="text-align: center; font-weight: bold;">Description of Document</div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="2" colspan="1">
                <div style="text-align: center; font-weight: bold;">Note</div>
                <div style="text-align: center; font-weight: bold; text-indent: -18pt; margin-left: 18pt;">Reference</div>
              </td>

  </tr>

  <tr>

    <td style="width: 1.25%; vertical-align: bottom; padding-bottom: 2px;"><br />
              </td>

    <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: bottom;">&#160;</td>

    <td style="width: 0.71%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.25%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 81%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">
                <div><a href="brhc20051581_ex31-1.htm">31.1*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 1.25%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="3">
                <div>Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: bottom;">&#160;</td>

    <td style="width: 0.71%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.25%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 81%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">
                <div><a href="brhc20051581_ex31-2.htm">31.2*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 1.25%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="3">
                <div>Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: bottom;">&#160;</td>

    <td style="width: 0.71%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.25%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 81%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="3">
                <div><a href="brhc20051581_ex32-1.htm">32.1**</a></div>
              </td>

    <td style="width: 1.25%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="3">
                <div>Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: bottom;">&#160;</td>

    <td style="width: 0.71%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.25%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 81%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="3">
                <div><a href="brhc20051581_ex32-2.htm">32.2**</a></div>
              </td>

    <td style="width: 1.25%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="3">
                <div>Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: bottom;">&#160;</td>

    <td style="width: 0.71%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.25%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 81%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="3">
                <div>101.INS</div>
              </td>

    <td style="width: 1.25%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="3">
                <div>Inline XBRL Instance Document** (the instance document does not appear in the Interactive Data File because its XBRL tags are</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 0.71%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 1.25%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="3">
                <div>embedded within the Inline XBRL document).</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">22</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td rowspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="font-weight: bold; text-align: center;">Exhibit</div>
                <div style="font-weight: bold; text-align: center;">Number</div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td rowspan="2" style="width: 81%; vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);"><br />
                <div style="font-weight: bold;">Description of Document</div>
              </td>

    <td rowspan="2" style="width: 1%; vertical-align: bottom; text-align: center; padding-bottom: 2px;">&#160;</td>

    <td colspan="1" rowspan="2" style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">Note</div>
                <div style="text-align: center; font-weight: bold;">Reference</div>
              </td>

  </tr>

  <tr>

    <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 3%; vertical-align: bottom;">&#160;&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 81%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div>101.SCH</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">
                <div>Inline XBRL Taxonomy Extension Schema Document**</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 3%; vertical-align: bottom;">&#160;&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 81%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div>101.CAL</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">
                <div>Inline XBRL Taxonomy Calculation Linkbase Document**</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 3%; vertical-align: bottom;">&#160;&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 81%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div>101.DEF</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">
                <div>Inline XBRL Taxonomy Extension Definition Linkbase Document**</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 3%; vertical-align: bottom;">&#160;&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 81%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div>101.LAB</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">
                <div>Inline XBRL Taxonomy Label Linkbase Document**</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 3%; vertical-align: bottom;">&#160;&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 81%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div>101.PRE</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">
                <div>Inline XBRL Taxonomy Presentation Linkbase Document**</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom;" colspan="3">&#160;</td>

    <td rowspan="1" style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div>104*</div>
              </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="3">
                <div>Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101)</div>
              </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>


</table>
        <div> <br />
        </div>

        <div>
          <hr style="height: 2px; width: 10%; color: #000000; background-color: #000000; border: none; margin-left: 0px; margin-right: auto;" /> </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 0.25pt;"><br />
              </td>

    <td style="width: 20.75pt; vertical-align: top;">*</td>

    <td style="width: auto; vertical-align: top;">
                <div>Filed herewith.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 0.25pt;"><br />
              </td>

    <td style="width: 20.75pt; vertical-align: top;">**</td>

    <td style="width: auto; vertical-align: top;">
                <div>Furnished herewith and not &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">23</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <a href="#INDEXTOFORM10-Q">Index</a></div>

            </div>

          </div>

        </div>

        <a id="SIGNATURES"><!--Anchor--></a>
        <div style="text-align: center; font-weight: bold;">SIGNATURES</div>

        <div><br />
        </div>

        <div style="text-indent: 21.5pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on May 15, 2023.</div>

        <div><br />
        </div>

        <div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;" rowspan="1" colspan="2">
                  <div>GALECTIN THERAPEUTICS INC.</div>
                </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 45%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                  <div>By:</div>
                </td>

    <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>/s/ Joel Lewis</div>
                </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                  <div>Name:</div>
                </td>

    <td style="width: 45%; vertical-align: top;">
                  <div>Joel Lewis</div>
                </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                  <div>Title:</div>
                </td>

    <td style="width: 45%; vertical-align: top;">
                  <div>Chief Executive Officer and President</div>
                </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 45%; vertical-align: top;">
                  <div>(principal executive officer)</div>
                </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 45%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                  <div>By:</div>
                </td>

    <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>/s/ Jack W. Callicutt</div>
                </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">Name:</td>

    <td style="width: 45%; vertical-align: top;">
                  <div>Jack W. Callicutt</div>
                </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                  <div>Title:</div>
                </td>

    <td style="width: 45%; vertical-align: top;">
                  <div>Chief Financial Officer</div>
                </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 45%; vertical-align: top;">
                  <div>(principal financial and accounting officer)</div>
                </td>

  </tr>


</table>
        </div>

        <div><br />
        </div>

        <div><br /></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">24</span></div>

        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    </div>

  </div>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>brhc20051581_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">


  <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; font-weight: bold;">Exhibit 31.1</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934</div>
    <div><br>
    </div>
    <div>I, Joel Lewis, certify that:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zadfedd1a2aca4b74831bf1b7da76918d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.25pt;"><br>
          </td>
          <td style="width: 23.75pt; vertical-align: top;">1.</td>
          <td style="width: auto; vertical-align: top;">
            <div>I have reviewed this quarterly report on Form 10-Q of Galectin Therapeutics Inc;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="ze4240fba5f5840269f703d791985987e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.25pt;"><br>
          </td>
          <td style="width: 23.75pt; vertical-align: top;">2.</td>
          <td style="width: auto; vertical-align: top;">
            <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
              circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zb5df4f3eabf6491f9c827eb77c53b836" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.25pt;"><br>
          </td>
          <td style="width: 23.75pt; vertical-align: top;">3.</td>
          <td style="width: auto; vertical-align: top;">
            <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
              operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z7d73c8d9821d4d1f97dc0a50678d8e1c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.25pt;"><br>
          </td>
          <td style="width: 23.75pt; vertical-align: top;">4.</td>
          <td style="width: auto; vertical-align: top;">
            <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
              15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z31e37ce41659420bb5b44211ae106488" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(a)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
              registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z20295a0c8dc249e3a601b1a650e70b2f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(b)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
              regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zfd48a8e7d494424b89699f95d86d3e75" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
              procedures, as of the end of the period covered by this report based on such evaluation; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zf495fd7d4aa9451dabd8212b79fdce44" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(d)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth
              fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z5c398b279a294019bc342d4896ade86f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.25pt;"><br>
          </td>
          <td style="width: 23.75pt; vertical-align: top;">5.</td>
          <td style="width: auto; vertical-align: top;">
            <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit
              committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z1a8311ca182c4f1d9c84e47a6c41d407" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(a)</td>
          <td style="width: auto; vertical-align: top;">
            <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s
              ability to record, process, summarize and report financial information; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z4df3d8b6bd2b438595abcb0136d761b7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(b)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z0e76160dd28941e6bf9650d0bf0ada7b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" rowspan="1">Date: May 15, 2023</td>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Joel Lewis</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;&#160;</td>
          <td style="width: 5%; vertical-align: top;" colspan="1">Name:</td>
          <td style="width: 45%; vertical-align: top;">
            <div>Joel Lewis</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;<br>
          </td>
          <td style="width: 5%; vertical-align: top;" colspan="1">
            <div>Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>Chief Executive Officer and President</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;<br>
          </td>
          <td style="width: 5%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 45%; vertical-align: top;">
            <div>(principal executive officer)</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div> <br>
    </div>
    <div>
      <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>brhc20051581_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">


  <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; font-weight: bold;">Exhibit 31.2</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934</div>
    <div><br>
    </div>
    <div>I, Jack W. Callicutt, certify that:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z55e03f44228f4bc19d324bed4ef32903" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.25pt;"><br>
          </td>
          <td style="width: 23.75pt; vertical-align: top;">1.</td>
          <td style="width: auto; vertical-align: top;">
            <div>I have reviewed this quarterly report on Form 10-Q of Galectin Therapeutics Inc;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zdc23ea913b4849689e195ee9a04e1666" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.25pt;"><br>
          </td>
          <td style="width: 23.75pt; vertical-align: top;">2.</td>
          <td style="width: auto; vertical-align: top;">
            <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
              circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z2eabd77723524d3a8700385cd94a439a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.25pt;"><br>
          </td>
          <td style="width: 23.75pt; vertical-align: top;">3.</td>
          <td style="width: auto; vertical-align: top;">
            <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
              operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z9698b70e12d243b8b9dfa57215689104" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.25pt;"><br>
          </td>
          <td style="width: 23.75pt; vertical-align: top;">4.</td>
          <td style="width: auto; vertical-align: top;">
            <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
              15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z2f5b80529ad64649b678871d068e3181" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(a)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
              registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="za51b33290938496b98961c2a0f2def79" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(b)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
              regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z93003cd2759942bfbffa2d785c7c86a3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
              procedures, as of the end of the period covered by this report based on such evaluation; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zef8d854835b24a8c89349cd0e7a13823" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(d)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth
              fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z4c66d22da8174be7ba0e79429f872219" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.25pt;"><br>
          </td>
          <td style="width: 23.75pt; vertical-align: top;">5.</td>
          <td style="width: auto; vertical-align: top;">
            <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit
              committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z50bdfcc459e743409e92aff11d259b58" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(a)</td>
          <td style="width: auto; vertical-align: top;">
            <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s
              ability to record, process, summarize and report financial information; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="za05a5700f4b7454b9bcdbc40aba6d943" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24pt;"><br>
          </td>
          <td style="width: 24pt; vertical-align: top;">(b)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z7a2022166d494933959d4aa2a053213b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" rowspan="1">
            <div>Date: May 15, 2023</div>
          </td>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Jack W. Callicutt</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;<br>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>Jack W. Callicutt</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>Chief Financial Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;&#160;</td>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: top;">
            <div>(principal financial and accounting officer)</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div> <br>
    </div>
    <div>
      <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>brhc20051581_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">


  <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; font-weight: bold;">Exhibit 32.1</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</div>
    <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div><br>
    </div>
    <div style="text-indent: 21.5pt; margin-right: 4pt;">In connection with the Quarterly Report of Galectin Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended
      March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Joel Lewis, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley
      Act of 2002, that, to my knowledge:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z84544eaf805441709e232211399bd697" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 26.6pt;"><br>
          </td>
          <td style="width: 45.4pt; vertical-align: top;">(1)</td>
          <td style="width: auto; vertical-align: top;">
            <div>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z99490b0e118d4dd0b131835d37763f22" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 26.6pt;"><br>
          </td>
          <td style="width: 45.4pt; vertical-align: top;">(2)</td>
          <td style="width: auto; vertical-align: top;">
            <div>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z1113307452494a28a1fc3a1ea9c5fbb1" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: bottom; padding-bottom: 2px;">
            <div>Date: May 15, 2023</div>
          </td>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Joel Lewis</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;"><br>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div>Name :</div>
          </td>
          <td style="width: 45%; vertical-align: bottom;">
            <div>Joel Lewis</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;"><br>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div>Title :</div>
          </td>
          <td style="width: 45%; vertical-align: bottom;">
            <div>Chief Executive Officer and President</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom;">
            <div>(principal executive officer)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 21.5pt; margin-right: 5pt;">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or
      otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Galectin Therapeutics Inc. and will be retained by Galectin Therapeutics Inc. and
      furnished to the Securities and Exchange Commission or its staff upon request.</div>
    <div style="text-indent: 21.5pt; margin-right: 5pt;"> <br>
      </div>
    <div style="text-indent: 21.5pt; margin-right: 5pt;"> <br>
      </div>
    <div style="text-indent: 21.5pt; margin-right: 5pt;">
      <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>brhc20051581_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; font-weight: bold;">Exhibit 32.2</div>
    <div><br>
    </div>
    <div style="font-weight: bold; text-align: center;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</div>
    <div style="font-weight: bold; text-align: center;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div><br>
    </div>
    <div style="text-indent: 21.5pt; margin-right: 6pt;">In connection with the Quarterly Report of Galectin Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date
      hereof (the &#8220;Report&#8221;), I, Jack W. Callicutt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z52e5f6b5cc88490e9d3f1cd09cf5f908">

        <tr>
          <td style="width: 26.6pt;"><br>
          </td>
          <td style="width: 45.4pt; vertical-align: top;">(1)</td>
          <td style="width: auto; vertical-align: top;">
            <div>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3cde0a9cc5b4474a8960083ffb420586">

        <tr>
          <td style="width: 26.6pt;"><br>
          </td>
          <td style="width: 45.4pt; vertical-align: top;">(2)</td>
          <td style="width: auto; vertical-align: top;">
            <div>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd18d0f4c4c0540d4b2cadfe6d48d44cf">

        <tr>
          <td style="width: 50%; vertical-align: bottom; padding-bottom: 2px;">
            <div>Date: May 15, 2023</div>
          </td>
          <td colspan="1" style="width: 4%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Jack W. Callicutt</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;"><br>
          </td>
          <td colspan="1" style="width: 4%; vertical-align: bottom;">Name:</td>
          <td style="width: 45%; vertical-align: bottom;">
            <div>Jack W. Callicutt</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;"><br>
          </td>
          <td colspan="1" style="width: 4%; vertical-align: bottom;">Title:</td>
          <td style="width: 45%; vertical-align: bottom;">
            <div>Chief Financial Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          <td colspan="1" style="width: 4%; vertical-align: bottom;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom;">
            <div>(principal financial and accounting officer)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 21.5pt; margin-right: 5pt;">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the
      electronic version of this written statement required by Section 906, has been provided to Galectin Therapeutics Inc. and will be retained by Galectin Therapeutics Inc. and furnished to the Securities and Exchange Commission or its staff upon
      request.</div>
    <div style="text-indent: 21.5pt; margin-right: 5pt;"> <br>
    </div>
    <div style="text-indent: 21.5pt; margin-right: 5pt;"> <br>
    </div>
    <div style="text-indent: 21.5pt; margin-right: 5pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>galt-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<xs:schema targetNamespace="http://galectintherapeutics.com/20230331" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:galt="http://galectintherapeutics.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://galectintherapeutics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" id="CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <!--Parent Role: CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)-->
        <link:definition>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" id="CondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" id="CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
        <link:definition>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidity" id="BasisOfPresentationAndLiquidity">
        <link:definition>060100 - Disclosure - Basis of Presentation and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpensesAndOther" id="AccruedExpensesAndOther">
        <link:definition>060200 - Disclosure - Accrued Expenses and Other</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty" id="ConvertibleNotesPayableRelatedParty">
        <link:definition>060300 - Disclosure - Convertible Notes Payable - Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
        <link:definition>060400 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>060500 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommonStockWarrants" id="CommonStockWarrants">
        <link:definition>060600 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LossPerShare" id="LossPerShare">
        <link:definition>060700 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommonStock" id="CommonStock">
        <link:definition>060800 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty" id="ConvertibleLineOfCreditRelatedParty">
        <link:definition>060900 - Disclosure - Convertible Line of Credit - Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>061000 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/Leases" id="Leases">
        <link:definition>061100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlc" id="GalectinSciencesLlc">
        <link:definition>061200 - Disclosure - Galectin Sciences LLC</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpensesAndOtherTables" id="AccruedExpensesAndOtherTables">
        <!--Parent Role: Accrued Expenses and Other-->
        <link:definition>080200 - Disclosure - Accrued Expenses and Other (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>080400 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>080500 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommonStockWarrantsTables" id="CommonStockWarrantsTables">
        <!--Parent Role: Common Stock Warrants-->
        <link:definition>080600 - Disclosure - Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LossPerShareTables" id="LossPerShareTables">
        <!--Parent Role: Loss Per Share-->
        <link:definition>080700 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LeasesTables" id="LeasesTables">
        <!--Parent Role: Leases-->
        <link:definition>081100 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails" id="BasisOfPresentationAndLiquidityDetails">
        <!--Parent Role: Basis of Presentation and Liquidity-->
        <link:definition>090100 - Disclosure - Basis of Presentation and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails" id="AccruedExpensesAndOtherDetails">
        <!--Parent Role: Accrued Expenses and Other-->
        <link:definition>090200 - Disclosure - Accrued Expenses and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails" id="ConvertibleNotesPayableRelatedPartyDetails">
        <!--Parent Role: Convertible Notes Payable - Related Party-->
        <link:definition>090300 - Disclosure - Convertible Notes Payable - Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails" id="FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>090400 - Disclosure - Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails" id="FairValueOfFinancialInstrumentsKeyAssumptionsDetails">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>090402 - Disclosure - Fair Value of Financial Instruments, Key Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails" id="FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>090404 - Disclosure - Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails" id="StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090500 - Disclosure - Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails" id="StockbasedCompensationStockOptionActivityDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090502 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" id="StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090504 - Disclosure - Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails" id="StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090506 - Disclosure - Stock-Based Compensation, Restricted Stock Grants and Employment Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommonStockWarrantsDetails" id="CommonStockWarrantsDetails">
        <!--Parent Role: Common Stock Warrants-->
        <link:definition>090600 - Disclosure - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LossPerShareDetails" id="LossPerShareDetails">
        <!--Parent Role: Loss Per Share-->
        <link:definition>090700 - Disclosure - Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommonStockDetails" id="CommonStockDetails">
        <!--Parent Role: Common Stock-->
        <link:definition>090800 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails" id="ConvertibleLineOfCreditRelatedPartyDetails">
        <!--Parent Role: Convertible Line of Credit - Related Party-->
        <link:definition>090900 - Disclosure - Convertible Line of Credit - Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>091000 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LeasesDetails" id="LeasesDetails">
        <!--Parent Role: Leases-->
        <link:definition>091100 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LeasesDetailsCalc2" id="LeasesDetailsCalc2">
        <!--Parent Role: Leases (Details)-->
        <link:definition>091102 - Disclosure - Leases (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlcDetails" id="GalectinSciencesLlcDetails">
        <!--Parent Role: Galectin Sciences LLC-->
        <link:definition>091200 - Disclosure - Galectin Sciences LLC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xs:element name="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" id="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="UndesignatedCapitalStockValue" id="galt_UndesignatedCapitalStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="UndesignatedCapitalStockParValue" id="galt_UndesignatedCapitalStockParValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="UndesignatedCapitalStockSharesAuthorized" id="galt_UndesignatedCapitalStockSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="UndesignatedCapitalStockSharesDesignated" id="galt_UndesignatedCapitalStockSharesDesignated" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ConvertiblePreferredStockDividendsShares" id="galt_ConvertiblePreferredStockDividendsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TemporaryEquityDividendsShares" id="galt_TemporaryEquityDividendsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ConvertiblePreferredStockDividends" id="galt_ConvertiblePreferredStockDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="TemporaryEquityDividends" id="galt_TemporaryEquityDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" id="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" id="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" id="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CommonStockWarrantsAbstract" id="galt_CommonStockWarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonStockWarrantsDisclosureTextBlock" id="galt_CommonStockWarrantsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LineOfCreditRelatedPartyAbstract" id="galt_LineOfCreditRelatedPartyAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IssuanceOfWarrantsValue" id="galt_IssuanceOfWarrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" id="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="WarrantTwoMember" id="galt_WarrantTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="UnsecuredConvertiblePromissoryNoteMember" id="galt_UnsecuredConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentAccruedInterest" id="galt_DebtInstrumentAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="WarrantOneMember" id="galt_WarrantOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SeriesAAndSeriesCPreferredStockMember" id="galt_SeriesAAndSeriesCPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommissionRate" id="galt_CommissionRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AggregateOfferingPrice" id="galt_AggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="TwoThousandTwentyMarketAgreementMember" id="galt_TwoThousandTwentyMarketAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FreeRentPeriod" id="galt_FreeRentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfOperatingLeases" id="galt_NumberOfOperatingLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="GalectinSciencesLLCMember" id="galt_GalectinSciencesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SBHSciencesIncMember" id="galt_SBHSciencesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CapitalContributionExpense" id="galt_CapitalContributionExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ContingentInterestAprilNoteMember" id="galt_ContingentInterestAprilNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ContingentInterestSeptemberNoteMember" id="galt_ContingentInterestSeptemberNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ContingentInterestDecemberNoteMember" id="galt_ContingentInterestDecemberNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ContractCancelationNoticePeriod" id="galt_ContractCancelationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RestrictedStockGrantsAbstract" id="galt_RestrictedStockGrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ConvertibleNotesPayableRelatedPartyAbstract" id="galt_ConvertibleNotesPayableRelatedPartyAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="QuarterlyInterestRate" id="galt_QuarterlyInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfPromissoryNotesEvidencedByLoansAgreement" id="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AnnualInterestRate" id="galt_AnnualInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AprilConvertiblePromissoryNoteMember" id="galt_AprilConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeptemberConvertiblePromissoryNoteMember" id="galt_SeptemberConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DecemberConvertiblePromissoryNoteMember" id="galt_DecemberConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AccruedResearchAndDevelopmentCostsAndOtherCurrent" id="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="BasisOfPresentationsAndLiquidityAbstract" id="galt_BasisOfPresentationsAndLiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>galt-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LeasesDetailsCalc2" xlink:type="simple" xlink:href="galt-20230331.xsd#LeasesDetailsCalc2" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LeasesDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#LeasesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#AccruedExpensesAndOtherDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent" xlink:label="DividendsPayableCurrent" xlink:title="DividendsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="DividendsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to DividendsPayableCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to DerivativeLiabilitiesNoncurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to OtherLiabilitiesNoncurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:label="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:title="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:title="calculation: Liabilities to ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:label="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:title="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:title="calculation: Liabilities to BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to TemporaryEquityCarryingAmountAttributableToParent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UndesignatedCapitalStockValue" xlink:label="UndesignatedCapitalStockValue" xlink:title="UndesignatedCapitalStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="UndesignatedCapitalStockValue" xlink:title="calculation: StockholdersEquity to UndesignatedCapitalStockValue" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="CommitmentsAndContingencies" xlink:title="calculation: LiabilitiesAndStockholdersEquity to CommitmentsAndContingencies" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="calculation: NonoperatingIncomeExpense to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: NonoperatingIncomeExpense to InvestmentIncomeInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestExpense" xlink:title="calculation: NonoperatingIncomeExpense to InterestExpense" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: NetIncomeLoss to NonoperatingIncomeExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="0.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OperatingIncomeLoss" xlink:title="calculation: NetIncomeLoss to OperatingIncomeLoss" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="NetIncomeLoss" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to NetIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="PreferredStockDividendsAndOtherAdjustments" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to PreferredStockDividendsAndOtherAdjustments" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OperatingLeaseRightOfUseAssetAmortizationExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="PaidInKindInterest" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to PaidInKindInterest" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to FairValueAdjustmentOfWarrants" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="IncreaseDecreaseInInterestPayableNet" xlink:title="IncreaseDecreaseInInterestPayableNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInInterestPayableNet" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInInterestPayableNet" order="5.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromLinesOfCredit" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromLinesOfCredit" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:label="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:title="AccruedResearchAndDevelopmentCostsAndOtherCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedResearchAndDevelopmentCostsAndOtherCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedProfessionalFeesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to EmployeeRelatedLiabilitiesCurrent" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LeasesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LeasesDetailsCalc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiability" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiability" order="1.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>galt-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlcDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#GalectinSciencesLlcDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LeasesDetailsCalc2" xlink:type="simple" xlink:href="galt-20230331.xsd#LeasesDetailsCalc2" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LeasesDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#LeasesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#ConvertibleLineOfCreditRelatedPartyDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommonStockDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#CommonStockDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShareDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#LossPerShareDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommonStockWarrantsDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#CommonStockWarrantsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#FairValueOfFinancialInstrumentsKeyAssumptionsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#ConvertibleNotesPayableRelatedPartyDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#AccruedExpensesAndOtherDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#BasisOfPresentationAndLiquidityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LeasesTables" xlink:type="simple" xlink:href="galt-20230331.xsd#LeasesTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShareTables" xlink:type="simple" xlink:href="galt-20230331.xsd#LossPerShareTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommonStockWarrantsTables" xlink:type="simple" xlink:href="galt-20230331.xsd#CommonStockWarrantsTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="galt-20230331.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesAndOtherTables" xlink:type="simple" xlink:href="galt-20230331.xsd#AccruedExpensesAndOtherTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlc" xlink:type="simple" xlink:href="galt-20230331.xsd#GalectinSciencesLlc" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/Leases" xlink:type="simple" xlink:href="galt-20230331.xsd#Leases" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="galt-20230331.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty" xlink:type="simple" xlink:href="galt-20230331.xsd#ConvertibleLineOfCreditRelatedParty" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommonStock" xlink:type="simple" xlink:href="galt-20230331.xsd#CommonStock" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShare" xlink:type="simple" xlink:href="galt-20230331.xsd#LossPerShare" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommonStockWarrants" xlink:type="simple" xlink:href="galt-20230331.xsd#CommonStockWarrants" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="galt-20230331.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty" xlink:type="simple" xlink:href="galt-20230331.xsd#ConvertibleNotesPayableRelatedParty" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesAndOther" xlink:type="simple" xlink:href="galt-20230331.xsd#AccruedExpensesAndOther" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidity" xlink:type="simple" xlink:href="galt-20230331.xsd#BasisOfPresentationAndLiquidity" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="galt-20230331.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertiblePreferredStockDividends" xlink:label="ConvertiblePreferredStockDividends" xlink:title="ConvertiblePreferredStockDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ConvertiblePreferredStockDividends" xlink:title="definition: StatementLineItems to ConvertiblePreferredStockDividends" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertiblePreferredStockDividendsShares" xlink:label="ConvertiblePreferredStockDividendsShares" xlink:title="ConvertiblePreferredStockDividendsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ConvertiblePreferredStockDividendsShares" xlink:title="definition: StatementLineItems to ConvertiblePreferredStockDividendsShares" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_TemporaryEquityDividends" xlink:label="TemporaryEquityDividends" xlink:title="TemporaryEquityDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquityDividends" xlink:title="definition: StatementLineItems to TemporaryEquityDividends" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_TemporaryEquityDividendsShares" xlink:label="TemporaryEquityDividendsShares" xlink:title="TemporaryEquityDividendsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquityDividendsShares" xlink:title="definition: StatementLineItems to TemporaryEquityDividendsShares" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="PreferredStockMember" xlink:title="definition: EquityComponentDomain to PreferredStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAPreferredStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesAndOther" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtDisclosureTextBlock" xlink:title="definition: DebtInstrumentLineItems to DebtDisclosureTextBlock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: DebtInstrumentTable to LongtermDebtTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember" xlink:label="LoansPayableMember" xlink:title="LoansPayableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="LoansPayableMember" xlink:title="definition: LongtermDebtTypeDomain to LoansPayableMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstruments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommonStockWarrants" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShare" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommonStock" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtDisclosureTextBlock" xlink:title="definition: DebtInstrumentLineItems to DebtDisclosureTextBlock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: DebtInstrumentTable to LongtermDebtTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="LineOfCreditMember" xlink:title="definition: LongtermDebtTypeDomain to LineOfCreditMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/Leases" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/GalectinSciencesLlc" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesAndOtherTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain_2" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain_2" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommonStockWarrantsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShareTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LeasesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_BasisOfPresentationsAndLiquidityAbstract" xlink:label="BasisOfPresentationsAndLiquidityAbstract" xlink:title="BasisOfPresentationsAndLiquidityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="BasisOfPresentationsAndLiquidityAbstract" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to BasisOfPresentationsAndLiquidityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to CashAndCashEquivalentsAtCarryingValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to LineOfCreditFacilityMaximumBorrowingCapacity" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="definition: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="CreditFacilityAxis" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to CreditFacilityAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain_2" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain_2" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UnsecuredConvertiblePromissoryNoteMember" xlink:label="UnsecuredConvertiblePromissoryNoteMember" xlink:title="UnsecuredConvertiblePromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="UnsecuredConvertiblePromissoryNoteMember" xlink:title="definition: CreditFacilityDomain to UnsecuredConvertiblePromissoryNoteMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertibleNotesPayableRelatedPartyAbstract" xlink:label="ConvertibleNotesPayableRelatedPartyAbstract" xlink:title="ConvertibleNotesPayableRelatedPartyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ConvertibleNotesPayableRelatedPartyAbstract" xlink:title="definition: DebtInstrumentLineItems to ConvertibleNotesPayableRelatedPartyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtConversionConvertedInstrumentAmount1" xlink:title="definition: DebtInstrumentLineItems to DebtConversionConvertedInstrumentAmount1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentMaturityDate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:label="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:title="NumberOfPromissoryNotesEvidencedByLoansAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:title="definition: DebtInstrumentLineItems to NumberOfPromissoryNotesEvidencedByLoansAgreement" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConvertibleConversionPrice1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateEffectivePercentage" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="InterestExpenseDebt" xlink:title="definition: DebtInstrumentLineItems to InterestExpenseDebt" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_QuarterlyInterestRate" xlink:label="QuarterlyInterestRate" xlink:title="QuarterlyInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="QuarterlyInterestRate" xlink:title="definition: DebtInstrumentLineItems to QuarterlyInterestRate" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AnnualInterestRate" xlink:label="AnnualInterestRate" xlink:title="AnnualInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="AnnualInterestRate" xlink:title="definition: DebtInstrumentLineItems to AnnualInterestRate" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="definition: DebtInstrumentLineItems to DerivativeLiabilitiesNoncurrent" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="definition: DebtInstrumentLineItems to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="AmortizationOfFinancingCosts" xlink:title="definition: DebtInstrumentLineItems to AmortizationOfFinancingCosts" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther" xlink:label="InterestExpenseOther" xlink:title="InterestExpenseOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="InterestExpenseOther" xlink:title="definition: DebtInstrumentLineItems to InterestExpenseOther" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RepaymentsOfDebt" xlink:title="definition: DebtInstrumentLineItems to RepaymentsOfDebt" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="17.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AprilConvertiblePromissoryNoteMember" xlink:label="AprilConvertiblePromissoryNoteMember" xlink:title="AprilConvertiblePromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="AprilConvertiblePromissoryNoteMember" xlink:title="definition: DebtInstrumentNameDomain to AprilConvertiblePromissoryNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_SeptemberConvertiblePromissoryNoteMember" xlink:label="SeptemberConvertiblePromissoryNoteMember" xlink:title="SeptemberConvertiblePromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="SeptemberConvertiblePromissoryNoteMember" xlink:title="definition: DebtInstrumentNameDomain to SeptemberConvertiblePromissoryNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DecemberConvertiblePromissoryNoteMember" xlink:label="DecemberConvertiblePromissoryNoteMember" xlink:title="DecemberConvertiblePromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="DecemberConvertiblePromissoryNoteMember" xlink:title="definition: DebtInstrumentNameDomain to DecemberConvertiblePromissoryNoteMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: DebtInstrumentTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="definition: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="StatementScenarioAxis" xlink:title="definition: DebtInstrumentTable to StatementScenarioAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="definition: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosure" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FinancialLiabilitiesFairValueDisclosure" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to DerivativeLiabilitiesNoncurrent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain_2" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain_2" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="FairValueInputsLevel12And3Member" xlink:title="FairValueInputsLevel12And3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel12And3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel12And3Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueInputsLevel12And3Member to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueInputsLevel12And3Member to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueInputsLevel12And3Member to FairValueInputsLevel3Member" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:label="ValuationTechniqueAndInputDescriptionAbstract" xlink:title="ValuationTechniqueAndInputDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="ValuationTechniqueAndInputDescriptionAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to ValuationTechniqueAndInputDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="DerivativeLiabilityMeasurementInput" xlink:title="DerivativeLiabilityMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="DerivativeLiabilityMeasurementInput" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to DerivativeLiabilityMeasurementInput" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="DebtInstrumentTerm" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to DebtInstrumentTerm" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="MeasurementInputTypeAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to MeasurementInputTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain_2" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain_2" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="MeasurementInputSharePriceMember" xlink:title="MeasurementInputSharePriceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputSharePriceMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputSharePriceMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="MeasurementInputConversionPriceMember" xlink:title="MeasurementInputConversionPriceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputConversionPriceMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputConversionPriceMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="MeasurementInputDiscountRateMember" xlink:title="MeasurementInputDiscountRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputDiscountRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputDiscountRateMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedDividendRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedDividendRateMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to DerivativeInstrumentRiskAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain_2" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain_2" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to DerivativeLiabilitiesNoncurrent" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAdjustmentOfWarrants" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain_2" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain_2" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpense" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_RestrictedStockGrantsAbstract" xlink:label="RestrictedStockGrantsAbstract" xlink:title="RestrictedStockGrantsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="RestrictedStockGrantsAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to RestrictedStockGrantsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpense" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:title="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:title="DeferredCompensationArrangementWithIndividualSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementWithIndividualSharesIssued" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:title="DeferredCompensationArrangementWithIndividualExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementWithIndividualExercisePrice" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="CommonStockSharesSubscribedButUnissued" xlink:title="CommonStockSharesSubscribedButUnissued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="CommonStockSharesSubscribedButUnissued" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to CommonStockSharesSubscribedButUnissued" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to SharesPaidForTaxWithholdingForShareBasedCompensation" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="19.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to TitleOfIndividualAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to AwardTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:title="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:title="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis to DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_2" xlink:title="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_2" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis to DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusMember" xlink:label="DeferredBonusMember" xlink:title="DeferredBonusMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="DeferredBonusMember" xlink:title="definition: DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain to DeferredBonusMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommonStockWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to WarrantsAndRightsOutstandingTerm" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to FinancialInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to ConvertibleNotesPayableMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="LineOfCreditMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to LineOfCreditMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to ConvertiblePreferredStockMember" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="definition: ClassOfStockLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AggregateOfferingPrice" xlink:label="AggregateOfferingPrice" xlink:title="AggregateOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="AggregateOfferingPrice" xlink:title="definition: ClassOfStockLineItems to AggregateOfferingPrice" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CommissionRate" xlink:label="CommissionRate" xlink:title="CommissionRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommissionRate" xlink:title="definition: ClassOfStockLineItems to CommissionRate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesIssued" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsShares" xlink:label="CommonStockDividendsShares" xlink:title="CommonStockDividendsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockDividendsShares" xlink:title="definition: ClassOfStockLineItems to CommonStockDividendsShares" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfStockByClassTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_TwoThousandTwentyMarketAgreementMember" xlink:label="TwoThousandTwentyMarketAgreementMember" xlink:title="TwoThousandTwentyMarketAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="TwoThousandTwentyMarketAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to TwoThousandTwentyMarketAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_SeriesAAndSeriesCPreferredStockMember" xlink:label="SeriesAAndSeriesCPreferredStockMember" xlink:title="SeriesAAndSeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAAndSeriesCPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAAndSeriesCPreferredStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="LineOfCreditFacilityLineItems" xlink:title="LineOfCreditFacilityLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_LineOfCreditRelatedPartyAbstract" xlink:label="LineOfCreditRelatedPartyAbstract" xlink:title="LineOfCreditRelatedPartyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditRelatedPartyAbstract" xlink:title="definition: LineOfCreditFacilityLineItems to LineOfCreditRelatedPartyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="definition: LineOfCreditFacilityLineItems to LineOfCreditFacilityMaximumBorrowingCapacity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentInterestRateIncreaseDecrease" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentMaturityDate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="SharePrice" xlink:title="definition: LineOfCreditFacilityLineItems to SharePrice" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ProceedsFromLinesOfCredit" xlink:title="definition: LineOfCreditFacilityLineItems to ProceedsFromLinesOfCredit" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: LineOfCreditFacilityLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="definition: LineOfCreditFacilityLineItems to CommonStockParOrStatedValuePerShare" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: LineOfCreditFacilityLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="DebtInstrumentInterestRateDuringPeriod" xlink:title="DebtInstrumentInterestRateDuringPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentInterestRateDuringPeriod" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentInterestRateDuringPeriod" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentInterestRateStatedPercentage" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentInterestRateEffectivePercentage" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DebtInstrumentAccruedInterest" xlink:label="DebtInstrumentAccruedInterest" xlink:title="DebtInstrumentAccruedInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentAccruedInterest" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentAccruedInterest" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: LineOfCreditFacilityLineItems to ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="definition: LineOfCreditFacilityLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="WarrantsAndRightsOutstandingMaturityDate" xlink:title="WarrantsAndRightsOutstandingMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="WarrantsAndRightsOutstandingMaturityDate" xlink:title="definition: LineOfCreditFacilityLineItems to WarrantsAndRightsOutstandingMaturityDate" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_IssuanceOfWarrantsValue" xlink:label="IssuanceOfWarrantsValue" xlink:title="IssuanceOfWarrantsValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="IssuanceOfWarrantsValue" xlink:title="definition: LineOfCreditFacilityLineItems to IssuanceOfWarrantsValue" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: LineOfCreditFacilityLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: LineOfCreditFacilityLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: LineOfCreditFacilityLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: LineOfCreditFacilityLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="InterestExpenseRelatedParty" xlink:title="InterestExpenseRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="InterestExpenseRelatedParty" xlink:title="definition: LineOfCreditFacilityLineItems to InterestExpenseRelatedParty" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="LineOfCreditFacilityTable" xlink:title="LineOfCreditFacilityTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditFacilityTable" xlink:title="definition: LineOfCreditFacilityLineItems to LineOfCreditFacilityTable" order="23.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: LineOfCreditFacilityTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: LineOfCreditFacilityTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="definition: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="CreditFacilityAxis" xlink:title="definition: LineOfCreditFacilityTable to CreditFacilityAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain_2" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain_2" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UnsecuredConvertiblePromissoryNoteMember" xlink:label="UnsecuredConvertiblePromissoryNoteMember" xlink:title="UnsecuredConvertiblePromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="UnsecuredConvertiblePromissoryNoteMember" xlink:title="definition: CreditFacilityDomain to UnsecuredConvertiblePromissoryNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="RangeAxis" xlink:title="definition: LineOfCreditFacilityTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: LineOfCreditFacilityTable to FinancialInstrumentAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_WarrantOneMember" xlink:label="WarrantOneMember" xlink:title="WarrantOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantOneMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantOneMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_WarrantTwoMember" xlink:label="WarrantTwoMember" xlink:title="WarrantTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantTwoMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantTwoMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LeasesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDescriptionAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDiscountRate" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDiscountRate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDue" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiability" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiability" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_NumberOfOperatingLeases" xlink:label="NumberOfOperatingLeases" xlink:title="NumberOfOperatingLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="NumberOfOperatingLeases" xlink:title="definition: LesseeLeaseDescriptionLineItems to NumberOfOperatingLeases" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseTermOfContract" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_FreeRentPeriod" xlink:label="FreeRentPeriod" xlink:title="FreeRentPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="FreeRentPeriod" xlink:title="definition: LesseeLeaseDescriptionLineItems to FreeRentPeriod" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="SecurityDeposit" xlink:title="SecurityDeposit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="SecurityDeposit" xlink:title="definition: LesseeLeaseDescriptionLineItems to SecurityDeposit" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseCost" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseCost" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseRightOfUseAsset" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilityCurrent" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilityNoncurrent" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeLeaseDescriptionTable" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeLeaseDescriptionTable" order="21.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: LesseeLeaseDescriptionTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LeasesDetailsCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/GalectinSciencesLlcDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:label="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:title="InvestmentsInAndAdvancesToAffiliatesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="PaymentsToAcquireEquityMethodInvestments" xlink:title="PaymentsToAcquireEquityMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="PaymentsToAcquireEquityMethodInvestments" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to PaymentsToAcquireEquityMethodInvestments" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:title="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to MinorityInterestOwnershipPercentageByParent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CapitalContributionExpense" xlink:label="CapitalContributionExpense" xlink:title="CapitalContributionExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="CapitalContributionExpense" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to CapitalContributionExpense" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="ScheduleOfInvestmentsTable" xlink:title="ScheduleOfInvestmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="ScheduleOfInvestmentsTable" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to ScheduleOfInvestmentsTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfInvestmentsTable" xlink:to="OwnershipAxis" xlink:title="definition: ScheduleOfInvestmentsTable to OwnershipAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain_2" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain_2" xlink:title="definition: OwnershipAxis to OwnershipDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_GalectinSciencesLLCMember" xlink:label="GalectinSciencesLLCMember" xlink:title="GalectinSciencesLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="GalectinSciencesLLCMember" xlink:title="definition: OwnershipDomain to GalectinSciencesLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfInvestmentsTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: ScheduleOfInvestmentsTable to CounterpartyNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_SBHSciencesIncMember" xlink:label="SBHSciencesIncMember" xlink:title="SBHSciencesIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="SBHSciencesIncMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to SBHSciencesIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfInvestmentsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: ScheduleOfInvestmentsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="InProcessResearchAndDevelopmentMember" xlink:title="InProcessResearchAndDevelopmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="InProcessResearchAndDevelopmentMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to InProcessResearchAndDevelopmentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="definition: AssetsAbstract to OtherAssetsNoncurrent" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>galt-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl">Accrued Expenses and Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent_lbl">Legal and accounting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl">Accrued expenses and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl1">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl2">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss to net cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl">Common stock purchase warrants issued in connection with related party line of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl">Reclassification of accrued compensation to additional paid in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Amortized expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCosts_lbl">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:title="label: AmortizationOfFinancingCosts to us-gaap_AmortizationOfFinancingCosts_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Amount excluded from calculation (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosure_lbl">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:title="label: AssetsFairValueDisclosure to us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosure_lbl1">Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl1" xlink:title="label: AssetsFairValueDisclosure to us-gaap_AssetsFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl1" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="BasisOfAccounting" xlink:title="BasisOfAccounting" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccounting_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" id="us-gaap_BasisOfAccounting_lbl">Basis of Presentation and Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:title="label: BasisOfAccounting to us-gaap_BasisOfAccounting_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccounting_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccounting_lbl1" xml:lang="en-US" id="us-gaap_BasisOfAccounting_lbl1">Basis of Accounting [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl1" xlink:title="label: BasisOfAccounting to us-gaap_BasisOfAccounting_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="CapitalLeaseObligationsIncurred" xlink:title="CapitalLeaseObligationsIncurred" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US" id="us-gaap_CapitalLeaseObligationsIncurred_lbl">Noncash right to use lease asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:title="label: CapitalLeaseObligationsIncurred to us-gaap_CapitalLeaseObligationsIncurred_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1">Amount expanded in cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl">NONCASH FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl">Warrants to purchase common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl">Exercise price of warrant (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl">Commitments and contingencies (Note 10)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsShares" xlink:label="CommonStockDividendsShares" xlink:title="CommonStockDividendsShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US" id="us-gaap_CommonStockDividendsShares_lbl">Common stock issued for dividends (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl" xlink:title="label: CommonStockDividendsShares to us-gaap_CommonStockDividendsShares_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="CommonStockSharesSubscribedButUnissued" xlink:title="CommonStockSharesSubscribedButUnissued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesSubscribedButUnissued_lbl">Shares unissued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:title="label: CommonStockSharesSubscribedButUnissued to us-gaap_CommonStockSharesSubscribedButUnissued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common stock, $0.001 par value; 150,000,000 shares authorized at March 31, 2023 and December 31, 2022, 59,582,253 and 59,426,005 issued and outstanding at March 31, 2023 and December 31, 2022, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl1">Issuance of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Common Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US" id="us-gaap_ConvertibleNotesPayableMember_lbl">Convertible Note Payable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:title="label: ConvertibleNotesPayableMember to us-gaap_ConvertibleNotesPayableMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_ConvertiblePreferredStockMember_lbl">Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:title="label: ConvertiblePreferredStockMember to us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" id="us-gaap_CreditFacilityDomain_lbl">Credit Facility [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" xlink:title="label: CreditFacilityDomain to us-gaap_CreditFacilityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" id="us-gaap_CreditFacilityAxis_lbl">Credit Facility [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:title="label: CreditFacilityAxis to us-gaap_CreditFacilityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl">Additional short term borrowing interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:title="label: DebtInstrumentInterestRateIncreaseDecrease to us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTerm_lbl">Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:title="label: DebtInstrumentTerm to us-gaap_DebtInstrumentTerm_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" id="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl">Convertible note principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:title="label: DebtConversionConvertedInstrumentAmount1 to us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl">Conversion price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:title="label: DebtInstrumentConvertibleConversionPrice1 to us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTable_lbl">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_DebtDisclosureTextBlock_lbl">Convertible Line of Credit - Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:title="label: DebtDisclosureTextBlock to us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DebtDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DebtDisclosureTextBlock_lbl1">Convertible Notes Payable - Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl1" xlink:title="label: DebtDisclosureTextBlock to us-gaap_DebtDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis_lbl">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems_lbl">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl">Debt financing arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="DebtInstrumentInterestRateDuringPeriod" xlink:title="DebtInstrumentInterestRateDuringPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl">Interest rate on short term loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:title="label: DebtInstrumentInterestRateDuringPeriod to us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl">Short term borrowing effective interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl1">Effective interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl1" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract_lbl">Convertible Notes Payable - Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl">Interest rate compounded annually</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1">Short term borrowing interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain_lbl">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentMaturityDate_lbl">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:title="label: DebtInstrumentMaturityDate to us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentMaturityDate_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentMaturityDate_lbl1">Borrowings repayment due date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl1" xlink:title="label: DebtInstrumentMaturityDate to us-gaap_DebtInstrumentMaturityDate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:title="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_lbl" xml:lang="en-US" id="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_lbl">Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_lbl" xlink:title="label: DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain to us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusMember" xlink:label="DeferredBonusMember" xlink:title="DeferredBonusMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredBonusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredBonusMember_lbl" xml:lang="en-US" id="us-gaap_DeferredBonusMember_lbl">Deferred Bonus [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredBonusMember" xlink:to="us-gaap_DeferredBonusMember_lbl" xlink:title="label: DeferredBonusMember to us-gaap_DeferredBonusMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:title="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl">Stock based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:title="label: DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense to us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1">Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense to us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:title="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_lbl" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_lbl">Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_lbl" xlink:title="label: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis to us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:title="DeferredCompensationArrangementWithIndividualExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_lbl" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_lbl">Common Stock Weighted average Grant Date fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_lbl" xlink:title="label: DeferredCompensationArrangementWithIndividualExercisePrice to us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:title="DeferredCompensationArrangementWithIndividualSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl">Common stock reserved for future issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl" xlink:title="label: DeferredCompensationArrangementWithIndividualSharesIssued to us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="DerivativeLiabilityMeasurementInput" xlink:title="DerivativeLiabilityMeasurementInput" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" id="us-gaap_DerivativeLiabilityMeasurementInput_lbl">Derivative liability, measurement input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:title="label: DerivativeLiabilityMeasurementInput to us-gaap_DerivativeLiabilityMeasurementInput_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeLiabilityMeasurementInput_lbl1" xml:lang="en-US" id="us-gaap_DerivativeLiabilityMeasurementInput_lbl1">Derivative Liability, Measurement Input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl1" xlink:title="label: DerivativeLiabilityMeasurementInput to us-gaap_DerivativeLiabilityMeasurementInput_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US" id="us-gaap_DerivativeInstrumentRiskAxis_lbl">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:title="label: DerivativeInstrumentRiskAxis to us-gaap_DerivativeInstrumentRiskAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_lbl" xml:lang="en-US" id="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_lbl">Change in fair value of derivative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_lbl" xlink:title="label: DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet to us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_lbl1" xml:lang="en-US" id="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_lbl1">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_lbl1" xlink:title="label: DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet to us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesNoncurrent_lbl">Derivative liabilities (Note 4)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:title="label: DerivativeLiabilitiesNoncurrent to us-gaap_DerivativeLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesNoncurrent_lbl1">Derivative Liability - Contingent Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl1" xlink:title="label: DerivativeLiabilitiesNoncurrent to us-gaap_DerivativeLiabilitiesNoncurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent_lbl2" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesNoncurrent_lbl2">Fair value of derivative liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl2" xlink:title="label: DerivativeLiabilitiesNoncurrent to us-gaap_DerivativeLiabilitiesNoncurrent_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent_lbl3" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesNoncurrent_lbl3">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl3" xlink:title="label: DerivativeLiabilitiesNoncurrent to us-gaap_DerivativeLiabilitiesNoncurrent_lbl3" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent_lbl4" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesNoncurrent_lbl4">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl4" xlink:title="label: DerivativeLiabilitiesNoncurrent to us-gaap_DerivativeLiabilitiesNoncurrent_lbl4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US" id="us-gaap_DerivativeContractTypeDomain_lbl">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" xlink:title="label: DerivativeContractTypeDomain to us-gaap_DerivativeContractTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent" xlink:label="DividendsPayableCurrent" xlink:title="DividendsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DividendsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_DividendsPayableCurrent_lbl">Accrued dividends payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_lbl" xlink:title="label: DividendsPayableCurrent to us-gaap_DividendsPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1">Earnings Per Share, Diluted, Other Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl">Net loss per common share - basic (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareTextBlock_lbl">Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:title="label: EarningsPerShareTextBlock to us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl">Loss Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl">Unrecognized compensation cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl">Unrecognized compensation cost, recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="us-gaap_EquityAbstract_lbl">Common Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="FairValueInputsLevel12And3Member" xlink:title="FairValueInputsLevel12And3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel12And3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel12And3Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel12And3Member_lbl">Fair Value, Inputs, Level 1, 2 and 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel12And3Member" xlink:to="us-gaap_FairValueInputsLevel12And3Member_lbl" xlink:title="label: FairValueInputsLevel12And3Member to us-gaap_FairValueInputsLevel12And3Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract_lbl">Assets and Liabilities Measured at Fair Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="us-gaap_FairValueAdjustmentOfWarrants_lbl">Change in fair value of derivative liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:title="label: FairValueAdjustmentOfWarrants to us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xml:lang="en-US" id="us-gaap_FairValueAdjustmentOfWarrants_lbl1">Fair Value Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xlink:title="label: FairValueAdjustmentOfWarrants to us-gaap_FairValueAdjustmentOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAdjustmentOfWarrants_lbl2" xml:lang="en-US" id="us-gaap_FairValueAdjustmentOfWarrants_lbl2">Fair Value Adjustment of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl2" xlink:title="label: FairValueAdjustmentOfWarrants to us-gaap_FairValueAdjustmentOfWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByMeasurementFrequencyAxis_lbl">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:title="label: FairValueByMeasurementFrequencyAxis to us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl">Key Assumptions Used in Model at Inception</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresAbstract_lbl">Fair Value of Financial Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:title="label: FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsRecurringMember_lbl">Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:title="label: FairValueMeasurementsRecurringMember to us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementFrequencyDomain_lbl">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:title="label: FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl">Roll Forward of Derivative Liability [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl">Roll Forward of Derivative Liability - Contingent Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:title="label: FinancialLiabilitiesFairValueDisclosure to us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1">Financial Liabilities Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xlink:title="label: FinancialLiabilitiesFairValueDisclosure to us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_FinancialInstrumentAxis_lbl">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:title="label: FinancialInstrumentAxis to us-gaap_FinancialInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:title="label: FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:title="label: FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember_lbl">General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="InProcessResearchAndDevelopmentMember" xlink:title="InProcessResearchAndDevelopmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US" id="us-gaap_InProcessResearchAndDevelopmentMember_lbl">IPR&amp;D [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:title="label: InProcessResearchAndDevelopmentMember to us-gaap_InProcessResearchAndDevelopmentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis_lbl">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain_lbl">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="IncreaseDecreaseInTemporaryEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInTemporaryEquityRollForward to us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl">Accounts payable, accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="IncreaseDecreaseInInterestPayableNet" xlink:title="IncreaseDecreaseInInterestPayableNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl">Accrued interest on convertible debt - related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:title="label: IncreaseDecreaseInInterestPayableNet to us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="InterestExpenseRelatedParty" xlink:title="InterestExpenseRelatedParty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseRelatedParty_lbl" xml:lang="en-US" id="us-gaap_InterestExpenseRelatedParty_lbl">Amortization of interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl" xlink:title="label: InterestExpenseRelatedParty to us-gaap_InterestExpenseRelatedParty_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="us-gaap_InterestExpense_lbl">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpense_lbl1" xml:lang="en-US" id="us-gaap_InterestExpense_lbl1">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl1" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" id="us-gaap_InterestExpenseDebt_lbl">Accrued interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:title="label: InterestExpenseDebt to us-gaap_InterestExpenseDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseDebt_lbl1" xml:lang="en-US" id="us-gaap_InterestExpenseDebt_lbl1">Interest Expense, Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl1" xlink:title="label: InterestExpenseDebt to us-gaap_InterestExpenseDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther" xlink:label="InterestExpenseOther" xlink:title="InterestExpenseOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US" id="us-gaap_InterestExpenseOther_lbl">Additional interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl" xlink:title="label: InterestExpenseOther to us-gaap_InterestExpenseOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseOther_lbl1" xml:lang="en-US" id="us-gaap_InterestExpenseOther_lbl1">Interest Expense, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl1" xlink:title="label: InterestExpenseOther to us-gaap_InterestExpenseOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest_lbl">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_lbl">Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_lbl" xlink:title="label: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract_lbl" xml:lang="en-US" id="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract_lbl">Galectin Sciences LLC [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract_lbl" xlink:title="label: InvestmentsInAndAdvancesToAffiliatesAbstract to us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:label="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:title="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_lbl">Galectin Sciences LLC</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_lbl" xlink:title="label: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock to us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:title="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl">Estimated fair value of asset contributed to joint venture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl" xlink:title="label: InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure to us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl1">Investments in Affiliates, Subsidiaries, Associates, and Joint Ventures, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl1" xlink:title="label: InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure to us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:label="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:title="InvestmentsInAndAdvancesToAffiliatesLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_lbl" xml:lang="en-US" id="us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_lbl">Investments in and Advances to Affiliates [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_lbl" xlink:title="label: InvestmentsInAndAdvancesToAffiliatesLineItems to us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock_lbl">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseTermOfContract_lbl">Term of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:title="label: LesseeOperatingLeaseTermOfContract to us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionTable_lbl">Lessee, Lease, Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:title="label: LesseeLeaseDescriptionTable to us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl">Maturity of Operating Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDiscountRate_lbl">Discount rate on present value of lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:title="label: LesseeOperatingLeaseDiscountRate to us-gaap_LesseeOperatingLeaseDiscountRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionLineItems_lbl">Lessee, Lease, Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:title="label: LesseeLeaseDescriptionLineItems to us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl">Lease Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:title="label: LesseeOperatingLeaseDescriptionAbstract to us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="us-gaap_LongtermDebtTypeAxis_lbl">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:title="label: LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="us-gaap_LongtermDebtTypeDomain_lbl">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xlink:title="label: LongtermDebtTypeDomain to us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" id="us-gaap_LeasesAbstract_lbl">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:title="label: LeasesAbstract to us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl1">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl1" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="LineOfCreditFacilityLineItems" xlink:title="LineOfCreditFacilityLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityLineItems_lbl">Line of Credit Facility [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:title="label: LineOfCreditFacilityLineItems to us-gaap_LineOfCreditFacilityLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditMember_lbl">Convertible Line of Credit - Related Party [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl" xlink:title="label: LineOfCreditMember to us-gaap_LineOfCreditMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditMember_lbl1" xml:lang="en-US" id="us-gaap_LineOfCreditMember_lbl1">Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl1" xlink:title="label: LineOfCreditMember to us-gaap_LineOfCreditMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="LineOfCreditFacilityAbstract" xlink:title="LineOfCreditFacilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityAbstract_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityAbstract_lbl">Convertible Line of Credit - Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityAbstract_lbl" xlink:title="label: LineOfCreditFacilityAbstract to us-gaap_LineOfCreditFacilityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="LineOfCreditFacilityTable" xlink:title="LineOfCreditFacilityTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityTable_lbl">Line of Credit Facility [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:title="label: LineOfCreditFacilityTable to us-gaap_LineOfCreditFacilityTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl">Line of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:title="label: LineOfCreditFacilityMaximumBorrowingCapacity to us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl1" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl1">Line of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl1" xlink:title="label: LineOfCreditFacilityMaximumBorrowingCapacity to us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember" xlink:label="LoansPayableMember" xlink:title="LoansPayableMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LoansPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LoansPayableMember_lbl" xml:lang="en-US" id="us-gaap_LoansPayableMember_lbl">Convertible Notes Payable - Related Party [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansPayableMember" xlink:to="us-gaap_LoansPayableMember_lbl" xlink:title="label: LoansPayableMember to us-gaap_LoansPayableMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputTypeDomain_lbl">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xlink:title="label: MeasurementInputTypeDomain to us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="MeasurementInputSharePriceMember" xlink:title="MeasurementInputSharePriceMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputSharePriceMember_lbl">Stock Price [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:title="label: MeasurementInputSharePriceMember to us-gaap_MeasurementInputSharePriceMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl">Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:title="label: MeasurementInputRiskFreeInterestRateMember to us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedTermMember_lbl">Term [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:title="label: MeasurementInputExpectedTermMember to us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputTypeAxis_lbl">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:title="label: MeasurementInputTypeAxis to us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="MeasurementInputConversionPriceMember" xlink:title="MeasurementInputConversionPriceMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputConversionPriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputConversionPriceMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputConversionPriceMember_lbl">Conversion Price of Conversion Feature [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputConversionPriceMember" xlink:to="us-gaap_MeasurementInputConversionPriceMember_lbl" xlink:title="label: MeasurementInputConversionPriceMember to us-gaap_MeasurementInputConversionPriceMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputPriceVolatilityMember_lbl">Volatility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:title="label: MeasurementInputPriceVolatilityMember to us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedDividendRateMember_lbl">Dividend Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:title="label: MeasurementInputExpectedDividendRateMember to us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="MeasurementInputDiscountRateMember" xlink:title="MeasurementInputDiscountRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputDiscountRateMember_lbl">Credit Adjusted Discount Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:title="label: MeasurementInputDiscountRateMember to us-gaap_MeasurementInputDiscountRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl">Equity ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:title="label: MinorityInterestOwnershipPercentageByParent to us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash from operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash flows from financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl2">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl">Net loss applicable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:title="label: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:title="label: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl">Total other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:title="label: OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList to us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl">Long term lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl">Amortization of right to use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl">Current lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl1">Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl">Maturity of Operating Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl">Present value of lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl1">Operating Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl">Right to use lease asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:title="label: OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList to us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseCost_lbl">Lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:title="label: OperatingLeaseCost to us-gaap_OperatingLeaseCost_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:title="label: OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList to us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Total operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl">Basis of Presentation and Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" id="us-gaap_PaidInKindInterest_lbl">Non-cash interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:title="label: PaidInKindInterest to us-gaap_PaidInKindInterest_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract_lbl">Accrued Expenses and Other [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl">Income tax payment withholding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:title="label: PaymentsRelatedToTaxWithholdingForShareBasedCompensation to us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="PaymentsToAcquireEquityMethodInvestments" xlink:title="PaymentsToAcquireEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl">Initial cash investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:title="label: PaymentsToAcquireEquityMethodInvestments to us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_PreferredStockMember_lbl">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:title="label: PreferredStockMember to us-gaap_PreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="PreferredStockLiquidationPreferenceValue" xlink:title="PreferredStockLiquidationPreferenceValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockLiquidationPreferenceValue_lbl">Series A 12% convertible preferred stock, liquidation value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:title="label: PreferredStockLiquidationPreferenceValue to us-gaap_PreferredStockLiquidationPreferenceValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US" id="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl">Preferred stock dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:title="label: PreferredStockDividendsAndOtherAdjustments to us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xlink:title="label: PreferredStockDividendsAndOtherAdjustments to us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl">Series A 12% convertible preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Series A 12% convertible preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl">Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,260,000 issued and outstanding at March 31, 2023 and December 31, 2022, liquidation value $1,260,500 at March 31, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl">Series A 12% convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromLinesOfCredit_lbl">Net proceeds from convertible line of credit - related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:title="label: ProceedsFromLinesOfCredit to us-gaap_ProceedsFromLinesOfCredit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromLinesOfCredit_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromLinesOfCredit_lbl1">Proceeds from lines of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl1" xlink:title="label: ProceedsFromLinesOfCredit to us-gaap_ProceedsFromLinesOfCredit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyDomain_lbl">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" id="us-gaap_RepaymentsOfDebt_lbl">Convertible note payable repayment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:title="label: RepaymentsOfDebt to us-gaap_RepaymentsOfDebt_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockMember_lbl">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:title="label: RestrictedStockMember to us-gaap_RestrictedStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Retained deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl">Retained Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl">Expected life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1">Expected life of the options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl">Unvested options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl">Weighted Average Assumptions Used to Determine Fair Value of Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl">Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl">Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:title="label: ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock to us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="ScheduleOfInvestmentsTable" xlink:title="ScheduleOfInvestmentsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfInvestmentsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfInvestmentsTable_lbl">Schedule of Investments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsTable_lbl" xlink:title="label: ScheduleOfInvestmentsTable to us-gaap_ScheduleOfInvestmentsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl">Components of Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl">Common Stock Warrant Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:title="label: ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock to us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable_lbl">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="SecurityDeposit" xlink:title="SecurityDeposit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" id="us-gaap_SecurityDeposit_lbl">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:title="label: SecurityDeposit to us-gaap_SecurityDeposit_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_SeriesAPreferredStockMember_lbl">Series A 12% Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:title="label: SeriesAPreferredStockMember to us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US" id="us-gaap_SeriesAPreferredStockMember_lbl1">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1" xlink:title="label: SeriesAPreferredStockMember to us-gaap_SeriesAPreferredStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl">Forfeited/cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl">Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharePrice_lbl" xml:lang="en-US" id="us-gaap_SharePrice_lbl">Share price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl">Common Stock Warrants shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1">Restricted stock awards granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl">Forfeited/cancelled (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl">Outstanding at beginning of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1">Outstanding at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl">Stock-Based Compensation Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl">Weighted Average Assumptions for Stock Options Granted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1">Expected volatility of the underlying stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl">Risk free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl">Expected dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1">Expected dividend rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl">Outstanding at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1">Outstanding at beginning of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl">Forfeited/cancelled (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl">Stock Option Activity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl">Shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl">Beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl1">Ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl">Shares withheld to cover income tax withholding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:title="label: SharesPaidForTaxWithholdingForShareBasedCompensation to us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssued1_lbl" xml:lang="en-US" id="us-gaap_StockIssued1_lbl">Payment of preferred stock dividends in common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:title="label: StockIssued1 to us-gaap_StockIssued1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssued1_lbl1" xml:lang="en-US" id="us-gaap_StockIssued1_lbl1">Stock Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssued1" xlink:to="us-gaap_StockIssued1_lbl1" xlink:title="label: StockIssued1 to us-gaap_StockIssued1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl">Stock-based compensation expense (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:title="label: StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl2">Total stockholders' equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">Stockholders' equity (deficit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl1">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl">Ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:title="label: TemporaryEquityCarryingAmountAttributableToParent to us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl1" xml:lang="en-US" id="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl1">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl1" xlink:title="label: TemporaryEquityCarryingAmountAttributableToParent to us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl2" xml:lang="en-US" id="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl2">Series C super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 shares issued and outstanding at March 31, 2023 and December 31, 2022, redemption value: $8,256,000, liquidation value: $1,760,000 at March 31, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl2" xlink:title="label: TemporaryEquityCarryingAmountAttributableToParent to us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:label="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:title="TemporaryEquityAggregateAmountOfRedemptionRequirement" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl" xml:lang="en-US" id="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl">Series C 6% super dividend redeemable convertible preferred stock, redemption value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:to="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl" xlink:title="label: TemporaryEquityAggregateAmountOfRedemptionRequirement to us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="TemporaryEquityLiquidationPreference" xlink:title="TemporaryEquityLiquidationPreference" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" id="us-gaap_TemporaryEquityLiquidationPreference_lbl">Series C 6% super dividend redeemable convertible preferred stock liquidation value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:title="label: TemporaryEquityLiquidationPreference to us-gaap_TemporaryEquityLiquidationPreference_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" id="us-gaap_TemporaryEquitySharesIssued_lbl">Series C 6% super dividend redeemable convertible preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:title="label: TemporaryEquitySharesIssued to us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_TemporaryEquitySharesAuthorized_lbl">Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:title="label: TemporaryEquitySharesAuthorized to us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_TemporaryEquitySharesOutstanding_lbl">Ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:title="label: TemporaryEquitySharesOutstanding to us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_TemporaryEquitySharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_TemporaryEquitySharesOutstanding_lbl1">Beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl1" xlink:title="label: TemporaryEquitySharesOutstanding to us-gaap_TemporaryEquitySharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquitySharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_TemporaryEquitySharesOutstanding_lbl2">Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl2" xlink:title="label: TemporaryEquitySharesOutstanding to us-gaap_TemporaryEquitySharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" id="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:title="label: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:label="ValuationTechniqueAndInputDescriptionAbstract" xlink:title="ValuationTechniqueAndInputDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAndInputDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationTechniqueAndInputDescriptionAbstract_lbl" xml:lang="en-US" id="us-gaap_ValuationTechniqueAndInputDescriptionAbstract_lbl">Key Assumptions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationTechniqueAndInputDescriptionAbstract" xlink:to="us-gaap_ValuationTechniqueAndInputDescriptionAbstract_lbl" xlink:title="label: ValuationTechniqueAndInputDescriptionAbstract to us-gaap_ValuationTechniqueAndInputDescriptionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="us-gaap_WarrantMember_lbl">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="WarrantsAndRightsOutstandingMaturityDate" xlink:title="WarrantsAndRightsOutstandingMaturityDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl">Warrants expiry date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:title="label: WarrantsAndRightsOutstandingMaturityDate to us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm_lbl">Weighted average expiration term of warrants outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1">Warrants and Rights Outstanding, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl">Weighted average common shares outstanding - diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:label xlink:type="resource" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US" id="srt_BoardOfDirectorsChairmanMember_lbl">Richard E. Uihlein [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:title="label: BoardOfDirectorsChairmanMember to srt_BoardOfDirectorsChairmanMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:label xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" id="srt_CounterpartyNameAxis_lbl">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:title="label: CounterpartyNameAxis to srt_CounterpartyNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" id="srt_ChiefExecutiveOfficerMember_lbl">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:title="label: ChiefExecutiveOfficerMember to srt_ChiefExecutiveOfficerMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember_lbl" xml:lang="en-US" id="srt_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:title="label: MaximumMember to srt_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember_lbl" xml:lang="en-US" id="srt_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:title="label: MinimumMember to srt_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipDomain_lbl" xml:lang="en-US" id="srt_OwnershipDomain_lbl">Ownership [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xlink:title="label: OwnershipDomain to srt_OwnershipDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipAxis_lbl" xml:lang="en-US" id="srt_OwnershipAxis_lbl">Ownership [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xlink:title="label: OwnershipAxis to srt_OwnershipAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis_lbl" xml:lang="en-US" id="srt_RangeAxis_lbl">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:title="label: RangeAxis to srt_RangeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember_lbl" xml:lang="en-US" id="srt_RangeMember_lbl">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember_lbl" xlink:title="label: RangeMember to srt_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="srt_RepurchaseAgreementCounterpartyNameDomain_lbl">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:title="label: RepurchaseAgreementCounterpartyNameDomain to srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioForecastMember_lbl" xml:lang="en-US" id="srt_ScenarioForecastMember_lbl">Forecast [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:title="label: ScenarioForecastMember to srt_ScenarioForecastMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="srt_ScenarioUnspecifiedDomain_lbl">Scenario [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xlink:title="label: ScenarioUnspecifiedDomain to srt_ScenarioUnspecifiedDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_StatementScenarioAxis_lbl" xml:lang="en-US" id="srt_StatementScenarioAxis_lbl">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:title="label: StatementScenarioAxis to srt_StatementScenarioAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="srt_TitleOfIndividualAxis_lbl">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:title="label: TitleOfIndividualAxis to srt_TitleOfIndividualAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:title="label: TitleOfIndividualWithRelationshipToEntityDomain to srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" id="dei_DocumentQuarterlyReport_lbl">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:title="label: DocumentQuarterlyReport to dei_DocumentQuarterlyReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport_lbl" xml:lang="en-US" id="dei_DocumentTransitionReport_lbl">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent_lbl">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany_lbl" xml:lang="en-US" id="dei_EntityShellCompany_lbl">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:title="label: EntityShellCompany to dei_EntityShellCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness_lbl" xml:lang="en-US" id="dei_EntitySmallBusiness_lbl">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:label="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:title="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" />
    <link:label xlink:type="resource" xlink:label="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl" xml:lang="en-US" id="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl">Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as borrowing and accrued interest under line of credit related party excluding current portion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:to="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl" xlink:title="label: BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent to galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl1" xml:lang="en-US" id="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl1">Borrowing and Accrued Interest Under Line of Credit, Net of Debt Discount, Related Party Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:to="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl1" xlink:title="label: BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent to galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl2" xml:lang="en-US" id="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl2">Borrowing and accrued interest under convertible line of credit, net of debt discount - related party (Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:to="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl2" xlink:title="label: BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent to galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:label="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:title="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl" xml:lang="en-US" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl">Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as convertible notes payable and accrued interest, net of debt discount of related party excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:to="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl" xlink:title="label: ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent to galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl1" xml:lang="en-US" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl1">Convertible Note Payable and Accrued Interest Net of Debt Discount - Related Party Non-Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:to="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl1" xlink:title="label: ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent to galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl2" xml:lang="en-US" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl2">Convertible notes payable and accrued interest, net of discounts - related party (Note 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:to="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl2" xlink:title="label: ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent to galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UndesignatedCapitalStockValue" xlink:label="UndesignatedCapitalStockValue" xlink:title="UndesignatedCapitalStockValue" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_UndesignatedCapitalStockValue_lbl" xml:lang="en-US" id="galt_UndesignatedCapitalStockValue_lbl">Aggregate par or stated value of shares which are not designated as common stock or preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockValue" xlink:to="galt_UndesignatedCapitalStockValue_lbl" xlink:title="label: UndesignatedCapitalStockValue to galt_UndesignatedCapitalStockValue_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_UndesignatedCapitalStockValue_lbl1" xml:lang="en-US" id="galt_UndesignatedCapitalStockValue_lbl1">Undesignated Capital Stock Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockValue" xlink:to="galt_UndesignatedCapitalStockValue_lbl1" xlink:title="label: UndesignatedCapitalStockValue to galt_UndesignatedCapitalStockValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_UndesignatedCapitalStockValue_lbl2" xml:lang="en-US" id="galt_UndesignatedCapitalStockValue_lbl2">Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at March 31, 2023 and December 31, 2022, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockValue" xlink:to="galt_UndesignatedCapitalStockValue_lbl2" xlink:title="label: UndesignatedCapitalStockValue to galt_UndesignatedCapitalStockValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UndesignatedCapitalStockParValue" xlink:label="UndesignatedCapitalStockParValue" xlink:title="UndesignatedCapitalStockParValue" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_UndesignatedCapitalStockParValue_lbl" xml:lang="en-US" id="galt_UndesignatedCapitalStockParValue_lbl">Face amount or stated value per share of undesignated capital stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockParValue" xlink:to="galt_UndesignatedCapitalStockParValue_lbl" xlink:title="label: UndesignatedCapitalStockParValue to galt_UndesignatedCapitalStockParValue_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockParValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_UndesignatedCapitalStockParValue_lbl1" xml:lang="en-US" id="galt_UndesignatedCapitalStockParValue_lbl1">Undesignated Capital Stock Par Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockParValue" xlink:to="galt_UndesignatedCapitalStockParValue_lbl1" xlink:title="label: UndesignatedCapitalStockParValue to galt_UndesignatedCapitalStockParValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockParValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_UndesignatedCapitalStockParValue_lbl2" xml:lang="en-US" id="galt_UndesignatedCapitalStockParValue_lbl2">Undesignated stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockParValue" xlink:to="galt_UndesignatedCapitalStockParValue_lbl2" xlink:title="label: UndesignatedCapitalStockParValue to galt_UndesignatedCapitalStockParValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UndesignatedCapitalStockSharesAuthorized" xlink:label="UndesignatedCapitalStockSharesAuthorized" xlink:title="UndesignatedCapitalStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_UndesignatedCapitalStockSharesAuthorized_lbl" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesAuthorized_lbl">The maximum number of undesignated capital stock permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesAuthorized" xlink:to="galt_UndesignatedCapitalStockSharesAuthorized_lbl" xlink:title="label: UndesignatedCapitalStockSharesAuthorized to galt_UndesignatedCapitalStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_UndesignatedCapitalStockSharesAuthorized_lbl1" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesAuthorized_lbl1">Undesignated Capital Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesAuthorized" xlink:to="galt_UndesignatedCapitalStockSharesAuthorized_lbl1" xlink:title="label: UndesignatedCapitalStockSharesAuthorized to galt_UndesignatedCapitalStockSharesAuthorized_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesAuthorized_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_UndesignatedCapitalStockSharesAuthorized_lbl2" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesAuthorized_lbl2">Undesignated stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesAuthorized" xlink:to="galt_UndesignatedCapitalStockSharesAuthorized_lbl2" xlink:title="label: UndesignatedCapitalStockSharesAuthorized to galt_UndesignatedCapitalStockSharesAuthorized_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UndesignatedCapitalStockSharesDesignated" xlink:label="UndesignatedCapitalStockSharesDesignated" xlink:title="UndesignatedCapitalStockSharesDesignated" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesDesignated_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_UndesignatedCapitalStockSharesDesignated_lbl" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesDesignated_lbl">Number of shares of undesignated capital stock which are designated as common stock or preferred stock by board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesDesignated" xlink:to="galt_UndesignatedCapitalStockSharesDesignated_lbl" xlink:title="label: UndesignatedCapitalStockSharesDesignated to galt_UndesignatedCapitalStockSharesDesignated_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesDesignated_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_UndesignatedCapitalStockSharesDesignated_lbl1" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesDesignated_lbl1">Undesignated Capital Stock Shares Designated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesDesignated" xlink:to="galt_UndesignatedCapitalStockSharesDesignated_lbl1" xlink:title="label: UndesignatedCapitalStockSharesDesignated to galt_UndesignatedCapitalStockSharesDesignated_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesDesignated_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_UndesignatedCapitalStockSharesDesignated_lbl2" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesDesignated_lbl2">Undesignated stock, shares designated (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesDesignated" xlink:to="galt_UndesignatedCapitalStockSharesDesignated_lbl2" xlink:title="label: UndesignatedCapitalStockSharesDesignated to galt_UndesignatedCapitalStockSharesDesignated_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertiblePreferredStockDividendsShares" xlink:label="ConvertiblePreferredStockDividendsShares" xlink:title="ConvertiblePreferredStockDividendsShares" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ConvertiblePreferredStockDividendsShares_lbl" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividendsShares_lbl">Number of shares of Convertible preferred stock issued as dividends during the period. Excludes stock splits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividendsShares" xlink:to="galt_ConvertiblePreferredStockDividendsShares_lbl" xlink:title="label: ConvertiblePreferredStockDividendsShares to galt_ConvertiblePreferredStockDividendsShares_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividendsShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ConvertiblePreferredStockDividendsShares_lbl1" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividendsShares_lbl1">Convertible Preferred Stock Dividends, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividendsShares" xlink:to="galt_ConvertiblePreferredStockDividendsShares_lbl1" xlink:title="label: ConvertiblePreferredStockDividendsShares to galt_ConvertiblePreferredStockDividendsShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividendsShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ConvertiblePreferredStockDividendsShares_lbl2" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividendsShares_lbl2">Series A 12% convertible preferred stock dividend (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividendsShares" xlink:to="galt_ConvertiblePreferredStockDividendsShares_lbl2" xlink:title="label: ConvertiblePreferredStockDividendsShares to galt_ConvertiblePreferredStockDividendsShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_TemporaryEquityDividendsShares" xlink:label="TemporaryEquityDividendsShares" xlink:title="TemporaryEquityDividendsShares" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_TemporaryEquityDividendsShares_lbl" xml:lang="en-US" id="galt_TemporaryEquityDividendsShares_lbl">Number of shares of common stock issued as dividends for temporary equity during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividendsShares" xlink:to="galt_TemporaryEquityDividendsShares_lbl" xlink:title="label: TemporaryEquityDividendsShares to galt_TemporaryEquityDividendsShares_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividendsShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_TemporaryEquityDividendsShares_lbl1" xml:lang="en-US" id="galt_TemporaryEquityDividendsShares_lbl1">Temporary Equity Dividends, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividendsShares" xlink:to="galt_TemporaryEquityDividendsShares_lbl1" xlink:title="label: TemporaryEquityDividendsShares to galt_TemporaryEquityDividendsShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividendsShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_TemporaryEquityDividendsShares_lbl2" xml:lang="en-US" id="galt_TemporaryEquityDividendsShares_lbl2">Series C super dividend redeemable convertible preferred stock dividend (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividendsShares" xlink:to="galt_TemporaryEquityDividendsShares_lbl2" xlink:title="label: TemporaryEquityDividendsShares to galt_TemporaryEquityDividendsShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertiblePreferredStockDividends" xlink:label="ConvertiblePreferredStockDividends" xlink:title="ConvertiblePreferredStockDividends" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ConvertiblePreferredStockDividends_lbl" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividends_lbl">Amount of paid and unpaid convertible preferred stock dividends declared with the form of settlement in cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividends" xlink:to="galt_ConvertiblePreferredStockDividends_lbl" xlink:title="label: ConvertiblePreferredStockDividends to galt_ConvertiblePreferredStockDividends_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividends_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ConvertiblePreferredStockDividends_lbl1" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividends_lbl1">Convertible Preferred Stock, Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividends" xlink:to="galt_ConvertiblePreferredStockDividends_lbl1" xlink:title="label: ConvertiblePreferredStockDividends to galt_ConvertiblePreferredStockDividends_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividends_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ConvertiblePreferredStockDividends_lbl2" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividends_lbl2">Series A 12% convertible preferred stock dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividends" xlink:to="galt_ConvertiblePreferredStockDividends_lbl2" xlink:title="label: ConvertiblePreferredStockDividends to galt_ConvertiblePreferredStockDividends_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_TemporaryEquityDividends" xlink:label="TemporaryEquityDividends" xlink:title="TemporaryEquityDividends" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_TemporaryEquityDividends_lbl" xml:lang="en-US" id="galt_TemporaryEquityDividends_lbl">Amount of paid and unpaid temporary equity dividends declared with the form of settlement in cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividends" xlink:to="galt_TemporaryEquityDividends_lbl" xlink:title="label: TemporaryEquityDividends to galt_TemporaryEquityDividends_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividends_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_TemporaryEquityDividends_lbl1" xml:lang="en-US" id="galt_TemporaryEquityDividends_lbl1">Temporary Equity Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividends" xlink:to="galt_TemporaryEquityDividends_lbl1" xlink:title="label: TemporaryEquityDividends to galt_TemporaryEquityDividends_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividends_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="galt_TemporaryEquityDividends_lbl2" xml:lang="en-US" id="galt_TemporaryEquityDividends_lbl2">Series C super dividend redeemable convertible preferred stock dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividends" xlink:to="galt_TemporaryEquityDividends_lbl2" xlink:title="label: TemporaryEquityDividends to galt_TemporaryEquityDividends_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" xlink:label="FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" xlink:title="FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" />
    <link:label xlink:type="resource" xlink:label="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl" xml:lang="en-US" id="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl">The fair value of the contingent interest derivative liability related to related party convertible note payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" xlink:to="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl" xlink:title="label: FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable to galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl1" xml:lang="en-US" id="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl1">Fair Value Of Derivative Related To Related Party Convertible Note Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" xlink:to="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl1" xlink:title="label: FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable to galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl2" xml:lang="en-US" id="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl2">Fair value of derivative related to related party convertible note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" xlink:to="galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl2" xlink:title="label: FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable to galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:label="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:title="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl" xml:lang="en-US" id="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl">Amount reclassified from accrued compensation to excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:to="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl" xlink:title="label: ReclassificationOfAccruedBonusToAdditionalPaidInCapital to galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl1" xml:lang="en-US" id="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl1">Reclassification Of Accrued Bonus To Additional Paid In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:to="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl1" xlink:title="label: ReclassificationOfAccruedBonusToAdditionalPaidInCapital to galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl2" xml:lang="en-US" id="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl2">Reclassification of accrued bonus to additional paid in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:to="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl2" xlink:title="label: ReclassificationOfAccruedBonusToAdditionalPaidInCapital to galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:label="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:title="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl" xml:lang="en-US" id="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl">The fair value of common stock purchase warrants issued in connection with related party line of credit in noncash financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:to="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl" xlink:title="label: CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit to galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl1" xml:lang="en-US" id="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl1">Common Stock Purchase Warrants Issued in Connection with Related Party Line of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:to="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl1" xlink:title="label: CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit to galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl2" xml:lang="en-US" id="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl2">Common stock purchase warrants issued in connection with related party line of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:to="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl2" xlink:title="label: CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit to galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CommonStockWarrantsAbstract" xlink:label="CommonStockWarrantsAbstract" xlink:title="CommonStockWarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockWarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_CommonStockWarrantsAbstract_lbl1" xml:lang="en-US" id="galt_CommonStockWarrantsAbstract_lbl1">Common Stock Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantsAbstract" xlink:to="galt_CommonStockWarrantsAbstract_lbl1" xlink:title="label: CommonStockWarrantsAbstract to galt_CommonStockWarrantsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CommonStockWarrantsDisclosureTextBlock" xlink:label="CommonStockWarrantsDisclosureTextBlock" xlink:title="CommonStockWarrantsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockWarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_CommonStockWarrantsDisclosureTextBlock_lbl" xml:lang="en-US" id="galt_CommonStockWarrantsDisclosureTextBlock_lbl">The entire disclosure for Equity warrants are instruments that bestow upon the holder of the instrument the right to buy a particular stock at a predetermined price within a stipulated time frame. ... This payment is to be adjusted against the final payment that needs to be paid in case the warrants are exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantsDisclosureTextBlock" xlink:to="galt_CommonStockWarrantsDisclosureTextBlock_lbl" xlink:title="label: CommonStockWarrantsDisclosureTextBlock to galt_CommonStockWarrantsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockWarrantsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_CommonStockWarrantsDisclosureTextBlock_lbl1" xml:lang="en-US" id="galt_CommonStockWarrantsDisclosureTextBlock_lbl1">Common Stock Warrants Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantsDisclosureTextBlock" xlink:to="galt_CommonStockWarrantsDisclosureTextBlock_lbl1" xlink:title="label: CommonStockWarrantsDisclosureTextBlock to galt_CommonStockWarrantsDisclosureTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockWarrantsDisclosureTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_CommonStockWarrantsDisclosureTextBlock_lbl2" xml:lang="en-US" id="galt_CommonStockWarrantsDisclosureTextBlock_lbl2">Common Stock Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantsDisclosureTextBlock" xlink:to="galt_CommonStockWarrantsDisclosureTextBlock_lbl2" xlink:title="label: CommonStockWarrantsDisclosureTextBlock to galt_CommonStockWarrantsDisclosureTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_LineOfCreditRelatedPartyAbstract" xlink:label="LineOfCreditRelatedPartyAbstract" xlink:title="LineOfCreditRelatedPartyAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_LineOfCreditRelatedPartyAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_LineOfCreditRelatedPartyAbstract_lbl1" xml:lang="en-US" id="galt_LineOfCreditRelatedPartyAbstract_lbl1">Line of Credit, Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="galt_LineOfCreditRelatedPartyAbstract_lbl1" xlink:title="label: LineOfCreditRelatedPartyAbstract to galt_LineOfCreditRelatedPartyAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_LineOfCreditRelatedPartyAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_LineOfCreditRelatedPartyAbstract_lbl2" xml:lang="en-US" id="galt_LineOfCreditRelatedPartyAbstract_lbl2">Convertible Line of Credit - Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="galt_LineOfCreditRelatedPartyAbstract_lbl2" xlink:title="label: LineOfCreditRelatedPartyAbstract to galt_LineOfCreditRelatedPartyAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl">Number of securities into which the class of additional warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:title="label: ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US" id="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1">Class of Additional Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:title="label: ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2" xml:lang="en-US" id="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2">Warrants to purchase additional common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2" xlink:title="label: ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_IssuanceOfWarrantsValue" xlink:label="IssuanceOfWarrantsValue" xlink:title="IssuanceOfWarrantsValue" />
    <link:label xlink:type="resource" xlink:label="galt_IssuanceOfWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_IssuanceOfWarrantsValue_lbl" xml:lang="en-US" id="galt_IssuanceOfWarrantsValue_lbl">The amount of issuance of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfWarrantsValue" xlink:to="galt_IssuanceOfWarrantsValue_lbl" xlink:title="label: IssuanceOfWarrantsValue to galt_IssuanceOfWarrantsValue_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_IssuanceOfWarrantsValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_IssuanceOfWarrantsValue_lbl1" xml:lang="en-US" id="galt_IssuanceOfWarrantsValue_lbl1">Issuance of Warrants Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfWarrantsValue" xlink:to="galt_IssuanceOfWarrantsValue_lbl1" xlink:title="label: IssuanceOfWarrantsValue to galt_IssuanceOfWarrantsValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_IssuanceOfWarrantsValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_IssuanceOfWarrantsValue_lbl2" xml:lang="en-US" id="galt_IssuanceOfWarrantsValue_lbl2">Warrants issuance value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfWarrantsValue" xlink:to="galt_IssuanceOfWarrantsValue_lbl2" xlink:title="label: IssuanceOfWarrantsValue to galt_IssuanceOfWarrantsValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl" xml:lang="en-US" id="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl">The percentage of exercise price per share or per unit of warrants equal to common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:to="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock to galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl1" xml:lang="en-US" id="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl1">Class of Warrant or Right, Exercise Price of Warrants or Rights, Percentage Equal to Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:to="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock to galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl2" xml:lang="en-US" id="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl2">Percentage of warrants equal to the closing price of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:to="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl2" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock to galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_WarrantTwoMember" xlink:label="WarrantTwoMember" xlink:title="WarrantTwoMember" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantTwoMember_lbl" xml:lang="en-US" id="galt_WarrantTwoMember_lbl">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantTwoMember" xlink:to="galt_WarrantTwoMember_lbl" xlink:title="label: WarrantTwoMember to galt_WarrantTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantTwoMember_lbl1" xml:lang="en-US" id="galt_WarrantTwoMember_lbl1">Warrant Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantTwoMember" xlink:to="galt_WarrantTwoMember_lbl1" xlink:title="label: WarrantTwoMember to galt_WarrantTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantTwoMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_WarrantTwoMember_lbl2" xml:lang="en-US" id="galt_WarrantTwoMember_lbl2">Warrant Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantTwoMember" xlink:to="galt_WarrantTwoMember_lbl2" xlink:title="label: WarrantTwoMember to galt_WarrantTwoMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UnsecuredConvertiblePromissoryNoteMember" xlink:label="UnsecuredConvertiblePromissoryNoteMember" xlink:title="UnsecuredConvertiblePromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_UnsecuredConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_UnsecuredConvertiblePromissoryNoteMember_lbl" xml:lang="en-US" id="galt_UnsecuredConvertiblePromissoryNoteMember_lbl">An unsecured convertible promissory note is a debt obligation in which a company borrows money from an investor in exchange for a promise of repayment and an option to convert the outstanding principal into equity of the company upon some triggering event. Notes have a maturity date and bear interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnsecuredConvertiblePromissoryNoteMember" xlink:to="galt_UnsecuredConvertiblePromissoryNoteMember_lbl" xlink:title="label: UnsecuredConvertiblePromissoryNoteMember to galt_UnsecuredConvertiblePromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_UnsecuredConvertiblePromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_UnsecuredConvertiblePromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_UnsecuredConvertiblePromissoryNoteMember_lbl1">Unsecured Convertible Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnsecuredConvertiblePromissoryNoteMember" xlink:to="galt_UnsecuredConvertiblePromissoryNoteMember_lbl1" xlink:title="label: UnsecuredConvertiblePromissoryNoteMember to galt_UnsecuredConvertiblePromissoryNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_UnsecuredConvertiblePromissoryNoteMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_UnsecuredConvertiblePromissoryNoteMember_lbl2" xml:lang="en-US" id="galt_UnsecuredConvertiblePromissoryNoteMember_lbl2">Unsecured Convertible Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnsecuredConvertiblePromissoryNoteMember" xlink:to="galt_UnsecuredConvertiblePromissoryNoteMember_lbl2" xlink:title="label: UnsecuredConvertiblePromissoryNoteMember to galt_UnsecuredConvertiblePromissoryNoteMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DebtInstrumentAccruedInterest" xlink:label="DebtInstrumentAccruedInterest" xlink:title="DebtInstrumentAccruedInterest" />
    <link:label xlink:type="resource" xlink:label="galt_DebtInstrumentAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DebtInstrumentAccruedInterest_lbl" xml:lang="en-US" id="galt_DebtInstrumentAccruedInterest_lbl">Accrued, but unpaid interest on the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAccruedInterest" xlink:to="galt_DebtInstrumentAccruedInterest_lbl" xlink:title="label: DebtInstrumentAccruedInterest to galt_DebtInstrumentAccruedInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DebtInstrumentAccruedInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DebtInstrumentAccruedInterest_lbl1" xml:lang="en-US" id="galt_DebtInstrumentAccruedInterest_lbl1">Debt Instrument, Accrued Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAccruedInterest" xlink:to="galt_DebtInstrumentAccruedInterest_lbl1" xlink:title="label: DebtInstrumentAccruedInterest to galt_DebtInstrumentAccruedInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DebtInstrumentAccruedInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DebtInstrumentAccruedInterest_lbl2" xml:lang="en-US" id="galt_DebtInstrumentAccruedInterest_lbl2">Accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAccruedInterest" xlink:to="galt_DebtInstrumentAccruedInterest_lbl2" xlink:title="label: DebtInstrumentAccruedInterest to galt_DebtInstrumentAccruedInterest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_WarrantOneMember" xlink:label="WarrantOneMember" xlink:title="WarrantOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantOneMember_lbl" xml:lang="en-US" id="galt_WarrantOneMember_lbl">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantOneMember" xlink:to="galt_WarrantOneMember_lbl" xlink:title="label: WarrantOneMember to galt_WarrantOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantOneMember_lbl1" xml:lang="en-US" id="galt_WarrantOneMember_lbl1">Warrant One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantOneMember" xlink:to="galt_WarrantOneMember_lbl1" xlink:title="label: WarrantOneMember to galt_WarrantOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantOneMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_WarrantOneMember_lbl2" xml:lang="en-US" id="galt_WarrantOneMember_lbl2">Warrant One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantOneMember" xlink:to="galt_WarrantOneMember_lbl2" xlink:title="label: WarrantOneMember to galt_WarrantOneMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl1">Share based Compensation Arrangement by Share based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl2" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl2">Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl3" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl3">Outstanding at end of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl3" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl2">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl">Weighted average price at which option holders acquired shares when converting their stock options into shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl2">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1">Share based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl2">Forfeited/cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_SeriesAAndSeriesCPreferredStockMember" xlink:label="SeriesAAndSeriesCPreferredStockMember" xlink:title="SeriesAAndSeriesCPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesAAndSeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SeriesAAndSeriesCPreferredStockMember_lbl" xml:lang="en-US" id="galt_SeriesAAndSeriesCPreferredStockMember_lbl">Outstanding nonredeemable series A and series C preferred stock or outstanding series A and series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAAndSeriesCPreferredStockMember" xlink:to="galt_SeriesAAndSeriesCPreferredStockMember_lbl" xlink:title="label: SeriesAAndSeriesCPreferredStockMember to galt_SeriesAAndSeriesCPreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesAAndSeriesCPreferredStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SeriesAAndSeriesCPreferredStockMember_lbl1" xml:lang="en-US" id="galt_SeriesAAndSeriesCPreferredStockMember_lbl1">Series A and Series C Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAAndSeriesCPreferredStockMember" xlink:to="galt_SeriesAAndSeriesCPreferredStockMember_lbl1" xlink:title="label: SeriesAAndSeriesCPreferredStockMember to galt_SeriesAAndSeriesCPreferredStockMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesAAndSeriesCPreferredStockMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SeriesAAndSeriesCPreferredStockMember_lbl2" xml:lang="en-US" id="galt_SeriesAAndSeriesCPreferredStockMember_lbl2">Series A and Series C Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAAndSeriesCPreferredStockMember" xlink:to="galt_SeriesAAndSeriesCPreferredStockMember_lbl2" xlink:title="label: SeriesAAndSeriesCPreferredStockMember to galt_SeriesAAndSeriesCPreferredStockMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CommissionRate" xlink:label="CommissionRate" xlink:title="CommissionRate" />
    <link:label xlink:type="resource" xlink:label="galt_CommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_CommissionRate_lbl" xml:lang="en-US" id="galt_CommissionRate_lbl">Percentage of commission rate to be paid to sales agent in gross proceeds from the sale of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionRate" xlink:to="galt_CommissionRate_lbl" xlink:title="label: CommissionRate to galt_CommissionRate_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_CommissionRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_CommissionRate_lbl1" xml:lang="en-US" id="galt_CommissionRate_lbl1">Commission Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionRate" xlink:to="galt_CommissionRate_lbl1" xlink:title="label: CommissionRate to galt_CommissionRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_CommissionRate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_CommissionRate_lbl2" xml:lang="en-US" id="galt_CommissionRate_lbl2">Percentage of commission rate to be paid to sales agent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionRate" xlink:to="galt_CommissionRate_lbl2" xlink:title="label: CommissionRate to galt_CommissionRate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AggregateOfferingPrice" xlink:label="AggregateOfferingPrice" xlink:title="AggregateOfferingPrice" />
    <link:label xlink:type="resource" xlink:label="galt_AggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AggregateOfferingPrice_lbl" xml:lang="en-US" id="galt_AggregateOfferingPrice_lbl">Amount of aggregate offering price of common stock which can be sold from time to time through the sales agent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateOfferingPrice" xlink:to="galt_AggregateOfferingPrice_lbl" xlink:title="label: AggregateOfferingPrice to galt_AggregateOfferingPrice_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AggregateOfferingPrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AggregateOfferingPrice_lbl1" xml:lang="en-US" id="galt_AggregateOfferingPrice_lbl1">Aggregate Offering Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateOfferingPrice" xlink:to="galt_AggregateOfferingPrice_lbl1" xlink:title="label: AggregateOfferingPrice to galt_AggregateOfferingPrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AggregateOfferingPrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_AggregateOfferingPrice_lbl2" xml:lang="en-US" id="galt_AggregateOfferingPrice_lbl2">Aggregate offering price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateOfferingPrice" xlink:to="galt_AggregateOfferingPrice_lbl2" xlink:title="label: AggregateOfferingPrice to galt_AggregateOfferingPrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_TwoThousandTwentyMarketAgreementMember" xlink:label="TwoThousandTwentyMarketAgreementMember" xlink:title="TwoThousandTwentyMarketAgreementMember" />
    <link:label xlink:type="resource" xlink:label="galt_TwoThousandTwentyMarketAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_TwoThousandTwentyMarketAgreementMember_lbl" xml:lang="en-US" id="galt_TwoThousandTwentyMarketAgreementMember_lbl">Agreement with a sales agent under which the Company may issue and sell shares of its common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoThousandTwentyMarketAgreementMember" xlink:to="galt_TwoThousandTwentyMarketAgreementMember_lbl" xlink:title="label: TwoThousandTwentyMarketAgreementMember to galt_TwoThousandTwentyMarketAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_TwoThousandTwentyMarketAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_TwoThousandTwentyMarketAgreementMember_lbl1" xml:lang="en-US" id="galt_TwoThousandTwentyMarketAgreementMember_lbl1">Two Thousand Twenty Market Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoThousandTwentyMarketAgreementMember" xlink:to="galt_TwoThousandTwentyMarketAgreementMember_lbl1" xlink:title="label: TwoThousandTwentyMarketAgreementMember to galt_TwoThousandTwentyMarketAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_TwoThousandTwentyMarketAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_TwoThousandTwentyMarketAgreementMember_lbl2" xml:lang="en-US" id="galt_TwoThousandTwentyMarketAgreementMember_lbl2">2020 Market Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoThousandTwentyMarketAgreementMember" xlink:to="galt_TwoThousandTwentyMarketAgreementMember_lbl2" xlink:title="label: TwoThousandTwentyMarketAgreementMember to galt_TwoThousandTwentyMarketAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_FreeRentPeriod" xlink:label="FreeRentPeriod" xlink:title="FreeRentPeriod" />
    <link:label xlink:type="resource" xlink:label="galt_FreeRentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_FreeRentPeriod_lbl" xml:lang="en-US" id="galt_FreeRentPeriod_lbl">Free rent period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FreeRentPeriod" xlink:to="galt_FreeRentPeriod_lbl" xlink:title="label: FreeRentPeriod to galt_FreeRentPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_FreeRentPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_FreeRentPeriod_lbl1" xml:lang="en-US" id="galt_FreeRentPeriod_lbl1">Free Rent Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FreeRentPeriod" xlink:to="galt_FreeRentPeriod_lbl1" xlink:title="label: FreeRentPeriod to galt_FreeRentPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_FreeRentPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_FreeRentPeriod_lbl2" xml:lang="en-US" id="galt_FreeRentPeriod_lbl2">Free rent period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FreeRentPeriod" xlink:to="galt_FreeRentPeriod_lbl2" xlink:title="label: FreeRentPeriod to galt_FreeRentPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_NumberOfOperatingLeases" xlink:label="NumberOfOperatingLeases" xlink:title="NumberOfOperatingLeases" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NumberOfOperatingLeases_lbl" xml:lang="en-US" id="galt_NumberOfOperatingLeases_lbl">Number of operating leases during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingLeases" xlink:to="galt_NumberOfOperatingLeases_lbl" xlink:title="label: NumberOfOperatingLeases to galt_NumberOfOperatingLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfOperatingLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NumberOfOperatingLeases_lbl1" xml:lang="en-US" id="galt_NumberOfOperatingLeases_lbl1">Number of Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingLeases" xlink:to="galt_NumberOfOperatingLeases_lbl1" xlink:title="label: NumberOfOperatingLeases to galt_NumberOfOperatingLeases_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfOperatingLeases_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_NumberOfOperatingLeases_lbl2" xml:lang="en-US" id="galt_NumberOfOperatingLeases_lbl2">Number of operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingLeases" xlink:to="galt_NumberOfOperatingLeases_lbl2" xlink:title="label: NumberOfOperatingLeases to galt_NumberOfOperatingLeases_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_GalectinSciencesLLCMember" xlink:label="GalectinSciencesLLCMember" xlink:title="GalectinSciencesLLCMember" />
    <link:label xlink:type="resource" xlink:label="galt_GalectinSciencesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_GalectinSciencesLLCMember_lbl" xml:lang="en-US" id="galt_GalectinSciencesLLCMember_lbl">Name of entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GalectinSciencesLLCMember" xlink:to="galt_GalectinSciencesLLCMember_lbl" xlink:title="label: GalectinSciencesLLCMember to galt_GalectinSciencesLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_GalectinSciencesLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_GalectinSciencesLLCMember_lbl1" xml:lang="en-US" id="galt_GalectinSciencesLLCMember_lbl1">Galectin Sciences, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GalectinSciencesLLCMember" xlink:to="galt_GalectinSciencesLLCMember_lbl1" xlink:title="label: GalectinSciencesLLCMember to galt_GalectinSciencesLLCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_GalectinSciencesLLCMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_GalectinSciencesLLCMember_lbl2" xml:lang="en-US" id="galt_GalectinSciencesLLCMember_lbl2">Galectin Sciences, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GalectinSciencesLLCMember" xlink:to="galt_GalectinSciencesLLCMember_lbl2" xlink:title="label: GalectinSciencesLLCMember to galt_GalectinSciencesLLCMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_SBHSciencesIncMember" xlink:label="SBHSciencesIncMember" xlink:title="SBHSciencesIncMember" />
    <link:label xlink:type="resource" xlink:label="galt_SBHSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SBHSciencesIncMember_lbl" xml:lang="en-US" id="galt_SBHSciencesIncMember_lbl">Name of counterparty. A counterparty is the other party that participates in a financial transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBHSciencesIncMember" xlink:to="galt_SBHSciencesIncMember_lbl" xlink:title="label: SBHSciencesIncMember to galt_SBHSciencesIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SBHSciencesIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SBHSciencesIncMember_lbl1" xml:lang="en-US" id="galt_SBHSciencesIncMember_lbl1">SBH Sciences, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBHSciencesIncMember" xlink:to="galt_SBHSciencesIncMember_lbl1" xlink:title="label: SBHSciencesIncMember to galt_SBHSciencesIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SBHSciencesIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SBHSciencesIncMember_lbl2" xml:lang="en-US" id="galt_SBHSciencesIncMember_lbl2">SBH [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBHSciencesIncMember" xlink:to="galt_SBHSciencesIncMember_lbl2" xlink:title="label: SBHSciencesIncMember to galt_SBHSciencesIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CapitalContributionExpense" xlink:label="CapitalContributionExpense" xlink:title="CapitalContributionExpense" />
    <link:label xlink:type="resource" xlink:label="galt_CapitalContributionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_CapitalContributionExpense_lbl" xml:lang="en-US" id="galt_CapitalContributionExpense_lbl">Capital contribution expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalContributionExpense" xlink:to="galt_CapitalContributionExpense_lbl" xlink:title="label: CapitalContributionExpense to galt_CapitalContributionExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_CapitalContributionExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_CapitalContributionExpense_lbl1" xml:lang="en-US" id="galt_CapitalContributionExpense_lbl1">Capital Contribution Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalContributionExpense" xlink:to="galt_CapitalContributionExpense_lbl1" xlink:title="label: CapitalContributionExpense to galt_CapitalContributionExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_CapitalContributionExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_CapitalContributionExpense_lbl2" xml:lang="en-US" id="galt_CapitalContributionExpense_lbl2">Contribution for expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalContributionExpense" xlink:to="galt_CapitalContributionExpense_lbl2" xlink:title="label: CapitalContributionExpense to galt_CapitalContributionExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestAprilNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ContingentInterestAprilNoteMember_lbl" xml:lang="en-US" id="galt_ContingentInterestAprilNoteMember_lbl">The derivative liability of contingent interest April Note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestAprilNoteMember" xlink:to="galt_ContingentInterestAprilNoteMember_lbl" xlink:title="label: ContingentInterestAprilNoteMember to galt_ContingentInterestAprilNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestAprilNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ContingentInterestAprilNoteMember_lbl1" xml:lang="en-US" id="galt_ContingentInterestAprilNoteMember_lbl1">Contingent Interest, April Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestAprilNoteMember" xlink:to="galt_ContingentInterestAprilNoteMember_lbl1" xlink:title="label: ContingentInterestAprilNoteMember to galt_ContingentInterestAprilNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestAprilNoteMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ContingentInterestAprilNoteMember_lbl2" xml:lang="en-US" id="galt_ContingentInterestAprilNoteMember_lbl2">April Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestAprilNoteMember" xlink:to="galt_ContingentInterestAprilNoteMember_lbl2" xlink:title="label: ContingentInterestAprilNoteMember to galt_ContingentInterestAprilNoteMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestSeptemberNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ContingentInterestSeptemberNoteMember_lbl" xml:lang="en-US" id="galt_ContingentInterestSeptemberNoteMember_lbl">The derivative liability of contingent interest September Note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestSeptemberNoteMember" xlink:to="galt_ContingentInterestSeptemberNoteMember_lbl" xlink:title="label: ContingentInterestSeptemberNoteMember to galt_ContingentInterestSeptemberNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestSeptemberNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ContingentInterestSeptemberNoteMember_lbl1" xml:lang="en-US" id="galt_ContingentInterestSeptemberNoteMember_lbl1">Contingent Interest, September Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestSeptemberNoteMember" xlink:to="galt_ContingentInterestSeptemberNoteMember_lbl1" xlink:title="label: ContingentInterestSeptemberNoteMember to galt_ContingentInterestSeptemberNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestSeptemberNoteMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ContingentInterestSeptemberNoteMember_lbl2" xml:lang="en-US" id="galt_ContingentInterestSeptemberNoteMember_lbl2">September Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestSeptemberNoteMember" xlink:to="galt_ContingentInterestSeptemberNoteMember_lbl2" xlink:title="label: ContingentInterestSeptemberNoteMember to galt_ContingentInterestSeptemberNoteMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestDecemberNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ContingentInterestDecemberNoteMember_lbl" xml:lang="en-US" id="galt_ContingentInterestDecemberNoteMember_lbl">The derivative liability of contingent interest December Note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestDecemberNoteMember" xlink:to="galt_ContingentInterestDecemberNoteMember_lbl" xlink:title="label: ContingentInterestDecemberNoteMember to galt_ContingentInterestDecemberNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestDecemberNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ContingentInterestDecemberNoteMember_lbl1" xml:lang="en-US" id="galt_ContingentInterestDecemberNoteMember_lbl1">Contingent Interest, December Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestDecemberNoteMember" xlink:to="galt_ContingentInterestDecemberNoteMember_lbl1" xlink:title="label: ContingentInterestDecemberNoteMember to galt_ContingentInterestDecemberNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestDecemberNoteMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ContingentInterestDecemberNoteMember_lbl2" xml:lang="en-US" id="galt_ContingentInterestDecemberNoteMember_lbl2">December Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestDecemberNoteMember" xlink:to="galt_ContingentInterestDecemberNoteMember_lbl2" xlink:title="label: ContingentInterestDecemberNoteMember to galt_ContingentInterestDecemberNoteMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContractCancelationNoticePeriod" xlink:label="ContractCancelationNoticePeriod" xlink:title="ContractCancelationNoticePeriod" />
    <link:label xlink:type="resource" xlink:label="galt_ContractCancelationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ContractCancelationNoticePeriod_lbl" xml:lang="en-US" id="galt_ContractCancelationNoticePeriod_lbl">Contract cancelation notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractCancelationNoticePeriod" xlink:to="galt_ContractCancelationNoticePeriod_lbl" xlink:title="label: ContractCancelationNoticePeriod to galt_ContractCancelationNoticePeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ContractCancelationNoticePeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ContractCancelationNoticePeriod_lbl1" xml:lang="en-US" id="galt_ContractCancelationNoticePeriod_lbl1">Contract Cancelation Notice Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractCancelationNoticePeriod" xlink:to="galt_ContractCancelationNoticePeriod_lbl1" xlink:title="label: ContractCancelationNoticePeriod to galt_ContractCancelationNoticePeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ContractCancelationNoticePeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ContractCancelationNoticePeriod_lbl2" xml:lang="en-US" id="galt_ContractCancelationNoticePeriod_lbl2">Contract cancelation notice period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractCancelationNoticePeriod" xlink:to="galt_ContractCancelationNoticePeriod_lbl2" xlink:title="label: ContractCancelationNoticePeriod to galt_ContractCancelationNoticePeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_RestrictedStockGrantsAbstract" xlink:label="RestrictedStockGrantsAbstract" xlink:title="RestrictedStockGrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_RestrictedStockGrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_RestrictedStockGrantsAbstract_lbl1" xml:lang="en-US" id="galt_RestrictedStockGrantsAbstract_lbl1">Restricted Stock Grants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockGrantsAbstract" xlink:to="galt_RestrictedStockGrantsAbstract_lbl1" xlink:title="label: RestrictedStockGrantsAbstract to galt_RestrictedStockGrantsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_RestrictedStockGrantsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_RestrictedStockGrantsAbstract_lbl2" xml:lang="en-US" id="galt_RestrictedStockGrantsAbstract_lbl2">Restricted Stock Grants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockGrantsAbstract" xlink:to="galt_RestrictedStockGrantsAbstract_lbl2" xlink:title="label: RestrictedStockGrantsAbstract to galt_RestrictedStockGrantsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl">The deferred compensation arrangement with individual cash award granted paid in cash percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl1">Deferred Compensation Arrangement With Individual Cash Award Granted Paid in Cash Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl1" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl2" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl2">Percentage of base salary paid in cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl2" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl">Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl1">Deferred Compensation Arrangement Percentage of Deferred Share Units Shall be Issued Period Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl1" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl2" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl2">Percentage of DSUs shall be credited on March 1, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl2" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl">Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl1">Deferred Compensation Arrangement Percentage of Deferred Share Units Shall be Issued Period Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl1" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl2" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl2">Percentage of DSUs shall be credited on September 1, 2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl2" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl">Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl1">Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl1" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl2" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl2">Percentage of DSUs shall be credited on March 1, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl2" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl">The deferred compensation arrangement with individual cash award granted paid in deferred stock units percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl1">Deferred Compensation Arrangement With Individual Cash Award Granted Paid in Deferred Stock Units Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl1" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl2" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl2">Percentage of base salary paid in deferred stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl2" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertibleNotesPayableRelatedPartyAbstract" xlink:label="ConvertibleNotesPayableRelatedPartyAbstract" xlink:title="ConvertibleNotesPayableRelatedPartyAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl1" xml:lang="en-US" id="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl1">Convertible Notes Payable, Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl1" xlink:title="label: ConvertibleNotesPayableRelatedPartyAbstract to galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl2" xml:lang="en-US" id="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl2">Convertible Notes Payable - Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl2" xlink:title="label: ConvertibleNotesPayableRelatedPartyAbstract to galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_QuarterlyInterestRate" xlink:label="QuarterlyInterestRate" xlink:title="QuarterlyInterestRate" />
    <link:label xlink:type="resource" xlink:label="galt_QuarterlyInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_QuarterlyInterestRate_lbl" xml:lang="en-US" id="galt_QuarterlyInterestRate_lbl">Contingent interest rate per quarter for funds borrowed, under the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyInterestRate" xlink:to="galt_QuarterlyInterestRate_lbl" xlink:title="label: QuarterlyInterestRate to galt_QuarterlyInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_QuarterlyInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_QuarterlyInterestRate_lbl1" xml:lang="en-US" id="galt_QuarterlyInterestRate_lbl1">Quarterly Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyInterestRate" xlink:to="galt_QuarterlyInterestRate_lbl1" xlink:title="label: QuarterlyInterestRate to galt_QuarterlyInterestRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_QuarterlyInterestRate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_QuarterlyInterestRate_lbl2" xml:lang="en-US" id="galt_QuarterlyInterestRate_lbl2">Additional interest rate per quarter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyInterestRate" xlink:to="galt_QuarterlyInterestRate_lbl2" xlink:title="label: QuarterlyInterestRate to galt_QuarterlyInterestRate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:label="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:title="NumberOfPromissoryNotesEvidencedByLoansAgreement" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl" xml:lang="en-US" id="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl">The number of promissory notes evidenced by loans agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:to="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl" xlink:title="label: NumberOfPromissoryNotesEvidencedByLoansAgreement to galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl1" xml:lang="en-US" id="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl1">Number of Promissory Notes Evidenced by Loans Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:to="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl1" xlink:title="label: NumberOfPromissoryNotesEvidencedByLoansAgreement to galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl2" xml:lang="en-US" id="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl2">Number of promissory notes evidenced by loans agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:to="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl2" xlink:title="label: NumberOfPromissoryNotesEvidencedByLoansAgreement to galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AnnualInterestRate" xlink:label="AnnualInterestRate" xlink:title="AnnualInterestRate" />
    <link:label xlink:type="resource" xlink:label="galt_AnnualInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AnnualInterestRate_lbl" xml:lang="en-US" id="galt_AnnualInterestRate_lbl">Contingent interest rate per annum for funds borrowed, under the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualInterestRate" xlink:to="galt_AnnualInterestRate_lbl" xlink:title="label: AnnualInterestRate to galt_AnnualInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AnnualInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AnnualInterestRate_lbl1" xml:lang="en-US" id="galt_AnnualInterestRate_lbl1">Annual Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualInterestRate" xlink:to="galt_AnnualInterestRate_lbl1" xlink:title="label: AnnualInterestRate to galt_AnnualInterestRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AnnualInterestRate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_AnnualInterestRate_lbl2" xml:lang="en-US" id="galt_AnnualInterestRate_lbl2">Additional interest rate per annum from issuance date to maturity date period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualInterestRate" xlink:to="galt_AnnualInterestRate_lbl2" xlink:title="label: AnnualInterestRate to galt_AnnualInterestRate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AprilConvertiblePromissoryNoteMember" xlink:label="AprilConvertiblePromissoryNoteMember" xlink:title="AprilConvertiblePromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_AprilConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AprilConvertiblePromissoryNoteMember_lbl" xml:lang="en-US" id="galt_AprilConvertiblePromissoryNoteMember_lbl">The type of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilConvertiblePromissoryNoteMember" xlink:to="galt_AprilConvertiblePromissoryNoteMember_lbl" xlink:title="label: AprilConvertiblePromissoryNoteMember to galt_AprilConvertiblePromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AprilConvertiblePromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AprilConvertiblePromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_AprilConvertiblePromissoryNoteMember_lbl1">April Convertible Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilConvertiblePromissoryNoteMember" xlink:to="galt_AprilConvertiblePromissoryNoteMember_lbl1" xlink:title="label: AprilConvertiblePromissoryNoteMember to galt_AprilConvertiblePromissoryNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AprilConvertiblePromissoryNoteMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_AprilConvertiblePromissoryNoteMember_lbl2" xml:lang="en-US" id="galt_AprilConvertiblePromissoryNoteMember_lbl2">April 2021 Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilConvertiblePromissoryNoteMember" xlink:to="galt_AprilConvertiblePromissoryNoteMember_lbl2" xlink:title="label: AprilConvertiblePromissoryNoteMember to galt_AprilConvertiblePromissoryNoteMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_SeptemberConvertiblePromissoryNoteMember" xlink:label="SeptemberConvertiblePromissoryNoteMember" xlink:title="SeptemberConvertiblePromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SeptemberConvertiblePromissoryNoteMember_lbl" xml:lang="en-US" id="galt_SeptemberConvertiblePromissoryNoteMember_lbl">A type of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberConvertiblePromissoryNoteMember" xlink:to="galt_SeptemberConvertiblePromissoryNoteMember_lbl" xlink:title="label: SeptemberConvertiblePromissoryNoteMember to galt_SeptemberConvertiblePromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberConvertiblePromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SeptemberConvertiblePromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_SeptemberConvertiblePromissoryNoteMember_lbl1">September Convertible Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberConvertiblePromissoryNoteMember" xlink:to="galt_SeptemberConvertiblePromissoryNoteMember_lbl1" xlink:title="label: SeptemberConvertiblePromissoryNoteMember to galt_SeptemberConvertiblePromissoryNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberConvertiblePromissoryNoteMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SeptemberConvertiblePromissoryNoteMember_lbl2" xml:lang="en-US" id="galt_SeptemberConvertiblePromissoryNoteMember_lbl2">September 2021 Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberConvertiblePromissoryNoteMember" xlink:to="galt_SeptemberConvertiblePromissoryNoteMember_lbl2" xlink:title="label: SeptemberConvertiblePromissoryNoteMember to galt_SeptemberConvertiblePromissoryNoteMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DecemberConvertiblePromissoryNoteMember" xlink:label="DecemberConvertiblePromissoryNoteMember" xlink:title="DecemberConvertiblePromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DecemberConvertiblePromissoryNoteMember_lbl" xml:lang="en-US" id="galt_DecemberConvertiblePromissoryNoteMember_lbl">The type of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberConvertiblePromissoryNoteMember" xlink:to="galt_DecemberConvertiblePromissoryNoteMember_lbl" xlink:title="label: DecemberConvertiblePromissoryNoteMember to galt_DecemberConvertiblePromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberConvertiblePromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DecemberConvertiblePromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_DecemberConvertiblePromissoryNoteMember_lbl1">December Convertible Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberConvertiblePromissoryNoteMember" xlink:to="galt_DecemberConvertiblePromissoryNoteMember_lbl1" xlink:title="label: DecemberConvertiblePromissoryNoteMember to galt_DecemberConvertiblePromissoryNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberConvertiblePromissoryNoteMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DecemberConvertiblePromissoryNoteMember_lbl2" xml:lang="en-US" id="galt_DecemberConvertiblePromissoryNoteMember_lbl2">December 2021 Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberConvertiblePromissoryNoteMember" xlink:to="galt_DecemberConvertiblePromissoryNoteMember_lbl2" xlink:title="label: DecemberConvertiblePromissoryNoteMember to galt_DecemberConvertiblePromissoryNoteMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:label="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:title="AccruedResearchAndDevelopmentCostsAndOtherCurrent" />
    <link:label xlink:type="resource" xlink:label="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl" xml:lang="en-US" id="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs and other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:to="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl" xlink:title="label: AccruedResearchAndDevelopmentCostsAndOtherCurrent to galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl1" xml:lang="en-US" id="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl1">Accrued Research and Development Costs and Other Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:to="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl1" xlink:title="label: AccruedResearchAndDevelopmentCostsAndOtherCurrent to galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl2" xml:lang="en-US" id="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl2">Accrued research and development costs and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:to="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl2" xlink:title="label: AccruedResearchAndDevelopmentCostsAndOtherCurrent to galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_BasisOfPresentationsAndLiquidityAbstract" xlink:label="BasisOfPresentationsAndLiquidityAbstract" xlink:title="BasisOfPresentationsAndLiquidityAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_BasisOfPresentationsAndLiquidityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_BasisOfPresentationsAndLiquidityAbstract_lbl1" xml:lang="en-US" id="galt_BasisOfPresentationsAndLiquidityAbstract_lbl1">Basis of Presentations and Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationsAndLiquidityAbstract" xlink:to="galt_BasisOfPresentationsAndLiquidityAbstract_lbl1" xlink:title="label: BasisOfPresentationsAndLiquidityAbstract to galt_BasisOfPresentationsAndLiquidityAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_BasisOfPresentationsAndLiquidityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_BasisOfPresentationsAndLiquidityAbstract_lbl2" xml:lang="en-US" id="galt_BasisOfPresentationsAndLiquidityAbstract_lbl2">Basis of Presentation and Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationsAndLiquidityAbstract" xlink:to="galt_BasisOfPresentationsAndLiquidityAbstract_lbl2" xlink:title="label: BasisOfPresentationsAndLiquidityAbstract to galt_BasisOfPresentationsAndLiquidityAbstract_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>galt-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlcDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#GalectinSciencesLlcDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LeasesDetailsCalc2" xlink:type="simple" xlink:href="galt-20230331.xsd#LeasesDetailsCalc2" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LeasesDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#LeasesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#ConvertibleLineOfCreditRelatedPartyDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommonStockDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#CommonStockDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShareDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#LossPerShareDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommonStockWarrantsDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#CommonStockWarrantsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#FairValueOfFinancialInstrumentsKeyAssumptionsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#ConvertibleNotesPayableRelatedPartyDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#AccruedExpensesAndOtherDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails" xlink:type="simple" xlink:href="galt-20230331.xsd#BasisOfPresentationAndLiquidityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LeasesTables" xlink:type="simple" xlink:href="galt-20230331.xsd#LeasesTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShareTables" xlink:type="simple" xlink:href="galt-20230331.xsd#LossPerShareTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommonStockWarrantsTables" xlink:type="simple" xlink:href="galt-20230331.xsd#CommonStockWarrantsTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="galt-20230331.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesAndOtherTables" xlink:type="simple" xlink:href="galt-20230331.xsd#AccruedExpensesAndOtherTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlc" xlink:type="simple" xlink:href="galt-20230331.xsd#GalectinSciencesLlc" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/Leases" xlink:type="simple" xlink:href="galt-20230331.xsd#Leases" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="galt-20230331.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty" xlink:type="simple" xlink:href="galt-20230331.xsd#ConvertibleLineOfCreditRelatedParty" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommonStock" xlink:type="simple" xlink:href="galt-20230331.xsd#CommonStock" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShare" xlink:type="simple" xlink:href="galt-20230331.xsd#LossPerShare" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommonStockWarrants" xlink:type="simple" xlink:href="galt-20230331.xsd#CommonStockWarrants" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="galt-20230331.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="galt-20230331.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty" xlink:type="simple" xlink:href="galt-20230331.xsd#ConvertibleNotesPayableRelatedParty" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesAndOther" xlink:type="simple" xlink:href="galt-20230331.xsd#AccruedExpensesAndOther" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidity" xlink:type="simple" xlink:href="galt-20230331.xsd#BasisOfPresentationAndLiquidity" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="galt-20230331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="galt-20230331.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentQuarterlyReport" xlink:title="presentation: CoverAbstract to DocumentQuarterlyReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent" xlink:label="DividendsPayableCurrent" xlink:title="DividendsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DividendsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DividendsPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:label="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:title="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DerivativeLiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:label="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:title="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquityCarryingAmountAttributableToParent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UndesignatedCapitalStockValue" xlink:label="UndesignatedCapitalStockValue" xlink:title="UndesignatedCapitalStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="UndesignatedCapitalStockValue" xlink:title="presentation: StockholdersEquityAbstract to UndesignatedCapitalStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquitySharesAuthorized" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquitySharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquitySharesIssued" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquitySharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquitySharesOutstanding" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquitySharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:label="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:title="TemporaryEquityAggregateAmountOfRedemptionRequirement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquityAggregateAmountOfRedemptionRequirement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="TemporaryEquityLiquidationPreference" xlink:title="TemporaryEquityLiquidationPreference" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquityLiquidationPreference" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquityLiquidationPreference" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UndesignatedCapitalStockParValue" xlink:label="UndesignatedCapitalStockParValue" xlink:title="UndesignatedCapitalStockParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="UndesignatedCapitalStockParValue" xlink:title="presentation: StockholdersEquityAbstract to UndesignatedCapitalStockParValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UndesignatedCapitalStockSharesAuthorized" xlink:label="UndesignatedCapitalStockSharesAuthorized" xlink:title="UndesignatedCapitalStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="UndesignatedCapitalStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to UndesignatedCapitalStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UndesignatedCapitalStockSharesDesignated" xlink:label="UndesignatedCapitalStockSharesDesignated" xlink:title="UndesignatedCapitalStockSharesDesignated" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="UndesignatedCapitalStockSharesDesignated" xlink:title="presentation: StockholdersEquityAbstract to UndesignatedCapitalStockSharesDesignated" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesAuthorized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="PreferredStockLiquidationPreferenceValue" xlink:title="PreferredStockLiquidationPreferenceValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockLiquidationPreferenceValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockLiquidationPreferenceValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: OperatingExpensesAbstract to OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="PreferredStockDividendsAndOtherAdjustments" xlink:title="presentation: IncomeStatementAbstract to PreferredStockDividendsAndOtherAdjustments" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareDiluted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OperatingLeaseRightOfUseAssetAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PaidInKindInterest" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to PaidInKindInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to FairValueAdjustmentOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="IncreaseDecreaseInInterestPayableNet" xlink:title="IncreaseDecreaseInInterestPayableNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInInterestPayableNet" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInInterestPayableNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromLinesOfCredit" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromLinesOfCredit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="StockIssued1" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to StockIssued1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" xlink:label="FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" xlink:title="FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:label="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:title="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to ReclassificationOfAccruedBonusToAdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:label="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:title="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="CapitalLeaseObligationsIncurred" xlink:title="CapitalLeaseObligationsIncurred" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CapitalLeaseObligationsIncurred" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to CapitalLeaseObligationsIncurred" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="IncreaseDecreaseInTemporaryEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="presentation: IncreaseDecreaseInTemporaryEquityRollForward to TemporaryEquityCarryingAmountAttributableToParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="TemporaryEquitySharesOutstanding" xlink:title="presentation: IncreaseDecreaseInTemporaryEquityRollForward to TemporaryEquitySharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent_2" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="TemporaryEquityCarryingAmountAttributableToParent_2" xlink:title="presentation: IncreaseDecreaseInTemporaryEquityRollForward to TemporaryEquityCarryingAmountAttributableToParent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding_2" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="TemporaryEquitySharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInTemporaryEquityRollForward to TemporaryEquitySharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="presentation: StatementOfStockholdersEquityAbstract to IncreaseDecreaseInTemporaryEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="PreferredStockMember" xlink:title="presentation: StatementEquityComponentsAxis to PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertiblePreferredStockDividends" xlink:label="ConvertiblePreferredStockDividends" xlink:title="ConvertiblePreferredStockDividends" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ConvertiblePreferredStockDividends" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to ConvertiblePreferredStockDividends" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertiblePreferredStockDividendsShares" xlink:label="ConvertiblePreferredStockDividendsShares" xlink:title="ConvertiblePreferredStockDividendsShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ConvertiblePreferredStockDividendsShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to ConvertiblePreferredStockDividendsShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_TemporaryEquityDividends" xlink:label="TemporaryEquityDividends" xlink:title="TemporaryEquityDividends" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="TemporaryEquityDividends" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to TemporaryEquityDividends" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_TemporaryEquityDividendsShares" xlink:label="TemporaryEquityDividendsShares" xlink:title="TemporaryEquityDividendsShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="TemporaryEquityDividendsShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to TemporaryEquityDividendsShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="BasisOfAccounting" xlink:title="BasisOfAccounting" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="BasisOfAccounting" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to BasisOfAccounting" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesAndOther">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember" xlink:label="LoansPayableMember" xlink:title="LoansPayableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="LoansPayableMember" xlink:title="presentation: LongtermDebtTypeDomain to LoansPayableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: DebtInstrumentTable to LongtermDebtTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtDisclosureTextBlock" xlink:title="presentation: DebtInstrumentLineItems to DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstruments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommonStockWarrants">
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CommonStockWarrantsAbstract" xlink:label="CommonStockWarrantsAbstract" xlink:title="CommonStockWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CommonStockWarrantsDisclosureTextBlock" xlink:label="CommonStockWarrantsDisclosureTextBlock" xlink:title="CommonStockWarrantsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsAbstract" xlink:to="CommonStockWarrantsDisclosureTextBlock" xlink:title="presentation: CommonStockWarrantsAbstract to CommonStockWarrantsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShare">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommonStock">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="LineOfCreditFacilityAbstract" xlink:title="LineOfCreditFacilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="LineOfCreditMember" xlink:title="presentation: LongtermDebtTypeDomain to LineOfCreditMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: DebtInstrumentTable to LongtermDebtTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtDisclosureTextBlock" xlink:title="presentation: DebtInstrumentLineItems to DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: LineOfCreditFacilityAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/Leases">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/GalectinSciencesLlc">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:label="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:title="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesAbstract to InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesAndOtherTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="presentation: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommonStockWarrantsTables">
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CommonStockWarrantsAbstract" xlink:label="CommonStockWarrantsAbstract" xlink:title="CommonStockWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsAbstract" xlink:to="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="presentation: CommonStockWarrantsAbstract to ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShareTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LeasesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="presentation: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UnsecuredConvertiblePromissoryNoteMember" xlink:label="UnsecuredConvertiblePromissoryNoteMember" xlink:title="UnsecuredConvertiblePromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="UnsecuredConvertiblePromissoryNoteMember" xlink:title="presentation: CreditFacilityDomain to UnsecuredConvertiblePromissoryNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="presentation: CreditFacilityAxis to CreditFacilityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="CreditFacilityAxis" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to CreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_BasisOfPresentationsAndLiquidityAbstract" xlink:label="BasisOfPresentationsAndLiquidityAbstract" xlink:title="BasisOfPresentationsAndLiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisOfPresentationsAndLiquidityAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: BasisOfPresentationsAndLiquidityAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisOfPresentationsAndLiquidityAbstract" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="presentation: BasisOfPresentationsAndLiquidityAbstract to LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="BasisOfPresentationsAndLiquidityAbstract" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to BasisOfPresentationsAndLiquidityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedProfessionalFeesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:label="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:title="AccruedResearchAndDevelopmentCostsAndOtherCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedResearchAndDevelopmentCostsAndOtherCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AprilConvertiblePromissoryNoteMember" xlink:label="AprilConvertiblePromissoryNoteMember" xlink:title="AprilConvertiblePromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="AprilConvertiblePromissoryNoteMember" xlink:title="presentation: DebtInstrumentNameDomain to AprilConvertiblePromissoryNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_SeptemberConvertiblePromissoryNoteMember" xlink:label="SeptemberConvertiblePromissoryNoteMember" xlink:title="SeptemberConvertiblePromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="SeptemberConvertiblePromissoryNoteMember" xlink:title="presentation: DebtInstrumentNameDomain to SeptemberConvertiblePromissoryNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DecemberConvertiblePromissoryNoteMember" xlink:label="DecemberConvertiblePromissoryNoteMember" xlink:title="DecemberConvertiblePromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="DecemberConvertiblePromissoryNoteMember" xlink:title="presentation: DebtInstrumentNameDomain to DecemberConvertiblePromissoryNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="presentation: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: DebtInstrumentTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="presentation: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: DebtInstrumentTable to StatementScenarioAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ConvertibleNotesPayableRelatedPartyAbstract" xlink:label="ConvertibleNotesPayableRelatedPartyAbstract" xlink:title="ConvertibleNotesPayableRelatedPartyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtConversionConvertedInstrumentAmount1" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtConversionConvertedInstrumentAmount1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtInstrumentMaturityDate" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:label="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:title="NumberOfPromissoryNotesEvidencedByLoansAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to NumberOfPromissoryNotesEvidencedByLoansAgreement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtInstrumentConvertibleConversionPrice1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtInstrumentInterestRateStatedPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtInstrumentInterestRateEffectivePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="InterestExpenseDebt" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to InterestExpenseDebt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_QuarterlyInterestRate" xlink:label="QuarterlyInterestRate" xlink:title="QuarterlyInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="QuarterlyInterestRate" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to QuarterlyInterestRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AnnualInterestRate" xlink:label="AnnualInterestRate" xlink:title="AnnualInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="AnnualInterestRate" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to AnnualInterestRate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DerivativeLiabilitiesNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="AmortizationOfFinancingCosts" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to AmortizationOfFinancingCosts" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther" xlink:label="InterestExpenseOther" xlink:title="InterestExpenseOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="InterestExpenseOther" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to InterestExpenseOther" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="RepaymentsOfDebt" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to RepaymentsOfDebt" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="ConvertibleNotesPayableRelatedPartyAbstract" xlink:title="presentation: DebtInstrumentLineItems to ConvertibleNotesPayableRelatedPartyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="presentation: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="FairValueInputsLevel12And3Member" xlink:title="FairValueInputsLevel12And3Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueInputsLevel12And3Member to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueInputsLevel12And3Member to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueInputsLevel12And3Member to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel12And3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel12And3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="AssetsFairValueDisclosure" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to AssetsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to FinancialLiabilitiesFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to DerivativeLiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="MeasurementInputSharePriceMember" xlink:title="MeasurementInputSharePriceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputSharePriceMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputSharePriceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="MeasurementInputConversionPriceMember" xlink:title="MeasurementInputConversionPriceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputConversionPriceMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputConversionPriceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="MeasurementInputDiscountRateMember" xlink:title="MeasurementInputDiscountRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputDiscountRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputDiscountRateMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedDividendRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedDividendRateMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="presentation: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="MeasurementInputTypeAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to MeasurementInputTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="presentation: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:label="ValuationTechniqueAndInputDescriptionAbstract" xlink:title="ValuationTechniqueAndInputDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="DerivativeLiabilityMeasurementInput" xlink:title="DerivativeLiabilityMeasurementInput" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationTechniqueAndInputDescriptionAbstract" xlink:to="DerivativeLiabilityMeasurementInput" xlink:title="presentation: ValuationTechniqueAndInputDescriptionAbstract to DerivativeLiabilityMeasurementInput" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationTechniqueAndInputDescriptionAbstract" xlink:to="DebtInstrumentTerm" xlink:title="presentation: ValuationTechniqueAndInputDescriptionAbstract to DebtInstrumentTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="ValuationTechniqueAndInputDescriptionAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to ValuationTechniqueAndInputDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="presentation: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to DerivativeLiabilitiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueAdjustmentOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent_2" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="DerivativeLiabilitiesNoncurrent_2" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to DerivativeLiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationAbstract to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to TitleOfIndividualAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:title="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:title="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusMember" xlink:label="DeferredBonusMember" xlink:title="DeferredBonusMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="DeferredBonusMember" xlink:title="presentation: DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain to DeferredBonusMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:title="presentation: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis to DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_RestrictedStockGrantsAbstract" xlink:label="RestrictedStockGrantsAbstract" xlink:title="RestrictedStockGrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: RestrictedStockGrantsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: RestrictedStockGrantsAbstract to AllocatedShareBasedCompensationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:title="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:title="DeferredCompensationArrangementWithIndividualSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementWithIndividualSharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:title="DeferredCompensationArrangementWithIndividualExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementWithIndividualExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="presentation: RestrictedStockGrantsAbstract to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="presentation: RestrictedStockGrantsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="CommonStockSharesSubscribedButUnissued" xlink:title="CommonStockSharesSubscribedButUnissued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="CommonStockSharesSubscribedButUnissued" xlink:title="presentation: RestrictedStockGrantsAbstract to CommonStockSharesSubscribedButUnissued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="presentation: RestrictedStockGrantsAbstract to SharesPaidForTaxWithholdingForShareBasedCompensation" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="presentation: RestrictedStockGrantsAbstract to PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="presentation: RestrictedStockGrantsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="RestrictedStockGrantsAbstract" xlink:title="presentation: ShareBasedCompensationAbstract to RestrictedStockGrantsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommonStockWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CommonStockWarrantsAbstract" xlink:label="CommonStockWarrantsAbstract" xlink:title="CommonStockWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to FinancialInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to WarrantsAndRightsOutstandingTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: CommonStockWarrantsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to ConvertibleNotesPayableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="LineOfCreditMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to LineOfCreditMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to ConvertiblePreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_TwoThousandTwentyMarketAgreementMember" xlink:label="TwoThousandTwentyMarketAgreementMember" xlink:title="TwoThousandTwentyMarketAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="TwoThousandTwentyMarketAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to TwoThousandTwentyMarketAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfStockByClassTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_SeriesAAndSeriesCPreferredStockMember" xlink:label="SeriesAAndSeriesCPreferredStockMember" xlink:title="SeriesAAndSeriesCPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAAndSeriesCPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAAndSeriesCPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_AggregateOfferingPrice" xlink:label="AggregateOfferingPrice" xlink:title="AggregateOfferingPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="AggregateOfferingPrice" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to AggregateOfferingPrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CommissionRate" xlink:label="CommissionRate" xlink:title="CommissionRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommissionRate" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommissionRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsShares" xlink:label="CommonStockDividendsShares" xlink:title="CommonStockDividendsShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockDividendsShares" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockDividendsShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: ClassOfStockLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="LineOfCreditFacilityAbstract" xlink:title="LineOfCreditFacilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="LineOfCreditFacilityTable" xlink:title="LineOfCreditFacilityTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: LineOfCreditFacilityTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="presentation: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: LineOfCreditFacilityTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_UnsecuredConvertiblePromissoryNoteMember" xlink:label="UnsecuredConvertiblePromissoryNoteMember" xlink:title="UnsecuredConvertiblePromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="UnsecuredConvertiblePromissoryNoteMember" xlink:title="presentation: CreditFacilityDomain to UnsecuredConvertiblePromissoryNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="presentation: CreditFacilityAxis to CreditFacilityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="CreditFacilityAxis" xlink:title="presentation: LineOfCreditFacilityTable to CreditFacilityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="RangeAxis" xlink:title="presentation: LineOfCreditFacilityTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_WarrantOneMember" xlink:label="WarrantOneMember" xlink:title="WarrantOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantOneMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_WarrantTwoMember" xlink:label="WarrantTwoMember" xlink:title="WarrantTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantTwoMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: LineOfCreditFacilityTable to FinancialInstrumentAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="LineOfCreditFacilityLineItems" xlink:title="LineOfCreditFacilityLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_LineOfCreditRelatedPartyAbstract" xlink:label="LineOfCreditRelatedPartyAbstract" xlink:title="LineOfCreditRelatedPartyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to LineOfCreditFacilityMaximumBorrowingCapacity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentInterestRateIncreaseDecrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentMaturityDate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="SharePrice" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to SharePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ProceedsFromLinesOfCredit" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ProceedsFromLinesOfCredit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to CommonStockParOrStatedValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="DebtInstrumentInterestRateDuringPeriod" xlink:title="DebtInstrumentInterestRateDuringPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateDuringPeriod" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentInterestRateDuringPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentInterestRateStatedPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentInterestRateEffectivePercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_DebtInstrumentAccruedInterest" xlink:label="DebtInstrumentAccruedInterest" xlink:title="DebtInstrumentAccruedInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentAccruedInterest" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentAccruedInterest" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="WarrantsAndRightsOutstandingMaturityDate" xlink:title="WarrantsAndRightsOutstandingMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="WarrantsAndRightsOutstandingMaturityDate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to WarrantsAndRightsOutstandingMaturityDate" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_IssuanceOfWarrantsValue" xlink:label="IssuanceOfWarrantsValue" xlink:title="IssuanceOfWarrantsValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="IssuanceOfWarrantsValue" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to IssuanceOfWarrantsValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="InterestExpenseRelatedParty" xlink:title="InterestExpenseRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="InterestExpenseRelatedParty" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to InterestExpenseRelatedParty" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditRelatedPartyAbstract" xlink:title="presentation: LineOfCreditFacilityLineItems to LineOfCreditRelatedPartyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="LineOfCreditFacilityLineItems" xlink:title="presentation: LineOfCreditFacilityTable to LineOfCreditFacilityLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAbstract" xlink:to="LineOfCreditFacilityTable" xlink:title="presentation: LineOfCreditFacilityAbstract to LineOfCreditFacilityTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_ContractCancelationNoticePeriod" xlink:label="ContractCancelationNoticePeriod" xlink:title="ContractCancelationNoticePeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ContractCancelationNoticePeriod" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to ContractCancelationNoticePeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LeasesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_NumberOfOperatingLeases" xlink:label="NumberOfOperatingLeases" xlink:title="NumberOfOperatingLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="NumberOfOperatingLeases" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to NumberOfOperatingLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LesseeOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_FreeRentPeriod" xlink:label="FreeRentPeriod" xlink:title="FreeRentPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="FreeRentPeriod" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to FreeRentPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="SecurityDeposit" xlink:title="SecurityDeposit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="SecurityDeposit" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to SecurityDeposit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseCost" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseLiabilityCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseLiabilityNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDescriptionAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDiscountRate" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDiscountRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="LesseeLeaseDescriptionLineItems" xlink:title="presentation: LesseeLeaseDescriptionTable to LesseeLeaseDescriptionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeLeaseDescriptionTable" xlink:title="presentation: LeasesAbstract to LesseeLeaseDescriptionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LeasesDetailsCalc2" />
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/GalectinSciencesLlcDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="ScheduleOfInvestmentsTable" xlink:title="ScheduleOfInvestmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_GalectinSciencesLLCMember" xlink:label="GalectinSciencesLLCMember" xlink:title="GalectinSciencesLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="GalectinSciencesLLCMember" xlink:title="presentation: OwnershipDomain to GalectinSciencesLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="presentation: OwnershipAxis to OwnershipDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInvestmentsTable" xlink:to="OwnershipAxis" xlink:title="presentation: ScheduleOfInvestmentsTable to OwnershipAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_SBHSciencesIncMember" xlink:label="SBHSciencesIncMember" xlink:title="SBHSciencesIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="SBHSciencesIncMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to SBHSciencesIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInvestmentsTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: ScheduleOfInvestmentsTable to CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="InProcessResearchAndDevelopmentMember" xlink:title="InProcessResearchAndDevelopmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="InProcessResearchAndDevelopmentMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to InProcessResearchAndDevelopmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInvestmentsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: ScheduleOfInvestmentsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:label="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:title="InvestmentsInAndAdvancesToAffiliatesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="PaymentsToAcquireEquityMethodInvestments" xlink:title="PaymentsToAcquireEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="PaymentsToAcquireEquityMethodInvestments" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to PaymentsToAcquireEquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:title="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to MinorityInterestOwnershipPercentageByParent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20230331.xsd#galt_CapitalContributionExpense" xlink:label="CapitalContributionExpense" xlink:title="CapitalContributionExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="CapitalContributionExpense" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to CapitalContributionExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesLineItems to InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInvestmentsTable" xlink:to="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:title="presentation: ScheduleOfInvestmentsTable to InvestmentsInAndAdvancesToAffiliatesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="ScheduleOfInvestmentsTable" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesAbstract to ScheduleOfInvestmentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029023024336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GALECTIN THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001133416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3562325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4960 Peachtree Industrial Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Norcross<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">620 -3186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GALT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,582,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029023496688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,799<span></span>
</td>
<td class="nump">$ 18,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,753<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">19,552<span></span>
</td>
<td class="nump">20,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,225<span></span>
</td>
<td class="nump">21,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,553<span></span>
</td>
<td class="nump">3,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">8,980<span></span>
</td>
<td class="nump">9,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Accrued dividends payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,533<span></span>
</td>
<td class="nump">13,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent', window );">Convertible notes payable and accrued interest, net of discounts - related party (Note 3)</a></td>
<td class="nump">30,200<span></span>
</td>
<td class="nump">29,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities (Note 4)</a></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent', window );">Borrowing and accrued interest under convertible line of credit, net of debt discount - related party (Note 9)</a></td>
<td class="nump">19,741<span></span>
</td>
<td class="nump">9,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">62,871<span></span>
</td>
<td class="nump">53,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series C super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 shares issued and outstanding at March 31, 2023 and December 31, 2022, redemption value: $8,256,000, liquidation value: $1,760,000 at March 31, 2023</a></td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_UndesignatedCapitalStockValue', window );">Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at March 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,260,000 issued and outstanding at March 31, 2023 and December 31, 2022, liquidation value $1,260,500 at March 31, 2023</a></td>
<td class="nump">510<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 150,000,000 shares authorized at March 31, 2023 and December 31, 2022, 59,582,253 and 59,426,005 issued and outstanding at March 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">276,156<span></span>
</td>
<td class="nump">275,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(321,094)<span></span>
</td>
<td class="num">(309,567)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="num">(44,369)<span></span>
</td>
<td class="num">(33,917)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">$ 20,225<span></span>
</td>
<td class="nump">$ 21,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as borrowing and accrued interest under line of credit related party excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as convertible notes payable and accrued interest, net of debt discount of related party excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_UndesignatedCapitalStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of shares which are not designated as common stock or preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_UndesignatedCapitalStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029024496624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series C 6% super dividend redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement', window );">Series C 6% super dividend redeemable convertible preferred stock, redemption value</a></td>
<td class="nump">$ 8,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Series C 6% super dividend redeemable convertible preferred stock liquidation value</a></td>
<td class="nump">$ 1,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_UndesignatedCapitalStockParValue', window );">Undesignated stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_UndesignatedCapitalStockSharesAuthorized', window );">Undesignated stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_UndesignatedCapitalStockSharesDesignated', window );">Undesignated stock, shares designated (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Series A 12% convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,742,500<span></span>
</td>
<td class="nump">1,742,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Series A 12% convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,260,000<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Series A 12% convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,260,000<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Series A 12% convertible preferred stock, liquidation value</a></td>
<td class="nump">$ 1,260,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">59,582,253<span></span>
</td>
<td class="nump">59,426,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">59,582,253<span></span>
</td>
<td class="nump">59,426,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_UndesignatedCapitalStockParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of undesignated capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_UndesignatedCapitalStockParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_UndesignatedCapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of undesignated capital stock permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_UndesignatedCapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_UndesignatedCapitalStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of undesignated capital stock which are designated as common stock or preferred stock by board of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_UndesignatedCapitalStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029023119344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 8,799<span></span>
</td>
<td class="nump">$ 8,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,342<span></span>
</td>
<td class="nump">9,935<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating loss</a></td>
<td class="num">(10,342)<span></span>
</td>
<td class="num">(9,935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivative</a></td>
<td class="num">(769)<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(460)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(1,185)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,527)<span></span>
</td>
<td class="num">(9,932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Preferred stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common stockholders</a></td>
<td class="num">$ (11,527)<span></span>
</td>
<td class="num">$ (9,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">59,480<span></span>
</td>
<td class="nump">59,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">59,480<span></span>
</td>
<td class="nump">59,354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029023090784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,527)<span></span>
</td>
<td class="num">$ (9,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">662<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right to use asset</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">769<span></span>
</td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="num">(1,372)<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest on convertible debt - related party</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash from operating activities</a></td>
<td class="num">(10,793)<span></span>
</td>
<td class="num">(8,042)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Net proceeds from convertible line of credit - related party</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows from financing activities</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(793)<span></span>
</td>
<td class="num">(8,042)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">18,592<span></span>
</td>
<td class="nump">39,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">17,999<span></span>
</td>
<td class="nump">31,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NONCASH FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Payment of preferred stock dividends in common stock</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital', window );">Reclassification of accrued bonus to additional paid in capital</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit', window );">Common stock purchase warrants issued in connection with related party line of credit</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Noncash right to use lease asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of common stock purchase warrants issued in connection with related party line of credit in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount reclassified from accrued compensation to excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029024044528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A 12% Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 527<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 271,001<span></span>
</td>
<td class="num">$ (270,694)<span></span>
</td>
<td class="nump">$ 893<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">1,302,500<span></span>
</td>
<td class="nump">59,341,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertiblePreferredStockDividends', window );">Series A 12% convertible preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertiblePreferredStockDividendsShares', window );">Series A 12% convertible preferred stock dividend (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_TemporaryEquityDividends', window );">Series C super dividend redeemable convertible preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_TemporaryEquityDividendsShares', window );">Series C super dividend redeemable convertible preferred stock dividend (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock-based compensation expense (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,932)<span></span>
</td>
<td class="num">(9,932)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 527<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">272,108<span></span>
</td>
<td class="num">(280,610)<span></span>
</td>
<td class="num">(7,916)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">1,302,500<span></span>
</td>
<td class="nump">59,388,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 510<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">275,081<span></span>
</td>
<td class="num">(309,567)<span></span>
</td>
<td class="num">$ (33,917)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">1,260,000<span></span>
</td>
<td class="nump">59,426,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertiblePreferredStockDividends', window );">Series A 12% convertible preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertiblePreferredStockDividendsShares', window );">Series A 12% convertible preferred stock dividend (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_TemporaryEquityDividends', window );">Series C super dividend redeemable convertible preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_TemporaryEquityDividendsShares', window );">Series C super dividend redeemable convertible preferred stock dividend (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Common stock purchase warrants issued in connection with related party line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock-based compensation expense (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,527)<span></span>
</td>
<td class="num">(11,527)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 510<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 276,156<span></span>
</td>
<td class="num">$ (321,094)<span></span>
</td>
<td class="num">$ (44,369)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">1,260,000<span></span>
</td>
<td class="nump">59,582,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ConvertiblePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid convertible preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ConvertiblePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ConvertiblePreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of Convertible preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ConvertiblePreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_TemporaryEquityDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid temporary equity dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_TemporaryEquityDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_TemporaryEquityDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends for temporary equity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_TemporaryEquityDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029026263360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation and Liquidity</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">1. Basis of Presentation and Liquidity<br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Galectin Therapeutics Inc. and subsidiaries (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and
          drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company&#8217;s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have
          application for drugs to treat other diseases and chronic health conditions.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of
          management, necessary to present fairly the financial position of the Company as of March 31, 2023 and the results of its operations for the three months ended March 31, 2023 and 2022 and its cash flows for the three months ended March 31, 2023
          and 2022. All adjustments made to the interim financial statements include all those of a normal and recurring nature. Amounts presented in the condensed consolidated balance sheet as of December 31, 2022 are derived from the Company&#8217;s audited
          consolidated financial statements as of that date, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The Company
          considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.
          Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the
          full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2022.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; margin-top: 8pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The







            Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At March 31, 2023, the company had $17,799,000 of unrestricted cash and cash equivalents available to fund future operations.&#160; In July 2022, the Company entered into a $60 million unsecured line of credit financing with its chairman, Richard E. Uihlein (See Note 10). The Company believes there is sufficient cash,
            including availability of the line of credit, to fund currently planned operations at least through December 31, 2024. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other
              strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when
              needed could have a material adverse effect on the Company&#8217;s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity
              concerns until a date when those concerns are relieved.</span></div>

<div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Company was
          founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name &#8220;Pro-Pharmaceuticals, Inc.,&#8221; and changed its name to &#8220;Galectin Therapeutics Inc.&#8221; on May&#160;26, 2011.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029025972016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2. Accrued Expenses and Other</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued expenses consist of the following:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="width: 100%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 76%;" valign="bottom">
                <div>&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;"> <span style="font-weight: bold;">March 31,<br/>
                    2023</span></div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;"><span style="font-weight: bold;">December 31,<br/>
                  </span> <span style="font-weight: bold;">2022</span></div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                <div style="text-align: center;">(in thousands)</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -27pt; margin-left: 27pt;">Legal and accounting fees</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>142</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>65</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -27pt; margin-left: 27pt;">Accrued compensation</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>386</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>973</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -27pt; margin-left: 27pt;">Lease liability</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>42</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>40</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -27pt; margin-left: 27pt;">Accrued research and development costs and other</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>8,410</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>7,980</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -27pt; margin-left: 27pt;">Total</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>8,980</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>9,058</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 24.5pt;">Research and development expenses, including personnel costs, allocated facility costs, lab supplies, outside services, contract laboratory costs related to
          manufacturing drug product, clinical trials and preclinical studies are charged to research and development expense as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research
          and development activities as expense when the service has been performed or when the goods have been received. Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors. We
          accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses and related expenses associated with the conduct of clinical trials, the significant
          factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients have been enrolled in the trial. We monitor patient enrollment levels and related activities
          to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We base our estimates on the best information available at the time. We monitor patient enrollment levels and related activities to the
          extent possible through discussions with CRO personnel and based our estimates of clinical trial costs on the best information available at the time. However, additional information may become available to us which will allow us to make a more
          accurate estimate in future periods. In that event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029025973392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable - Related Party<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Convertible Notes Payable - Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable - Related Party</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">3. Convertible Notes Payable &#8211; Related Party</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;">On April&#160;16, 2021, the Company and
          Richard E. Uihlein entered into a debt financing arrangement whereby Mr.&#160;Uihlein loaned $10,000,000 to Company. In consideration for
          the loan, the Company issued a convertible promissory note (the &#8220;April 2021 Note&#8221;) in the principal amount of ten million dollars.</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;"><br/>
          </span> </div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;">The April 2021 Note has a maturity date
          of April 16, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#8217;s
          common stock at a conversion price equal to $5.00 per share at the option of the noteholder. The April 2021 Note bears interest at the
          rate of two percent (2%) per annum, compounded annually with an effective interest rate of approximately 3%. For the three months ended March 31, 2023 and 2022, approximately $50,000 and $50,000, respectively, of interest expense was accrued and
          included with the principal in the financial statements.<br/>
        </div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;"><br/>
          </span> </div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;">The April 2021 Note also includes a
          contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per
          quarter (10% per annum) (the &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date,
          provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the April 2021 Note into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on
          creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the April 2021 Note at its inception. The fair value of
          the contingent interest derivative liability was $420,000 at note inception (April 16, 2021). The fair value of the contingent interest
          derivative liability was $587,000 and $249,000
          at March 31, 2023 and December 31, 2022, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability for the three months ended March 31, 2023 and 2022 of $338,000 and $(104,000), respectively,
          was charged to other expense/(income) for the three months ended March 31, 2023 and 2022. The amortization of the original $420,000
          debt discount of $26,000 and $26,000
          was recorded as additional interest expense for the three months ended March 31, 2023 and 2022, respectively<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.</span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal; background-color: rgb(255, 255, 255);"><br/>
          </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;">The September 2021 Note has a maturity
          date of September 17, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the
          Company&#8217;s common stock at a conversion price equal to $8.64 per share at the option of the noteholder. The September 2021 Note bears
          interest at the rate of two percent (2%) per annum, compounded annually with an effective interest rate of approximately 3%. For the three months ended March 31, 2023 and 2022, approximately $50,000 and $50,000, respectively, of interest expense was accrued and
          included with the principal in the financial statements. </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt;"><span style="letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>The September 2021 Note
          also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%)
          per quarter (10% per annum) (the &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date,
          provided however, that such payment is only required if and only if the noteholder elects&#160;&#160; to convert the entire balance of the September 2021 Note into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on
          creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the September Note at its inception. The fair value of the
          contingent interest derivative liability was $433,000 at note inception (September 17, 2021). The fair value of the contingent interest
          derivative liability was $276,000 and $109,000
          and March 31, 2023 and December 31, 2022, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability three months ended March 31, 2023 and 2022 of $167,000 and ($62,000), respectively,
          was recorded to other expense/(income) for three months ended March 31, 2023 and 2022. The amortization of the original $433,000 debt
          discount of $27,000 and $27,000
          was recorded as additional interest expense for the three months ended March 31, 2023 and 2022<span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;">.</span><span class="HorizontalTab" style="width: 9pt; font-size: 10pt; display: inline-block; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">&#160; </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: left; text-indent: 24.5pt; text-transform: none;"><span style="font-weight: normal;">On</span> December 20, 2021, the
          second of the two promissory notes under the Loan Agreement was executed and delivered, (the &#8220;December 2021 Note&#8221;) to evidence the
          second loan in the principal amount of $10,000,000. The December 2021 Note has a maturity date of December 20, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#8217;s common stock at a
          conversion price equal to $5.43 per share at the option of the noteholder. The December Note bears interest at the rate of two percent
          (2%) per annum, compounded annually with an effective interest rate of approximately 3%. For three months ended March 31, 2023 and 2022, approximately $50,000
          and $50,000, respectively, of interest expense was accrued and included with the principal in the financial statements.</div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">The </span>December 2021
          Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%)
          per quarter (10% per annum) (the &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date,
          provided however, that such payment is only required if and only if the noteholder elects&#160;&#160; to convert the entire balance of the December 2021 Note into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on
          creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the December Note at its inception. The fair value of the
          contingent interest derivative liability was $415,000 at note inception (December 20, 2021). The fair value of the contingent interest
          derivative liability was $479,000 and $215,000
          at March 31, 2023 and December 31, 2022, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability for three months ended March 31, 2023 and 2022.of $264,000 and ($63,000), respectively was
          recorded to other expense/(income) for three months ended March 31, 2023 and 2022.. The amortization of the original $415,000 debt
          discount of $26,000 and $26,000
          was recorded as additional interest expense for three months ended March 31, 2023 and 2022, respectively<span style="font-weight: normal;">. </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company&#8217;s contractual cash obligations related to the outstanding
              convertible notes payable is a repayment of the April 2021 Note of the $10,000,000 plus accrued interest on April&#160;16, 2025 and a
              repayment of the September 2021 Note of the $10,000,000 <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">plus accrued interest on September 17, 2025 and a
                repayment of the December 2021 Note of the $10,000,000 plus accrued interest on December 30, 2025, unless converted at the option
                of the noteholder.</span></span> </span> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029026240288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">4. Fair Value of Financial Instruments</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">The Company has
            certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than
            quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to
            develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximate their carrying value due to their short-term nature. There were no level 1 or 2 assets or liabilities at March 31, 2023 or December 31, 2022. See below for Fair Value of Derivatives related to Convertible
            Notes Payable at March 31, 2023 and December 31, 2022, which are level 3 liabilities.</div>

<div><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">Level 3 assets
              and liabilities measured and recorded at fair value on a recurring basis at March 31, 2023 and December 31, 2022 were as follows:</div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br/>
            </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td colspan="1" style="vertical-align: bottom; padding-left: 23%; padding-bottom: 2px;" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span> </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">
                  <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                  </div>
                  <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2022</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div><span style="font-family: 'Times New Roman'; font-size: 10pt;">Derivative Liability &#8211; Contingent Interest April Note </span> </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">587,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">249,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Derivative Liability &#8211; Contingent Interest September Note </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">276,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">109,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">Derivative Liability &#8211; Contingent Interest December Note</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">479,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">215,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; margin-right: 41pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The April Note derivative liability &#8211;
            contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">
                  <div style="text-align: center; font-weight: bold;">
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                    </div>
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                  </div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" valign="bottom">
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2022</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Stock Price</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">2.10</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">1.13</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Conversion Price of conversion feature</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">5.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">5.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Term</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160; 2.04 years<br/>
                  </span> </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">2.29 years</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Risk Free Interest Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">4.06</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">4.41</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">14.04</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">14.76</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Volatility</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">85</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">81</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Dividend Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%<br/>
                </span> </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%<br/>
                </span> </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/></div>

<div><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt; margin-left: 9pt;">The roll forward of the April Note derivative liability &#8211; contingent interest is as follows for the three months ended March 31, 2023 and 2022:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2022</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">249,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">338,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">587,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2021<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">495,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">Fair Value Adjustment</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">(104,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2022</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">391,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">The September
              Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </span> </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                    </div>
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold;">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">2022</span></div>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Stock Price</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">2.10</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">1.13</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Conversion Price of conversion feature</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.64</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.64</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Term</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: right; text-indent: -18pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">2.47</span> years
                      <br/>
                    </span> </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: 6pt; text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">2.72</span> years</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Risk Free Interest Rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">3.94</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">4.22</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Credit Adjusted Discount Rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">14.04</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">14.76</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Volatility</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">80</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">81</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Dividend Rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">0</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">%</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">0</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">%</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 27pt; text-transform: none;">The roll forward of the September
            Note derivative liability &#8211; contingent interest is as follows: </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2022</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">109,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; text-align: left; width: 88%; padding-bottom: 2px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">167,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">276,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2021</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">250,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">Fair Value Adjustment</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">(62,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom">Balance &#8211; March 31, 2022</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">188,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; margin-right: 23pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The December Note derivative
                liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
              <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                      <div style="text-align: center; font-weight: bold;">
                        <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                        </div>
                        <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                      </div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2022</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock Price</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.10</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.13</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Conversion Price of conversion feature</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.43</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.43</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Term</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> 2.73 years<br/>
                    </span></td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.97 years</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Risk Free Interest Rate</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3.81</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">4.22</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Credit Adjusted Discount Rate</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">14.04</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">14.76</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Volatility</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">80</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">83</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Dividend Rate</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">0</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</span></td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">0</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</span></td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;">The roll forward
                of the December Note derivative liability &#8211; contingent interest is as follows: </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2022</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">215,000</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">264,000</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2023</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">479,000</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2021<br/>
                    </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom">$ <br/>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom">109,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">167,000</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2022</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">276,000</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029030512256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">5. Stock-Based Compensation</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">Three Months Ended<br/>
                    March 31,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2023<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2022<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>Research and development</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>270</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>225</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>General and administrative</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>392</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>633</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="margin-left: 9pt;">Total stock-based compensation expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>662</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>858</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the stock option activity in the Company&#8217;s equity incentive plans, including non-plan grants to Company executives, from
            December&#160;31, 2022 through March 31, 2023:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">Weighted Average<br/>
                    Exercise Price</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>Outstanding, December 31, 2022</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>5,745,561</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>2.90</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                  <div style="margin-left: 9pt;">Granted</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>800,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>1.11</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="margin-left: 9pt;">Exercised</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>&#8212;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#8212;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="margin-left: 9pt;">Options forfeited/cancelled</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div>(18,803</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>3.59</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>Outstanding, March 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>6,526,758</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>2.67</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">As of March 31, 2023, there was $2,268,000 of
            unrecognized compensation related to 2,850,833 unvested options, which is expected to be recognized over a weighted&#8211;average period
            of approximately 1.29 years. The weighted-average grant date fair value for options granted during the three months ended March 31,
            2022 was $0.80. The Company granted 800,000
            stock options during the three months ended March 31, 2023.<br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">Three<br/>
                    Months Ended<br/>
                    March 31,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">Three<br/>
                    Months Ended<br/>
                    March 31,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2023<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2022<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>Risk-free interest rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>3.76</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>%</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>1.23</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>%</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
                  <div>Expected life of the options</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-align: right;">5.5 years </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-align: right;">5.5 years <br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>Expected volatility of the underlying stock</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>86</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>%</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>95</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>%</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                  <div>Expected dividend rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>0</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>0</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">In January 2023, the Company&#8217;s board chairman elected to take restricted stock grants in lieu of cash retainers for 2023. A total of 36,036 shares of restricted stock valued at approximately $40,000 is being amortized to expense on a straight-line basis until December 31, 2023 when the stock vests in full. In January 2022, the Company&#8217;s board chairman elected to take restricted stock grants in lieu
            of cash retainers for 2022. A total of 17,677 shares of restricted stock valued at approximately $35,000 is being amortized to expense on a straight-line basis until December 31, 2022 when the stock vested in full.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">In September 2020, the Company entered into an employment agreement with its new Chief Executive Officer whereby 20% of his base salary and performance bonuses will be paid in cash, and 80%
            will be paid in the form of deferred stock units (&#8220;DSUs&#8221;) in accordance with the terms and subject to the provisions set forth in the DSU Agreement. DSUs credited to Mr. Lewis as of any date shall be fully vested and nonforfeitable at all
            times. Pursuant to an amendment to the DSU Agreement in July 2022, the Company shall issue the shares underlying the outstanding whole number of DSUs credited to Mr. Lewis as follows: twenty five percent shall be issued on March 1, 2023, fifty percent
            shall be issued on March 1, 2024 and twenty five percent shall be issued on September 1, 2028.&#160; On March 1, 2023, twenty five percent of the DSU&#8217;s were issued to Mr. Lewis in accordance with the DSU Agreement.&#160;&#160; A total of 183,900 shares were due to be issued; however, 75,529
            shares were withheld to cover income tax withholding of $156,345 resulting in 108,371 shares actually issued.<br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">For the three months ended March 31, 2023, approximately $112,000
            of his compensation was recorded as stock compensation expense representing 72,440 shares of common stock to be issued under the DSU
            agreement with a weighted average grant date fair value of $1.55 per share.&#160; For the three months ended March 31, 2022, approximately
            $103,000 of his compensation was recorded as stock compensation expense representing 55,626 shares of common stock to be issued under the DSU agreement with a weighted average grant date fair value of $1.86 per share.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Also, Mr. Lewis&#8217; bonus for the year ended December 31, 2022 of $210,000
            (which was included in accrued compensation at December 31, 2022) was approved in January 2023 and represents 143,836 shares of
            common stock to be issued under the DSU agreement with a grant date fair value of $1.46 per share. The $210,000 was reclassified from accrued compensation to additional paid in capital in January 2023. There is no unrecognized compensation expense related to the DSUs.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029026407136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CommonStockWarrantsAbstract', window );"><strong>Common Stock Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CommonStockWarrantsDisclosureTextBlock', window );">Common Stock Warrants</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">6. Common Stock Warrants</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the common stock warrant activity from December 31, 2022 through March 31, 2023:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                <div>&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted Average<br/>
                  Exercise Price</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Outstanding, December 31, 2022</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>11,557,964</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>4.37</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="margin-left: 9pt;">Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>200,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>3.26</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="margin-left: 9pt;">Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="margin-left: 9pt;">Forfeited/cancelled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Outstanding, March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>11,757,964</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>4.35</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The weighted average expiration of the warrants outstanding as of March 31, 2023 is 1.8 years.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_CommonStockWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_CommonStockWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_CommonStockWarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Equity warrants are instruments that bestow upon the holder of the instrument the right to buy a particular stock at a predetermined price within a stipulated time frame. ... This payment is to be adjusted against the final payment that needs to be paid in case the warrants are exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_CommonStockWarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029029591776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">7. Loss Per Share</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding
          during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares
          consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the
          issuance of common shares that have an anti-dilutive effect on net loss per share. </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would
          have been anti-dilutive are as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                <div>&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31,</div>
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31,</div>
                <div style="text-align: center; font-weight: bold;">2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">(shares) <br/>
              </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">(shares) <br/>
              </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Warrants to purchase shares of common stock</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>11,757,964</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>10,857,964</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div>Options to purchase shares of common stock</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>6,526,758</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,630,561</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Shares of common stock issuable upon conversion of convertible notes payable &#8211; related party</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>5,966,437</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>5,365,259</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">Shares of common stock issuable upon conversion of convertible line of credit &#8211; related party<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">6,727,849</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#8212;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Shares of common stock issuable upon conversion of preferred stock</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>503,340</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>510,424</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div>&#160;</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>31,482,348</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>22,364,208</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029026436592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">8. Common Stock</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">2020 At Market Issuance of Common Stock</div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 21.5pt; margin-top: 3pt; margin-bottom: 3pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 11, 2020, the Company entered into an At Market Issuance Sales Agreement (the
          &#8220;2020 At Market Agreement&#8221;) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $40.0 million from time to time through the sales agent. Sales of the Company&#8217;s common stock through the sales agent, if any, will be made by any method that is deemed an &#8220;at the market&#8221; offering as defined by the
          U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to 3.0% of the gross proceeds
          from the sale of any shares of common stock sold through the sales agent under the 2020 At Market Agreement. During the quarter ended March 31, 2023, there were no issuances of shares of common stock under the 2020 At Market Agreement.</div>

<div style="margin-top: 3pt; margin-bottom: 3pt; font-family: 'Times New Roman';"><br/>
          </div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">For each of the three months ended March 31, 2023 and 2022, the Company issued a total of 30,200 and 30,625 shares of common stock, respectively, for
            dividends on Series A and Series C Preferred Stock.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029023197280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Line of Credit - Related Party<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Convertible Line of Credit - Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Line of Credit - Related Party</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-right: 11pt; font-weight: bold;">9. Convertible Line of Credit &#8211; Related Party</div>

<div><span style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">On July 25, 2022, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into a Line of Credit Letter Agreement (the &#8220;Credit Agreement&#8221;),
        pursuant to which the Lender shall provide the Company a line of credit of up to $60.0 million (the &#8220;Line of Credit&#8221;) to finance the
        Company&#8217;s working capital needs. The Company may draw upon the Line of Credit through July 31, 2024.</div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">Each advance made pursuant to the Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a
        &#8220;Promissory Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at the Applicable Federal Rate for short term loans, plus two (2%)
        percent. Principal and interest on the Promissory Notes are due on or before January 31, 2026. Only with the consent of the Lender, may
        the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid.</div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the
        Company&#8217;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share.</div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">In connection with the Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 1,700,000 shares of the Company&#8217;s common stock, par value $0.001
        per share (collectively, the &#8220;Warrants&#8221;). Upon execution of the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 500,000
        shares of Company&#8217;s Common Stock at an exercise price of $5.00 per share, which Warrant is exercisable upon issuance. Further, pursuant
        to the Credit Agreement, the Company shall issue to the Lender additional Warrants to purchase up to the remaining 1,200,000 shares of
        the Company&#8217;s common stock, ratably, upon borrowings under the Credit Agreement, with exercise prices equal to 150% of the closing price
        of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor
        less than $3.00 per share. The Warrants expire on July 31, 2029.</div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">The fair value of the 500,000
        warrants vested at closing on July 25, 2022 was $738,000 at the date of issuance based on the following assumptions: an expected life of
        7 years, volatility of 92%,
        risk free interest rate of 3.19% and zero
        dividends. The fair value of the vested warrants was recorded in other assets (non-current) as a deferred financing cost and will be amortized on a straight-line basis from July 25, 2022 through January 31, 2026. Amortization for the three months
        ended March 31, 2023 of $52,000 was recorded as interest expense.</div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">On December 19, 2022, the Company executed a $10
        million Promissory Note under the Line of Credit. The interest rate on this draw is 6.46% (Applicable Federal Rate for short term loans
        on date of draw of 4.46% plus 2%).









        The effective interest rate is approximately 7.1%. Accrued interest on this draw was $23,000 at December 31, 2022. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#8217;s Common Stock at an exercise price of $3.00
        per share, which Warrant is exercisable upon issuance.</div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">The fair value of the 200,000
        warrants vested at closing on December 19, 2022 was $160,780 at the date of issuance based on the following assumptions: an expected life
        of 7 years, volatility of 91%,
        risk free interest rate of 4.06% and zero
        dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal to be amortized on a straight-line basis, which is not
        materially different than the effective interest method, from December 19, 2022 through January 31, 2026. Amortization for the three months ended March 31, 2023 of $13,000 was recorded as interest expense. The fair value of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the remaining period through January
        31, 2026.</div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">On March 31, 2023, the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 6.41%
        (Applicable Federal Rate for short term loans on date of draw of 4.41% plus 2%). The effective interest rate is approximately 7.1%.&#160; The
        principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance with the Credit Agreement,
        the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#8217;s Common Stock at an exercise price of $3.26 per share, which Warrant is exercisable upon issuance.</div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">The fair value of the 200,000
        warrants vested at closing on March 31, 2023 was $296,680 at the date of issuance based on the following assumptions: an expected life of
        6.33 years, volatility of 88%,
        risk free interest rate of 3.94% and zero
        dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal to be amortized on a straight-line basis, which is not
        materially different than the effective interest method, from March 31, 2023 through January 31, 2026.</div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman';"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;">The fair value of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the
        remaining period through January 31, 2026.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029026240288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">10. Commitments and Contingencies</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Other Legal Proceedings</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable, and the related damages are
          estimable. There are no significant pending legal proceedings.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Clinical Trial and Research Commitments</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company has entered into agreements with contractors for research and development activities to further its product candidates. The contracts generally may be
          canceled at any time by providing thirty days&#8217; notice.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029026433072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div><br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">11. Leases</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company has one operating lease for its office
          space which was amended effective March 1, 2022 for a term of 38 months with no residual value guarantees or material restrictive
          covenants. The amended lease provided for free rent for the first <span style="-sec-ix-hidden:Fact_3257fbc22511431091132ea0cf902d08">six and a half months</span> of the lease and continues the security
          deposit of $6,000. In addition to base rental payments included in the contractual obligations table above, the Company is responsible
          for our pro-rata share of the operating expenses for the building. Our lease cost for the three-month periods ended March 31, 2023 and 2022 was approximately $13,000 for each period and is included in general and administrative expenses. As of March 31, 2023, the right to use lease asset consisted of $78,000 and is included in <span style="-sec-ix-hidden:Fact_ca7b3631a1474b9799fb873ed35a3567">other assets</span>. Also, at March 31,
          2023, current lease liability of $42,000 is included in <span style="-sec-ix-hidden:Fact_26a5d647f0b84359bcf1207a54ef8756">accrued expenses</span> and long term lease liability was $55,000 and included in <span style="-sec-ix-hidden:Fact_8c9f7ebb1d3c4996a11d58878cfc0b06">other liabilities</span>.<br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 27pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Maturity of operating lease as of March 31, 2023 in thousands:</span></div>

<div style="margin-left: 9pt;"> <br/>
            </div>

<div style="margin-left: 9pt;"> <br/>
            </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>38</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>2024</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>51</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">2025</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">18</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>Total</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>107</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Less imputed interest</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>10</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div>Present value of lease liability</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>97</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 24.5pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The
              discount rate used in calculating the present value of the lease payments was 11%</span>.  </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029030512256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Galectin Sciences LLC<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract', window );"><strong>Galectin Sciences LLC [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock', window );">Galectin Sciences LLC</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">12. Galectin Sciences LLC</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">In January 2014, we created Galectin Sciences, LLC (the &#8220;LLC&#8221; or &#8220;Investee&#8221;), a collaborative joint venture co-owned by SBH Sciences, Inc. (&#8220;SBH&#8221;),
          to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $400,000
          cash investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (&#8220;IPR&amp;D&#8221;) contributed by SBH.&#160;The estimated fair value of the IPR&amp;D contributed by
          SBH, on the date of contribution, was $400,000.&#160;Initially, the Company and SBH each had a 50% equity ownership interest in the LLC, with neither party having control over the LLC.&#160;Accordingly, from inception through the fourth quarter of 2014, the Company
          accounted for its investment in the LLC using the equity method of accounting.&#160;Under the equity method of accounting, the Company&#8217;s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize
          additional investments in or distributions from the Investee, as well as the Company&#8217;s share of the Investee&#8217;s earnings, losses and/or changes in capital. The estimated fair value of the IPR&amp;D contributed to the LLC was immediately expensed
          upon contribution as there was no alternative future use available at the point of contribution.&#160;The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial
          capitalization, then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $400,000 in cash, SBH decided not to contribute its share of the funding required. Cumulatively, the Company has contributed a total of $3,364,000, including $126,000 for the
          three months ended March 31, 2023, for expenses of the LLC. Since the end of 2014, SBH has contributed $158,000 for expenses in the
          LLC. As of March 31, 2023, the Company&#8217;s ownership percentage in the LLC was 85.8%. The Company accounts for the interest in the LLC
          as a consolidated, less than wholly owned subsidiary. Because the LLC&#8217;s equity is immaterial, the value of the non-controlling interest is also deemed to be immaterial.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029025962432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued expenses consist of the following:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="width: 100%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 76%;" valign="bottom">
                <div>&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;"> <span style="font-weight: bold;">March 31,<br/>
                    2023</span></div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;"><span style="font-weight: bold;">December 31,<br/>
                  </span> <span style="font-weight: bold;">2022</span></div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                <div style="text-align: center;">(in thousands)</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -27pt; margin-left: 27pt;">Legal and accounting fees</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>142</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>65</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -27pt; margin-left: 27pt;">Accrued compensation</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>386</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>973</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -27pt; margin-left: 27pt;">Lease liability</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>42</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>40</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -27pt; margin-left: 27pt;">Accrued research and development costs and other</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>8,410</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>7,980</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -27pt; margin-left: 27pt;">Total</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>8,980</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>9,058</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029022875264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">Level 3 assets
              and liabilities measured and recorded at fair value on a recurring basis at March 31, 2023 and December 31, 2022 were as follows:</div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br/>
            </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td colspan="1" style="vertical-align: bottom; padding-left: 23%; padding-bottom: 2px;" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span> </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">
                  <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                  </div>
                  <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2022</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div><span style="font-family: 'Times New Roman'; font-size: 10pt;">Derivative Liability &#8211; Contingent Interest April Note </span> </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">587,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">249,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Derivative Liability &#8211; Contingent Interest September Note </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">276,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">109,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">Derivative Liability &#8211; Contingent Interest December Note</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">479,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">215,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember', window );">April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Key Assumptions Used in Model at Inception</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; margin-right: 41pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The April Note derivative liability &#8211;
            contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">
                  <div style="text-align: center; font-weight: bold;">
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                    </div>
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                  </div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" valign="bottom">
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2022</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Stock Price</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">2.10</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">1.13</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Conversion Price of conversion feature</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">5.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">5.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Term</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160; 2.04 years<br/>
                  </span> </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">2.29 years</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Risk Free Interest Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">4.06</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">4.41</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">14.04</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">14.76</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Volatility</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">85</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">81</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Dividend Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%<br/>
                </span> </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;">%<br/>
                </span> </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Roll Forward of Derivative Liability - Contingent Interest</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt; margin-left: 9pt;">The roll forward of the April Note derivative liability &#8211; contingent interest is as follows for the three months ended March 31, 2023 and 2022:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2022</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">249,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">338,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">587,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2021<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">495,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">Fair Value Adjustment</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">(104,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2022</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">391,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember', window );">September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Key Assumptions Used in Model at Inception</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">The September
              Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </span> </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                    </div>
                    <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold;">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">2022</span></div>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Stock Price</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">2.10</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">1.13</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Conversion Price of conversion feature</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.64</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.64</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Term</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: right; text-indent: -18pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">2.47</span> years
                      <br/>
                    </span> </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: 6pt; text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">2.72</span> years</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Risk Free Interest Rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">3.94</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">4.22</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Credit Adjusted Discount Rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">14.04</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">14.76</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Volatility</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">80</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">81</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Dividend Rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">0</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">%</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">0</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">%</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Roll Forward of Derivative Liability - Contingent Interest</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 27pt; text-transform: none;">The roll forward of the September
            Note derivative liability &#8211; contingent interest is as follows: </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2022</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">109,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; text-align: left; width: 88%; padding-bottom: 2px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">167,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">276,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2021</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">250,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">Fair Value Adjustment</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">(62,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom">Balance &#8211; March 31, 2022</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">188,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember', window );">December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Key Assumptions Used in Model at Inception</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; margin-right: 23pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The December Note derivative
                liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
              <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                      <div style="text-align: center; font-weight: bold;">
                        <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">March 31</span>,
                        </div>
                        <div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"><span style="text-indent: 0pt;">2023</span></div>
                      </div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31, </div>
                      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2022</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock Price</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.10</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.13</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Conversion Price of conversion feature</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.43</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.43</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Term</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> 2.73 years<br/>
                    </span></td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.97 years</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Risk Free Interest Rate</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3.81</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">4.22</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Credit Adjusted Discount Rate</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">14.04</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">14.76</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Volatility</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">80</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">83</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Dividend Rate</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">0</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</span></td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">0</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"><span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</span></td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Roll Forward of Derivative Liability - Contingent Interest</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;">The roll forward
                of the December Note derivative liability &#8211; contingent interest is as follows: </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2022</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">215,000</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">264,000</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2023</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">479,000</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; December 31, 2021<br/>
                    </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom">$ <br/>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom">109,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Adjustment</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">167,000</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Balance &#8211; March 31, 2022</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">276,000</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029021019936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Components of Stock-Based Compensation Expense</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">Three Months Ended<br/>
                    March 31,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2023<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2022<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>Research and development</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>270</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>225</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>General and administrative</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>392</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>633</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="margin-left: 9pt;">Total stock-based compensation expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>662</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>858</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the stock option activity in the Company&#8217;s equity incentive plans, including non-plan grants to Company executives, from
            December&#160;31, 2022 through March 31, 2023:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">Weighted Average<br/>
                    Exercise Price</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>Outstanding, December 31, 2022</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>5,745,561</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>2.90</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                  <div style="margin-left: 9pt;">Granted</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>800,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>1.11</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="margin-left: 9pt;">Exercised</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>&#8212;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#8212;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="margin-left: 9pt;">Options forfeited/cancelled</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div>(18,803</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>3.59</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>Outstanding, March 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>6,526,758</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>2.67</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average Assumptions Used to Determine Fair Value of Options Granted</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">Three<br/>
                    Months Ended<br/>
                    March 31,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">Three<br/>
                    Months Ended<br/>
                    March 31,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2023<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2022<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>Risk-free interest rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>3.76</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>%</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>1.23</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>%</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
                  <div>Expected life of the options</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-align: right;">5.5 years </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-align: right;">5.5 years <br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>Expected volatility of the underlying stock</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>86</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>%</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>95</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>%</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                  <div>Expected dividend rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>0</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>0</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029026244992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CommonStockWarrantsAbstract', window );"><strong>Common Stock Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Common Stock Warrant Activity</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the common stock warrant activity from December 31, 2022 through March 31, 2023:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                <div>&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted Average<br/>
                  Exercise Price</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Outstanding, December 31, 2022</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>11,557,964</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>4.37</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="margin-left: 9pt;">Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>200,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>3.26</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="margin-left: 9pt;">Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="margin-left: 9pt;">Forfeited/cancelled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Outstanding, March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>11,757,964</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>4.35</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_CommonStockWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_CommonStockWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029025889216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would
          have been anti-dilutive are as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                <div>&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31,</div>
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31,</div>
                <div style="text-align: center; font-weight: bold;">2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">(shares) <br/>
              </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">(shares) <br/>
              </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Warrants to purchase shares of common stock</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>11,757,964</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>10,857,964</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div>Options to purchase shares of common stock</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>6,526,758</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,630,561</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Shares of common stock issuable upon conversion of convertible notes payable &#8211; related party</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>5,966,437</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>5,365,259</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">Shares of common stock issuable upon conversion of convertible line of credit &#8211; related party<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">6,727,849</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#8212;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Shares of common stock issuable upon conversion of preferred stock</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>503,340</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>510,424</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div>&#160;</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>31,482,348</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>22,364,208</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029028799872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Operating Lease</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 27pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Maturity of operating lease as of March 31, 2023 in thousands:</span></div>

<div style="margin-left: 9pt;"> <br/>
            </div>

<div style="margin-left: 9pt;"> <br/>
            </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>38</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>2024</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>51</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">2025</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">18</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>Total</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>107</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Less imputed interest</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>10</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div>Present value of lease liability</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>97</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029022922016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_BasisOfPresentationsAndLiquidityAbstract', window );"><strong>Basis of Presentation and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,799<span></span>
</td>
<td class="nump">$ 18,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Unsecured Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_BasisOfPresentationsAndLiquidityAbstract', window );"><strong>Basis of Presentation and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_BasisOfPresentationsAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_BasisOfPresentationsAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=galt_UnsecuredConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=galt_UnsecuredConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029020631392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal and accounting fees</a></td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">386,000<span></span>
</td>
<td class="nump">973,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent', window );">Accrued research and development costs and other</a></td>
<td class="nump">8,410,000<span></span>
</td>
<td class="nump">7,980,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 8,980,000<span></span>
</td>
<td class="nump">$ 9,058,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs and other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029019066960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable - Related Party (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 17, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 16, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>USD ($) </div>
<div>PromissoryNote </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 17, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(769,000)<span></span>
</td>
<td class="nump">$ 229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_AprilConvertiblePromissoryNoteMember', window );">April 2021 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
<td class="num">(104,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Additional interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_AprilConvertiblePromissoryNoteMember', window );">April 2021 Note [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Convertible note payable repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_AprilConvertiblePromissoryNoteMember', window );">April 2021 Note [Member] | Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt financing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible note principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate compounded annually</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_QuarterlyInterestRate', window );">Additional interest rate per quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_AnnualInterestRate', window );">Additional interest rate per annum from issuance date to maturity date period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="nump">587,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_SeptemberConvertiblePromissoryNoteMember', window );">September 2021 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Additional interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_SeptemberConvertiblePromissoryNoteMember', window );">September 2021 Note [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Convertible note payable repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_SeptemberConvertiblePromissoryNoteMember', window );">September 2021 Note [Member] | Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 17,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate compounded annually</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_QuarterlyInterestRate', window );">Additional interest rate per quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_AnnualInterestRate', window );">Additional interest rate per annum from issuance date to maturity date period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
<td class="nump">$ 433,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_DecemberConvertiblePromissoryNoteMember', window );">December 2021 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible note principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 20,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfPromissoryNotesEvidencedByLoansAgreement', window );">Number of promissory notes evidenced by loans agreement | PromissoryNote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate compounded annually</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_QuarterlyInterestRate', window );">Additional interest rate per quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_AnnualInterestRate', window );">Additional interest rate per annum from issuance date to maturity date period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,000<span></span>
</td>
<td class="num">(63,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Additional interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_DecemberConvertiblePromissoryNoteMember', window );">December 2021 Note [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Convertible note payable repayment</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_AnnualInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent interest rate per annum for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_AnnualInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ConvertibleNotesPayableRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ConvertibleNotesPayableRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NumberOfPromissoryNotesEvidencedByLoansAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of promissory notes evidenced by loans agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NumberOfPromissoryNotesEvidencedByLoansAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_QuarterlyInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent interest rate per quarter for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_QuarterlyInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=galt_AprilConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=galt_AprilConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=galt_SeptemberConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=galt_SeptemberConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=galt_DecemberConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=galt_DecemberConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029023827984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">$ 1,342,000<span></span>
</td>
<td class="nump">$ 573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember', window );">April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">587,000<span></span>
</td>
<td class="nump">249,000<span></span>
</td>
<td class="nump">$ 391,000<span></span>
</td>
<td class="nump">$ 495,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember', window );">September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
<td class="nump">188,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember', window );">December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">479,000<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="nump">$ 276,000<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">587,000<span></span>
</td>
<td class="nump">249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">$ 479,000<span></span>
</td>
<td class="nump">$ 215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029023867776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments, Key Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock Price [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock Price [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock Price [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Conversion Price of Conversion Feature [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Conversion Price of Conversion Feature [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">8.64<span></span>
</td>
<td class="nump">8.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Conversion Price of Conversion Feature [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">5.43<span></span>
</td>
<td class="nump">5.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">2 years 14 days<span></span>
</td>
<td class="text">2 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">2 years 5 months 19 days<span></span>
</td>
<td class="text">2 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">2 years 8 months 23 days<span></span>
</td>
<td class="text">2 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk Free Interest Rate [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.0406<span></span>
</td>
<td class="nump">0.0441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk Free Interest Rate [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.0394<span></span>
</td>
<td class="nump">0.0422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk Free Interest Rate [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.0381<span></span>
</td>
<td class="nump">0.0422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Credit Adjusted Discount Rate [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.1404<span></span>
</td>
<td class="nump">0.1476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Credit Adjusted Discount Rate [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.1404<span></span>
</td>
<td class="nump">0.1476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Credit Adjusted Discount Rate [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.1404<span></span>
</td>
<td class="nump">0.1476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.85<span></span>
</td>
<td class="nump">0.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.80<span></span>
</td>
<td class="nump">0.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.80<span></span>
</td>
<td class="nump">0.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Rate [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Rate [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Rate [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAndInputDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029023129568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll Forward of Derivative Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">$ 573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment</a></td>
<td class="nump">769,000<span></span>
</td>
<td class="num">$ (229,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">1,342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember', window );">April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll Forward of Derivative Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">249,000<span></span>
</td>
<td class="nump">495,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment</a></td>
<td class="nump">338,000<span></span>
</td>
<td class="num">(104,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">587,000<span></span>
</td>
<td class="nump">391,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember', window );">September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll Forward of Derivative Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">109,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment</a></td>
<td class="nump">167,000<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="nump">188,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember', window );">December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll Forward of Derivative Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">215,000<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment</a></td>
<td class="nump">264,000<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">$ 479,000<span></span>
</td>
<td class="nump">$ 276,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029024427312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 662<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029022978672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Option Activity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">5,745,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/cancelled (in shares) | shares</a></td>
<td class="num">(18,803)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">6,526,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">3.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost | $</a></td>
<td class="nump">$ 2,268,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested options (in shares) | shares</a></td>
<td class="nump">2,850,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">1 year 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029023156784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted Average Assumptions for Stock Options Granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">1.23%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of the options</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of the underlying stock</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029023922288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Restricted Stock Grants and Employment Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_RestrictedStockGrantsAbstract', window );"><strong>Restricted Stock Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Amortized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 662,000<span></span>
</td>
<td class="nump">$ 858,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_RestrictedStockGrantsAbstract', window );"><strong>Restricted Stock Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares)</a></td>
<td class="nump">36,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Amortized expense</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_RestrictedStockGrantsAbstract', window );"><strong>Restricted Stock Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Deferred Bonus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_RestrictedStockGrantsAbstract', window );"><strong>Restricted Stock Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent', window );">Percentage of base salary paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent', window );">Percentage of base salary paid in deferred stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne', window );">Percentage of DSUs shall be credited on March 1, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo', window );">Percentage of DSUs shall be credited on March 1, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree', window );">Percentage of DSUs shall be credited on September 1, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,440<span></span>
</td>
<td class="nump">55,626<span></span>
</td>
<td class="nump">143,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice', window );">Common Stock Weighted average Grant Date fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Reclassification of accrued compensation to additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Shares unissued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to cover income tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Income tax payment withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The deferred compensation arrangement with individual cash award granted paid in cash percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The deferred compensation arrangement with individual cash award granted paid in deferred stock units percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_RestrictedStockGrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_RestrictedStockGrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share price that the individual must pay to acquire shares under the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued pursuant to the terms of a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=us-gaap_DeferredBonusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=us-gaap_DeferredBonusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029018964352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted average expiration term of warrants outstanding</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Common Stock Warrants shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">11,557,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/cancelled (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">11,757,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">3.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029024296384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">31,482,348<span></span>
</td>
<td class="nump">22,364,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">11,757,964<span></span>
</td>
<td class="nump">10,857,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">6,526,758<span></span>
</td>
<td class="nump">5,630,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Note Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">5,966,437<span></span>
</td>
<td class="nump">5,365,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_LineOfCreditMember', window );">Convertible Line of Credit - Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">6,727,849<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">503,340<span></span>
</td>
<td class="nump">510,424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029024281952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">59,582,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,426,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=galt_TwoThousandTwentyMarketAgreementMember', window );">2020 Market Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_AggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CommissionRate', window );">Percentage of commission rate to be paid to sales agent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=galt_TwoThousandTwentyMarketAgreementMember', window );">2020 Market Agreement [Member] | Series A and Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Common stock issued for dividends (in shares)</a></td>
<td class="nump">30,200<span></span>
</td>
<td class="nump">30,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_AggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate offering price of common stock which can be sold from time to time through the sales agent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_AggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_CommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission rate to be paid to sales agent in gross proceeds from the sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_CommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=galt_TwoThousandTwentyMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=galt_TwoThousandTwentyMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=galt_SeriesAAndSeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=galt_SeriesAAndSeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029020107792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Line of Credit - Related Party (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 19, 2022</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">1.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_IssuanceOfWarrantsValue', window );">Warrants issuance value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Amortization of interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=galt_WarrantOneMember', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_IssuanceOfWarrantsValue', window );">Warrants issuance value</a></td>
<td class="nump">$ 160,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Amortization of interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=galt_WarrantTwoMember', window );">Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_IssuanceOfWarrantsValue', window );">Warrants issuance value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock', window );">Percentage of warrants equal to the closing price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Unsecured Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Additional short term borrowing interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Borrowings repayment due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate on short term loans</a></td>
<td class="nump">6.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Short term borrowing interest rate</a></td>
<td class="nump">4.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Short term borrowing effective interest rate</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Unsecured Convertible Promissory Note [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Unsecured Convertible Promissory Note [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Richard E. Uihlein [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase additional common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of additional warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of exercise price per share or per unit of warrants equal to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DebtInstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued, but unpaid interest on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DebtInstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_IssuanceOfWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_IssuanceOfWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_LineOfCreditRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_LineOfCreditRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=galt_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=galt_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=galt_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=galt_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=galt_UnsecuredConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=galt_UnsecuredConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029029611632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ContractCancelationNoticePeriod', window );">Contract cancelation notice period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ContractCancelationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract cancelation notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ContractCancelationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029024210784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lease Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfOperatingLeases', window );">Number of operating leases | Lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">38 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_FreeRentPeriod', window );">Free rent period</a></td>
<td class="text">6 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right to use lease asset</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liability</a></td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term lease liability</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Operating Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate on present value of lease payments</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lease Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_FreeRentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Free rent period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_FreeRentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating leases during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140029023663808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Galectin Sciences LLC (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">99 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract', window );"><strong>Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Amount expanded in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (793,000)<span></span>
</td>
<td class="num">$ (8,042,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=galt_GalectinSciencesLLCMember', window );">Galectin Sciences, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract', window );"><strong>Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Initial cash investment</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Amount expanded in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CapitalContributionExpense', window );">Contribution for expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,364,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=galt_GalectinSciencesLLCMember', window );">Galectin Sciences, LLC [Member] | SBH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract', window );"><strong>Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Equity ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CapitalContributionExpense', window );">Contribution for expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=galt_GalectinSciencesLLCMember', window );">Galectin Sciences, LLC [Member] | SBH [Member] | IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract', window );"><strong>Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure', window );">Estimated fair value of asset contributed to joint venture</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_CapitalContributionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital contribution expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_CapitalContributionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments in an entity not consolidated. Includes, but is not limited to, investments in an entity that is affiliated with the reporting entity by means of direct or indirect ownership, an entity in which the reporting entity shares control of the entity with another party or group, an entity which the company has significant influence, but does not have control and subsidiaries that are not required to be consolidated and are accounted for using the equity or cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=galt_GalectinSciencesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=galt_GalectinSciencesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=galt_SBHSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=galt_SBHSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>brhc20051581_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:galt="http://galectintherapeutics.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="galt-20230331.xsd" xlink:type="simple"/>
    <context id="c20230101to20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230101to20230331_LongtermDebtTypeAxis_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_LongtermDebtTypeAxis_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="c20210416to20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="c20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220101to20220331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="c20221231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20220331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20250416to20250416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-16</startDate>
            <endDate>2025-04-16</endDate>
        </period>
    </context>
    <context id="c20251230to20251230_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <context id="c20250917to20250917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-17</startDate>
            <endDate>2025-09-17</endDate>
        </period>
    </context>
    <context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230101to20230331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230131_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230331_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20230331_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230331_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230331_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandTwentyMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220101to20220331_StatementClassOfStockAxis_SeriesAAndSeriesCPreferredStockMember_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesAAndSeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandTwentyMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementClassOfStockAxis_SeriesAAndSeriesCPreferredStockMember_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesAAndSeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandTwentyMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20221219to20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-19</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220725to20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-19</instant>
        </period>
    </context>
    <context id="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-19</instant>
        </period>
    </context>
    <context id="c20230331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20220725_FinancialInstrumentAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20221219_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-19</instant>
        </period>
    </context>
    <context id="c20230331_FinancialInstrumentAxis_WarrantTwoMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220725to20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="c20230331_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220725to20220725_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20221219to20221219_FinancialInstrumentAxis_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-19</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20140101to20140131_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_InProcessResearchAndDevelopmentMember_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="c20230331_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20141001to20141231_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-10-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20140101to20220331_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="U001">
        <measure>shares</measure>
    </unit>
    <unit id="U002">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>galt:PromissoryNote</measure>
    </unit>
    <unit id="U005">
        <measure>pure</measure>
    </unit>
    <unit id="U006">
        <measure>galt:Lease</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20230101to20230331"
      id="Fact_b5c6b10bb3b04e32a8ba29c18b62c100">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20230101to20230331"
      id="Fact_05210424cb2a497c9ee9e2e3e6885795">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20230101to20230331"
      id="Fact_89db6ac3bea245e2987aee853eb229e5">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20230101to20230331"
      id="Fact_5d58903a20da445abe4743e2328c16cc">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20230101to20230331"
      id="Fact_d394eed4075c43e6883c52aaa31f9083">0001133416</dei:EntityCentralIndexKey>
    <galt:FreeRentPeriod
      contextRef="c20230101to20230331"
      id="Fact_3257fbc22511431091132ea0cf902d08">P6M15D</galt:FreeRentPeriod>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="c20230331"
      id="Fact_ca7b3631a1474b9799fb873ed35a3567">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="c20230331"
      id="Fact_26a5d647f0b84359bcf1207a54ef8756">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="c20230331"
      id="Fact_8c9f7ebb1d3c4996a11d58878cfc0b06">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20230331"
      id="Fact_81cc316c68af4b039a5f536f55cc0be6"
      unitRef="U002"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20221231"
      id="Fact_286f6ac5954e459db05211ea9b77408f"
      unitRef="U002"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="c20230101to20230331"
      id="Fact_5416128e21c2421bb8a3e92830e5e206">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="c20230101to20230331"
      id="Fact_e27edeace03f40c0815f4046fb23c697">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20230101to20230331"
      id="Fact_414ca40c28be4a0ebb20d5255bb75dfe">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20230101to20230331"
      id="Fact_404a2187bc734a44981313dcaea48599">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20230101to20230331"
      id="Fact_15203ffc74d849c1b7c4d855ecab106c">001-31791</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20230101to20230331"
      id="Fact_cae960854d514a5e8546447138a154c5">GALECTIN THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230101to20230331"
      id="Fact_79fb6e6cc15248449415a97252d59e02">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230101to20230331"
      id="Fact_da3dc7722e374ea2a9fbdf9a6287fd83">04-3562325</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230101to20230331"
      id="Fact_ae79b549e17447dd89492bff8ab8c740">4960 Peachtree Industrial Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20230101to20230331"
      id="Fact_467e3efc462e419fb9fec4ec39e6bf71">Suite 240</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20230101to20230331"
      id="Fact_1ab10db30f11449e834553990dfe0490">Norcross</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20230101to20230331"
      id="Fact_968efe8504a844988a4bc76c877c5079">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230101to20230331"
      id="Fact_4a7ee412e41c40969993d5df971a9955">30071</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20230101to20230331"
      id="Fact_fabc0378f443497b87c54834ad07079c">678</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230101to20230331"
      id="Fact_8938cb6c47094d32b0c92c67f928b152">620 -3186</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20230101to20230331"
      id="Fact_726d4b94c2724053bc0e6a0c071f4b3a">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230101to20230331"
      id="Fact_f318bd771be54ab18b747223180990dd">GALT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20230101to20230331"
      id="Fact_1337bfc3368f4e3aaecea0fe785e1e6a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="c20230101to20230331"
      id="Fact_02ff16d30a944144a979b12668087078">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20230101to20230331"
      id="Fact_7642f982732d4badae7a6e5932ea2035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20230101to20230331"
      id="Fact_143a99f0849f45b4b2a1583ed46f85c9">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20230101to20230331"
      id="Fact_19f811eb251045be95c94a91cdb77818">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230101to20230331"
      id="Fact_deb5c908c090445fabde5e3b252d2248">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="c20230101to20230331"
      id="Fact_0b69dcf1c42940f8ad57c9b72e177a8e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20230508"
      decimals="INF"
      id="Fact_f1ceed76e7404d39acf65581f718cf35"
      unitRef="U001">59582253</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_048390694a224842af7ead63ca0520f3"
      unitRef="U002">17799000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20221231"
      decimals="-3"
      id="Fact_7b08fd2fdf08411bbab4bbd80800804c"
      unitRef="U002">18592000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_95e7a73ce3df46a9b240df0b9d38e041"
      unitRef="U002">1753000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_5a5c52185a4c49f38b19b567612a6d2b"
      unitRef="U002">1960000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_b4299004a4c94f78982968383d152410"
      unitRef="U002">19552000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_481d78605dc84683a1b5c6c92551753d"
      unitRef="U002">20552000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_67c33afa06f64e8195bf7fc4793bd8b2"
      unitRef="U002">673000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_d4bcf7aa9894439f8e66de1ad520938e"
      unitRef="U002">733000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="c20230331"
      decimals="-3"
      id="Fact_28b0eff6345b4537adee904ce32990d6"
      unitRef="U002">20225000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20221231"
      decimals="-3"
      id="Fact_2b7ad816704b40f89c79d2e5ddbfca8b"
      unitRef="U002">21285000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_ac620a4e6de046a7bf8b1cc033220611"
      unitRef="U002">2553000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_5c3cfe2373c04786804d3351d2917c50"
      unitRef="U002">3890000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_fc92e46c13fc454490966bb81ae99d58"
      unitRef="U002">8980000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_9f93a80fecca434ab53b40a8163c600a"
      unitRef="U002">9058000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_6ffb726881b84b088488721408f7717d"
      unitRef="U002">0</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_f28eaa8bdbf34d9786e5087f79d4aaf8"
      unitRef="U002">64000</us-gaap:DividendsPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_974c3c633c1044888966158e6766110a"
      unitRef="U002">11533000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_a3c808d9f2154c8aae345e24c2cde12d"
      unitRef="U002">13012000</us-gaap:LiabilitiesCurrent>
    <galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_5785c1d950e34918b7cbe16cccd7c45d"
      unitRef="U002">30200000</galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent>
    <galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_22c2e40bc25a4598a361d29d45886966"
      unitRef="U002">29964000</galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_41296a2760d64e7ebf680e986da820fa"
      unitRef="U002">1342000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_7504870ed1bc409888e96b9b4d2242de"
      unitRef="U002">573000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_d23e229317c74450ae2397116e1a5f81"
      unitRef="U002">19741000</galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent>
    <galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_7af49d1b324545638c01930c61bfc1ca"
      unitRef="U002">9864000</galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_5cf985e3956d4bdeb75f078682ed793a"
      unitRef="U002">55000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_5dee13a731c8470a9f89120857ed8426"
      unitRef="U002">66000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20230331"
      decimals="-3"
      id="Fact_c1ae96c4e3d646f0bd594a7b1fafc358"
      unitRef="U002">62871000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20221231"
      decimals="-3"
      id="Fact_bdb934c0c5c64bbc80533ce2b8a95f69"
      unitRef="U002">53479000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c20221231"
      decimals="0"
      id="Fact_3adf82f0d55c482893d996e0b3511720"
      unitRef="U001">1000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c20230331"
      decimals="0"
      id="Fact_c155b67dd88e4ed8b3bc65418c950c0a"
      unitRef="U001">1000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20221231"
      decimals="0"
      id="Fact_f227ac5925104148896b3c7bea6d447c"
      unitRef="U001">176</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20230331"
      decimals="0"
      id="Fact_4823bc712c8c4f9ebfc4dca37b503b0e"
      unitRef="U001">176</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c20221231"
      decimals="0"
      id="Fact_c94ccf29245e4886adb92b3ede1ce558"
      unitRef="U001">176</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c20230331"
      decimals="0"
      id="Fact_1865c60374f44284a76bcf91933c9852"
      unitRef="U001">176</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement
      contextRef="c20230331"
      decimals="0"
      id="Fact_55be00149c554c43910d80c81d1403ef"
      unitRef="U002">8256000</us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="c20230331"
      decimals="0"
      id="Fact_c4ec59ebcde14d6ea37a2239d688c7db"
      unitRef="U002">1760000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_8fc45eb45a7c4f2784b724873c995461"
      unitRef="U002">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_a8a2adcae1d847039380f7b465591edb"
      unitRef="U002">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <galt:UndesignatedCapitalStockParValue
      contextRef="c20221231"
      decimals="2"
      id="Fact_1ff215f7983d4886b5d91084e3cae7c7"
      unitRef="U003">0.01</galt:UndesignatedCapitalStockParValue>
    <galt:UndesignatedCapitalStockParValue
      contextRef="c20230331"
      decimals="2"
      id="Fact_45c698f9da9a46e0944545df4dffb359"
      unitRef="U003">0.01</galt:UndesignatedCapitalStockParValue>
    <galt:UndesignatedCapitalStockSharesAuthorized
      contextRef="c20221231"
      decimals="0"
      id="Fact_39e68ef9f0e34b1ba83fe4128462b921"
      unitRef="U001">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
    <galt:UndesignatedCapitalStockSharesAuthorized
      contextRef="c20230331"
      decimals="0"
      id="Fact_e47de5bff8d3455195b6e8066a582e5e"
      unitRef="U001">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
    <galt:UndesignatedCapitalStockSharesDesignated
      contextRef="c20221231"
      decimals="0"
      id="Fact_4b6cc646002042c3b563f484767dd4fb"
      unitRef="U001">20000000</galt:UndesignatedCapitalStockSharesDesignated>
    <galt:UndesignatedCapitalStockSharesDesignated
      contextRef="c20230331"
      decimals="0"
      id="Fact_f5346b636a4d47eeb3efcb9f3d3c4941"
      unitRef="U001">20000000</galt:UndesignatedCapitalStockSharesDesignated>
    <galt:UndesignatedCapitalStockValue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_db397f7c2e7648419aa6ae641adf97d1"
      unitRef="U002">0</galt:UndesignatedCapitalStockValue>
    <galt:UndesignatedCapitalStockValue
      contextRef="c20221231"
      decimals="-3"
      id="Fact_ebce82607ae04fbe8be20f9f679ffcfb"
      unitRef="U002">0</galt:UndesignatedCapitalStockValue>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20221231"
      decimals="0"
      id="Fact_e7a0af64b22b4b03a983094ce4f70418"
      unitRef="U001">1742500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20230331"
      decimals="0"
      id="Fact_7fb556f95513454cb38e944cdb330297"
      unitRef="U001">1742500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20221231"
      decimals="0"
      id="Fact_ea7edb4f96fd420380997e88882523c9"
      unitRef="U001">1260000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20230331"
      decimals="0"
      id="Fact_e3677fee33f04843a51596b70020ab1c"
      unitRef="U001">1260000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20230331"
      decimals="0"
      id="Fact_d7787b946a9e40d6bdb558611e6bcfaa"
      unitRef="U001">1260000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20221231"
      decimals="0"
      id="Fact_215c2b1e35cc4c93a9fab96ab439b13d"
      unitRef="U001">1260000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="c20230331"
      decimals="0"
      id="Fact_ab1368a6db964eb39d77462d7adc3001"
      unitRef="U002">1260500</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_10c4337e634342c3ae90aa73baae5b84"
      unitRef="U002">510000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="c20221231"
      decimals="-3"
      id="Fact_f40e85d17a6c49ca9ab1b6a4c55b23cc"
      unitRef="U002">510000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20221231"
      decimals="3"
      id="Fact_a9df48d8259c46d89ee1a799cffa37ac"
      unitRef="U003">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20230331"
      decimals="3"
      id="Fact_e9f2a954bf12463dba75995ae4e95478"
      unitRef="U003">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20221231"
      decimals="0"
      id="Fact_1da61028e8134559a69fc746134a6ecc"
      unitRef="U001">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20230331"
      decimals="0"
      id="Fact_013f93bd39d841cb9a69c9721a127225"
      unitRef="U001">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20230331"
      decimals="0"
      id="Fact_fde9bb43f79847768742806e2b17d764"
      unitRef="U001">59582253</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20230331"
      decimals="0"
      id="Fact_01db0080873f4b61ad2fc19068f102ac"
      unitRef="U001">59582253</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20221231"
      decimals="0"
      id="Fact_e1eb627f570647e3a346e1607d93552a"
      unitRef="U001">59426005</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20221231"
      decimals="0"
      id="Fact_5635979cfb334598baa66ef34f07b99f"
      unitRef="U001">59426005</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_02b6c803d2484223a69ce00dc62f2f1e"
      unitRef="U002">59000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20221231"
      decimals="-3"
      id="Fact_3b6dbf6d6dcb418289fa35f1d7446a64"
      unitRef="U002">59000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20230331"
      decimals="-3"
      id="Fact_0a33e91948ae492e9a30664804d13942"
      unitRef="U002">276156000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20221231"
      decimals="-3"
      id="Fact_7308101c5ed4456e855f36805516b0a2"
      unitRef="U002">275081000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20230331"
      decimals="-3"
      id="Fact_c17eff7fbf124577a8baedfadbe4eecb"
      unitRef="U002">-321094000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20221231"
      decimals="-3"
      id="Fact_cab00d1fa98a426eb49538a56ceac1a9"
      unitRef="U002">-309567000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20230331"
      decimals="-3"
      id="Fact_d04ef4259619420d96654775a50c1bc4"
      unitRef="U002">-44369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="-3"
      id="Fact_923dad082ca64f379c1f2a7c6871d0b7"
      unitRef="U002">-33917000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20230331"
      decimals="-3"
      id="Fact_2bc5b1b60c88471d9c819e3fbdf44b91"
      unitRef="U002">20225000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20221231"
      decimals="-3"
      id="Fact_0ccca35e90474617adfd39a00e4c417b"
      unitRef="U002">21285000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_bf72f95a0c3c454895f6a83940492c89"
      unitRef="U002">8799000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_1ba5c475c97f401a87ff0c2af0461af5"
      unitRef="U002">8058000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_8c58c0163b3d490a83e8efe398b8b5b5"
      unitRef="U002">1543000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_de4e4f4257ee43868aa61c8e6cead624"
      unitRef="U002">1877000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_23aab4c9aa1f482ea8ca2e51e308d1c4"
      unitRef="U002">10342000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_0d92307596a942259f87efaaa87d09c8"
      unitRef="U002">9935000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_0307830d95bc412a85d46150d94beaa3"
      unitRef="U002">-10342000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_463676cc0b60485fa3a8866efdbcd8d6"
      unitRef="U002">-9935000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_fa6a412b0b7b4850b8e3d86063875f48"
      unitRef="U002">44000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_895840ba930c4767b199d17b1a95add8"
      unitRef="U002">1000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_ebaabe365c3f46a98ddb5018df310d23"
      unitRef="U002">-769000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_ac39b8dcd7654e3e99b83593ce36a448"
      unitRef="U002">229000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:InterestExpense
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_1805cdff81784e2eb47debebc2f43067"
      unitRef="U002">460000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_4777fa2602ed4fe9947d3b58e39e3b37"
      unitRef="U002">227000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_2986330ec2224221a50a0c77eacd79b9"
      unitRef="U002">-1185000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_95216f74bba24b4ca7e8d652ff33bdee"
      unitRef="U002">3000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_0545a3fad7c5421784263f7243965381"
      unitRef="U002">-11527000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_1f5e71a253d9499d93c25dfe85cd2d4c"
      unitRef="U002">-9932000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_56cbdf6d54bc40cd92bc75de5e295dfd"
      unitRef="U002">-0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_58f13404940548b890c85cb079dc0d08"
      unitRef="U002">-16000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_116747b254d24618bfbbb2cb1ca803b9"
      unitRef="U002">-11527000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_e9cc04f4d716477cb84a36c1db53305f"
      unitRef="U002">-9916000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230101to20230331"
      decimals="2"
      id="Fact_e69a89510e5348299add8113cb8a10e8"
      unitRef="U003">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230101to20230331"
      decimals="2"
      id="Fact_154a66e1a175401096ae6706327e2374"
      unitRef="U003">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20220101to20220331"
      decimals="2"
      id="Fact_cc6c840abe07436e9e0a1e0af54bef7d"
      unitRef="U003">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20220101to20220331"
      decimals="2"
      id="Fact_2be1c25f45294fb387c369cedad06ff1"
      unitRef="U003">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_c3ddcedc3ca94fbbb41baa5916ab0d24"
      unitRef="U001">59480000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_312d48a7b66147668c561cca3c5a19ef"
      unitRef="U001">59480000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_eeeeb967115a4ae28a50ef9f4e3a2c6d"
      unitRef="U001">59354000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_9c9c152a51e14e5180b6cb828f7a81ca"
      unitRef="U001">59354000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_18e78584b5454f1da65532a5e4a67074"
      unitRef="U002">-11527000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_419ebe65401644b3941e8f8b14bbca93"
      unitRef="U002">-9932000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_973e0e5e588f4d77939ce2ed1c1beecd"
      unitRef="U002">662000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_465b2a3547f74a12842bbf4f835ab075"
      unitRef="U002">858000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_3cc7eebc3ab5415b965f410554efafe8"
      unitRef="U002">32000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_02c9b2f22c544df58a5ba4bb0c23cf80"
      unitRef="U002">10000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:PaidInKindInterest
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_a9db1d4cc4054fb891559d4815afcf0f"
      unitRef="U002">144000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_1e00a2aa52dd4345b59eaa026218bdeb"
      unitRef="U002">80000</us-gaap:PaidInKindInterest>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_6abc72b7ecfb49abaf06de7c29dbc109"
      unitRef="U002">769000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_c790fb4fba2f49789ab202a3a35f171c"
      unitRef="U002">-229000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_239de87574954b03b1e0be0545c12630"
      unitRef="U002">-183000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_ef6252ab03904a8191b9bec176ffb471"
      unitRef="U002">-160000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_7906d66885f04d63aa6cc22097ce62da"
      unitRef="U002">-1372000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_a4522627f6b6494a9f71090b519846b7"
      unitRef="U002">864000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_3d1641f3b3a1498aa0cce8c8c2c1eb3b"
      unitRef="U002">316000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_c79e7d38581c43c0acfb633d10a7a050"
      unitRef="U002">147000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_3b6e688b22654bb7a0eb4208bf705c28"
      unitRef="U002">-10793000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_d7414eb79aec4b37939091493e2c3346"
      unitRef="U002">-8042000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_f8bfb43dbfd54e67abe1cb04c484d2a6"
      unitRef="U002">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_03f02b206b8847d388ad75786f76f03c"
      unitRef="U002">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_a66e527a48984c72b34c0412ddd19cc9"
      unitRef="U002">10000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_c86e1ea78a774c2a910cb35365642a57"
      unitRef="U002">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_cb5b49cf304546e68e5a65655e18521c"
      unitRef="U002">-793000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_a064cf171f3a446ab81a2aa76f83c547"
      unitRef="U002">-8042000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20221231"
      decimals="-3"
      id="Fact_de2da9b686cf4aeabca66ba4b7e4d80e"
      unitRef="U002">18592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20211231"
      decimals="-3"
      id="Fact_e9539b6347fa4991b114699e17c10b40"
      unitRef="U002">39648000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20230331"
      decimals="-3"
      id="Fact_f4b73644fa3e4a108b54cf9b8fe77294"
      unitRef="U002">17999000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20220331"
      decimals="-3"
      id="Fact_7d22327c8389401583cefa2d72e05e01"
      unitRef="U002">31606000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_c2a5c710e3e24badb340f51050724527"
      unitRef="U002">62000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_2cf1bdca9cda4c5b92ccb3d2d7d607a3"
      unitRef="U002">49000</us-gaap:StockIssued1>
    <galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_19008fdf19664140990be12b7e47254c"
      unitRef="U002">210000</galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital>
    <galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_73e12b5508684244b1cfc3aac65a04c2"
      unitRef="U002">200000</galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital>
    <galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_f63b67df6315479eba298ce1db7edf49"
      unitRef="U002">297000</galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit>
    <galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_f12b5fb7eff842dbb96f3015b8b38191"
      unitRef="U002">0</galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_c8afd37641894454a0c2ee8cb65e9d7d"
      unitRef="U002">0</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_378eb3b33cd54fccabbc53b4c14aa0de"
      unitRef="U002">111000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20211231"
      decimals="0"
      id="Fact_3a7c96e460d141c3bbd8eb2d27265f41"
      unitRef="U001">176</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_13cf6e1bcb6843f29ca72bcde6f1b570"
      unitRef="U002">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20220331"
      decimals="0"
      id="Fact_2a7f8f2c93db4926bd544ea67047d606"
      unitRef="U001">176</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20220331"
      decimals="-3"
      id="Fact_8370b9a4e6ba4dcc95077d8b6619cb3e"
      unitRef="U002">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20221231"
      decimals="0"
      id="Fact_922d027a686a4c51b532f61e8b945a92"
      unitRef="U001">176</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_39904421b53c4095b42a0793cb2b8c26"
      unitRef="U002">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20230331"
      decimals="0"
      id="Fact_6f5dfabf1af945c487f27962feff0fb1"
      unitRef="U001">176</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_38e5a0a728fd4f78bd86ad5fcfec2c87"
      unitRef="U002">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="0"
      id="Fact_311f05cc06124e61b4d3b760b4287b6c"
      unitRef="U001">1302500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_b8a82d7ad653459cb60dc42ffe42faab"
      unitRef="U002">527000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_21f567c5f52846059fe80fe18408d1d1"
      unitRef="U001">59341305</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_52fea6fa9b8246e6ab75f411c4728048"
      unitRef="U002">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_fecb1d0b9f0e4d93a2a4055c21255887"
      unitRef="U002">271001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_2e56a59ef91c4cdb88e6dce621baaef4"
      unitRef="U002">-270694000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231"
      decimals="-3"
      id="Fact_bac80c3c7ab9435ab9204818217d3a44"
      unitRef="U002">893000</us-gaap:StockholdersEquity>
    <galt:ConvertiblePreferredStockDividendsShares
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_9ba03e3c79d947c8b9f74a714fb0349e"
      unitRef="U001">13025</galt:ConvertiblePreferredStockDividendsShares>
    <galt:ConvertiblePreferredStockDividends
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_13aa72b998d9421aaa246b98e5b7b9f3"
      unitRef="U002">20000</galt:ConvertiblePreferredStockDividends>
    <galt:ConvertiblePreferredStockDividends
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_aed8127e18d64e0ba44197541465e34c"
      unitRef="U002">18000</galt:ConvertiblePreferredStockDividends>
    <galt:ConvertiblePreferredStockDividends
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_2d09b66379cc40fb86e6f8ee56604f64"
      unitRef="U002">38000</galt:ConvertiblePreferredStockDividends>
    <galt:TemporaryEquityDividendsShares
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_2bed236b15b846d4b5463ea0365e0234"
      unitRef="U001">17600</galt:TemporaryEquityDividendsShares>
    <galt:TemporaryEquityDividends
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7e1585a4359e49c695ab6df66b6e752e"
      unitRef="U002">-29000</galt:TemporaryEquityDividends>
    <galt:TemporaryEquityDividends
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6f04bf8ac268450a89f7ebc2525145fb"
      unitRef="U002">2000</galt:TemporaryEquityDividends>
    <galt:TemporaryEquityDividends
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_b636ec147f6d4dfb84ea4341a4752b1b"
      unitRef="U002">-27000</galt:TemporaryEquityDividends>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_438a169a0e934f38b45e315228643fdf"
      unitRef="U001">16588</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_ca3053ceadc748e2858595230351f178"
      unitRef="U002">1058000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_7cf7d113da3b45f28d23443cb1e5ab58"
      unitRef="U002">1058000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_49a27127e4fc450492127046b5ebd747"
      unitRef="U002">-9932000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_da998332a8e14c8ab3ee051cc7ab32c2"
      unitRef="U002">-9932000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20220331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="0"
      id="Fact_79eba817db224d31aa64fd6b1978f645"
      unitRef="U001">1302500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20220331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_9fb580fd37d74fd0a66508cc0fee2f45"
      unitRef="U002">527000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_12059f081504430184e3d121c33d49f9"
      unitRef="U001">59388518</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_9d0a9a7705894032b2b877944d54c4f3"
      unitRef="U002">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_2a57b495a8db40a695f4691732e34b92"
      unitRef="U002">272108000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_dce0c9d83b4e4f21953e654330e504a9"
      unitRef="U002">-280610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220331"
      decimals="-3"
      id="Fact_96e0654a320148e58c9290e72462e0a4"
      unitRef="U002">-7916000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="0"
      id="Fact_3b506f6021574825b5877e85fc062df0"
      unitRef="U001">1260000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_6c0ca1becf244969a0e232ddeafa3f16"
      unitRef="U002">510000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e880803a32e14acab761f7031b14e3dd"
      unitRef="U001">59426005</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_d98bc72a0a86450a8f077609f1aa23ab"
      unitRef="U002">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0187ab9474d743b89e5862742261cfdc"
      unitRef="U002">275081000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d536101d36b04032b6861829c9e75f1d"
      unitRef="U002">-309567000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="-3"
      id="Fact_b145318a8a144871896b88cad11d63c2"
      unitRef="U002">-33917000</us-gaap:StockholdersEquity>
    <galt:ConvertiblePreferredStockDividendsShares
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_cd7d7b572b3b4530a3e1140a9db7b7b0"
      unitRef="U001">12600</galt:ConvertiblePreferredStockDividendsShares>
    <galt:ConvertiblePreferredStockDividends
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_e42abda7d204496196725af337cb618d"
      unitRef="U002">26000</galt:ConvertiblePreferredStockDividends>
    <galt:ConvertiblePreferredStockDividends
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_3295a101549e4cc28d9b39b17613476f"
      unitRef="U002">-11000</galt:ConvertiblePreferredStockDividends>
    <galt:ConvertiblePreferredStockDividends
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_5a3b636e8fdc4d20894bf86b9555a781"
      unitRef="U002">15000</galt:ConvertiblePreferredStockDividends>
    <galt:TemporaryEquityDividendsShares
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f85c8f6773714e83ae226535e785384b"
      unitRef="U001">17600</galt:TemporaryEquityDividendsShares>
    <galt:TemporaryEquityDividends
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3f68130f931445b4ac4bbf25884ebd9d"
      unitRef="U002">-36000</galt:TemporaryEquityDividends>
    <galt:TemporaryEquityDividends
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a302ff3be2e94027aa901c94acf8eadd"
      unitRef="U002">-11000</galt:TemporaryEquityDividends>
    <galt:TemporaryEquityDividends
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_317c242461874cb38cdd5790f7cc4d01"
      unitRef="U002">-47000</galt:TemporaryEquityDividends>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_86ab1cf408ce4fd58fc87a4cd9fd188a"
      unitRef="U002">297000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_0156a06b9a32484aab6d696d6b192063"
      unitRef="U002">297000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_6430fea247174267ae98b310c7ca23fe"
      unitRef="U001">126048</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d6d927cbc5d9499eb69eabfc931df86e"
      unitRef="U002">716000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_624003e1bc2441f29aa3e910e1acf3f4"
      unitRef="U002">716000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e067a89aff2e416cbcaad997fe9be1d0"
      unitRef="U002">-11527000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_c0d2096c0aba4491b4caca682a723098"
      unitRef="U002">-11527000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20230331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="0"
      id="Fact_e8c1257f6884443090b1830aa7c58090"
      unitRef="U001">1260000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_36ad5b29ae394792ac41fc49549fc148"
      unitRef="U002">510000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e81de51a0aaa47428e6eaf35188a6557"
      unitRef="U001">59582253</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6e362ec4848d4313a562ffaea5fb0664"
      unitRef="U002">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_57533dd62f52417f9c5e720b8ffa93c2"
      unitRef="U002">276156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e6452ebfab00402dbe9b84401a45f40d"
      unitRef="U002">-321094000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331"
      decimals="-3"
      id="Fact_857432e4fc3a42feabc57140c95c975d"
      unitRef="U002">-44369000</us-gaap:StockholdersEquity>
    <us-gaap:BasisOfAccounting
      contextRef="c20230101to20230331"
      id="Text_ec4126679081413a9c2641eed9147e57">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;1. Basis of Presentation and Liquidity&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Galectin Therapeutics Inc. and subsidiaries (the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and
          drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company&#x2019;s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have
          application for drugs to treat other diseases and chronic health conditions.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of
          management, necessary to present fairly the financial position of the Company as of March 31, 2023 and the results of its operations for the three months ended March 31, 2023 and 2022 and its cash flows for the three months ended March 31, 2023
          and 2022. All adjustments made to the interim financial statements include all those of a normal and recurring nature. Amounts presented in the condensed consolidated balance sheet as of December 31, 2022 are derived from the Company&#x2019;s audited
          consolidated financial statements as of that date, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The Company
          considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.
          Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the
          full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2022.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; margin-top: 8pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The







            Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At March 31, 2023, the company had $17,799,000 of unrestricted cash and cash equivalents available to fund future operations.&#160; In July 2022, the Company entered into a $60 million unsecured line of credit financing with its chairman, Richard E. Uihlein (See Note 10). The Company believes there is sufficient cash,
            including availability of the line of credit, to fund currently planned operations at least through December 31, 2024. &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other
              strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when
              needed could have a material adverse effect on the Company&#x2019;s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity
              concerns until a date when those concerns are relieved.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company was
          founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name &#x201c;Pro-Pharmaceuticals, Inc.,&#x201d; and changed its name to &#x201c;Galectin Therapeutics Inc.&#x201d; on May&#160;26, 2011.&lt;/div&gt;
</us-gaap:BasisOfAccounting>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_b63276500f0e409b95e3c574fda4aadc"
      unitRef="U002">17799000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-6"
      id="Fact_b7dfd5dc38324d868d9e7b712d1ed9f0"
      unitRef="U002">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_58eb7977e7d046628a599c133f135850">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2. Accrued Expenses and Other&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued expenses consist of the following:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="width: 100%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt; &lt;span style="font-weight: bold;"&gt;March 31,&lt;br/&gt;
                    2023&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;December 31,&lt;br/&gt;
                  &lt;/span&gt; &lt;span style="font-weight: bold;"&gt;2022&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -27pt; margin-left: 27pt;"&gt;Legal and accounting fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;142&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;65&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -27pt; margin-left: 27pt;"&gt;Accrued compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;386&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;973&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -27pt; margin-left: 27pt;"&gt;Lease liability&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;42&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;40&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -27pt; margin-left: 27pt;"&gt;Accrued research and development costs and other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8,410&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,980&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -27pt; margin-left: 27pt;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8,980&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,058&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 24.5pt;"&gt;Research and development expenses, including personnel costs, allocated facility costs, lab supplies, outside services, contract laboratory costs related to
          manufacturing drug product, clinical trials and preclinical studies are charged to research and development expense as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research
          and development activities as expense when the service has been performed or when the goods have been received. Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors. We
          accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses and related expenses associated with the conduct of clinical trials, the significant
          factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients have been enrolled in the trial. We monitor patient enrollment levels and related activities
          to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We base our estimates on the best information available at the time. We monitor patient enrollment levels and related activities to the
          extent possible through discussions with CRO personnel and based our estimates of clinical trial costs on the best information available at the time. However, additional information may become available to us which will allow us to make a more
          accurate estimate in future periods. In that event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.&lt;/div&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_a58dce520b5a4eb99d760a06cd017f08">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued expenses consist of the following:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="width: 100%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt; &lt;span style="font-weight: bold;"&gt;March 31,&lt;br/&gt;
                    2023&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;December 31,&lt;br/&gt;
                  &lt;/span&gt; &lt;span style="font-weight: bold;"&gt;2022&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -27pt; margin-left: 27pt;"&gt;Legal and accounting fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;142&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;65&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -27pt; margin-left: 27pt;"&gt;Accrued compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;386&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;973&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -27pt; margin-left: 27pt;"&gt;Lease liability&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;42&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;40&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -27pt; margin-left: 27pt;"&gt;Accrued research and development costs and other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8,410&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,980&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -27pt; margin-left: 27pt;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8,980&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,058&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_cb33e893f3aa4861a353d1dfe5139050"
      unitRef="U002">142000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_2b65ac529b5c4979bb419d128bd01830"
      unitRef="U002">65000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_a8a5951d6086494fb73d9cf589584b33"
      unitRef="U002">386000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_eb8895a82cd64f36962fa12545b64585"
      unitRef="U002">973000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_ca684e33620e4ff9bc0881c53815c7ec"
      unitRef="U002">42000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_72ad09eb584c48f4982ea540397224c6"
      unitRef="U002">40000</us-gaap:OperatingLeaseLiabilityCurrent>
    <galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_88eaab65ce7c4f66a4a670d95cd1a620"
      unitRef="U002">8410000</galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent>
    <galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_b2cabe0a533f45ec95d7c356e6cd785f"
      unitRef="U002">7980000</galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_803311fc2a2e46238ca364ffe6953ee0"
      unitRef="U002">8980000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_932446db74a04b44a04380264a052e87"
      unitRef="U002">9058000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="c20230101to20230331_LongtermDebtTypeAxis_LoansPayableMember"
      id="Text_daff77bcc5784263b876e49cd149b3d8">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;3. Convertible Notes Payable &#x2013; Related Party&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;"&gt;On April&#160;16, 2021, the Company and
          Richard E. Uihlein entered into a debt financing arrangement whereby Mr.&#160;Uihlein loaned $10,000,000 to Company. In consideration for
          the loan, the Company issued a convertible promissory note (the &#x201c;April 2021 Note&#x201d;) in the principal amount of ten million dollars.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;"&gt;The April 2021 Note has a maturity date
          of April 16, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#x2019;s
          common stock at a conversion price equal to $5.00 per share at the option of the noteholder. The April 2021 Note bears interest at the
          rate of two percent (2%) per annum, compounded annually with an effective interest rate of approximately 3%. For the three months ended March 31, 2023 and 2022, approximately $50,000 and $50,000, respectively, of interest expense was accrued and
          included with the principal in the financial statements.&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;"&gt;The April 2021 Note also includes a
          contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per
          quarter (10% per annum) (the &#x201c;Additional Interest&#x201d;) beginning on the date of issuance of this Note and ending on the maturity date,
          provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the April 2021 Note into the Company&#x2019;s common stock on or prior to maturity. As the contingent event is not based on
          creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the April 2021 Note at its inception. The fair value of
          the contingent interest derivative liability was $420,000 at note inception (April 16, 2021). The fair value of the contingent interest
          derivative liability was $587,000 and $249,000
          at March 31, 2023 and December 31, 2022, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability for the three months ended March 31, 2023 and 2022 of $338,000 and $(104,000), respectively,
          was charged to other expense/(income) for the three months ended March 31, 2023 and 2022. The amortization of the original $420,000
          debt discount of $26,000 and $26,000
          was recorded as additional interest expense for the three months ended March 31, 2023 and 2022, respectively&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal; background-color: rgb(255, 255, 255);"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;"&gt;The September 2021 Note has a maturity
          date of September 17, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the
          Company&#x2019;s common stock at a conversion price equal to $8.64 per share at the option of the noteholder. The September 2021 Note bears
          interest at the rate of two percent (2%) per annum, compounded annually with an effective interest rate of approximately 3%. For the three months ended March 31, 2023 and 2022, approximately $50,000 and $50,000, respectively, of interest expense was accrued and
          included with the principal in the financial statements. &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt;"&gt;&lt;span style="letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;The September 2021 Note
          also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%)
          per quarter (10% per annum) (the &#x201c;Additional Interest&#x201d;) beginning on the date of issuance of this Note and ending on the maturity date,
          provided however, that such payment is only required if and only if the noteholder elects&#160;&#160; to convert the entire balance of the September 2021 Note into the Company&#x2019;s common stock on or prior to maturity. As the contingent event is not based on
          creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the September Note at its inception. The fair value of the
          contingent interest derivative liability was $433,000 at note inception (September 17, 2021). The fair value of the contingent interest
          derivative liability was $276,000 and $109,000
          and March 31, 2023 and December 31, 2022, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability three months ended March 31, 2023 and 2022 of $167,000 and ($62,000), respectively,
          was recorded to other expense/(income) for three months ended March 31, 2023 and 2022. The amortization of the original $433,000 debt
          discount of $27,000 and $27,000
          was recorded as additional interest expense for the three months ended March 31, 2023 and 2022&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-weight: normal;"&gt;.&lt;/span&gt;&lt;span class="HorizontalTab" style="width: 9pt; font-size: 10pt; display: inline-block; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: left; text-indent: 24.5pt; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt;On&lt;/span&gt; December 20, 2021, the
          second of the two promissory notes under the Loan Agreement was executed and delivered, (the &#x201c;December 2021 Note&#x201d;) to evidence the
          second loan in the principal amount of $10,000,000. The December 2021 Note has a maturity date of December 20, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#x2019;s common stock at a
          conversion price equal to $5.43 per share at the option of the noteholder. The December Note bears interest at the rate of two percent
          (2%) per annum, compounded annually with an effective interest rate of approximately 3%. For three months ended March 31, 2023 and 2022, approximately $50,000
          and $50,000, respectively, of interest expense was accrued and included with the principal in the financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt;The &lt;/span&gt;December 2021
          Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%)
          per quarter (10% per annum) (the &#x201c;Additional Interest&#x201d;) beginning on the date of issuance of this Note and ending on the maturity date,
          provided however, that such payment is only required if and only if the noteholder elects&#160;&#160; to convert the entire balance of the December 2021 Note into the Company&#x2019;s common stock on or prior to maturity. As the contingent event is not based on
          creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the December Note at its inception. The fair value of the
          contingent interest derivative liability was $415,000 at note inception (December 20, 2021). The fair value of the contingent interest
          derivative liability was $479,000 and $215,000
          at March 31, 2023 and December 31, 2022, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability for three months ended March 31, 2023 and 2022.of $264,000 and ($63,000), respectively was
          recorded to other expense/(income) for three months ended March 31, 2023 and 2022.. The amortization of the original $415,000 debt
          discount of $26,000 and $26,000
          was recorded as additional interest expense for three months ended March 31, 2023 and 2022, respectively&lt;span style="font-weight: normal;"&gt;. &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 24.5pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company&#x2019;s contractual cash obligations related to the outstanding
              convertible notes payable is a repayment of the April 2021 Note of the $10,000,000 plus accrued interest on April&#160;16, 2025 and a
              repayment of the September 2021 Note of the $10,000,000 &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;plus accrued interest on September 17, 2025 and a
                repayment of the December 2021 Note of the $10,000,000 plus accrued interest on December 30, 2025, unless converted at the option
                of the noteholder.&lt;/span&gt;&lt;/span&gt; &lt;/span&gt; &lt;/div&gt;
</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_14a116e3061e44908a4e6c22288a730c"
      unitRef="U002">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c20210416to20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_35b13f39c45c4be59bc2179e4a7a4abb"
      unitRef="U002">10000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_0b91cb6851824360b6b9d57a726cd44d">2025-04-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_47d259e2e11b451ab520a8300ce28783"
      unitRef="U003">5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_13d3ff2c9ded45f0b3b63142fcf789f9"
      unitRef="U005">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_7cd3466342b943f2b3f9cf4d07095f16"
      unitRef="U005">0.03</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_52315b5e710f43caae8dbad4a8d6dac4"
      unitRef="U002">50000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c20220101to20220331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_4bd2da8be0374ed3aa303bc40f29ad41"
      unitRef="U002">50000</us-gaap:InterestExpenseDebt>
    <galt:QuarterlyInterestRate
      contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_2d80bce2ba934f54b9dfb9fe0b8af3e9"
      unitRef="U005">0.025</galt:QuarterlyInterestRate>
    <galt:AnnualInterestRate
      contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_3d16b54aabf041a4bfc71ae367a09cde"
      unitRef="U005">0.10</galt:AnnualInterestRate>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_513eb784f4264cd68cbda02565907647"
      unitRef="U002">420000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_50d1d85a9d66440cb1cb27f67c3aa139"
      unitRef="U002">587000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_15c562d8192443138c655c8782502544"
      unitRef="U002">249000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_f30d49e8268a4180a384eceb8c17adf2"
      unitRef="U002">338000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20220101to20220331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_1dc3e760ece44cd9a7996bf41f126ae4"
      unitRef="U002">-104000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_883e844578d64d73baaf0a289dfa1c41"
      unitRef="U002">420000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseOther
      contextRef="c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_6466a3ac9afe4fe6b91316985be8a581"
      unitRef="U002">26000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="c20220101to20220331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_e6cfd25d67354ce0a528a75e1641ffa9"
      unitRef="U002">26000</us-gaap:InterestExpenseOther>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_1873ba1b171b4e42b5c17da7e64dc9a9">2025-09-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_38e7fc764d394ee39ba7aa53fad0018a"
      unitRef="U003">8.64</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_6d98aac880a14e09a14132dc052449bf"
      unitRef="U005">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_f43ee19911a84dd1bc5090abf06bb33a"
      unitRef="U005">0.03</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_025112e9e1c4407b94216e32a96d5cb0"
      unitRef="U002">50000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c20220101to20220331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_a6cdf50e959f4ad78a24bb1c053c7319"
      unitRef="U002">50000</us-gaap:InterestExpenseDebt>
    <galt:QuarterlyInterestRate
      contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_321596370b0445359548a8fb430b4856"
      unitRef="U005">0.025</galt:QuarterlyInterestRate>
    <galt:AnnualInterestRate
      contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_2d67b634995040f7b1de9359c77384fa"
      unitRef="U005">0.10</galt:AnnualInterestRate>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_397b74c232744ef087048e65ff2d531a"
      unitRef="U002">433000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_60439042d1ed458da9dfd1d0c5f08716"
      unitRef="U002">276000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_6a3103a7157c4494a03822939bc01233"
      unitRef="U002">109000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_414a8f654e9c4a848f1a83249d5b1532"
      unitRef="U002">167000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20220101to20220331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_1ea6e7412e694f5ab6a6852f2082c3b0"
      unitRef="U002">-62000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_44f2081cc6d14ef2a7e72a1fd7c50659"
      unitRef="U002">433000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseOther
      contextRef="c20230101to20230331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_69e4bc4336ba420392d38923506eb874"
      unitRef="U002">27000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="c20220101to20220331_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_8de61bd7bd4d497b8819baa420148df8"
      unitRef="U002">27000</us-gaap:InterestExpenseOther>
    <galt:NumberOfPromissoryNotesEvidencedByLoansAgreement
      contextRef="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact_2e358460dba84b699bc466561a414f9e"
      unitRef="U004">2</galt:NumberOfPromissoryNotesEvidencedByLoansAgreement>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_00a4fd5b8a8d43599bcee7482d75f7e9"
      unitRef="U002">10000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      id="Fact_db83ca325d9d4023bc91fce3dac12ec2">2025-12-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="2"
      id="Fact_7e829753d06446d4a4bbc34d9fce4c7d"
      unitRef="U003">5.43</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="2"
      id="Fact_922fc5a4f7924e77bba022248fc579ff"
      unitRef="U005">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="2"
      id="Fact_d62c5efe1129464482fab099d27b0a7c"
      unitRef="U005">0.03</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_103ccc24369c47299f8ff5b761b875d0"
      unitRef="U002">50000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c20220101to20220331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_3c4765043eb04e38a6915bac31d46867"
      unitRef="U002">50000</us-gaap:InterestExpenseDebt>
    <galt:QuarterlyInterestRate
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="3"
      id="Fact_d2d2636f8f81438aaac3596ee8eac95d"
      unitRef="U005">0.025</galt:QuarterlyInterestRate>
    <galt:AnnualInterestRate
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="2"
      id="Fact_f41ef027e69d49969e66c971a2cb92ee"
      unitRef="U005">0.10</galt:AnnualInterestRate>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_7968ddfa3a834190a1cccc0e24cb7232"
      unitRef="U002">415000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_fdd53a1e09994413a64202dd08fb473e"
      unitRef="U002">479000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_e93131c413524c1498aaf9bcc39a4db4"
      unitRef="U002">215000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_12c294cf534b4c9c88f28d2f3af0696a"
      unitRef="U002">264000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20220101to20220331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_b75621a59df64d968e196d051de78c53"
      unitRef="U002">-63000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_ec5f2725cf1a481090559d8c058e05cc"
      unitRef="U002">415000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseOther
      contextRef="c20230101to20230331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_f681710a74794b398fa98f9443e2bfb4"
      unitRef="U002">26000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="c20220101to20220331_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_c7b11a80020a4ecba0e2d9a8fde22eb4"
      unitRef="U002">26000</us-gaap:InterestExpenseOther>
    <us-gaap:RepaymentsOfDebt
      contextRef="c20250416to20250416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember"
      decimals="0"
      id="Fact_067ab0804cb844ad918c4fb87c0e5600"
      unitRef="U002">10000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="c20250917to20250917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember"
      decimals="0"
      id="Fact_f1003953679641568e0d776a314aba97"
      unitRef="U002">10000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="c20251230to20251230_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember"
      decimals="0"
      id="Fact_fe4d6cd317c447b1bf434bfb410c3298"
      unitRef="U002">10000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="c20230101to20230331"
      id="Text_25979fe1fc7f493298783fb9c5e9efaa">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;4. Fair Value of Financial Instruments&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;"&gt;The Company has
            certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than
            quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to
            develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximate their carrying value due to their short-term nature. There were no level 1 or 2 assets or liabilities at March 31, 2023 or December 31, 2022. See below for Fair Value of Derivatives related to Convertible
            Notes Payable at March 31, 2023 and December 31, 2022, which are level 3 liabilities.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;"&gt;Level 3 assets
              and liabilities measured and recorded at fair value on a recurring basis at March 31, 2023 and December 31, 2022 were as follows:&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-left: 23%; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;
                  &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;,
                  &lt;/div&gt;
                  &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31, &lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Derivative Liability &#x2013; Contingent Interest April Note &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;587,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;249,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Derivative Liability &#x2013; Contingent Interest September Note &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;276,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;109,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;Derivative Liability &#x2013; Contingent Interest December Note&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;479,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;215,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; margin-right: 41pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The April Note derivative liability &#x2013;
            contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;
                    &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;,
                    &lt;/div&gt;
                    &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31, &lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.10&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1.13&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Conversion Price of conversion feature&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Term&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&#160; 2.04 years&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.29 years&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Risk Free Interest Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4.06&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4.41&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;14.04&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;14.76&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;85&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;81&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Dividend Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt; margin-left: 9pt;"&gt;The roll forward of the April Note derivative liability &#x2013; contingent interest is as follows for the three months ended March 31, 2023 and 2022:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;249,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Adjustment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;338,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;587,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2021&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;495,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;Fair Value Adjustment&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;(104,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; March 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;391,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;The September
              Note derivative liability &#x2013; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;
                    &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;,
                    &lt;/div&gt;
                    &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold;"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31, &lt;/div&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock Price&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.10&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1.13&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Conversion Price of conversion feature&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;8.64&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;8.64&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Term&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: right; text-indent: -18pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;2.47&lt;/span&gt; years
                      &lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: 6pt; text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;2.72&lt;/span&gt; years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Risk Free Interest Rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3.94&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4.22&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;14.04&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;14.76&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Volatility&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;80&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;81&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Dividend Rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 27pt; text-transform: none;"&gt;The roll forward of the September
            Note derivative liability &#x2013; contingent interest is as follows: &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;109,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: left; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Adjustment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;167,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; March 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;276,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2021&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;250,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;Fair Value Adjustment&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;(62,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;Balance &#x2013; March 31, 2022&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;188,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; margin-right: 23pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The December Note derivative
                liability &#x2013; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
              &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;
                      &lt;div style="text-align: center; font-weight: bold;"&gt;
                        &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;,
                        &lt;/div&gt;
                        &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;
                      &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31, &lt;/div&gt;
                      &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2022&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Stock Price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.10&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.13&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Conversion Price of conversion feature&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.43&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.43&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Term&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; 2.73 years&lt;br/&gt;
                    &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.97 years&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Risk Free Interest Rate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3.81&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;4.22&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;14.04&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;14.76&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Volatility&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;80&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;83&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Dividend Rate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;0&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;0&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/span&gt;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;"&gt;The roll forward
                of the December Note derivative liability &#x2013; contingent interest is as follows: &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;215,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Adjustment&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;264,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; March 31, 2023&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;479,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;109,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Adjustment&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;167,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; March 31, 2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;276,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_ed929c584ec541ac9fc92b0abd98701b"
      unitRef="U002">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_bd84f3d9838b4f768206e55ba40252b0"
      unitRef="U002">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_76365f60bead4f0db8e098eff3b670e2"
      unitRef="U002">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_613dec05f24a49bf847b89c3ea0fae6f"
      unitRef="U002">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_52684fcafd004618a162a1ebabcd4029"
      unitRef="U002">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_248de12f43804583b53c8190eb5a5971"
      unitRef="U002">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_1fa7ae58e1ef47e3bad681197dc832b9"
      unitRef="U002">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_1c9b29ebf08843498473942e1a39552b"
      unitRef="U002">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_ff5d2961b06540fda0733d4919c91a0c">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;"&gt;Level 3 assets
              and liabilities measured and recorded at fair value on a recurring basis at March 31, 2023 and December 31, 2022 were as follows:&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-left: 23%; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;
                  &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;,
                  &lt;/div&gt;
                  &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31, &lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Derivative Liability &#x2013; Contingent Interest April Note &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;587,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;249,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Derivative Liability &#x2013; Contingent Interest September Note &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;276,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;109,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;Derivative Liability &#x2013; Contingent Interest December Note&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;479,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;215,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_8d62ac7305274dcfbbbf590af5e821a9"
      unitRef="U002">587000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_efcc20fb1ef7415c9d2a6a2b778f1da6"
      unitRef="U002">249000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_2c46bc0eb3fa4f259b6a78bacf0ecda3"
      unitRef="U002">276000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_6a04870b55dd476fa0bdf7417fdd2f4b"
      unitRef="U002">109000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_1a843d3b8b374804ac17bcae56181e56"
      unitRef="U002">479000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_6f7c1e0bd3844c43bdfad7e6a6f11566"
      unitRef="U002">215000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      id="Text_71a49c3b39dc4f25b3b0d738831877a3">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; margin-right: 41pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The April Note derivative liability &#x2013;
            contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;
                    &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;,
                    &lt;/div&gt;
                    &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31, &lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.10&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1.13&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Conversion Price of conversion feature&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Term&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&#160; 2.04 years&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.29 years&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Risk Free Interest Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4.06&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4.41&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;14.04&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;14.76&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;85&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;81&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Dividend Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_28b37c8ac90145e9ac272c74474b4c2b"
      unitRef="U005">2.1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_3d91d0f255f04c1d98c9f4b1c5f4945b"
      unitRef="U005">1.13</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_4fe2ef302d984153aaf98cc8fbfaf019"
      unitRef="U005">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_27f4299b80b04c57b5a6e8f66be59d33"
      unitRef="U005">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_82057babbdf94652a489de269b486f92">P2Y14D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_584d3cec687f46e19a6ef6a209e95fcb">P2Y3M14D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_519ffb766b0f4c77a460e57d8604d069"
      unitRef="U005">0.0406</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_701aa842fe684c5380c4f1cece4e3947"
      unitRef="U005">0.0441</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_bea351d585e84e9a9506651d566ec551"
      unitRef="U005">0.1404</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_8cb06bc1a431417fa4f48f4f3c87a6fc"
      unitRef="U005">0.1476</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_c8b0bb4e0f1541cf8dd76cb2473ee9ae"
      unitRef="U005">0.85</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_95bc2cdd69c0468a85791d973e8a14de"
      unitRef="U005">0.81</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="Fact_40119d080ff3447eaae3076bfc74e009"
      unitRef="U005">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="Fact_c89b16f6d2494aa7956b316afe83de01"
      unitRef="U005">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      id="Text_88c1952d6b0f4acb987d4f94377f3270">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt; margin-left: 9pt;"&gt;The roll forward of the April Note derivative liability &#x2013; contingent interest is as follows for the three months ended March 31, 2023 and 2022:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;249,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Adjustment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;338,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;587,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2021&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;495,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;Fair Value Adjustment&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;(104,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; March 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;391,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      decimals="0"
      id="Fact_90b889ea631544209d761f5f7fa8ee65"
      unitRef="U002">249000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      decimals="0"
      id="Fact_99506e06e9d2477782e6c6fa43e1814e"
      unitRef="U002">338000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      decimals="0"
      id="Fact_d24dfecd5da44800b9cd2359a5e81f57"
      unitRef="U002">587000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      decimals="0"
      id="Fact_53fcead1aa3f4abda44a5d9b9563ceec"
      unitRef="U002">495000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      decimals="0"
      id="Fact_26a7c701920f49e199393639596487ea"
      unitRef="U002">-104000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      decimals="0"
      id="Fact_cbfd0a8e8f9345aab3bea70143d03632"
      unitRef="U002">391000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      id="Text_4cc7676293e04353aca15577dedcadc9">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; margin-right: 22pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;The September
              Note derivative liability &#x2013; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;
                    &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;,
                    &lt;/div&gt;
                    &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold;"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31, &lt;/div&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock Price&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.10&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1.13&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Conversion Price of conversion feature&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;8.64&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;8.64&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Term&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: right; text-indent: -18pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;2.47&lt;/span&gt; years
                      &lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: 6pt; text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;2.72&lt;/span&gt; years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Risk Free Interest Rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3.94&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4.22&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;14.04&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;14.76&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Volatility&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;80&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;81&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Dividend Rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_d785533d436049ad985894b1cf46400e"
      unitRef="U005">2.1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_edfea0f792824775a519b10dc1f32daf"
      unitRef="U005">1.13</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_b2b4012924cd44a48c9f7e4dcfc7c8e5"
      unitRef="U005">8.64</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_d9a1e9b83be74a2491e025b20623ea61"
      unitRef="U005">8.64</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_2335d44520224816888de71c8e471756">P2Y5M19D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_ea28aefacd9a4daba5f92629eef9d3a1">P2Y8M19D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_2dac7004572f438fb0e82b83f78bf9ba"
      unitRef="U005">0.0394</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_2fde38a786434ee5926f901ba941ebaa"
      unitRef="U005">0.0422</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_d8404b89cee34cc09bb88ab285649c82"
      unitRef="U005">0.1404</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_098afd0c6f204f73a16db0315a05fb88"
      unitRef="U005">0.1476</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_3d9f5b00b9c748a2a0c952590660af0e"
      unitRef="U005">0.80</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_341ba63eadaa4d668dc3455a3132b469"
      unitRef="U005">0.81</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="Fact_5410e056fc9748feb241e977d88d8522"
      unitRef="U005">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="Fact_4464d6e2d64d4f49bc821bbee11e6f50"
      unitRef="U005">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      id="Text_63a1ce19f8c0480caf772ae2e622a4ff">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 27pt; text-transform: none;"&gt;The roll forward of the September
            Note derivative liability &#x2013; contingent interest is as follows: &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;109,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: left; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Adjustment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;167,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; March 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;276,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2021&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;250,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;Fair Value Adjustment&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;(62,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;Balance &#x2013; March 31, 2022&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;188,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      decimals="0"
      id="Fact_79356b0a05d040aabdac5b8a7a7f8522"
      unitRef="U002">109000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      decimals="0"
      id="Fact_230e6307dd01401f99d9eb0c318059bf"
      unitRef="U002">167000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      decimals="0"
      id="Fact_e174be3285ae4a7cbb6909f3f58c6120"
      unitRef="U002">276000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      decimals="0"
      id="Fact_0348ab9cbcc644a982a736f3406ef66c"
      unitRef="U002">250000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      decimals="0"
      id="Fact_9c0cf2eae69a454ea3b89e8c5d90e491"
      unitRef="U002">-62000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      decimals="0"
      id="Fact_8c0ab58a8d3b4fad97ae2d6d1f40e043"
      unitRef="U002">188000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      id="Text_c005da4a81184f22aaea744c41a61011">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; margin-right: 23pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The December Note derivative
                liability &#x2013; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at March 31, 2023 and December 31, 2022 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
              &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;
                      &lt;div style="text-align: center; font-weight: bold;"&gt;
                        &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;,
                        &lt;/div&gt;
                        &lt;div style="text-align: center; text-indent: 6pt; font-size: 10pt; font-weight: bold; font-family: 'Times New Roman';"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;
                      &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31, &lt;/div&gt;
                      &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2022&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Stock Price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.10&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.13&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Conversion Price of conversion feature&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.43&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.43&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Term&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; 2.73 years&lt;br/&gt;
                    &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.97 years&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Risk Free Interest Rate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3.81&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;4.22&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;14.04&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;14.76&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Volatility&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;80&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;83&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Dividend Rate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;0&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;0&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/span&gt;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_5d2c538b609b435fb0a9fbf946b3588f"
      unitRef="U001">2.1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_6341985977234b0a9c957b53c2ddceb2"
      unitRef="U001">1.13</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_d1da775388274b07919d4864c4ca4482"
      unitRef="U001">5.43</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_031b1c530e1e4ce7aab27b853a6738b4"
      unitRef="U001">5.43</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_66306581f19c452a8612be7d5b1e4760">P2Y8M23D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20220101to20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_b67069ef080e4451b5225fa158adf34d">P2Y11M19D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_dd1340170e5f49a596940c5fb3a15bdb"
      unitRef="U001">0.0381</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_2cb026185ddd4815bd5d3581d6d457c2"
      unitRef="U001">0.0422</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_5fe3f2065df5403ba567db2a618916d3"
      unitRef="U001">0.1404</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_3e892bafb74b4ec1b16536b987732ccb"
      unitRef="U001">0.1476</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_1a05b4d99390419796892046bf03a8e6"
      unitRef="U001">0.80</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_29e82476119b41ef96c9c55df1babf45"
      unitRef="U001">0.83</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="Fact_8efa115e0c1842608bfd5ee538d48d95"
      unitRef="U001">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="0"
      id="Fact_916b427eca62408eae18a05518489182"
      unitRef="U001">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      id="Text_ee0173543a324ac591423b0e77c656d7">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;"&gt;The roll forward
                of the December Note derivative liability &#x2013; contingent interest is as follows: &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;215,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Adjustment&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;264,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; March 31, 2023&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;479,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; December 31, 2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;109,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Adjustment&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;167,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance &#x2013; March 31, 2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;276,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      decimals="0"
      id="Fact_0f5fc27da1a04d80b880fd71dc5bb0a8"
      unitRef="U002">215000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      decimals="0"
      id="Fact_418fede2267d4d9b93b38453fa9b3f2a"
      unitRef="U002">264000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20230331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      decimals="0"
      id="Fact_2926570b101f45c484c8a3f2b0c70262"
      unitRef="U002">479000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20211231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      decimals="0"
      id="Fact_a3d3eb498a874aeba0dc359276a49bad"
      unitRef="U002">109000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20220101to20220331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      decimals="0"
      id="Fact_8f62bc77f6fb4b7489c27b1832333076"
      unitRef="U002">167000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20220331_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      decimals="0"
      id="Fact_33460354015042b390e6b11ceea25aac"
      unitRef="U002">276000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20230101to20230331"
      id="Text_05c0875528b141e0953a9a16053997aa">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;5. Stock-Based Compensation&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Three Months Ended&lt;br/&gt;
                    March 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;270&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;225&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;General and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;392&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;633&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt;"&gt;Total stock-based compensation expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;662&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;858&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes the stock option activity in the Company&#x2019;s equity incentive plans, including non-plan grants to Company executives, from
            December&#160;31, 2022 through March 31, 2023:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted Average&lt;br/&gt;
                    Exercise Price&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Outstanding, December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;5,745,561&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;2.90&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;800,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;1.11&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt;"&gt;Exercised&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt;"&gt;Options forfeited/cancelled&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(18,803&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;3.59&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Outstanding, March 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;6,526,758&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;2.67&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As of March 31, 2023, there was $2,268,000 of
            unrecognized compensation related to 2,850,833 unvested options, which is expected to be recognized over a weighted&#x2013;average period
            of approximately 1.29 years. The weighted-average grant date fair value for options granted during the three months ended March 31,
            2022 was $0.80. The Company granted 800,000
            stock options during the three months ended March 31, 2023.&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Three&lt;br/&gt;
                    Months Ended&lt;br/&gt;
                    March 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Three&lt;br/&gt;
                    Months Ended&lt;br/&gt;
                    March 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Risk-free interest rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;3.76&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;1.23&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
                  &lt;div&gt;Expected life of the options&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: right;"&gt;5.5 years &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: right;"&gt;5.5 years &lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Expected volatility of the underlying stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;86&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;95&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                  &lt;div&gt;Expected dividend rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;0&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;0&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In January 2023, the Company&#x2019;s board chairman elected to take restricted stock grants in lieu of cash retainers for 2023. A total of 36,036 shares of restricted stock valued at approximately $40,000 is being amortized to expense on a straight-line basis until December 31, 2023 when the stock vests in full. In January 2022, the Company&#x2019;s board chairman elected to take restricted stock grants in lieu
            of cash retainers for 2022. A total of 17,677 shares of restricted stock valued at approximately $35,000 is being amortized to expense on a straight-line basis until December 31, 2022 when the stock vested in full.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In September 2020, the Company entered into an employment agreement with its new Chief Executive Officer whereby 20% of his base salary and performance bonuses will be paid in cash, and 80%
            will be paid in the form of deferred stock units (&#x201c;DSUs&#x201d;) in accordance with the terms and subject to the provisions set forth in the DSU Agreement. DSUs credited to Mr. Lewis as of any date shall be fully vested and nonforfeitable at all
            times. Pursuant to an amendment to the DSU Agreement in July 2022, the Company shall issue the shares underlying the outstanding whole number of DSUs credited to Mr. Lewis as follows: twenty five percent shall be issued on March 1, 2023, fifty percent
            shall be issued on March 1, 2024 and twenty five percent shall be issued on September 1, 2028.&#160; On March 1, 2023, twenty five percent of the DSU&#x2019;s were issued to Mr. Lewis in accordance with the DSU Agreement.&#160;&#160; A total of 183,900 shares were due to be issued; however, 75,529
            shares were withheld to cover income tax withholding of $156,345 resulting in 108,371 shares actually issued.&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;For the three months ended March 31, 2023, approximately $112,000
            of his compensation was recorded as stock compensation expense representing 72,440 shares of common stock to be issued under the DSU
            agreement with a weighted average grant date fair value of $1.55 per share.&#160; For the three months ended March 31, 2022, approximately
            $103,000 of his compensation was recorded as stock compensation expense representing 55,626 shares of common stock to be issued under the DSU agreement with a weighted average grant date fair value of $1.86 per share.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Also, Mr. Lewis&#x2019; bonus for the year ended December 31, 2022 of $210,000
            (which was included in accrued compensation at December 31, 2022) was approved in January 2023 and represents 143,836 shares of
            common stock to be issued under the DSU agreement with a grant date fair value of $1.46 per share. The $210,000 was reclassified from accrued compensation to additional paid in capital in January 2023. There is no unrecognized compensation expense related to the DSUs.&lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="c20230101to20230331"
      id="Text_9011ea0c898a4c6f9241e95bcb9bc839">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Three Months Ended&lt;br/&gt;
                    March 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;270&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;225&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;General and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;392&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;633&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt;"&gt;Total stock-based compensation expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;662&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;858&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20230331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_d7b6824e8aa2443882c0014c399a0c16"
      unitRef="U002">270000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_ca299e72048546ccb4e89961336d0a0a"
      unitRef="U002">225000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20230331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_ccfaeea94e734fa3872c7e65e029a26f"
      unitRef="U002">392000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_f381947dd48f4bd4aa948b8317f7bb45"
      unitRef="U002">633000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_00d5992cc92447c8b2f3a98039042f1c"
      unitRef="U002">662000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220331"
      decimals="-3"
      id="Fact_bbb82c9690074a86bf01cdd1005b983d"
      unitRef="U002">858000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_9d9c277515224ec0b9771a85dca8d706">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes the stock option activity in the Company&#x2019;s equity incentive plans, including non-plan grants to Company executives, from
            December&#160;31, 2022 through March 31, 2023:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted Average&lt;br/&gt;
                    Exercise Price&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Outstanding, December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;5,745,561&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;2.90&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;800,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;1.11&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt;"&gt;Exercised&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt;"&gt;Options forfeited/cancelled&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(18,803&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;3.59&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Outstanding, March 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;6,526,758&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;2.67&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20221231"
      decimals="0"
      id="Fact_ea7dd9c9e6764230860bc44948226997"
      unitRef="U001">5745561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20221231"
      decimals="2"
      id="Fact_ae0cc01126ca482eb4c0a22af53b5e50"
      unitRef="U003">2.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_26c1cf14771d4f0384976db02c584b58"
      unitRef="U001">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20230331"
      decimals="2"
      id="Fact_311d3f2540b145aea3d1618845d6f356"
      unitRef="U003">1.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230101to20230331"
      decimals="INF"
      id="Fact_145d86e1fad44d74a91b218790b886cf"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_69dd3fe4ae5346f1bf8993878d882140"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_84148206ffc6414d9480d7ec5001e25e"
      unitRef="U001">18803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20230331"
      decimals="2"
      id="Fact_27f7e374b56b46dab1410be17ba2cc91"
      unitRef="U003">3.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20230331"
      decimals="0"
      id="Fact_58b44c444064492eb911300a57ae8ce9"
      unitRef="U001">6526758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20230331"
      decimals="2"
      id="Fact_92d3df653b804204a09bdb773096f156"
      unitRef="U003">2.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c20230331"
      decimals="0"
      id="Fact_b158ab53432a4724b5f37c9fbce04415"
      unitRef="U002">2268000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c20230331"
      decimals="0"
      id="Fact_43ee3b627bfa48bea8d8026ec0d4ef44"
      unitRef="U001">2850833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20230101to20230331"
      id="Fact_6cb167ce40a84105b3a2e2dc18dff3b6">P1Y3M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230101to20230331"
      decimals="2"
      id="Fact_48331ab24b0f4ad18ce272c125881566"
      unitRef="U003">0.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_56ec89f1597240c385e01d65ab66b745"
      unitRef="U001">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_582ace65091b4b42a8c3336a8eae29e7">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Three&lt;br/&gt;
                    Months Ended&lt;br/&gt;
                    March 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Three&lt;br/&gt;
                    Months Ended&lt;br/&gt;
                    March 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Risk-free interest rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;3.76&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;1.23&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
                  &lt;div&gt;Expected life of the options&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: right;"&gt;5.5 years &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: right;"&gt;5.5 years &lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Expected volatility of the underlying stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;86&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;95&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                  &lt;div&gt;Expected dividend rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;0&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;0&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20230331"
      decimals="4"
      id="Fact_538c8594b3004eefa79272d86ffde775"
      unitRef="U005">0.0376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220101to20220331"
      decimals="4"
      id="Fact_03583d38ca3d42a6a01f839f840fdb6a"
      unitRef="U005">0.0123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20230331"
      id="Fact_2f769be158fc4fb8a6084c1b32108514">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20220101to20220331"
      id="Fact_5672c992ac8c4c2ca64c285f935881fa">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230101to20230331"
      decimals="2"
      id="Fact_7626d3df4cac4167a9a91a127645fb73"
      unitRef="U005">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20220101to20220331"
      decimals="2"
      id="Fact_fc64d1600933426da564082766d47753"
      unitRef="U005">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230101to20230331"
      decimals="2"
      id="Fact_9cb6e846f2044f7aad6d81184c4e0c30"
      unitRef="U005">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20220101to20220331"
      decimals="2"
      id="Fact_d5a820fd201046d5b28775776be10d4d"
      unitRef="U005">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20230101to20230131_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_5ee97d5c0e6747df8b66f8216dcaa833"
      unitRef="U001">36036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20230131_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_8f256336a3f24b0ebff993f4463393da"
      unitRef="U002">40000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_8a66b848e27f47bb833e2931ae7197eb"
      unitRef="U001">17677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_5084b10e9385458ca990fd874d1862a9"
      unitRef="U002">35000</us-gaap:AllocatedShareBasedCompensationExpense>
    <galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent
      contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_bf1c35fd875c4466af1968364790d092"
      unitRef="U005">0.20</galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent>
    <galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent
      contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_adb81f26837041a5a11b4c1b0acd8d70"
      unitRef="U005">0.80</galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent>
    <galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne
      contextRef="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_40693188436147cb8fa33e826f09f312"
      unitRef="U005">0.25</galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne>
    <galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo
      contextRef="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_b00cba5586d1451289aea97373c911bf"
      unitRef="U005">0.50</galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo>
    <galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree
      contextRef="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_f6fd0a639b9d458ea34abe9f04071867"
      unitRef="U005">0.25</galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree>
    <galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne
      contextRef="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_4907daf555b54f74ae8e0a21c0fc63e3"
      unitRef="U005">0.25</galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="c20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_47c2b8ed1da5469790ef42ceafaf811b"
      unitRef="U001">183900</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_9896ee18d85047de8cf8b82bfadd6138"
      unitRef="U001">75529</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_acddf4c1dea54b62954b79182c4ccda4"
      unitRef="U002">156345</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_9732f880dac54156a49329c012d16255"
      unitRef="U001">108371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_1e806bb70d0c42a8b9cc1093f1133758"
      unitRef="U002">112000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_39b0aa5de6494fb184611af57cdcea99"
      unitRef="U001">72440</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice
      contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_164c9e8aa5c043efb6f79135ed2270fd"
      unitRef="U003">1.55</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_960fcfb5302f4139b756eac6f39eb672"
      unitRef="U002">103000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="c20220101to20220331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_79add5ba61b84c1e99f4716cc5abb984"
      unitRef="U001">55626</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice
      contextRef="c20220101to20220331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_ae8f227ebd9b4ceea7797dcee5fea340"
      unitRef="U003">1.86</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_21d1691ae87b4c068b0eb681bff749a2"
      unitRef="U002">210000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_86828f61790a4602915129c0d65b147a"
      unitRef="U001">143836</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice
      contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_bd49f57fefac45248d8f28a83acfe2ce"
      unitRef="U003">1.46</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20230331_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_ed963e0ec57d4dcc90bc0c9df9ad0b8f"
      unitRef="U002">210000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c20230331_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_94ed2ece97ba427f8cbb5fd5b750ad9a"
      unitRef="U002">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <galt:CommonStockWarrantsDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_cb469a68106c4223b8be9a79a50c410a">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;6. Common Stock Warrants&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes the common stock warrant activity from December 31, 2022 through March 31, 2023:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted Average&lt;br/&gt;
                  Exercise Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Outstanding, December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;11,557,964&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4.37&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;200,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.26&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Forfeited/cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Outstanding, March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;11,757,964&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4.35&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The weighted average expiration of the warrants outstanding as of March 31, 2023 is 1.8 years.&lt;/div&gt;
</galt:CommonStockWarrantsDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="c20230101to20230331"
      id="Text_cc3a2ef89d4a4c63a639c940b07f21a7">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes the common stock warrant activity from December 31, 2022 through March 31, 2023:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted Average&lt;br/&gt;
                  Exercise Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Outstanding, December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;11,557,964&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4.37&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;200,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.26&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Forfeited/cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Outstanding, March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;11,757,964&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4.35&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20221231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_80611eeabdee4889b5860de2401c349b"
      unitRef="U001">11557964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20221231_FinancialInstrumentAxis_WarrantMember"
      decimals="2"
      id="Fact_9b8a82abd4ec4799922cc58edfba216d"
      unitRef="U003">4.37</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_39355c2fbb0c422eb9933f5c8d0e7576"
      unitRef="U001">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="2"
      id="Fact_67326353f2404bb09ef71332e73a737e"
      unitRef="U003">3.26</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="INF"
      id="Fact_6ffe0727189843cca0567f6decb7d908"
      unitRef="U001">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_987d9c3807a44d5cbf9513967587e987"
      unitRef="U003">0</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="INF"
      id="Fact_d63c9e05cd434c499f9cd48cfc0bbcc9"
      unitRef="U001">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <galt:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_84652e37cc0f48fc81e3f74e28ef890c"
      unitRef="U003">0</galt:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_5fa19e2cdccc4effb02246e8e282ffc6"
      unitRef="U001">11757964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="2"
      id="Fact_7fd173a26f3747d6825220e261aa5c9a"
      unitRef="U003">4.35</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20230331"
      id="Fact_a0c81e861cae4cf98a7345ded32f7bb0">P1Y9M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="c20230101to20230331"
      id="Text_70f50e9e8d5a491a839ddd22c6db5b52">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;7. Loss Per Share&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding
          during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares
          consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the
          issuance of common shares that have an anti-dilutive effect on net loss per share. &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would
          have been anti-dilutive are as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31,&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31,&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;(shares) &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;(shares) &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Warrants to purchase shares of common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;11,757,964&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;10,857,964&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Options to purchase shares of common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,526,758&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,630,561&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Shares of common stock issuable upon conversion of convertible notes payable &#x2013; related party&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,966,437&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,365,259&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;Shares of common stock issuable upon conversion of convertible line of credit &#x2013; related party&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;6,727,849&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Shares of common stock issuable upon conversion of preferred stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;503,340&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;510,424&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;31,482,348&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;22,364,208&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20230101to20230331"
      id="Text_10f05d5c6af74e8eb70b6f2658f631a0">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would
          have been anti-dilutive are as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31,&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31,&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;(shares) &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;(shares) &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Warrants to purchase shares of common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;11,757,964&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;10,857,964&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Options to purchase shares of common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,526,758&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,630,561&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Shares of common stock issuable upon conversion of convertible notes payable &#x2013; related party&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,966,437&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,365,259&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;Shares of common stock issuable upon conversion of convertible line of credit &#x2013; related party&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;6,727,849&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Shares of common stock issuable upon conversion of preferred stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;503,340&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;510,424&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;31,482,348&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;22,364,208&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_8ee69841c61c423caaca6da5c5437ce5"
      unitRef="U001">11757964</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_b61f5e5f5e7d418da5e297a4e7559897"
      unitRef="U001">10857964</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_4dbc264a794f40659e7f2315a6f5f2ae"
      unitRef="U001">6526758</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_ed27ad9ab58f427ba20800fe8a4adf4a"
      unitRef="U001">5630561</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember"
      decimals="0"
      id="Fact_51f4d2487da24cb6836fdca8984f2bdc"
      unitRef="U001">5966437</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember"
      decimals="0"
      id="Fact_026bbdc453dc4be09db12aa7e25da518"
      unitRef="U001">5365259</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember"
      decimals="0"
      id="Fact_101f884cccb046e09e785a529057f667"
      unitRef="U001">6727849</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember"
      decimals="INF"
      id="Fact_9895351692274d1fad229e6a3f6ceb6b"
      unitRef="U001">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"
      decimals="0"
      id="Fact_98ddf7fd466e4654b6e20c691914361e"
      unitRef="U001">503340</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"
      decimals="0"
      id="Fact_9ab090f499d840c0a812f7bbd95eb571"
      unitRef="U001">510424</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_320d49c400d2401e85e58e48ca2d2a72"
      unitRef="U001">31482348</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_d2c1aebaaf254ba5b60ebe699121aed3"
      unitRef="U001">22364208</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_fe79eb8bb40d4eecb286764802f0cf9a">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;8. Common Stock&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2020 At Market Issuance of Common Stock&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 21.5pt; margin-top: 3pt; margin-bottom: 3pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On May 11, 2020, the Company entered into an At Market Issuance Sales Agreement (the
          &#x201c;2020 At Market Agreement&#x201d;) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $40.0 million from time to time through the sales agent. Sales of the Company&#x2019;s common stock through the sales agent, if any, will be made by any method that is deemed an &#x201c;at the market&#x201d; offering as defined by the
          U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to 3.0% of the gross proceeds
          from the sale of any shares of common stock sold through the sales agent under the 2020 At Market Agreement. During the quarter ended March 31, 2023, there were no issuances of shares of common stock under the 2020 At Market Agreement.&lt;/div&gt;

&lt;div style="margin-top: 3pt; margin-bottom: 3pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;For each of the three months ended March 31, 2023 and 2022, the Company issued a total of 30,200 and 30,625 shares of common stock, respectively, for
            dividends on Series A and Series C Preferred Stock.&lt;/div&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <galt:AggregateOfferingPrice
      contextRef="c20230331_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"
      decimals="-5"
      id="Fact_2c82746a23d6434a9ac88ce9a0395ad7"
      unitRef="U002">40000000</galt:AggregateOfferingPrice>
    <galt:CommissionRate
      contextRef="c20230331_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"
      decimals="3"
      id="Fact_422b62ae021d49c3967b6e2a170ac5b3"
      unitRef="U005">0.03</galt:CommissionRate>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20230331_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"
      decimals="INF"
      id="Fact_c867370700a04c0eaa5eb0aeed5bbaf8"
      unitRef="U001">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockDividendsShares
      contextRef="c20230101to20230331_StatementClassOfStockAxis_SeriesAAndSeriesCPreferredStockMember_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"
      decimals="0"
      id="Fact_c8ba1352c6ad4072af285780a6faf3bb"
      unitRef="U001">30200</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockDividendsShares
      contextRef="c20220101to20220331_StatementClassOfStockAxis_SeriesAAndSeriesCPreferredStockMember_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"
      decimals="0"
      id="Fact_3aa2d152831a43fdab4b8f31e7228ad2"
      unitRef="U001">30625</us-gaap:CommonStockDividendsShares>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="c20230101to20230331_LongtermDebtTypeAxis_LineOfCreditMember"
      id="Text_59159bc46d974297a6e5dd5e3871aa13">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-right: 11pt; font-weight: bold;"&gt;9. Convertible Line of Credit &#x2013; Related Party&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;"&gt;On July 25, 2022, the Company and Richard E. Uihlein (the &#x201c;Lender&#x201d;) entered into a Line of Credit Letter Agreement (the &#x201c;Credit Agreement&#x201d;),
        pursuant to which the Lender shall provide the Company a line of credit of up to $60.0 million (the &#x201c;Line of Credit&#x201d;) to finance the
        Company&#x2019;s working capital needs. The Company may draw upon the Line of Credit through July 31, 2024.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;"&gt;Each advance made pursuant to the Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a
        &#x201c;Promissory Note,&#x201d; and collectively, the &#x201c;Promissory Notes&#x201d;), and bear interest at the Applicable Federal Rate for short term loans, plus two (2%)
        percent. Principal and interest on the Promissory Notes are due on or before January 31, 2026. Only with the consent of the Lender, may
        the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;"&gt;At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the
        Company&#x2019;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;"&gt;In connection with the Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 1,700,000 shares of the Company&#x2019;s common stock, par value $0.001
        per share (collectively, the &#x201c;Warrants&#x201d;). Upon execution of the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 500,000
        shares of Company&#x2019;s Common Stock at an exercise price of $5.00 per share, which Warrant is exercisable upon issuance. Further, pursuant
        to the Credit Agreement, the Company shall issue to the Lender additional Warrants to purchase up to the remaining 1,200,000 shares of
        the Company&#x2019;s common stock, ratably, upon borrowings under the Credit Agreement, with exercise prices equal to 150% of the closing price
        of the Company&#x2019;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor
        less than $3.00 per share. The Warrants expire on July 31, 2029.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;"&gt;The fair value of the 500,000
        warrants vested at closing on July 25, 2022 was $738,000 at the date of issuance based on the following assumptions: an expected life of
        7 years, volatility of 92%,
        risk free interest rate of 3.19% and zero
        dividends. The fair value of the vested warrants was recorded in other assets (non-current) as a deferred financing cost and will be amortized on a straight-line basis from July 25, 2022 through January 31, 2026. Amortization for the three months
        ended March 31, 2023 of $52,000 was recorded as interest expense.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;"&gt;On December 19, 2022, the Company executed a $10
        million Promissory Note under the Line of Credit. The interest rate on this draw is 6.46% (Applicable Federal Rate for short term loans
        on date of draw of 4.46% plus 2%).









        The effective interest rate is approximately 7.1%. Accrued interest on this draw was $23,000 at December 31, 2022. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#x2019;s Common Stock at an exercise price of $3.00
        per share, which Warrant is exercisable upon issuance.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;"&gt;The fair value of the 200,000
        warrants vested at closing on December 19, 2022 was $160,780 at the date of issuance based on the following assumptions: an expected life
        of 7 years, volatility of 91%,
        risk free interest rate of 4.06% and zero
        dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal to be amortized on a straight-line basis, which is not
        materially different than the effective interest method, from December 19, 2022 through January 31, 2026. Amortization for the three months ended March 31, 2023 of $13,000 was recorded as interest expense. The fair value of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the remaining period through January
        31, 2026.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;"&gt;On March 31, 2023, the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 6.41%
        (Applicable Federal Rate for short term loans on date of draw of 4.41% plus 2%). The effective interest rate is approximately 7.1%.&#160; The
        principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance with the Credit Agreement,
        the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#x2019;s Common Stock at an exercise price of $3.26 per share, which Warrant is exercisable upon issuance.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;"&gt;The fair value of the 200,000
        warrants vested at closing on March 31, 2023 was $296,680 at the date of issuance based on the following assumptions: an expected life of
        6.33 years, volatility of 88%,
        risk free interest rate of 3.94% and zero
        dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal to be amortized on a straight-line basis, which is not
        materially different than the effective interest method, from March 31, 2023 through January 31, 2026.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 21.5pt; margin-right: 11pt;"&gt;The fair value of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the
        remaining period through January 31, 2026.&lt;/div&gt;
</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-5"
      id="Fact_d4e741de393c4bbba01be91267ca536a"
      unitRef="U002">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20220725to20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_481f955a563f4da6bd2c6aa44348a1a5"
      unitRef="U005">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20220725to20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_6610b622ae8f4631b5b28290803eb3a0">2026-01-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:SharePrice
      contextRef="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_8d363a1a39da41688da57d0f1aef2a5d"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b47d8c016ccf400a99da864e47748d84"
      unitRef="U001">1700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact_aba99699f8964f7db703ae2eaf3b45f0"
      unitRef="U003">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_9e209327449d4517844b054925a4967b"
      unitRef="U001">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220725_FinancialInstrumentAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_f0774d15fbee4aa58eb203bb7edcc0ec"
      unitRef="U003">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <galt:ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220725to20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d4d5bd30c90041548d4fb78ca6433e88"
      unitRef="U001">1200000</galt:ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock
      contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_e218fe87b5b9486b84ec3a57b94862ef"
      unitRef="U005">1.50</galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock>
    <us-gaap:SharePrice
      contextRef="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_3495431564c84d0b83fd0cd0e206f645"
      unitRef="U003">10</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c20220725_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_34e1c455b4dc4b7db7e5063d1b9f04ff"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="c20230331_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_dc5a64b7b3f04e5bbf2acc028ea91cac">2029-07-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d02279202074444f871fe418fecefde1"
      unitRef="U001">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:IssuanceOfWarrantsValue
      contextRef="c20220725to20220725_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_d87dea8e83d24b1893b885fad9005dca"
      unitRef="U002">738000</galt:IssuanceOfWarrantsValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"
      id="Fact_17340297b99c4201929f281ad1fc4c32">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="2"
      id="Fact_f7e7294e8e8744f6a262b965313ea257"
      unitRef="U005">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="4"
      id="Fact_3be4aa9a7def4f2ca1f4cb50107ba9d2"
      unitRef="U005">0.0319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_f654edd32beb4fc58ba13b8e17833bfd"
      unitRef="U005">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_8250218113a948968b6666bff3951bee"
      unitRef="U002">52000</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20221219to20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-6"
      id="Fact_5ed892abf47d49a1a4f0707e56680f09"
      unitRef="U002">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c20221219to20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_cf68dd6a845b4280ab207f1074cf955a"
      unitRef="U005">0.0646</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_6c35b055836e413fb31b7a1cbfeb661e"
      unitRef="U005">0.0446</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20221219to20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_37e90b0662fe4b138d07fc40cb8c0713"
      unitRef="U005">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_7b506e3fc9f34e2dab42ddb15a02b87e"
      unitRef="U005">0.071</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <galt:DebtInstrumentAccruedInterest
      contextRef="c20221231_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_c412a6372d7040169ba16326d2a735e9"
      unitRef="U002">23000</galt:DebtInstrumentAccruedInterest>
    <us-gaap:SharePrice
      contextRef="c20221219_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_ff660f1f8cb44578ab7d220ef42a90d5"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_faa71843e0f3453596a98a74fc1e4630"
      unitRef="U001">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20221219_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_7b337cde9f484885a2a03b2e6aeadc5e"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_62ef045a39374fe191dbd127dcf9b171"
      unitRef="U001">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:IssuanceOfWarrantsValue
      contextRef="c20221219to20221219_FinancialInstrumentAxis_WarrantOneMember"
      decimals="0"
      id="Fact_8e847481ae97487db2612cab0c2f4dcd"
      unitRef="U002">160780</galt:IssuanceOfWarrantsValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember"
      id="Fact_72d03402cb9e4ed68b1ca2ce49e4380e">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember"
      decimals="2"
      id="Fact_b9af8daf2fd94287ab0a988f48ffad0d"
      unitRef="U005">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember"
      decimals="4"
      id="Fact_c7c8178ed13c400a846e19c0955ba07f"
      unitRef="U005">0.0406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember"
      decimals="0"
      id="Fact_48bf9a3a50b542338b4b22b68b431dde"
      unitRef="U005">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantOneMember"
      decimals="0"
      id="Fact_a5eeb7e4d42449629dae49de34f55cc8"
      unitRef="U002">13000</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20230101to20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-6"
      id="Fact_dc32105a50824fea9ad980232659c6b7"
      unitRef="U002">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c20230101to20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_c1eb18f7f8cc4f538119e87b65aadfa4"
      unitRef="U005">0.0641</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_203dea1e2c4f4ca49ee86e23dbc0d80f"
      unitRef="U005">0.0441</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20230101to20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_a91c530959e14d00aebd6b50b774f8ac"
      unitRef="U005">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_6d9687379c1d4950889e586cc78c4f8e"
      unitRef="U005">0.071</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:SharePrice
      contextRef="c20230331_CreditFacilityAxis_UnsecuredConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_0e8cff3cae2840469e5fa929a22c16be"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20230331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_237f7613f32a4483865db4d0e421119f"
      unitRef="U001">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20230331_FinancialInstrumentAxis_WarrantTwoMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_fa98249d2a534b689dca92ed89e7d7b3"
      unitRef="U003">3.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20230331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_207785f2908b417ca0195d18ed6a33b2"
      unitRef="U001">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:IssuanceOfWarrantsValue
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_b111c105be574df984a62abfa9c30012"
      unitRef="U002">296680</galt:IssuanceOfWarrantsValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember"
      id="Fact_77d712b8ee26417aa2593a6c4232cab1">P6Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="2"
      id="Fact_5d256ebe81924e47b42ee4172f5b2649"
      unitRef="U005">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="4"
      id="Fact_9eea12dbfc1047b88f79bfc20b7a636e"
      unitRef="U005">0.0394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230101to20230331_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_c3fc2065c7834a9eb5f73de28d18c4e0"
      unitRef="U005">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_53cdaeb5abb840608a6e2bae192f5e97">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;10. Commitments and Contingencies&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other Legal Proceedings&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable, and the related damages are
          estimable. There are no significant pending legal proceedings.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Clinical Trial and Research Commitments&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has entered into agreements with contractors for research and development activities to further its product candidates. The contracts generally may be
          canceled at any time by providing thirty days&#x2019; notice.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <galt:ContractCancelationNoticePeriod
      contextRef="c20230101to20230331"
      id="Fact_ee080835a3e14e7e9a0afaf101fab543">P30D</galt:ContractCancelationNoticePeriod>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="c20230101to20230331"
      id="Text_6e591e11b032468d8268ec4e00d962ab">
&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;11. Leases&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has one operating lease for its office
          space which was amended effective March 1, 2022 for a term of 38 months with no residual value guarantees or material restrictive
          covenants. The amended lease provided for free rent for the first &lt;span style="-sec-ix-hidden:Fact_3257fbc22511431091132ea0cf902d08"&gt;six and a half months&lt;/span&gt; of the lease and continues the security
          deposit of $6,000. In addition to base rental payments included in the contractual obligations table above, the Company is responsible
          for our pro-rata share of the operating expenses for the building. Our lease cost for the three-month periods ended March 31, 2023 and 2022 was approximately $13,000 for each period and is included in general and administrative expenses. As of March 31, 2023, the right to use lease asset consisted of $78,000 and is included in &lt;span style="-sec-ix-hidden:Fact_ca7b3631a1474b9799fb873ed35a3567"&gt;other assets&lt;/span&gt;. Also, at March 31,
          2023, current lease liability of $42,000 is included in &lt;span style="-sec-ix-hidden:Fact_26a5d647f0b84359bcf1207a54ef8756"&gt;accrued expenses&lt;/span&gt; and long term lease liability was $55,000 and included in &lt;span style="-sec-ix-hidden:Fact_8c9f7ebb1d3c4996a11d58878cfc0b06"&gt;other liabilities&lt;/span&gt;.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 27pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"&gt;Maturity of operating lease as of March 31, 2023 in thousands:&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 9pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="margin-left: 9pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;38&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;51&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;2025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;18&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;107&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Less imputed interest&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;10&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Present value of lease liability&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;97&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 24.5pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 18pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The
              discount rate used in calculating the present value of the lease payments was 11%&lt;/span&gt;.  &lt;/div&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <galt:NumberOfOperatingLeases
      contextRef="c20230101to20230331"
      decimals="INF"
      id="Fact_675fec9b57ee4167b7f53c72a13bda26"
      unitRef="U006">1</galt:NumberOfOperatingLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="c20230331"
      id="Fact_286d6e0129084259a1180fc375dc174a">P38M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SecurityDeposit
      contextRef="c20230331"
      decimals="0"
      id="Fact_8cb8a6ec24354735ba61641435dd30e3"
      unitRef="U002">6000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseCost
      contextRef="c20220101to20220331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_bc25b5bae4c541a9a6b5b0baa3eca571"
      unitRef="U002">13000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20230101to20230331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_1ac1b1769f47488da954c961dd8d125c"
      unitRef="U002">13000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20230331"
      decimals="0"
      id="Fact_7a4f03d6dd884259a8864090a507771a"
      unitRef="U002">78000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_76b82fcfa2b347b3818811361eaae660"
      unitRef="U002">42000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_cc852b6bf7e446c68ee738c90508558f"
      unitRef="U002">55000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_cdb1e7194c3b41d78d8af2d85111e30a">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 27pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"&gt;Maturity of operating lease as of March 31, 2023 in thousands:&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 9pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="margin-left: 9pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;38&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;51&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;2025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;18&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;107&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Less imputed interest&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;10&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Present value of lease liability&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;97&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="c20230331"
      decimals="-3"
      id="Fact_b57e964bf75e4b719e044ef4cc175097"
      unitRef="U002">38000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20230331"
      decimals="-3"
      id="Fact_7ae77091d27c4d8bad5b3b0f2f392059"
      unitRef="U002">51000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20230331"
      decimals="-3"
      id="Fact_a8696612bae548cdb27a1c8e2706460e"
      unitRef="U002">18000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_0975167fd3d0403fb39a060bb356cebc"
      unitRef="U002">107000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20230331"
      decimals="-3"
      id="Fact_f0990472ca3042b5a6c601a12857e452"
      unitRef="U002">10000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20230331"
      decimals="-3"
      id="Fact_99e0c72e20b344168cb84e79e6d8629b"
      unitRef="U002">97000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c20230331"
      decimals="2"
      id="Fact_a190bc0b96094bd9a6d694f16c71f776"
      unitRef="U005">0.11</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock
      contextRef="c20230101to20230331"
      id="Text_35069dec59d94ffe8cbda9e93b94156e">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;12. Galectin Sciences LLC&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;In January 2014, we created Galectin Sciences, LLC (the &#x201c;LLC&#x201d; or &#x201c;Investee&#x201d;), a collaborative joint venture co-owned by SBH Sciences, Inc. (&#x201c;SBH&#x201d;),
          to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $400,000
          cash investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) contributed by SBH.&#160;The estimated fair value of the IPR&amp;amp;D contributed by
          SBH, on the date of contribution, was $400,000.&#160;Initially, the Company and SBH each had a 50% equity ownership interest in the LLC, with neither party having control over the LLC.&#160;Accordingly, from inception through the fourth quarter of 2014, the Company
          accounted for its investment in the LLC using the equity method of accounting.&#160;Under the equity method of accounting, the Company&#x2019;s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize
          additional investments in or distributions from the Investee, as well as the Company&#x2019;s share of the Investee&#x2019;s earnings, losses and/or changes in capital. The estimated fair value of the IPR&amp;amp;D contributed to the LLC was immediately expensed
          upon contribution as there was no alternative future use available at the point of contribution.&#160;The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial
          capitalization, then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $400,000 in cash, SBH decided not to contribute its share of the funding required. Cumulatively, the Company has contributed a total of $3,364,000, including $126,000 for the
          three months ended March 31, 2023, for expenses of the LLC. Since the end of 2014, SBH has contributed $158,000 for expenses in the
          LLC. As of March 31, 2023, the Company&#x2019;s ownership percentage in the LLC was 85.8%. The Company accounts for the interest in the LLC
          as a consolidated, less than wholly owned subsidiary. Because the LLC&#x2019;s equity is immaterial, the value of the non-controlling interest is also deemed to be immaterial.&lt;/div&gt;
</us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="c20140101to20140131_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_1faba6d199064d8286f1b37875c8c2fd"
      unitRef="U002">400000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
      contextRef="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_InProcessResearchAndDevelopmentMember_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_7f70b2f1b7f04cb8907bdf75b533501b"
      unitRef="U002">400000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="2"
      id="Fact_a45588565c634b05947d7d1d0fbd160b"
      unitRef="U005">0.50</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20141001to20141231_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_102eac83c15e4ad5b0b1faecc892bc88"
      unitRef="U002">400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <galt:CapitalContributionExpense
      contextRef="c20140101to20220331_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_2ae0ea1ff4514aa6a41cdb71cf5f256f"
      unitRef="U002">3364000</galt:CapitalContributionExpense>
    <galt:CapitalContributionExpense
      contextRef="c20230101to20230331_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_61eb59d85b544464a1d0983baad2ca6a"
      unitRef="U002">126000</galt:CapitalContributionExpense>
    <galt:CapitalContributionExpense
      contextRef="c20220101to20220331_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_9063a0ce9fb44130addcf80b60c2f7bf"
      unitRef="U002">158000</galt:CapitalContributionExpense>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20230331_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="3"
      id="Fact_b082526be1b34595abc84ea7303f86a3"
      unitRef="U005">0.858</us-gaap:MinorityInterestOwnershipPercentageByParent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ML&QW5K^[4>DZ/^Y>I$JE<7ZYX@S@:P%XOTQA@"QN] EZ^8O)^']02P,$%
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M8G'JWP<,-:60Y#U6YSV.5BO>60YB;#7FPO/\K->Y ;IU?:_+*V3LKOV4?U9
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M#*RV,0Y)<["K@9H:!:URDZ8Q'(I=#=2O *4Y4+2JGJ6U@=7>QC5+41 E\BT
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M5ZB7Z>/+YGCZA(7<1COU0M,"HJ/!<_QL=>FS4%H$6\=/,7,;@JWB8TD2R/@
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MLE95[G(E.*I  KB_4,IV7\C!]GWIU?\!4$L#!!0    ( %(^KU8G02_]P@(
M $D&   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;)552V_;, R^^U<(
M[M!3X&=>2Y, 2=L]#L6*9EL/PPZ*3<=";<F3Y#K=KQ\E)VZ"I<%VB42)WZ>/
MI,E,&R&?5 Z@R;8LN)JYN=;5Q/=5DD-)E2<JX'B3"5E2C:;<^*J20%,+*@L_
M"H*A7U+&W?G4GMW+^534NF <[B51=5E2^;*$0C0S-W3W!P]LDVMSX,^G%=W
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ML=L<9SU(XX#WF1!Z;Y@'NG^/^1]02P,$%     @ 4CZO5O1-#ED1!   8@H
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MZP/87QM#AXU/</QS6O\&4$L#!!0    ( %(^KU:!G G1_04  "\.   9
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;)U7VW+;-A!]UU=@%">3SC"ZV_'$
MMF9LIVW<268\<=,^=/H D4L1"0G0 "C%_?J>!2A*<A3W\B+Q@CV[9R\'X/G:
MV"^N(/+B:U5J=]$OO*_?#(<N+:B2;F!JTGB3&UM)CUN['+K:DLR"454.)Z/1
MR;"22O?GY^'9K9V?F\:72M.M%:ZI*FD?KJ@TZXO^N+]Y\%$M"\\/AO/S6B[I
MCORG^M;B;MBA9*HB[931PE)^T;\<O[F:\?JPX#=%:[=S+9C)PI@O?'.37?1'
M'!"5E'I&D/A;T365)0,AC/L6L]^Y9,/=ZPWZ3X$[N"RDHVM3_JXR7UST3_LB
MHUPVI?]HUN^HY7/,>*DI7?@5Z[AV.NV+M''>5*TQ(JB4CO_R:YN''8/3T7<,
M)JW!),0='84HWTHOY^?6K(7EU4#CBT U6",XI;DH=][BK8*=G_\L0WZTN$L5
MZ92<>/_^^GSH <T+AFD+<Q5A)M^!F8H/1OO"B1]U1MF^_1 A=7%--G%=39X$
M_"#M0$S'B9B,)M,G\*8=SVG F_X7GN*/RX7S%IWQYR'*$7%V&)&GY8VK94H7
M?8R#([NB_OS%L_')Z.R)>&==O+.GT/]]79Z&&4\&XC#U&RU^D;K!("+%XUDB
MUB12C+6G[%N+))B\] 6)%\].)Y/1&>[#U?A,&+MY>*-7Y#Q1^^:'1$B!!BWE
MPEC)TR<^&Z6]6)'VC84_\\JL-1PN'L3=U;L==S<Z'8B7+2Q>=8@];P1G6]JT
M$%)GF, 5E*46KI)EB5B64JM45 8,FI*$TH5:*&^L$R87RY;8JZF GF&U+(7,
M,%:*VX!E8B!^!4EFNY8.ULHKX#Z(5-;*RU+]A6C7RL.W.)J-1LEH-.JETA58
MRMPA5UX@Q+Q!:'D36!X*-ZP+B@0'3'A=**Q@G[4U*Y7%I'#"KTU52_V0!'-7
M4ZIR$ 0'+$2NW/?Q-_F[N?WX0E;UV=M-%I%X[:U:-+[+?>0-!JH*+9!+9<5*
ME@UQWCB.#N61=0_6B8# \J(,QFS0+4%*DT!KDZT!:MLF-=GE%Z+G)B )*H7,
MD.'CT7-!]XWR#X+[Q+I"U6#N"90]+H(]:I7$DFC"+UE12PN+0JZ47L9((*MF
MA3?M^H&X3%-C,[SG*')K*J"E5(>-PA?6-,LB+,Y-8X%\CSF!5V86AV4G\)X$
M5J-#TM!3RKO=7M@&*1K'\?!=RZDB7YB,05L(O!^(3U!0^T_+]B+@LHY?G^WY
MW>]>2TP7$4J/A"!W(5^N63CX"*V8?6ZBI>/V9?!46OO $<<N"'.7FJ7&"/1D
MEBG.%<9GZY,=LAAD/$QM[5U,;NB?5AS0R YB@V'%_R$6KI!VVW4[DA+>HM4U
MHL+(E,8YB!GZ9@BO:2'UDD(,[:S^WY9N^7<:4%64*2 @C_05AR%'6:^IT2B[
M3=Z20>!LHXV0)1I&1]5KA:!Q).1**N@AE FE8#=U4,1'(Q-#Q\F+10DED$M+
M%.K:J@,[ X#*Q5[/9X;8N8<,.&5#T;;,0FNBWBA:EV+6*79@N=<L-TCNV^YK
MNZ?7*9^,PXQWL:?-UG'2QA5B91F.^6W1>3SQ$ ,98]C.<HP#HX>-!VGEX@&H
M-C8.8BR$-YYENN+6WRO4_MRRL#PYLUMJ7%I6F%!.'@M^N!&HV$&N2((:9=!;
M7L%)_3:;>ZWZ.)<#<=U431E:X+'8%6B272JR90FHHVDR/9EQ) F3*YL >C2>
MG(3H6&. U(-*$6&?"Z>NR.)#V 4VAZ8D+&T[UFV"#.IWQTF+$J.S;8*8[^/
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M/@ZH;G=%:UA5^_G<*(O3[H\EKE?0S@&_YTK9G>$"] M[^1M02P,$%     @
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ML:Z<DB4\&&ZKHA#F[0J4WDPZ_<YVXU$N<T<;P72\$DMX O=M]6#P+6A1,EE
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MAQ<2O\SQ!@B&!/!\H;7;OI"!]DXY_0M02P,$%     @ 4CZO5O'R-%:G @
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M^Y.13U3=9^J%D5M7VVMIL%.X:8&M&90UP/-<2K-?V !MLT_^ %!+ P04
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MZ8(?AC6]J*B= ZU7BO9MFK@$\QN]^0=02P,$%     @ 4CZO5EATP.5= @
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M_BZK&JW]IA[@,<N_-X=]_7]02P,$%     @ 4CZO5J--AK<U!0  ZBT  !D
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ML2+26".:&=C86&]4PW*3Q2<M<9>AGPZ?M(@6YQ,,1$RF(L/+H:B)[QEYM1'
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M-I4/;/<;K1_(*_ BEHKR%^WJLM8 15LA658'JQ9D25[]D^>:B%: PND/P'4
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MT8B(=:]$H)ZY1KML9[,+?)C/0!TS%)K.?..9;;-I/LU\_)K.*J^PS1,I>I4
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M88A4>08O!T;FQ;EW)@V>HHO;)7ZW@+(+\/E<2K,=6 /UE]#T+U!+ P04
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M3TD4)8D; <SM((HP!)Y&',$<@ <,B2+S'MQ['P6;]U2P_0_M^#=02P,$%
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( %(^KU9Y:()B[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( %(^KU:97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 4CZO
M5G8E*GCJ!0  Q!\  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( %(^KU8&R#L5)P8  #T9   8
M      " @2T.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" !2/J]6W7DVW&0$  !?$P  &               @(&*%   >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 4CZO5DS/?&)X!   A1   !@
M             ("!)!D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( %(^KU9$1$QIX@4  '@6   8              " @=(=  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !2/J]6Y3^O4]0'  !M
M/   &               @('J(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ 4CZO5A^TIG+]!P  ZA(  !@              ("!]"L
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( %(^KU:U;>R[
M;04  .D,   8              " @2<T  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " !2/J]6MU**)) &  "G$P  &
M@('*.0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 4CZO
M5@8EXL__!0  -A0  !D              ("!D$   'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " !2/J]6JZQ@4@@(   [%0  &0
M        @('&1@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( %(^KU8G02_]P@(  $D&   9              " @05/  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 4CZO5O1-#ED1!   8@H
M !D              ("!_E$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " !2/J]6$*DLYLL#  #;"   &0              @(%&5@
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( %(^KU:<>A@,
M= @  ((<   9              " @4A:  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ 4CZO5JHI])@, P  S 8  !D
M ("!\V(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !2
M/J]68D>5I!H#  "H!@  &0              @($V9@  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( %(^KU:!G G1_04  "\.   9
M          " @8=I  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#
M%     @ 4CZO5@A2\+2@ @  O 4  !D              ("!NV\  'AL+W=O
M<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !2/J]6&-*[&:8%  !V
M&0  &0              @(&2<@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
M;%!+ 0(4 Q0    ( %(^KU;4QMK5; 0  %\*   9              " @6]X
M  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ 4CZO5O'R
M-%:G @  ^ 4  !D              ("!$GT  'AL+W=O<FMS:&5E=',O<VAE
M970R,BYX;6Q02P$"% ,4    " !2/J]6,'&SV&P#  "O!P  &0
M    @('P?P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M %(^KU98=,#E70(  #X%   9              " @9.#  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ 4CZO5G&^/W#+ @  #PH  !D
M             ("!)X8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " !2/J]6@V_OO*H"  "D!P  &0              @($IB0  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( %(^KU:A,;;P10T
M #:Y   9              " @0J,  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ 4CZO5J--AK<U!0  ZBT  !D              ("!
MAID  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !2/J]6
MU<R]LB('  !%/P  &0              @('RG@  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %(^KU8!"Y@JW ,  !T3   9
M      " @4NF  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ 4CZO5@UY+'<' P  :@L  !D              ("!7JH  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !2/J]6N/"G>!@$  "H#@
M&0              @(&<K0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( %(^KU;1O^'U[0(  $$(   9              " @>NQ  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 4CZO5L[JB-1J
M!@  <2H  !D              ("!#[4  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " !2/J]6H \8#'X#   5#0  &0
M@(&PNP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( %(^
MKU:+P?3A^0,  )L4   9              " @66_  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ 4CZO5G75<+2F P  AA   !D
M         ("!E<,  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    " !2/J]6D1V%P9T+   1@0  &0              @(%RQP  >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( %(^KU8/.&_N&@(  ,8$
M   9              " @4;3  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ 4CZO5JZ8SL18!0  @QX  !D              ("!E]4
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !2/J]6?N.,
M3L0$  "P(0  &0              @($FVP  >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( %(^KU;O@1MR4 ,  *X5   -
M  "  2'@  !X;"]S='EL97,N>&UL4$L! A0#%     @ 4CZO5I>*NQS
M$P(   L              ( !G.,  %]R96QS+RYR96QS4$L! A0#%     @
M4CZO5IC,**>G P  K1L   \              ( !A>0  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( %(^KU8I78B@DP$  .(8   :              "
M 5GH  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %(^
MKU:(C*DWI0$  "\9   3              "  23J  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     Q #$ 3@T  /KK      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>183</ContextCount>
  <ElementCount>227</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Basis of Presentation and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidity</Role>
      <ShortName>Basis of Presentation and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Accrued Expenses and Other</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/AccruedExpensesAndOther</Role>
      <ShortName>Accrued Expenses and Other</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Convertible Notes Payable - Related Party</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty</Role>
      <ShortName>Convertible Notes Payable - Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Convertible Line of Credit - Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty</Role>
      <ShortName>Convertible Line of Credit - Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - Galectin Sciences LLC</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/GalectinSciencesLlc</Role>
      <ShortName>Galectin Sciences LLC</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>080200 - Disclosure - Accrued Expenses and Other (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/AccruedExpensesAndOtherTables</Role>
      <ShortName>Accrued Expenses and Other (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/AccruedExpensesAndOther</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>080400 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/StockbasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080600 - Disclosure - Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/CommonStockWarrants</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080700 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/LossPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>081100 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>090100 - Disclosure - Basis of Presentation and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails</Role>
      <ShortName>Basis of Presentation and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Accrued Expenses and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails</Role>
      <ShortName>Accrued Expenses and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/AccruedExpensesAndOtherTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Convertible Notes Payable - Related Party (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails</Role>
      <ShortName>Convertible Notes Payable - Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>090402 - Disclosure - Fair Value of Financial Instruments, Key Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails</Role>
      <ShortName>Fair Value of Financial Instruments, Key Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>090404 - Disclosure - Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090502 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation, Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090504 - Disclosure - Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090506 - Disclosure - Stock-Based Compensation, Restricted Stock Grants and Employment Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails</Role>
      <ShortName>Stock-Based Compensation, Restricted Stock Grants and Employment Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CommonStockWarrantsDetails</Role>
      <ShortName>Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/CommonStockWarrantsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/LossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/LossPerShareTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/CommonStockWarrantsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Convertible Line of Credit - Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails</Role>
      <ShortName>Convertible Line of Credit - Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>091100 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/LeasesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="brhc20051581_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>091200 - Disclosure - Galectin Sciences LLC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/GalectinSciencesLlcDetails</Role>
      <ShortName>Galectin Sciences LLC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/GalectinSciencesLlc</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept InterestExpenseRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. brhc20051581_10q.htm 7588, 7636</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: galt:FreeRentPeriod -  brhc20051581_10q.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="brhc20051581_10q.htm">brhc20051581_10q.htm</File>
    <File>brhc20051581_ex31-1.htm</File>
    <File>brhc20051581_ex31-2.htm</File>
    <File>brhc20051581_ex32-1.htm</File>
    <File>brhc20051581_ex32-2.htm</File>
    <File>galt-20230331.xsd</File>
    <File>galt-20230331_cal.xml</File>
    <File>galt-20230331_def.xml</File>
    <File>galt-20230331_lab.xml</File>
    <File>galt-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="465">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc20051581_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 465,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 183,
   "dts": {
    "calculationLink": {
     "local": [
      "galt-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "galt-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "brhc20051581_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "galt-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "galt-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "galt-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 392,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 5,
    "http://galectintherapeutics.com/20230331": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 11
   },
   "keyCustom": 36,
   "keyStandard": 191,
   "memberCustom": 13,
   "memberStandard": 31,
   "nsprefix": "galt",
   "nsuri": "http://galectintherapeutics.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://galectintherapeutics.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060400 - Disclosure - Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://galectintherapeutics.com/role/FairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060500 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://galectintherapeutics.com/role/StockbasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "galt:CommonStockWarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060600 - Disclosure - Common Stock Warrants",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://galectintherapeutics.com/role/CommonStockWarrants",
     "shortName": "Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "galt:CommonStockWarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060700 - Disclosure - Loss Per Share",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://galectintherapeutics.com/role/LossPerShare",
     "shortName": "Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060800 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://galectintherapeutics.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331_LongtermDebtTypeAxis_LineOfCreditMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060900 - Disclosure - Convertible Line of Credit - Related Party",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty",
     "shortName": "Convertible Line of Credit - Related Party",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331_LongtermDebtTypeAxis_LineOfCreditMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061000 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://galectintherapeutics.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061100 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://galectintherapeutics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061200 - Disclosure - Galectin Sciences LLC",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://galectintherapeutics.com/role/GalectinSciencesLlc",
     "shortName": "Galectin Sciences LLC",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080200 - Disclosure - Accrued Expenses and Other (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://galectintherapeutics.com/role/AccruedExpensesAndOtherTables",
     "shortName": "Accrued Expenses and Other (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080400 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080500 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080600 - Disclosure - Common Stock Warrants (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://galectintherapeutics.com/role/CommonStockWarrantsTables",
     "shortName": "Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080700 - Disclosure - Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://galectintherapeutics.com/role/LossPerShareTables",
     "shortName": "Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081100 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://galectintherapeutics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090100 - Disclosure - Basis of Presentation and Liquidity (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails",
     "shortName": "Basis of Presentation and Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090200 - Disclosure - Accrued Expenses and Other (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails",
     "shortName": "Accrued Expenses and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090300 - Disclosure - Convertible Notes Payable - Related Party (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails",
     "shortName": "Convertible Notes Payable - Related Party (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090400 - Disclosure - Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
     "shortName": "Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AssetsFairValueDisclosure",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090402 - Disclosure - Fair Value of Financial Instruments, Key Assumptions (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
     "shortName": "Fair Value of Financial Instruments, Key Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquitySharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquitySharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090404 - Disclosure - Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
     "shortName": "Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090500 - Disclosure - Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090502 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation, Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "U005",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090504 - Disclosure - Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
     "shortName": "Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090506 - Disclosure - Stock-Based Compensation, Restricted Stock Grants and Employment Agreement (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails",
     "shortName": "Stock-Based Compensation, Restricted Stock Grants and Employment Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230131_AwardTypeAxis_RestrictedStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090600 - Disclosure - Common Stock Warrants (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://galectintherapeutics.com/role/CommonStockWarrantsDetails",
     "shortName": "Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090700 - Disclosure - Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://galectintherapeutics.com/role/LossPerShareDetails",
     "shortName": "Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090800 - Disclosure - Common Stock (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://galectintherapeutics.com/role/CommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230331_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember",
      "decimals": "-5",
      "lang": null,
      "name": "galt:AggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090900 - Disclosure - Convertible Line of Credit - Related Party (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
     "shortName": "Convertible Line of Credit - Related Party (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20220725to20220725_FinancialInstrumentAxis_WarrantMember",
      "decimals": "0",
      "lang": null,
      "name": "galt:IssuanceOfWarrantsValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "galt:ContractCancelationNoticePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091000 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "galt:ContractCancelationNoticePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "galt:NumberOfOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U006",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091100 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://galectintherapeutics.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "galt:NumberOfOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U006",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091200 - Disclosure - Galectin Sciences LLC (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails",
     "shortName": "Galectin Sciences LLC (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20140101to20140131_OwnershipAxis_GalectinSciencesLLCMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060100 - Disclosure - Basis of Presentation and Liquidity",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidity",
     "shortName": "Basis of Presentation and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060200 - Disclosure - Accrued Expenses and Other",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://galectintherapeutics.com/role/AccruedExpensesAndOther",
     "shortName": "Accrued Expenses and Other",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331_LongtermDebtTypeAxis_LoansPayableMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060300 - Disclosure - Convertible Notes Payable - Related Party",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty",
     "shortName": "Convertible Notes Payable - Related Party",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20051581_10q.htm",
      "contextRef": "c20230101to20230331_LongtermDebtTypeAxis_LoansPayableMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs and other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research and Development Costs and Other Current",
        "terseLabel": "Accrued research and development costs and other"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsAndOtherCurrent",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_AggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate offering price of common stock which can be sold from time to time through the sales agent.",
        "label": "Aggregate Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "AggregateOfferingPrice",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_AnnualInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent interest rate per annum for funds borrowed, under the debt agreement.",
        "label": "Annual Interest Rate",
        "terseLabel": "Additional interest rate per annum from issuance date to maturity date period"
       }
      }
     },
     "localname": "AnnualInterestRate",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "galt_AprilConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of debt instrument.",
        "label": "April Convertible Promissory Note [Member]",
        "terseLabel": "April 2021 Note [Member]"
       }
      }
     },
     "localname": "AprilConvertiblePromissoryNoteMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_BasisOfPresentationsAndLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentations and Liquidity [Abstract]",
        "terseLabel": "Basis of Presentation and Liquidity [Abstract]"
       }
      }
     },
     "localname": "BasisOfPresentationsAndLiquidityAbstract",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as borrowing and accrued interest under line of credit related party excluding current portion.",
        "label": "Borrowing and Accrued Interest Under Line of Credit, Net of Debt Discount, Related Party Noncurrent",
        "terseLabel": "Borrowing and accrued interest under convertible line of credit, net of debt discount - related party (Note 9)"
       }
      }
     },
     "localname": "BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_CapitalContributionExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital contribution expense.",
        "label": "Capital Contribution Expense",
        "terseLabel": "Contribution for expenses"
       }
      }
     },
     "localname": "CapitalContributionExpense",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of additional warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Additional Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase additional common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of exercise price per share or per unit of warrants equal to common stock.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Percentage Equal to Common Stock",
        "terseLabel": "Percentage of warrants equal to the closing price of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "galt_CommissionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission rate to be paid to sales agent in gross proceeds from the sale of common stock.",
        "label": "Commission Rate",
        "terseLabel": "Percentage of commission rate to be paid to sales agent"
       }
      }
     },
     "localname": "CommissionRate",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of common stock purchase warrants issued in connection with related party line of credit in noncash financing activities.",
        "label": "Common Stock Purchase Warrants Issued in Connection with Related Party Line of Credit",
        "terseLabel": "Common stock purchase warrants issued in connection with related party line of credit"
       }
      }
     },
     "localname": "CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_CommonStockWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants [Abstract]"
       }
      }
     },
     "localname": "CommonStockWarrantsAbstract",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "xbrltype": "stringItemType"
    },
    "galt_CommonStockWarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Equity warrants are instruments that bestow upon the holder of the instrument the right to buy a particular stock at a predetermined price within a stipulated time frame. ... This payment is to be adjusted against the final payment that needs to be paid in case the warrants are exercised.",
        "label": "Common Stock Warrants Disclosure [Text Block]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsDisclosureTextBlock",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "galt_ContingentInterestAprilNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The derivative liability of contingent interest April Note.",
        "label": "Contingent Interest, April Note [Member]",
        "terseLabel": "April Note [Member]"
       }
      }
     },
     "localname": "ContingentInterestAprilNoteMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_ContingentInterestDecemberNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The derivative liability of contingent interest December Note.",
        "label": "Contingent Interest, December Note [Member]",
        "terseLabel": "December Note [Member]"
       }
      }
     },
     "localname": "ContingentInterestDecemberNoteMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_ContingentInterestSeptemberNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The derivative liability of contingent interest September Note.",
        "label": "Contingent Interest, September Note [Member]",
        "terseLabel": "September Note [Member]"
       }
      }
     },
     "localname": "ContingentInterestSeptemberNoteMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_ContractCancelationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract cancelation notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Contract Cancelation Notice Period",
        "terseLabel": "Contract cancelation notice period"
       }
      }
     },
     "localname": "ContractCancelationNoticePeriod",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as convertible notes payable and accrued interest, net of debt discount of related party excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Note Payable and Accrued Interest Net of Debt Discount - Related Party Non-Current",
        "terseLabel": "Convertible notes payable and accrued interest, net of discounts - related party (Note 3)"
       }
      }
     },
     "localname": "ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_ConvertibleNotesPayableRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable, Related Party [Abstract]",
        "terseLabel": "Convertible Notes Payable - Related Party [Abstract]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableRelatedPartyAbstract",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "galt_ConvertiblePreferredStockDividends": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid convertible preferred stock dividends declared with the form of settlement in cash.",
        "label": "Convertible Preferred Stock, Dividends",
        "terseLabel": "Series A 12% convertible preferred stock dividend"
       }
      }
     },
     "localname": "ConvertiblePreferredStockDividends",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_ConvertiblePreferredStockDividendsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of Convertible preferred stock issued as dividends during the period. Excludes stock splits.",
        "label": "Convertible Preferred Stock Dividends, Shares",
        "terseLabel": "Series A 12% convertible preferred stock dividend (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockDividendsShares",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "galt_DebtInstrumentAccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued, but unpaid interest on the debt instrument.",
        "label": "Debt Instrument, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentAccruedInterest",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_DecemberConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of debt instrument.",
        "label": "December Convertible Promissory Note [Member]",
        "terseLabel": "December 2021 Note [Member]"
       }
      }
     },
     "localname": "DecemberConvertiblePromissoryNoteMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underlying the outstanding whole number of DSUs credited individuals during period.",
        "label": "Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period One",
        "terseLabel": "Percentage of DSUs shall be credited on March 1, 2023"
       }
      }
     },
     "localname": "DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underlying the outstanding whole number of DSUs credited individuals during period.",
        "label": "Deferred Compensation Arrangement Percentage of Deferred Share Units Shall be Issued Period Three",
        "terseLabel": "Percentage of DSUs shall be credited on September 1, 2028"
       }
      }
     },
     "localname": "DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underlying the outstanding whole number of DSUs credited individuals during period.",
        "label": "Deferred Compensation Arrangement Percentage of Deferred Share Units Shall be Issued Period Two",
        "terseLabel": "Percentage of DSUs shall be credited on March 1, 2024"
       }
      }
     },
     "localname": "DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferred compensation arrangement with individual cash award granted paid in cash percentage.",
        "label": "Deferred Compensation Arrangement With Individual Cash Award Granted Paid in Cash Percent",
        "terseLabel": "Percentage of base salary paid in cash"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferred compensation arrangement with individual cash award granted paid in deferred stock units percentage.",
        "label": "Deferred Compensation Arrangement With Individual Cash Award Granted Paid in Deferred Stock Units Percent",
        "terseLabel": "Percentage of base salary paid in deferred stock units"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "galt_FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of the contingent interest derivative liability related to related party convertible note payable.",
        "label": "Fair Value Of Derivative Related To Related Party Convertible Note Payable",
        "terseLabel": "Fair value of derivative related to related party convertible note payable"
       }
      }
     },
     "localname": "FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_FreeRentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free rent period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Free Rent Period",
        "terseLabel": "Free rent period"
       }
      }
     },
     "localname": "FreeRentPeriod",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "galt_GalectinSciencesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity.",
        "label": "Galectin Sciences, LLC [Member]",
        "terseLabel": "Galectin Sciences, LLC [Member]"
       }
      }
     },
     "localname": "GalectinSciencesLLCMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_IssuanceOfWarrantsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of issuance of warrants.",
        "label": "Issuance of Warrants Value",
        "terseLabel": "Warrants issuance value"
       }
      }
     },
     "localname": "IssuanceOfWarrantsValue",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_LineOfCreditRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit, Related Party [Abstract]",
        "terseLabel": "Convertible Line of Credit - Related Party [Abstract]"
       }
      }
     },
     "localname": "LineOfCreditRelatedPartyAbstract",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "galt_NumberOfOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating leases during period.",
        "label": "Number of Operating Leases",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "localname": "NumberOfOperatingLeases",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "galt_NumberOfPromissoryNotesEvidencedByLoansAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of promissory notes evidenced by loans agreement.",
        "label": "Number of Promissory Notes Evidenced by Loans Agreement",
        "terseLabel": "Number of promissory notes evidenced by loans agreement"
       }
      }
     },
     "localname": "NumberOfPromissoryNotesEvidencedByLoansAgreement",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "galt_QuarterlyInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent interest rate per quarter for funds borrowed, under the debt agreement.",
        "label": "Quarterly Interest Rate",
        "terseLabel": "Additional interest rate per quarter"
       }
      }
     },
     "localname": "QuarterlyInterestRate",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount reclassified from accrued compensation to excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Reclassification Of Accrued Bonus To Additional Paid In Capital",
        "terseLabel": "Reclassification of accrued bonus to additional paid in capital"
       }
      }
     },
     "localname": "ReclassificationOfAccruedBonusToAdditionalPaidInCapital",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_RestrictedStockGrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Grants [Abstract]",
        "terseLabel": "Restricted Stock Grants [Abstract]"
       }
      }
     },
     "localname": "RestrictedStockGrantsAbstract",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "galt_SBHSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "SBH Sciences, Inc. [Member]",
        "terseLabel": "SBH [Member]"
       }
      }
     },
     "localname": "SBHSciencesIncMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_SeptemberConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A type of debt instrument.",
        "label": "September Convertible Promissory Note [Member]",
        "terseLabel": "September 2021 Note [Member]"
       }
      }
     },
     "localname": "SeptemberConvertiblePromissoryNoteMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_SeriesAAndSeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A and series C preferred stock or outstanding series A and series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A and Series C Preferred Stock [Member]",
        "terseLabel": "Series A and Series C Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAAndSeriesCPreferredStockMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price",
        "negatedLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based Compensation Arrangement by Share based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Forfeitures In Period Weighted Average Exercise Price",
        "negatedLabel": "Forfeited/cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "galt_TemporaryEquityDividends": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid temporary equity dividends declared with the form of settlement in cash.",
        "label": "Temporary Equity Dividends",
        "negatedLabel": "Series C super dividend redeemable convertible preferred stock dividend"
       }
      }
     },
     "localname": "TemporaryEquityDividends",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_TemporaryEquityDividendsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock issued as dividends for temporary equity during the period.",
        "label": "Temporary Equity Dividends, Shares",
        "terseLabel": "Series C super dividend redeemable convertible preferred stock dividend (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityDividendsShares",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "galt_TwoThousandTwentyMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with a sales agent under which the Company may issue and sell shares of its common stock.",
        "label": "Two Thousand Twenty Market Agreement [Member]",
        "terseLabel": "2020 Market Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyMarketAgreementMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_UndesignatedCapitalStockParValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of undesignated capital stock.",
        "label": "Undesignated Capital Stock Par Value",
        "terseLabel": "Undesignated stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "UndesignatedCapitalStockParValue",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "galt_UndesignatedCapitalStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of undesignated capital stock permitted to be issued by an entity's charter and bylaws.",
        "label": "Undesignated Capital Stock, Shares Authorized",
        "terseLabel": "Undesignated stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "UndesignatedCapitalStockSharesAuthorized",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "galt_UndesignatedCapitalStockSharesDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of undesignated capital stock which are designated as common stock or preferred stock by board of directors.",
        "label": "Undesignated Capital Stock Shares Designated",
        "terseLabel": "Undesignated stock, shares designated (in shares)"
       }
      }
     },
     "localname": "UndesignatedCapitalStockSharesDesignated",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "galt_UndesignatedCapitalStockValue": {
     "auth_ref": [],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of shares which are not designated as common stock or preferred stock.",
        "label": "Undesignated Capital Stock Value",
        "terseLabel": "Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at March 31, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "UndesignatedCapitalStockValue",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "galt_UnsecuredConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An unsecured convertible promissory note is a debt obligation in which a company borrows money from an investor in exchange for a promise of repayment and an option to convert the outstanding principal into equity of the company upon some triggering event. Notes have a maturity date and bear interest.",
        "label": "Unsecured Convertible Promissory Note [Member]",
        "terseLabel": "Unsecured Convertible Promissory Note [Member]"
       }
      }
     },
     "localname": "UnsecuredConvertiblePromissoryNoteMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_WarrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant One [Member]",
        "terseLabel": "Warrant One [Member]"
       }
      }
     },
     "localname": "WarrantOneMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "galt_WarrantTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant Two [Member]",
        "terseLabel": "Warrant Two [Member]"
       }
      }
     },
     "localname": "WarrantTwoMember",
     "nsuri": "http://galectintherapeutics.com/20230331",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Richard E. Uihlein [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r233",
      "r261",
      "r467",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r285",
      "r428",
      "r449",
      "r463",
      "r464",
      "r479",
      "r483",
      "r488",
      "r522",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r285",
      "r428",
      "r449",
      "r463",
      "r464",
      "r479",
      "r483",
      "r488",
      "r522",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r277",
      "r285",
      "r313",
      "r314",
      "r315",
      "r404",
      "r428",
      "r449",
      "r463",
      "r464",
      "r479",
      "r483",
      "r488",
      "r518",
      "r522",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r277",
      "r285",
      "r313",
      "r314",
      "r315",
      "r404",
      "r428",
      "r449",
      "r463",
      "r464",
      "r479",
      "r483",
      "r488",
      "r518",
      "r522",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r144",
      "r145",
      "r233",
      "r261",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r286",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r163",
      "r286",
      "r496",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r163",
      "r286",
      "r496",
      "r497",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r513",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesAndOther"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r487"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails",
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Legal and accounting fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r487"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r507",
      "r508",
      "r509",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Reclassification of accrued compensation to additional paid in capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r79",
      "r80",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r50",
      "r57",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Common stock purchase warrants issued in connection with related party line of credit"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Amortized expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r24",
      "r252",
      "r377",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Amount excluded from calculation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r105",
      "r124",
      "r143",
      "r184",
      "r186",
      "r188",
      "r194",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r333",
      "r335",
      "r359",
      "r487",
      "r520",
      "r521",
      "r536"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r120",
      "r128",
      "r143",
      "r194",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r333",
      "r335",
      "r359",
      "r487",
      "r520",
      "r521",
      "r536"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "verboseLabel": "Basis of Presentation and Liquidity"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r37",
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Noncash right to use lease asset"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r122",
      "r466"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails",
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r31",
      "r36",
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r31",
      "r91"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Amount expanded in cash",
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NONCASH FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r143",
      "r167",
      "r168",
      "r171",
      "r173",
      "r180",
      "r181",
      "r194",
      "r221",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r259",
      "r260",
      "r263",
      "r267",
      "r274",
      "r359",
      "r465",
      "r495",
      "r504",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails",
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price of warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Warrants to purchase common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r100",
      "r108"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r48",
      "r215",
      "r216",
      "r462",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsShares": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.",
        "label": "Common stock issued for dividends (in shares)"
       }
      }
     },
     "localname": "CommonStockDividendsShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r507",
      "r508",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common Stock [Abstract]"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, issued (in shares)",
        "terseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails",
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Shares unissued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r487"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value; 150,000,000 shares authorized at March 31, 2023 and December 31, 2022, 59,582,253 and 59,426,005 issued and outstanding at March 31, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r0",
      "r97",
      "r104",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Note Payable [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r259",
      "r260",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r37",
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Convertible note principal"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r52",
      "r140",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r246",
      "r253",
      "r254",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Convertible Line of Credit - Related Party",
        "verboseLabel": "Convertible Notes Payable - Related Party"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r97",
      "r98",
      "r104",
      "r146",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r378",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r51",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r93",
      "r95",
      "r230",
      "r378",
      "r475",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt financing arrangement"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r17",
      "r93",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Interest rate on short term loans"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r17",
      "r93",
      "r257",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate",
        "verboseLabel": "Short term borrowing effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Additional short term borrowing interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r17",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Interest rate compounded annually",
        "terseLabel": "Short term borrowing interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r129",
      "r474",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Maturity date",
        "terseLabel": "Borrowings repayment due date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r18",
      "r146",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r378",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r18",
      "r58",
      "r61",
      "r62",
      "r63",
      "r92",
      "r93",
      "r95",
      "r103",
      "r146",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r378",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable - Related Party [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": {
     "auth_ref": [
      "r67",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.",
        "label": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]"
       }
      }
     },
     "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredBonusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An contractual arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a bonus, as defined in the agreement, of the entity or portion thereof. Employer contributions may be discretionary or may be based on a fixed formula related to individual, group and entity-wide performance goals, compensation, or other factors. It is a form of incentive compensation to employees in addition to their regular salary and profit sharing.",
        "label": "Deferred Bonus [Member]"
       }
      }
     },
     "localname": "DeferredBonusMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).",
        "label": "Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": {
     "auth_ref": [
      "r67",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.",
        "label": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share price that the individual must pay to acquire shares under the deferred compensation arrangement.",
        "label": "Common Stock Weighted average Grant Date fair Value (in dollars per share)"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement.",
        "label": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r82",
      "r83",
      "r85",
      "r86",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r84",
      "r526"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Change in fair value of derivative"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative liabilities (Note 4)",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Fair value of derivative liability",
        "verboseLabel": "Derivative Liability - Contingent Interest"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability, measurement input"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r290",
      "r318",
      "r319",
      "r321",
      "r325",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r137",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r164",
      "r167",
      "r171",
      "r172",
      "r173",
      "r177",
      "r348",
      "r349",
      "r447",
      "r448",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r137",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r167",
      "r171",
      "r172",
      "r173",
      "r177",
      "r348",
      "r349",
      "r447",
      "r448",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Unrecognized compensation cost, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r57",
      "r116",
      "r133",
      "r134",
      "r135",
      "r147",
      "r148",
      "r149",
      "r152",
      "r160",
      "r162",
      "r179",
      "r198",
      "r276",
      "r322",
      "r323",
      "r324",
      "r328",
      "r329",
      "r347",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r395",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r34",
      "r53"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair Value Adjustment",
        "verboseLabel": "Change in fair value of derivative liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r351",
      "r352",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Key Assumptions Used in Model at Inception"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r244",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r352",
      "r401",
      "r402",
      "r403",
      "r475",
      "r476",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r351",
      "r352",
      "r354",
      "r355",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).",
        "label": "Fair Value, Inputs, Level 1, 2 and 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel12And3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r244",
      "r278",
      "r283",
      "r352",
      "r401",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r244",
      "r278",
      "r283",
      "r352",
      "r402",
      "r475",
      "r476",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r244",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r352",
      "r403",
      "r475",
      "r476",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Roll Forward of Derivative Liability [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Roll Forward of Derivative Liability - Contingent Interest"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r244",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r401",
      "r402",
      "r403",
      "r475",
      "r476",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r356",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities Measured at Fair Value [Abstract]"
       }
      }
     },
     "localname": "FairValueNetAssetLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r255",
      "r272",
      "r337",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r473",
      "r514",
      "r515",
      "r516",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r430",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r46",
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "IPR&amp;D [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Accrued interest on convertible debt - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r94",
      "r102",
      "r136",
      "r183",
      "r376"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r28",
      "r250",
      "r258",
      "r477",
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Accrued interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense classified as other.",
        "label": "Interest Expense, Other",
        "terseLabel": "Additional interest expense"
       }
      }
     },
     "localname": "InterestExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Amortization of interest expense"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r26",
      "r182"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments in an entity not consolidated. Includes, but is not limited to, investments in an entity that is affiliated with the reporting entity by means of direct or indirect ownership, an entity in which the reporting entity shares control of the entity with another party or group, an entity which the company has significant influence, but does not have control and subsidiaries that are not required to be consolidated and are accounted for using the equity or cost method.",
        "label": "Investments in Affiliates, Subsidiaries, Associates, and Joint Ventures, Fair Value Disclosure",
        "terseLabel": "Estimated fair value of asset contributed to joint venture"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Galectin Sciences LLC [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Investments in and Advances to Affiliates [Line Items]"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in and Advances to Affiliates, Schedule of Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.",
        "label": "Galectin Sciences LLC"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Commitments [Abstract]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Discount rate on present value of lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Maturity of Operating Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://galectintherapeutics.com/role/LeasesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/LeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/LeasesDetailsCalc2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r143",
      "r194",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r334",
      "r335",
      "r336",
      "r359",
      "r471",
      "r520",
      "r536",
      "r537"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r99",
      "r107",
      "r487",
      "r506",
      "r517",
      "r531"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r121",
      "r143",
      "r194",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r334",
      "r335",
      "r336",
      "r359",
      "r487",
      "r520",
      "r536",
      "r537"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Line of Credit - Related Party [Abstract]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of credit",
        "terseLabel": "Line of credit"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r13",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Convertible Line of Credit - Related Party [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Convertible Notes Payable - Related Party [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r18",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputConversionPriceMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using price per share at which convertible share can be converted into common stock.",
        "label": "Conversion Price of Conversion Feature [Member]"
       }
      }
     },
     "localname": "MeasurementInputConversionPriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Credit Adjusted Discount Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Stock Price [Member]"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Equity ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r31",
      "r32",
      "r35"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r35",
      "r101",
      "r109",
      "r119",
      "r131",
      "r132",
      "r135",
      "r143",
      "r151",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r169",
      "r184",
      "r185",
      "r187",
      "r189",
      "r194",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r349",
      "r359",
      "r472",
      "r520"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r164",
      "r165",
      "r170",
      "r173",
      "r184",
      "r185",
      "r187",
      "r189",
      "r472"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss applicable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r42",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r157",
      "r163",
      "r177",
      "r190",
      "r191",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r374",
      "r375",
      "r379",
      "r380",
      "r381",
      "r382",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r431",
      "r432",
      "r433",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r184",
      "r185",
      "r187",
      "r189",
      "r472"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Total operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r387",
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity of Operating Lease [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/LeasesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current lease liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesAndOtherDetails",
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Long term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right to use lease asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of right to use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Liquidity [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Income tax payment withholding"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Initial cash investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r43",
      "r512"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedLabel": "Preferred stock dividends"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r141",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Series A 12% convertible preferred stock, liquidation value"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Series A 12% convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Series A 12% convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Series A 12% convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r487"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,260,000 issued and outstanding at March 31, 2023 and December 31, 2022, liquidation value $1,260,500 at March 31, 2023"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r501"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r30",
      "r505"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Net proceeds from convertible line of credit - related party",
        "verboseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r284",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r284",
      "r396",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/BasisOfPresentationAndLiquidityDetails",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Convertible note payable repayment"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r81",
      "r113",
      "r544"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r64",
      "r106",
      "r456",
      "r461",
      "r487"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r116",
      "r147",
      "r148",
      "r149",
      "r152",
      "r160",
      "r162",
      "r198",
      "r322",
      "r323",
      "r324",
      "r328",
      "r329",
      "r347",
      "r452",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesAndOtherTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r75",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Components of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r287",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r70",
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Weighted Average Assumptions Used to Determine Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r125",
      "r126",
      "r127",
      "r180",
      "r259",
      "r260",
      "r261",
      "r263",
      "r267",
      "r272",
      "r274",
      "r479",
      "r495",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r65",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Common Stock Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r499",
      "r500",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A 12% Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited/cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Common Stock Warrants shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted Average Assumptions for Stock Options Granted [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend rate",
        "terseLabel": "Expected dividend"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility of the underlying stock",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited/cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stock Option Activity [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at beginning of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Shares issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Forfeited/cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of the options",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Unvested options (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Shares withheld to cover income tax withholding (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockGrantsAndEmploymentAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r143",
      "r167",
      "r168",
      "r171",
      "r173",
      "r180",
      "r181",
      "r194",
      "r221",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r259",
      "r260",
      "r263",
      "r267",
      "r274",
      "r359",
      "r465",
      "r495",
      "r504",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails",
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r57",
      "r116",
      "r133",
      "r134",
      "r135",
      "r147",
      "r148",
      "r149",
      "r152",
      "r160",
      "r162",
      "r179",
      "r198",
      "r276",
      "r322",
      "r323",
      "r324",
      "r328",
      "r329",
      "r347",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r395",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r179",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Payment of preferred stock dividends in common stock"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r4",
      "r5",
      "r57",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock-based compensation expense (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r57",
      "r64",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r45",
      "r487",
      "r506",
      "r517",
      "r531"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r142",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r276",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity.",
        "label": "Series C 6% super dividend redeemable convertible preferred stock, redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAggregateAmountOfRedemptionRequirement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r221",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229"
     ],
     "calculation": {
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Series C super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 shares issued and outstanding at March 31, 2023 and December 31, 2022, redemption value: $8,256,000, liquidation value: $1,760,000 at March 31, 2023",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Series C 6% super dividend redeemable convertible preferred stock liquidation value"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Series C 6% super dividend redeemable convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r192",
      "r193",
      "r255",
      "r272",
      "r337",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r514",
      "r515",
      "r516",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueAndInputDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key Assumptions [Abstract]"
       }
      }
     },
     "localname": "ValuationTechniqueAndInputDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants expiry date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Weighted average expiration term of warrants outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r166",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r164",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galectintherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r491": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r492": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r493": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r494": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001140361-23-024499-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-024499-xbrl.zip
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MCP$-YMN*(-JDK>^GY_%8!]K:NSHY_L6Z1Q^2S/$Q=W0R=^G#76QO;AGM:#Q
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M"2S%P+5.-(_EG1FB4_U=]Z('>\G^(&"%_NVAW[JZ_%L.V$\,K#,/M!RPUW-
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MY)IC2A@KBT%![1GT:9!:"JT_A:9/TAIQ:!!'][\8-NA/M4%I&<79<1@?'&.
M&M(-C34X9A9G^,_S?Q=<M-I'8_:RC3JV(%JW>2O=?^,&SRO@J*D[$FU=(&:W
M X2)#3P[9Z&992ZB=XNGYFX6.+;7F>]LY/R)6B%!QBP-I(\5Q4Q"X4OSBA M
MN8# DRMX>R!;CO<9;%V^NKI\-9%$_DYHX]#<$IA?ZV]A8IDWM>NO.:@;<X%Y
M@!*L",2<://*P]B'+N608$E6@/IOG<_=D]OS"^?V]^YUYZK[]?;\Y,8YOSAY
MM\QPV BU.3]]F@%'/GL+Y0JAO)KU/AR,_3/D"=C0:EUMQENJQ>=]8W,\C,R.
M;(M<EED1/YY$*J_4/@N$ISTIS42&J7$-,"2<^8@@19@&: /7(+%/>XBC[[9-
MUIV\T-^YXJNY!D_:.?OI&B[#K@?_EO\\'RV$RTP <V:#XL;]\GV$M.MCS1$W
M8E !XQZB?J"HNXK9@(]<XB'7[A\J>60+_9,:ZL";#-C638N,NQ [_V>\LT2%
MF1-GG;(PKP1OFP"L-^?OKM_=O'.Z]P^]Z-%T:1I'UDQ=O1\O=#/;N:!@T";C
M6B<]6$)'':5BG22C?^P1HS!'15S[3!#,-/2--:<499@A$024"VK<&K "%6%C
M%SI7FLN[--;:.>^K@;$@0]YS/O6^JSG;[K 8P5OJ.\H'QCQ?NSJ0V$,:0\/!
M+- 2:^DR[8G AROT_680&@I"&,SU<ID_.6K3B7EY&=]&/_IYM])ZCTJX((#0
M3,J:NI@0ES&@ @TP6T4H%U$LXRA)-FU7QJV7\969R V/YFT&YE$=&/,?8&XM
M!DHY%M+W)/5]28"_0CC1. *+G-VEK+:FG@WM]BVKVE5DC*#>_Q<^S%A;F/O:
M ,V"36+ /,:8JXB9^'W(&2.KN% N /Y\I.#5S/BC ;:S^U5L<!D^&);I_M0R
M.^W6N0S,5*F39LSU!A^.!<C69O2]C^J]6:B>EF4[L>8S"AEP(8'KTP!C%S-?
M4,-@V) M5\ W3+9*^,[SZ:PZOEU,L9\C@Z:K.^/OS_D$E+E4"D]B'S"L7"2
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MSRL8U\+N6S^@MU;Y>SHI+)_=\(,3I@;+,JLL_Y2<,%N@_[RO],^BPOQ%$"H
M5=V/9EB S?G"XVN?-+#.J0SFX?F#$"ILT\FED?#%3??4,:]N+C^?GW9NNZ<+
MGC[3K.DWPQ,=9HK=SIWG,/K>&5[@O)EL_7];K#TK'0ZTVHD&E8%IBD F9"6#
M-&O7RTX$_IX]V)*:Y=9))]8[@&#V]J.A75R4HG"B+;M93V;.<_;:"YXZ<\3
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MAOT [\!65W8+1NB9T 94W(, 44UM:(,P[K% &D/<O..>7I%[*O$65VL_@&[
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MM550WJZWVU6S!%)J:LGB%;DRI]8M;L=;80UN#,%.7YT^ ; [G!IR"W B\%'
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M?&%,2R"H=A7U@.=2GP2X\(C5"N+C>+7:VGL!D%:']DR'*",4 \&9"R3V/5]
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M#NM0J0_-BK\;=;_XIRE]"0 _!$88AQVD PO'O#"MX3&3Y(\5\QL6S[OX\+<
M#8^/!/4L$\F#*+W*IO_ZOOR.( _#42HGG>Z\%XM'9ZNJ_+U\U.SOMI??]]5#
M?"4-?/A?62\.1AD'2H3-]X=J/)L[L33[82%)IN.5CE>FO/+)N?#C.)S">!@@
M7TV"PYT:)<8]%RT3!REA,0T<\;V!&ICP'>&,2ULXO]F"NTS?J5$"X=M9EMAX
M>#_EI?*5*1"G%P.RQ@O>__O%SQ\_O/F@OKB?1T[]_C+\JXJSZ4L6WOAF&/8S
MFNF&*>(#\%WDT(55UE3I+C#UXN/?3:)=7RQD>13-=JPM9O-E%D?7U'#ZBY_8
M"A+/+_X^+.Y:1RI=*Q^6_M=,];^IAWP%*>?5U8^WH^ES2NNGI%MBVYKS2_JR
M^&N5PMEMN:&433E5H84!5:M=RS^]"("U8GL+B_^[4W;E\<YMJ4:WKE+(<^3?
M]0RGXCD.G&,2_JKL=A1-IW][^^[U+__G\_LW[S_^!L'UO[_XZ6V0JS]^_(NJ
MV6S$Z24"+ K5XN__Z_KZP\?WOM=WC[SYT>5N_%WX^3O^W7??75__-/>QZL_I
M]T-I@<+P6CS7\@3F#F/A9#8DFNZZJ!<__>WEK[^\^OSV7?;Y[[]\?/GAEW]\
M?OOJ4_;VW:N;]1)TD"^/1_)R8&Z'HT#Y;7]1R6!_]_[S+Y\^O__'NY?_>/WV
M\R^O%Q\6V":])?O\/IN]*7OU/C#9NT_%3Y_>__KV]<OX\INW[UZ^>_7VY:_9
MI\_AA=]^>??YTPFV7V-\+'YGY6^%/Q!8U8UZ9L&M^5GEO?R]?VE, (SQ[*;^
M<V"Y_W"&0,08ET!  K&2!C$"G;,2$N[J;^H7\MM=\&'N(^:/)F7/J-Y@XNS+
M<?D50%KON&(<(D0LIEH#0KT#"GA!M=7)WC\X^>!-EO8=!WI]"/9,4$)%MV(U
ML-FOO>#=!07]L(K&4P>K).A/\Y0N]U@\;T;*S?ML0!RT2)RI25*:'<4&9LM>
MU2@#D1LZ@]G#L&$B4942!R$2:D(D?&XB_2TX\<$1'V2?;UWP9MTDN,QY]G9@
M;A*[Y1.=!W93,:TN^_/XUF7_U[\)A, /,?*I!@_I-_C#]UE@5Q74=+ _36$:
M?G&9[@WO;U70JB8]-KQNBD]EXULU3A^YO^\_!+$.BC,/RB-J]?RV=Q\'WGV9
M+BPW/9?*!P:VJBCM:/(EL^ZKZP_OHQ$:C5<3C)IQ,&;#CL=I.W'5P48/1JL>
M#<,2HEGLXH2]N#<3JQ)&-W'GX1434X&BB1M6-0IK3\W"P_G'/5<V"_D/P4X.
MYH^+<!1%=+;0^_ 5KC?(HR=@;M-3?G</V9T+]!L/1TF> TGZPR]A(7$!]VI\
M6_[J)X,4#IFM)@:6@XT4%M//A\'>>LANU5=7)4"D72!J8M*XQTB09,*/(Q6R
M8:3 =+]YL>';T3"<3[#/5']\FPS\=+66WQQ7,G 3R2#GEHP3PP=I0B1Z;B(%
M;FWF,F8JST8N>J3%?,OQ;8"#?Y^H\/NH_Y!]3'^*\O<FF.59-)S#VWV4M" 1
M_4P]-O%Z%+>KXD$N&]X'' J?'?JJP(0]!%2*G[D*$&%<GJO10Q28^T+)9E[U
MXG?')SPN^7Z8)R&)TEO!@KC^\,JT8"FX[<&J2%(6WQ0>..F/TSLBL@WO7>&F
M%V@4WS$.WH'+[@)!;_/,!;+9NF>%'U#Z(3[%J/PVNN[?=GC*'&"4#[S)7BY0
M\"X ;T*.\,A>='E[=_6'UAN8_B2\-QY!P*X\#1U5I>N4OF#DS&04.TT'2RY&
M8\*7W47;+9]2>7K<;A6WZ+)<++]U;ER2^74XKNC63/>%$KH&;='[&OEK-+RK
MQ>F2+ZM$V(HQTU$'#(WONLKT)/PTC"&2N?V7_- ;%%'OJ8'FA\-Q$4T9Q79Q
MH[BCP"TS"S;0(3RE=]\/[_CB!H$Q^OWT=W=?H<T_!DF@TG5C6L_+9,VI=/)1
M.?3=V-7'8J(&F5)B<>>]J&"SH#3C1B,/Q2!6$8C/BRT/33B_+ 4/TD+F3R,2
M)-%#N[ 0MR J52*&/Y;#:Y. #>/(YDS-<CG"&N(,9^.*0;;A&)/^=J-X@1KL
M\G'OKMCY*+X>WSKN^:!+58S1E4LMZ5M]:H _TQ_FD>^J6_\4K)CPYBCCY=ZC
M,@V;<.&[OJK^)'%#$*;AY,MMVE3:Z#BIXI7[4U]5KQ\C[W&)>KK?@OY3 (C'
M-96H^]0NL/AL9*8I!@6T#>^Q29=_31(U_73:9M3]X>EQ5(E)3!L>&0&H4/#S
M#X_T*K&ANG\_"?SZX%1A[#0$[ 7\RV^'D[Z-*POFQG1$\7^69DPQHSB"ULM!
MT(3]&CS_?V<@%A=6@M>2G&]GF1Q>K\V%9!KK=-I$I[/#ZO1JJ%5L0XSMXM,[
M#MT^Z%#MSY&[5P_4GG+HK9IJWL!909!4ZJN8Y;T(.[U"FP70G0)W?/MMX.3!
M,'!T0(F)F\?2\*;@0?3N$RXER8R/"S]_Z_7[LW.><77$Q]RYA ]^4JK"\8)Z
MOBH5X73!-OO3^GO>5\$&>#FP\?_B-6_ KI1\,GZE1J/H2"UV(-4,(\XH !XX
M J26U&%#.?%6$:6LV??J=WU-)[_B<OG&-U9Y1C29#$:S"12%<5-X9>$'][BW
M>9@-?I(MR5FQJFZ*7(G@MF;_SR2@:42.JSFT2H'\I%[#0]0F*O_:&[CW_E4:
MIA[(V.OWQ@^_J3]Z=Y.[GX>CT?!;H/0K%6]UYN[9-;?>4FNPP$&R!1-6.JZ#
MG%OHK/0UA;H(<$3_8_Z+4B;1/P(H!T4<^\\.TCUVV/^'8.8$'3,</;P+]D59
MU?:QF /_(8Z!_US1YC\_5/^2GOGS4(WL>_\ZZ$P3_=%7M\'>#3*_.4N)S8Z<
M;3ARMESKE@6DZ4<:3Z9[6AA7/U4WP3::J0U3KNTJ^QB,^[#N[)>;[!^]VWYP
ML+,_QQNK2(, *-_/RZAV_5X0WCSY_U$E9_G$^UX,(8P3:UW-8T5AT,6O+MDL
M'<%4U\VO\VK&@-'$#0\,G!: >3"(@8)'"S\"0_"YQS-[8E&ID9OYM@9' =Q=
M(OC[ _(PNXOF83RY4CA-D:8;C!QG\WE9C"9+C&P$:HY4+Y\SX*8?F]+..CV.
M1HU+.2V/G!(>&?8>SJN\_PR_WP=&'Q3QHV0W)OMH,1TCX$T0BAAQJ9J^-]G?
MA]\"VXRN2KXQX71TM-*"-Q"LR60!)\BO[B/A?GC7%)MF9GDRCR8!YN?,ZZAF
MDI5?O-^-[AZ7^2V0H6#DL,%Y'IQ^6_B"H4[6<86C?0H1U3WYVZT;+&X^GD4R
M]:+AEBQ@%2WJ8#E&Y\V&_8?#<-Y')WM%Y$M/@OH,5NM5U<6M,O^@:CW.(DSS
M0AHU;7SX=*=A:S: U</,_H^:,^G)2+NOX0EE &M40-ICG+&<WQ=4N:^X]':2
MSJ,_#94OTB$L*WQ36&WTR,+."VL_4JQT:F=OB*;ZJ( 4NWC)O<XBW<=H9$V,
M1CXU&G>[CVZ_K;>8N+),]9H+K<:TYTUH+YXO[0]!<]&$YO+<@<\G=]0+P>Y9
MQMB1P]ZRT;TKJ!>YR[>D3B-RC_0[C_@<22#V"RD\VG4JGPN>Q646D=G2N03A
M6\.;HO,P'-T/BP!#&;A-$=MH%+US7Y55Z5,J'- H?1!F\5E%@""ZG-/;U.#:
M77^8NRH-%E:\A+TJ+UC+^SLU^.**RX#TZ6#DE ]8?8T[?4#@C]_40^$H(Q8=
M$0BWBJZ=,U%D_O<VIC!MF\E2IK#D']1#M-)?#FQX911 []=>808'&_?U+'H=
MI?CG_M#\7LEWH<)I+CEWW +"&!**2FD@QAYB*NCF]JR;\UVT)4A!*3GR@& +
M)')".8<Y50(#;X^3[Q(OI I:9+],[?G([N^C9[1/6LOF[32@P5):RW$E84O)
M;$R#VJR531_"LSKA>F;_9&Z=G?1=RMQ:8/+/D?WK^%M188VC"&BJB--26LZ"
MQF+& L@]V*9?Z2;^=IX(9Y$*ZH43A;$P4G!)D%/<6^G($G^?VJJ<RL',KTV7
M=OEX&@SPPWX_11__NDHNFAD,FP^\ 9>0@DOJOW'S430XOWK9W.D$IE5WJ[W-
M8]"W-OECTX?H/O0M2%5$C(SK]\L:A=1T*/Y>5D:EWXML\.)/12*V\>/TT=H4
M[*64[_WU\?R%W')EV'+SW#T* ^N; A<;Y&PQQ;QB"\SSSL(;EDO:UBVQ4E*V
MSW+A=S^L*23=:@%HXP(62B7#]Y?]K>=L]%546U=W\5.V[&8OU,_-[M.6'=C'
M?S9T";[@TSG[ L[*'ANYHWKULII!9I&.38^+-W;MY*/ZRM3U->1+;<B/@*7M
MA<W#B0#;]%V->/O/*: PG.3!%<IKJX1/0YVV<5:UR7UDJU6Q)$"N,H1%&4O:
MZ@AFG>P17VIEGUYZ\=.O[DN9Z%C)Z//.U8[K/-$![5JO?G25L\_:5F!$;3>(
M8])W0W>( VUKPZ3BPAO\,!IZE^?I@OQ-8+571?9!==2'QM@)B3U6B@@&%:;8
M0NL=A5B"^M#0X;)\"-JJJ4,G#4]K;9VD-I!4I!E5AB*IJ2&22ZT)E!8BH2V(
M0QUJ4L0@.I2D,OHT!?74)L>AC(EIM,]49LQ?CJ'W5!:P'C\."!*_W-WWAP_.
ME8F9E9CX,DZH>+M#H65 ,"*)UQQ;:3P5D@H2M/U1-3H6V_7"[/CR22^@E8+A
MM @RH 0REA&/F63(*X@HH9H1*NA1%:CDVW7:;Z=@/'7//-9U]TO>>7@2ALTS
M6%L;K/?W1?[RX$OBH2G\/-3XV8H)XC!F"#CBO=0&" $-Q0)2P]UQJVDZ-[M;
MVW,70(Z4!=+I8 0;(CR1 CE%"<"2(T0,.ZKV)]O-\;HX 3RY75 [1/K /O5C
M"<G SK6),<-\7.27#:OY96<XP>V'#Y\4H+:ZKFTG6.VS])V ZXOJCZ=!OX\E
MI[T<V->/?/8JLEEX*24Q+@.9$$XIS:AQW!#/F"**<6 E-1:J8%X<U9(05V3+
MF83/6A+:N:I./D\AGQH9I1U0%&-/J#.26FXP98X9RP7U1S4T^)443TX^VQE]
MJ.T ?RA;Y/-PK/JM,A&WI4 +8&ZKM2\@2FQ'7$YHV -26G^#>3)*;'7IN39<
M*Z+5 KU!"CG"PGJ-PHQX[YBDV+ECVSDMP]&G+Y"7O/8.3%H.)A(C0IC5G"A
M-(G_Q@(@%GZ@R(F:CL^'O/NY E0\3S"I-=T>?ZY.H-FM8.;QI^:E,[4]UC9]
MZ, ]UL[>7/9X^VU6N[- H!<_?5P5CIM6NEU56C'=NU$^' Q<OPC67<5VFT-3
M="8LFV1-_])7.LLGL1-R?,1P,HXM+K/<C;[VC$M-@@;C**M9V2IH."H_.NLE
M,QY6N3IL:A*^8SQ)+4Q3C^G[T=!.S/CJL>O,.#;,*6*(]R-7:7H=EE^VCXX]
MJ[X4S2]71B++K6=%)7E$.[O0<*ZL&4X]Y<))C5SL]Y-*MI3]FIH2W:N'HCMC
M?,N786HO&=MVEP0HFA9-&Q5-\J).O6S1-%U8=?^+:ZPVX,EG*RY;Y<P(G3KZ
MI&Z:X>@BBKK4B7+VMF)ACSTW ]%<[-QZD[V?C*;=M+)W+__Y]F\O/_^R0.C8
MQ$N[>!SQH(N&P3IVZ>V-['5L^O3P>,HS6@]'7]2@]]_3WE!A,:\^OH^<-(W[
M9E_=P Y'^4WVK_FNVDD//19@IGZK\^NIT.1QNV%%\1O*ON&3^[)_TK23J<U4
M:H,;"SF_#4>_SYI%I1[C3J5F4>'A-[$_YN(7NFI5])1O'U_,\Z'II==2^[1I
M:]V)2=^VP+5%*ZXXL:WGP\N#<77SD?-CH_(IHY2K3^W1(ETBUT];X*86!FG6
M2/R6^_"NQ(=N,!KV^\Y>+;PA$<U5.L0'#52>1^JW.AD]=C(O&CK'EV>/K?1K
M+;]@VG"A)-N_4AOD7EC^]$/E.Q,;]R-+S]/O\12K%"B;( <,BQ^['^9Y+_74
M*MN1I6ZKL4_9R'WMN6^I#5;\(1&Z9,+8[K3HP95Z-@P#<^?WJ<]J$)1T0I%1
MTHHCLP30&E4;WA:[TN&5^=;"LRZ(91>R\ &WU[;+O59WOVK;L:WN).6UYK,=
M5% Z/K_LES^_ET7N*Z%WQSW.>K-5^L15/U8TR T"M="2=S)M#9[P+^J0;_&U
M<6RG_WOJ?38<+<I^9,-'J:V 9=F\]R;VF$R@FAH)7V7?W+1![ZS=<\+\<.YV
MKL?V%IH@7_Z^1PPM.2L=Z4R@HB8LMIZGW4P[J.W;V./0XUY.,@@L.\0HL,V5
M62T8!L97#@.;7_Y>X\"RE@X$JS_FK4>"975#P6I$H%UCP>J$JE;0#M) YQ@%
M_-ERNZZ6]MPJ:=6XU<]KI\?K6_E8Y3WGVAC*!4$,:\&9(])82*3&=G.KD__X
M=3CX$HV,^%V?'^Y=:O#[ZS!LK6PP-&WJNZDEBE($0H0P-H 3*9UVC'@#=;S\
MXL&[;MX2I=E!SC?269Z]>9SV7_@FJS1:3KV%\ZRD9&JQ!>$/69F>G*6.ROOT
M)=I,\P8'->M]<A$RUBS,L9D&#0BW-(*KB0740I(?JZ/C9GHV. 32<2^M;0*T
MZ4/-)T =H$M>;3#T& A=:QN_^.G]('MY/^KUB\@U3%T-$9SO-KXP-JZFG?S"
M;(#4<ORQ);T:C6+7Q>2G?8O-P?5#]MNHG#@P?40_:%ZW<7A#5-9O!WE0Q?%I
M;Y1QQ6RDRA4') I"YC!@T!$B@5#$,8,0$D)Q#&HRS"$@D/W'_*.3-9 HTX;Q
M 6!VQP(VE9*#.!LB_F]YBD XF_)(DP\^G68TBQK-17%B[_YAG!XPUW>^F$>D
MXF=GJOY^1I4T WMNQF&B8&*I9!$\SCHL//)RD%.,",YB>YL9H#B1&$LIS\;9
MRL&E!\$*0V"J(?98&D(-T8Y*;1#DTA'%%5%:KV"(9"I>+FM<Y\Y$]HCCTW,W
M>/'3V VF<R266</&20"C?:<8;D;:!O#,ZO7:TV]!O)DP#:C)#VVJ[4S=$RJW
M<]EOM3WP-WUH70_\9\WGM=WM-WVH>7?[)V#4Q1O0!<V;[A?3K)+)*(:\X[R.
MJF \*M[5$9E'%?A;^9C7X2D530NTA$8S0:% !#.@F99!&A1'S%A"[.:@3 LT
M;=6\BE2Z3K-!(S6NK7JXCJ/VKJ,^+0A<6LQT,8AQ%>]<[T?NOHR E-<QP_NZ
M0:C!&OIV.PSO2J,.TQB>-&TMSJSIW16CEGOYG-&5+.V:\3+5,S7#N[#VP-=#
M\WLQO<W,+*=H>AD7AP+%FZ7A;G9WY30>;;$/\8%5NXMPBZATR$&H"85*4P1B
M+@4P#@DN5C5@: ,/5*TM7+6VT-:&.+VI,\'OW2C+;]/HRSJ&B/9S8 1;SM1>
M$F(=F"\OKE#CS5_QC.J1C\K6^>-OP_A=\<(E^_,N1_NV?/;'\*#4B-]^*!ZC
MOE0E'6*+O4=&6F<)]4!CS3 DR!O/A?3R0LZ6UI_M-=IPN,MUQ-]]G\Y6#<)[
MK[+I[/'H*Z7IG?V'XM8WZ/5B.E2\R9^=X_34U'WPI?Y(]Z;A TV/[9?I%]2>
M'#<6$\8P05H2[)'&7AI/+.! 4@]KZC^?U,DM=Y_XKD@8V6VB]-7"66V S^GQ
ME,WY(RTK1T(1AE13QR'P!!NEG+!:6:*$9589<A%J\P"Q"[HB;A&)OA>!B;;(
M*A%L0\R)LUBI0#9M"/!(!CK#NJF24P*CIT_@-(GNOL",_L-5&KD^A:99OEHT
M'\O"X(5X8)G.5,F=>@SKE'&>VBG;A\W?W.P0-+FZ6S$EJ7/*(&A$S_KQ)UWX
MX;!GT^CV$ZZX_NQX'3:Z%(5+MZ+//001M-5PJBV"-IEW55,?Z.BNS%1/,J('
M\:64+5@F!^:+(UV#ASV?UOCH'*DY?R@E+@_<]:WJ^TW.4:I^_O=)4,YNU'^H
M6M?53J16 !V<6:TD)IX2+:W7TCN@A?+8U3A!K;Q.F#.E\0Y.T,UR,]3"#:J>
M['\51%Q+Z)?)1UI!96PATY0HI7V@GB+:&PZ5PXPK((UUETCE'1R6FC83WSVZ
MFM_/W[8]BL&4F+,;-^V^] :#>!U;Y@[;4C3BG5XJA$@QB%Y>RFH0EN !5=X_
M%SJ<FP$>'*&OO6@ WCZ.@ [2E^8WE]45,7PU' 1':9;BV_.E0(87>XO1C\S%
M67QY,1(Z'5>14QY 8A1SOON/"UZ&F56AL?EX6 RZC**E&GV_X6QW-]G+?)K_
M/T6DE*<<=Q 6.,W2GIL,70PW_S8<!?H5HYW3WKU3*1&Y_&3*]NP_%#GM_6'N
M$CFF)33I2V^'*9][RK2S+OFC>!#A[7>3\'<=*-#SDU%1SE-DIIOAET'0!S9+
M4=Y P=Y7E6(,LVY^Q;.*J_F8C%Y<MPYJ*:B*.>0!JMW]X^QI'Y@[%MY-(N47
M[XKK +QV&=&1V!ALG'ZN4LOX;C@P2^6,0<DZS07Q!#%B+!-&6P40950"SDA-
M.6,KL:&A.T?0*H=Y7-S$SPXP^_-<M!I^7W.BJXZQ>M(G.%%@H1542<L8(<!H
M:#3BGG$3O':(+R6PV-1!%[QQ"&1[&D-J* O&"Y2($ RQ,(Q2([A -,@.J8DW
MI2+@)T)C1&0MC>?*6,9U@;_J**0R"C@?."GO:;:"XS(R$I-P8@.?A.53Q9;?
M.C<N1+086#N+HRP);.VS_<[QS/BXK?GKD0<"?XU?NU@*%]?_,O^[L\'*^%)Y
MP]]4;_#K,,_?N2H'>@PLD4X@)H(7)8#"@@3B:F$@5]:CHT4\#\)!&(LU4KKQ
MNN5P9(368,<9"*0C0?U)Q:5DVA/H(6+*U0GR8>*:&\B82O.O=\A9([7T_'Y!
MOJH2&I5.I4*X*$@M@Y5_^7,<*WWGOF\@"(74J;M@RY6UKU-)&XYZX5"":;U!
M3EY6/OO>OYEF0:9N67/MZ[ 3A% N+".68ZV4!PJ)X$,J:.IBTFT2@56FQ[RQ
M,&=J;@28A1A^:BM6(1@CC"FLC%3>$>^8EA!#)@753B@J6DXPQ YUM[%(%\>,
MMXA:QC$E)C9<0T)QZB +..!5C<5T&A#8BRZ+HEY4@Y8*M2;8,[VFV%W@YS%F
M.?)91L&N^[TOR9O+ZZ-DUT;=5_[4=^.PLNMR).Q""&UUH(Z(FMXBQ2=C'N?C
M\U(A3_JHC91)8#,KE0NGTIM]6>7O9?AO]O=I/#*\T@]^:_:_LMY=[ X0MA,V
MUQ^J\2S0>G.:0&NCP@>XHO*A"US#1O40<*D@XNE>TJQJ 41IZOXS&["P\BKG
MR ?8*&,:KDB9WFJO]61Z7F+3*+,:+J56/[?[GD_N?EPXR*O23N?,PS+^O'_:
M*131?(8:<JB)(TC3X$9:Q<,!V6 NUL:,-EJ&L\VT,/7TD="0GS?]M'J@:\/M
MIT\_Q<)Q;WC@ 2R)<UAJQ96BV"L+ !1JATCB.7CA "FHXH:1O5-0ZX0ZI:'.
MIP#-9:2>+ V562F4,D( !8D#,OP;8F0-H(@0J6MZ3+?VC)]A*JHGV#DH)81*
M$&NA-A1($.]YF=887Y*$/J5TU*!.@J'CI(.&$,"U)"C6TR(EF:5&US8<;J4Z
M;7-*JF+&>@J<I-(39;E0B&@- W)APS%L%K5Y6D0^4UKJL9/S&A4'0K%?N]5]
M?(73MMS8&,%Y:J&UI=YOIXHM-*JKA*TKK%S@F:?%'FT1RRE+KO (YN[.Y[,\
M+S.U$R-()<,<:$ (Q512(I3PFF"@B: U55(02,C;J)0/F]XYE_<76&#O]$YD
M&=<,!ZRA@ #/-;1.!H(;SK$@OL8)N Q*=RF>6Z5X%DV BG]OE^Y9%Y#H4CYW
M3?E\I.*V&9^+X;[S9'QBR34G!F'$"7$>" Z(<(QZCRS%\)+@HFGJ!<9;9WTN
M!8I;G/G) ,$2$&1A+"D75DGK+;3 T'C*.Q4F7^C)(MX\260'.BL, 58<4FX(
MD40!'/2'Q'$4-PR&_P[9GQ=*YX (FS- ![7!MHM) 6UMZB>!)!C2C!(G3?B)
M" ^5P(A(2S6DN%GJY[:,>!CV86N2M/]\0E)"IYCC!"+')/%4:::8H,@C()#!
M=8': \80#YL"RE"C#-!96MBF%-#6I7\2$H\)&L,L#'8,4MQQI*"WW%# Z''O
MK(]KAT1[<\YT.%P*J'1$F_#%3"L2.%@BBX5$.%#,:<&;-<HX*=%0\_J.#;01
MUC&H+=>66!*,9"&@U"J2"1)A?4U#]-.!P5ZT.5TJZ(7DK%6R,:L+GHXH?(SW
M51:W$'"\UK&=_N%SO9I'&*?#*/X></:_P^=4_[/2TX%Z)PJ(-VH1@L"^V9(U
MH>GCM.C?>+>R]V5$S521QSDS^TRO.=*,FM5S:-:-KSG5C!JQ:49-[02:S9-K
MNADU3VU&S5X3'QIU\D'-IYKL/1IG1R#<?/?='"_?#Z8M?6:1 00J/?2KQY@'
MPR6&PPM_8LU]20%#[_V\I97_$B/P ^/LSP]I3,W++\&PN9L/[B"'J2 ,6!U<
M:\VD#.8R8Y3!<)S$R[IF&>&40='K//Y49P5.M[:3$4BJ1N#;=V^V;E/^;5B3
MLSC?8C[/8D);8=Y%4F0S4B0+T?WAS&0:*+>N'WS'41RG6+U'J1S78F_ZX$NZ
MDM0KCC VQE_7PGZ+;-;'Q-57V_2P!T"1('5:*&$)IO%<77#]!;*<>E[;:N9(
MYWKXN02%S[U\('4MBP^3,&ZUP$9A1*VT)'@ VDCHC<-6&8B<:1:#VIJ:VV9Y
M+R)*:WH,+V=V+]P+G2[)FSN!)*?8 A;GFA-%M#:86!F.DQA>TW'ZL-+0N#DP
M6<[\W#4S>\8?JUL#UR5B5\_J&#G9$B%O:( K+A%QG&NM@F^-B BO<NEK<K(/
M>R3/,)':,F2H\RX04I(@" )YI8&4%G$=S+6ZD3>M(/F:[.>S9#Y#@(TQL76]
M-(0C*;WPGFK.H!:<VF:9SZ?4LBLR:1<OMO8B$@ZD8100[#0@#@O%)*3!N\/0
M$B983<^E+0*-+2!2@W3CYJUOCSO#K]GT0]2VS,Z+#8,U/[E&G4;1\^@TNM7)
M1<.H/*HYCZ)ZE'7-2"\S3=4BBQAF04T)2 (4JP##5#+GA%-&TJ.;ORW/+?4$
M.@\0=RSX>5(RZ1@SDD.%C);(K8J&G-TNZA)"=TD(K8D<=/F@N^:#SCN3%Y,.
MRB43UGJ%E< $2J!@,. -<(@8S5%=-E$KHF$$TJUS.)<"R^U-X?364JR@"ZZG
M) 1BQ4A8L+4@5DYP7(.WK?":"*_/!SQLWJ63&.+8V0W3P)V0Q,IU+[4Q6"IB
M]2Y=-T])'+2"59]<N\RM4\1.FR\)D4&2&$\QT<1((X1'PB*/E0=,LMHB^5;%
M)!"K[^YX\G1)S2E#4%%I/2,V* X');. 0NNX,+0N\?E4@8M=LR7K,^\6LB4C
MML_-ACMXLN3)LB6=H1YQ1(V'B@@()*#A&(4!5#A 34V LV5"L%+A'R]9TC,!
M.02*!_5&-);"J_"_H)>Q0]K7Z9N6T>QX+3,-U['G2%@94,09K8+!:*42WCJ$
M7*TJ;E<(\RA=,P_5,7,Y7?%$P;-&W2,1Z8)G9P][MNX,FN?X'2\9>)OF&"UI
M%_"Y-O0R&$>@BLD 1N6WV5"GGKJQ#FPQ"#*<C/.Q2J&HQ0R^:H)"D0LT37_H
M1><A94.DP,F*Z3#ERQL4R,?I8_+W?K$]$N-* P&(T8(09244AG@MN &.,E!S
M24CCS)&D/.A>TT<^32^0/ADW""<Q+'+TRU_># /<JWQ\FJ2=[+X_>;P+FVF4
M0,BTE2)^-QV.702>%D]RZ:CJ*KOW/BX/ <"28L8E"U98L/J!Y3P601*EE:RY
MKJ2Q8+@\KGU+AUMU9*=O;MVZ?BHO?EK)M\M-->O9MH9Q:R+0^_.M(Y89BV&L
MT@WVJO8$DVBW0V PDC7U/!0&N[W@V_C3'C9JN]AVY8D]!IC*!+FKL)2^RV=9
M;-'RK692+1_E<FK5S."93NK<86+G/G;)<2R& H<7T\7G?U_X;:EM=$MLBD53
M=&[=\7_'J<&952G\5$.:)HW1ZVHZYFH5TB_9O%V],M_UC>J-_ADCG*][>;Q1
MBB >;>Z?8X'7BT<3'%')I7?0&^Z)C #"!?9:&NJD\VIS&/%%YH(LW\>2F""(
M=9Z6C@%MKQP&0!!@K>!(0^014H I@TS][-^I!:N#^.W.5B]^(C=9I$'VSVF8
M]\TLX:82$9P3WTH*[3;>R^9]-2#&4K+-08BQ7]O]O2<6K^TZ6*WTPC6%7OAP
M70CW:'2_;\'FG#,)Q7+M6F,VJTT-VO2AYIE!BUYQ]<A&99T76EG/U@J=L0SJ
M<YYIK"^8MPA,L!E4;U#)V5-Y[L9Y,@3[C_=[E<#:N'+)5")1^CD/9E"P5.Z"
M-6HS_9#]ZKZZ?@:#_7(??-ML,@Z/^N^ 5SIWHZ_)?;5JK(JD 95G_S491NLE
M)=#'>_A,%>G%X0!^=[%)Z:9O0HO?E!Y_/PSV4UY&_\>W:L$BVO"M18I'S$^O
M+-OUTL-LZM?2?RC*"Z:_;5XG7ESG9+!(DW+1J8"A9U*:99%1$0YC7!0T#(;E
M&M,GKLHWEGDG12*\B_Y 3&V)222Q0<IP?N\V+F=XG_(>AM\&\>0G=\EJS,NK
M134:/<0'%'4^D0E\S%A)1NF&R\D\A5A3U".N*= C*J6KE-B1GC4KX2BR/9*I
M6T9G\VJ&<_R>WNAQ+<7EI@W_*R(GO5A!$#9Z'2D=3(7HU*7E!S)\B__:<!V3
MV+W&IJC>Q5B)@MD0!_91 I61WDBD@=(VV!0 ZE7WV+.G_OPP^_'O/3>*0>:'
MQ S)R9C][6WBB_0'5+HEE4?\YE1<5U3N;^(YNX%YF/]\Y1WY1Q?OXP/!&KLL
M2W5J^Q-26T$\#E3#0A//F4" .4JU(L&50?5]MO%^A(071\B9-5=)KUA/5LXP
MHYX![90E'E@M')#">8\UX\#5I 1U_%E+2 9Q^%Y /2(J#E,0A&LA#78*!(N#
MK1RN\*P(N3M_4L2"W!OE+0"$0:$@0PHZK;2)Q8@K)QQW9%U+5D2$=<'T)5@
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M[$-XU/5M7Q<0%>+$ =&?55\-C)NASM)DERY(>B$^R*$YHP4]4EI%CT/-2Y1
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M><E$>_3&@8:I5O7*BF#STP@KMP;;3QMB/L:VCQIN/O*^_WR8X#)BBAL.H$3
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MHF6B?^JK^Q4.1)VNK-49[7$PYJ=]MD.O',D(J>79Y^1R; GGS\4S.1@Y#N7
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MGKG_FA1_C9@7!X.$W<3T_O!"?Q+U?)R/<!U?S+X4F?SCX?0AF?O#F4G\5/B
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M&Q9^M)((8+DS-)@R#E%WFI@+%%<"/*V2S)7'_7T'&N>NB3T)3AR"5XYL+=5
MPY;V$N*>.\R)IDP39E5L9P^T@URK6"((3Q/WP3=4/BG0:+L-M:(^:->LF_ET
MX?;CX89MMQ,J5]@I95W?N;=T4-MKKSV=_Y)^*9N'"DV((80 1HA$3DL(,0"*
M<N6$<;5C#@YEBK$KBM@5?T+5BRV/4;5Y%R<^BDM*!CKRCMN6(221Q=8SBK4
M! &B@-16<XZ!9![67_0=RLQ#-XQW:'3L NKFQ4&RT1PJ<.[RN^95T\VG58%&
MI#I[I>++/!OZ!;/]*M8@CESV3>79G];#U58#H=X-!U]='I$H E6>>CI5_QZ'
M0KT;CO\_-WX<%U5M^P"I4)IB@I$B' 7/U&-NI-?& 4)@36^R35UI=ABW>(68
MJ$T:"F2;E];)8#1;_7R7JLJ4IBW 7V\&?[T"_&>$+NS.LIRWFHA%L'-8,\2U
M5T1HIX05 #%G@"7.3X<"'<?^1%>"@BM1TZ M/+U8]^/@JH"A@2-[>6KQ94KJ
MZ3CQ:D;C88#N3&7?2C57#N55A;;+[E/08_Z( J>K^_O1\(^PH+'K/ZP?#G@T
MWB[B,6^&H_*E^#Y8O;(R&C)N(DJ( "Q48X4<L@8*ZWTXO2U",)6#N,Z=^:N=
MC!Z<&L6$&B07BW>S^*?\)HM5RU-J7D_IF.J),QOHE7G5&T4E.XG%S:/I617O
M".=ATPU]JE\>I^DY=\7T'!>GYSQ"S/R1I&+C+8#FL/F)"Z91^N/KL,79"/2J
MR 2.A4H'W &>* N#FX8X,A!1(8)Y=*)$*'#S_[/W[MUM&TG>\%?!D]WLD<^A
M-+A?DGURCFS',YXGB;VQ,[/O7WL:W0T),4EP"-*R]M._5=7=0 ,$+Z(HB;*9
MW4E$$I>^5->]?I6N\B"U9:;.V^S#4R9Z1L!*T@S4Q@P8M<N#-)*N)^*(Y7&<
M)T,XDH^9Z-DEO4ZKO%VIEP3DQ1/H%WNUP_2^]7Z8WEX-,;W=.V(.GQ4[-0GY
MB3IC=;V<J._6@F=$J0]60QRYF9>'>>BSE =!$+-4,NEG<J#:Z^YM,%,_YB+R
M>)!X81SR5$82=( @8G',@M1]<I64P#-:48-">SQV*M1)5V0.* A"+N1\4D[A
MT[(V1_CE&,RS<]BF:@SO4W>=SV C\8)))>18\<X6I,,(/L<(/M9N%_P(ZO 2
M-OG1 3"\O3IA>IM;86ZE@#W(YAE#8'A[]<+T-C?#W&FY=@/!6(=\<0"D"PL&
MSH*B/L%?G" 0K#:8&SM??LL=,D]T=**CYY(!<.*NQW<J3IU63S1QZK1Z]$5P
M/_U>UI_."W0*E;AQLEXX<[8XPK83SRVYX/FE*1U[&D#CP;:\34B^;X!ZWVKB
M_1UHU_;9!BE/HRS, [!JI2Q8DOF)+]*X*(1,DKOZ;"/;9QLV/MMS?VO*9Q(?
M?R[ X0C@^Q/[.+&/KX!]N$&4!@)X" M$Z+.8N5Z1!EF1AFXA\GA[S]7#L _O
MPG\&929/Q3X>2]?:,."?32!_7!;DU4<_O?;G/X5]^3 <8KLM<;=]7L_0MX6H
M]LTE&6(!9N\^ROG$SE3PBR3.<NE%:<'#(D]9[*8A]_+ ]]PT\@;327;-5(@N
MHN%$A2,Q@IY*PISH]OYT&\6)S[/,9SSE(?<YB^'?:51D 29U%+O(K'WH]LC-
M^J_8@F^$S^=J# 0UQFX*6@3!@^1\?(LQ8,H(.:GE)[7\.:CEAJ3_T5!T3S%/
M8C_&U/Z0,QYZ<<(REGG,\Y,XC(H\">YCU_N[*^;IR:H_L8\3^WAV[ -A(P0L
MK)L%00B<A$5QZ*; /6(1)DDTP#YVM^OOP#ZRZ,0^ULWM*?2O790L^% *.15'
M&B4Y2JYWG*SM^/G7:TUK/>Z5\3R6:1@7OAN&1<*8B$7J>6G(0^GRX*ZP7_MR
MKV<+-OS]Z7B>CN?#'4\1L=1W"X$J0QB+*/=3T"F2),ZEYXKPKJV<3\>S&<U1
MUA%[>W5?]IYQ^^7]EVJO#J]>\M1+]7;J_)W!;.>W;0WQ2A_3O )VX?!K8!CP
M'$>.F]+.!?N$Q9WU8E[25ZHX2S<S+:?.N)1+]-AQ5E_#=0M63N6<D!M5199S
M"4]9L#%>\T!L[F=JPOIV"F-<$@;7.RQ)^7C-IH.E<;:[6<HL$1%W99R$B2C2
M/(X+6))8<,;28(LGQ@N\_Z$!?+R=R<LO9?T_OS?K1(5&OTJ%,G. RKD@'KG!
MJL/&J:F0&!=W98^H2D<X;-&KK=U2T'DY'E<<RZ*']P/EQ[2V149:^%&,M5!!
M@;68,B^*+ N*,(0OLT ,^.SOO8A[%HV'P]6'6*R42_0SLTD%?/]_%>5+-5,'
MVP##DLX92OGS,= WV)4UW+,$9C!>Z6<7@&204ZN5,)8ATU$IEN/QA=,]C_Y#
MG,>NE%E[./WC/IPIB^,<.*KTDR),\AS.H_2SP&,R\;)$YAM5$>R5]&B'TTM&
M<;**EW(,AS-RTS#W7)D%:03RB;,L ^TN34+AI;'/!G"M[KV(>Q[.('J$P^D/
M'4XL5]2G\\&5B+WZ9GOI4RL13Z%O[=4 V\N>>JF OW^0LX4B.R YM\/A'<HP
M)XH#*D;63F 6R!D==C67Q$O!S%A<.R4P]"F\ZM5U*0OL8ZN:Q3OOBJ+D\.P;
MQ(+);]<P[BLV7OSP6A9R/E_+L_\)KWD[):?@DHU?@9"@PZY[D+UGI7@[Q6^!
M-6-FO W]4G@\B)"11!P$?<P*+XO3( X3V XW\[=Z<?[G3D/[^0L?+S&S?47&
MU)=3\;X"!B 7Y5P)(CF518E K,BTWA6#+T)69GYX64V7M6)D__.Q7&#Q>/MF
MNI)VH-D O?Y#K&]?<]=?Y7O?H]BX1N8'LW5J-D:%@4T%XJ?0LZ8<6!T.'2CR
MIAR/$81E!EN&O SE_8BN?ECB,(\@6? '+$2]2BI,Y*E7^$ ="1Q/%C'/RS$5
MR65<I"+9[O [D4H70F.55+KZ7I\8%E1./Y\@00D]$2W]<$"U<X9JI^_^^/K#
M'S7]Z?WX F]DG%=S081&#(D@..1\4A-EU<O\3]!*22>%'T")^5S65)1?RP6^
M$%F8>CL\V+DTS.T"/]8.AU&46J?]=7[A_")O@-@9:4O()PG8!A0H-1<4SK=&
M6./;8?ZZ.0!5:J,>-1YWUV&!S/K">;^<UTN$RE'\%NA_*HC)ZH%W!H<C_OMR
M/*":Z[&4V/-&Z0]*N;.R5"AOLH7Y P9=P="F!/F$T]H\;X5X4/]PCR.K#Q^[
MLFB9C@$=S0\X@9=2=>U1VO:[:0=0QXU!O4[3,(B],.%Y6C!0N5,_+MRL"+Q!
MIOZ-GT_*,(,=OH&#4LOI=S\M;F#<MTZ!@GKEH,[4_K1D3=0D4(E5Y;,-SMLC
MTL#'F\H6[*[+<Q9%:2R\,/+\-&.294F0!#P#QCW8F^E$ UT:*,H"2&#=[G>9
MU!92".\IQ.].#5@/;B<;Q(5P61QD>29 WY8L"%DNL\(-W00LR$'<FQ,]'(8G
MM&:$(H;T0H6UG'=/R2]Z,B-S$\&**(KR*"R2D,E4NLSWN%OP.)"#'M03?>Q!
M'SHI%G2(QDE(X$>:7#K:Q!K=K:N&*5K2%+6S'Q"6<5)-2=_7S?Z6><WG90X+
MN5P S=!P; ))N)^G4GB"16&<@7THB]#GDA6L2$&B?%,$LG>OGF"4#?G&M Y*
MA"!0+ZU:#O*C<UW=R,]ROHX[=%R[-1IT;ZKY1_8%EQ8T5UQ.^&+8T6@G=*19
M+*67BC1RPT3(E!=IGOIYP82(O6!["^G35EM;G42CR%_ML+*B-#3;CJ?[6HZ)
M W!"7BVGO)H +; OZD>UE7BTMSB7S3K^KF!Q/U9W)P:PZ3&OV1,23GL>^QG\
M.\F\U.<AYX)MKSOZ.HEA3Y>X%\6C(%S-L\1PPG*\P%T%5O] @1O%%I3D'XC.
M@$W@%VGJ"L:C$ ;*PBSP,^YZOO!B/]I>G/YU[O2^'-Y-1T&RVE';''7X"$,9
MWVK>_A0XIWM!SOO?(N2\OQ?DO/_D^)[ X'>#V1W=+6AYIX-^YPBG)U,WSO/$
M%2Y'7-8\X]QSLZ#PO"!(HF]5_]A7Y'C^#@C-.C31 =-'K' $@9\CO<#?RL/<
MN<0$;>=R!DQ-3DF"'9!V;)%E44B0Y2YCD9!QF(5%[J5A['E@LR9<@!V2#?9V
M^@8H9%\-U1^%X7I;!+--R$;4!&";),I9;FS1+DGU@I]L%?=W&/!^NUI[Q\T;
M;L;CQ2'/9 IDQ-TPD$4>%Z#7!I$4OI^XQ4!>[#=!0WN"YGL7T8!6.P/:("HR
M?JY=!9+?$TA=RGI2Z93%;L&+/ I<OP@]X$1)%$O&XR+(9!XG S&57C[UUTDW
M^THG-UC7\^4Y":0D8T)$.8N]'%$Y9)858>+%G$<LS[-TP$K^)HAB3X$41:/8
MWY@:NZ- .G89Q&1:@+21N<CRD$O)DB1+0(6148%QF8%,BF^";/:600,%\)8,
M>G K<:_&(?[S;1QRCZ5Z\DE?CNMJU$98= A&Y5]1.C6R$ 23T>K):M[I@7G$
MG141WQ->G'G 0Q)@'FZ<8J9^G'IY421AQC8K(I0(_%4RCWW;SWF[-#(Z4\W2
M4!$II[@>*M.8<3Y?]GO1L<4JT;R@6TFU_:QNM2MY*#6@T5SJ1]!;TCCUTR+V
MDLQE8>SZF1=YZ/,5<91[8;(9G>GKI:%]?;YA,$HWUO1TJ6EO+>9)E99<A%D1
M)84L& \C/TP%*#$I2P/&"^ES^8W2S-Y*2[A1::'>2=MJ2,2?RWI!2_*QNA2"
MVARRL4GWGI4+S0!6I(K=/>MW^:]E69<+TX51!8BLQHD6#4B1Q8%T)8\2$0K.
M,S?G+L]$ 7:0FZ>#267?@//DP++'&+S8E*@L2N +Q;R:#$L;S(5M=MY*&Z?-
M[PL:HBI*-=DB8QZCZ6P62N&#H,R2G(5^4J0\SZ,"K.DD<IG(!JL-D8(>8Z]6
M,GNFU5!+U77M:%MO1-.65O/T>D=KI*-NB\.U_%KW7#X&E9>JXZ]_="9L?E5.
MSQ?5S+2UTM^8;@3JT:9KULO?W[]Y#S;UR[EDGR[A7WU\!'I1[^(W5;7 K='O
M[S;$&AKM\&-4&UYZZ88V$/!$1 K88Q'3QLHP322F2"5C<Q$^L/D.@R[_^1=\
MTZ89Z$',8/3G.2[9.2M@D#\X;'S#;NLUZ[J*.?&?UW/S+-T\0R^BB[TB!C:4
MVJJK7^WE=J[US*C'A$%74OTW!H&7]$_?68;:]HWZFV1B[7ZO3&T-0D3_( SN
MR5TW5N\A\LN2DUG,G.LY<HM_>_O;ZY__^^.[-^]^_]5SS_\+2\*$_/*??V%K
M)MX:T+T%&3I]*]_UO^E^MC_9?]/G>W"(]2WKFHW66]'9%?I@L:E!Q%E*6[42
M#?_)YE0C_+JL^;BJE_/!#IT\#^.,@47KQCST_2!/<YFQ)&.1RT//W5*&OE.'
MSB 4@J=)7( F&V(TR!.I\/U8BMR'_U^-X*_VD=G#]Q!?.&HQ'%H-QRS'NHZ7
MW=4=]KALG\D>TQ_N-'G?Z:_XFW81A8=8@\$.M=MNND.#6MQ,3*V3\UH5R8/6
M(\WFOIO_CLM6#U(ZQ[[C19J)D(4\#C ]GV>AF[M)X7OL$+UH79$&J1^Z7B+R
M,,LR%D0!1JW [!=2YNF3YZIT>\2J(K!Z.0&1!5?5I#=U[.4;M:Z82 7Z'V9;
MHVZ\ZJ9;7(/4NKKN);SLU5UV?\H;;"V[[::-G66W[^<>1/#$G67W7]_!MK+;
M;MK857:WI=JMJZQ2RXZLP>PJ<-40C.6=02SOVOQP:^O#M?!;C]_B;H>W'J#!
MW<Y0<_OTO%-^X(=:Z:?H:W<B@SW(X)\F#'ZIPN#K^R48+[!#;N"O@W V@/<=
MA ?>LY$"L<1W;=GY:%6K>8Q]>!K8\R.$D'YH!O3@D.</B4BZ%0VL\0XK%YT=
M?'1CSY.2Y:!0A6F:Y5$:NT*BTL6#,!N" Z/PT9MRRJ:\9./VK>3ZU9;6(0-Z
MWBB*DE$6ASNBEWYK)'WB%[L?P']_;/WV*?D*>?P>CJE8TM&H,EJ361>USO*4
MI3[PFE#R, &#SO<YCU(IBIPA/.@!F<V>D>#P(EA%'/Q*V<QC:V#;]&8=U\*5
M@--!C@P-BW5<FM81LL=CU)F>A6*T%B8UR((HXGZ1YUC_YLL\RX*@B'@J7)E$
M2;P]N>+Q-"3?'4Y=."J^=8PZT.DD/]9)?F!5I'N,=]1&XB3PXR!"?&TWA'.>
MR2+Q@L"72<"2(!G(H3O $=]3+PDN!FHQGO/Y?@;NGPUZB2&I(]-,OG*;[N0#
MVL C?ZLT,UQAE@VQVKRO**2;^(F79FD8<,[<*$Z*&/A-GHC,W:&\_[[JS=O?
MWJSC?D7Y18KS_Y7S"O<\!1OPQ^/F?4=Q[DYLXAM@$P^L1QE6<5=5*DN!:_ @
M=1,6AB+B>9%%7I#%290F$GY\>%5JK;7T#3.31]>Q[I)OL$&[>J,@J*7X"T>H
MQ?'XV/2L)PB<[T=*W?@V#%/'MGOY*<?(1N\S]"-S,C7T/.!G$G' ,^E&7(1!
MR,,L*S+X,^4%=_.<\QU0=$Z*V-$<S*^/@QQ1BM!F?G&'@3Z<PI7ORQJ6\SNK
M7&D81[X,$L[=(DP+GGHR*))0^BGF,+O\I'(]+I4_N;(5XJ!7E4>4E[X;CAP_
M2.%?4?1BQWRG;J[V<2M@N\_]&)EL3]?!PC!1+3&IN:OL',,$#Z+-/<@,CTSI
M6Y]R%17,RZ3/!><\E$61N[X?QC(%UNT7!1\,+3YN0-'S1LES2+EZ%FS@6^5J
M!Y_-\TCI>JQI/Y.4KZ007A(P/RX"[ 4=IW[D^Z[T8P]!/]<#"SQJRM<J:N8W
MRN8&E=CV;ZPEHY*I.U>5M7_M7U\6[5-?%C]U2>5>A;;[+]*3SQ=+2%< 'N67
M63E7,]$==W3E:-UI[:?Z%'8-#PL?9;CVU]3V7DZ%*NZUF-1'.9_84(\NFLEI
M['$F0UYD*4N",!)2!'Z1Y/E@TTPJ[.VCD8CE'&'I".ZP7[Q*@'6[08M8&_Z(
MA&>^>?Z0!@U"#IM/8;>Q32H)MJ'R[L0M(E?"B1$1"S./I4$F!)P<'HL\RJ/M
MO76WEW?GA2N$6XC8C67HR3SW$R^,XS3+1!0$(7\8((/DPOFEJFL')N_0[.^#
M8+!]"GO,^X@0#/:?^2!NP;:;@J?FQJ#BX6F1"V>,-(*09J: 'TG%T>C.2V36
M^:U#*$ZFZ6IS%_O,RC$565,WI+;^7^,LX)V+(;;?-FFU7]KA^;:B 5S5O'M&
MKM +YW4YIK$=VPP0)+)"Y=B950M$N&;CWA7PX]2>Z(7S?OA*>P6 PNJR7JR^
M#R$):?S+6:6Z_S+X9@(CE:8V%.Y!G*AK>0[WR5N-T% IQ9T&W,A<:GB]9MP]
MF"R.;HQY;4GNV;S3[5B!XZDM:"2\&-HVM5^B@I=,JX6> #[27@&:*/;76UF"
MQ35;.->P,=1O&(9^3F_!]GZR*+!G,EI!*R^\>&"^,(@JL>VF\*GYPH/!OVR?
M^1[+%>T,_W()CS9D\4%R8"B+4M8*NE"*-_-J\JJEU'?%+HJ#YQ9N)"(>,PRO
MI#)/W#PN_#A*BSCPV/9.Z]L5AXQ%@9OF@5=$1<CS.&<N2SS!<@%6<^R+)\>%
M>6U.FNF11PB\O%J.D0$AQYI9_<"12]ALR5;Q%5<J6Q>#XDP*T1?A$)$UV+"^
MQ(38F"_'BM)RR=FR)KY1SAVF3OX-CL1F(\0G<BG[G (YD-45_+  --O)> _:
MCS<!I&PGG#VH[6@!:!YTJ0Z,)=.'[CN V72"D;G;$!_$*7[LH"*-\V1X!_9[
M* 6 UZ"3/+VG](AR5$YD^,!DZ'_=9'BP))(Y:#=;:!832@YP(@;>M-M^KH]\
M/,QYV6%)AB)\&R8P/- SI2._&.CH<D^2')C!P*CN$&)Z&!YYHHAOA2(>/>=M
M#PPO$QY"PQ2,5'[-:KFFB=EQY;B=JK2>;956TQ/D?MZHRPD,<&'G_$H99VGH
M\=CCH1]PQCB+!8MX% 8)ESMTA[_GB%[>#C_@&\]#.XJC>N(L)\ZR-V?)8Z^(
M9 3_2T3HI<!3I)\E+)1)%&5I-E# V6^"^<PXBSM*ORW.\MBZVOHB QV1?&[Z
MV!&RQF/D?T?,Y$*1<S\.69*%1>C&42:3P@^\B,5%5/AL!\"?AV1R39NOMAW<
M 1E>/(K\&+2I]+CYW3&J2Z>#_]P/OA1^@EWL\B@M0C_)F>^FKEO(E(5,%.'F
M#JO/_.!'HSAP1U'L?54'_SEXGCX,*C6]5*YN?I7ZM"CQYVFU@+MG[)8NICI:
M[\<F/6O&YHO;XU*03F;ER:SL,=[(*T+AAVDBF(])%VD0%X(S!!TK_%SL4*3^
MD(SW57O:L$E8_5Z=M8,RWRR.1^&W@RE]8C3',]IOB=&X?IP#/PFC /Z52S<3
MN><SED@_$BSR!O ,'U/#>PQ&$\31R(^R;X71/':F1->U=4_5;EQ.58+[7(IR
ML4:W>X18\5'9PUO&]]2V\9[) KO:R8_++H'U%6D:<LYS-XR!7<HDC5CD9VZ4
M%'&\ U[C0[++7^!XO"M>T>$XJ LL\9-1&@[QR&^(:D^'_AL]]%F:14'DQ9GO
M)Z'P"B9\/Y,Q"XJ8RSP>:O7UB#K2G0[]O3$+GQO!/KJ_:S";]7&<8+T"P^-R
M<MUQ78[2(-V:&?[<3-;#3^@HC-HL%:)("A'&L0SC*,QCZ;L\SKS,"X/8>^)X
MI674OC<GED(8AS1KW6 4A$?>V>AX6<*)K9W8VA&R-9:[F5N$62;2T.4N2SV"
MWQ%9)/,H\8[&5_=P;,US1Z%_Y*EG#\P2'EJC[<UH+63N$Q6R'@XA\CC9KH9W
M/>P #\I'.R,\"L88^*X(,QZZKL#^VS*-9)3*,.7,%SY+=H&H.@!S"KQ1F/J@
M=AUYJM@@*N)ST*U.A_9K.K3"YQZ3.6.%#Q8:B_+8E;F,L\SSX7L1;-5F#M,"
M%@YL'(Y\]QLXM(.:0_OW04!*'PVLSGSS]8 Q?K!PU12@,,:\7Y<U'U?U<AAC
MJ9!))O,TST.0@%+RW$_C) Y3UR]<7@RC!-\18XDG45BD80(OB4+I!LR% \.8
M]/THB3(6/PPX8WKAO%)^SP^V+W,?:,;M$]ACUL\"FG'[)/:8^0HTHYH&_OV#
M4R[@C/ ?G4YS,C_9#SP+:-1U+A>(:_M)+IRW%L+=6MHX^!H-PM1MNVD%IFYH
MC8Z>/ 8AY[;=%-T/<JW#8KL@;)X"8=.DM:AF/SB!]861C/2=A>S=-LFX^X*_
MFP+QW3J>@E2&QR"H&JHY;'KK$)H!8:TM*H16'*#4#Z"#U,[EU5P2?+QSU@-M
MQ#B;[_[8(_3F>OK9^_$%* *+:X<Y-3V.7>&CEK L<XW_9H]J N/%()$D?+A:
MCL=6D5BYJ+OAI&OVF?"CI_!4>.L56^#Q*B3AB<X0DAYO6\ZPZ.S?-R#G7YJ[
MW^F;^W#V/D_])(R9'X@X#$*6,9ZF7&9 /EG$Q&#B!'JL/M[.$)VPA> G7]/'
MF^KC=;6L88H?;^#+6[5RS<(-N9Q\6T$\CQH-,=X&<^]>K/K1'2"B,:Y! 7JO
MLR@G!)"J_GL]KY97:E.L#;O0Q*#!0/5V4: U^;&W*VL>,7+* K;J=@3T -N:
M2]AL(1&"E39>+JXKH= ^RQKF*A'E%'96$QE\C<^;T$IIRFKWFN$=13E58+ ]
M,OWCX@,,O]'YB;) \;_&/2%6# 0'BZ$030TATAAG0(T:V- F7D;S57<Y<R0Z
M^:\E&^.E&XBL?=/O<(M=G^;[>>PSZ?H>^@&P?RJ&?)B7N(Q'^8 I<6CBBFSB
M"AK:.O>WMJ=?I:WO#8U<S0F0=5YQ*44'[E91G5Y4O!P7?+@6%-W>8AU%:2Z"
MWZ[C01?.ZQ9=&#9I#DP/6!^"3';QYHDYSJ4"H]QL2BKI3<);A;F187;:;'-0
M8X/$35R7N2%W)6.1S%T&ZQ#E.2L&VVP?=D=W3)L@5'O8UALPNVLY_>ZG:;7*
M+ PV+VW.FFW:82=VDO:'QS"U"6]_96(0PW/;32M-&782_ENF:'20SKQV6-K[
MS'YE(FOMR?NJ+&\J.)X,SJ5F(G#R)7!]N.ZZ'CRWQ,W1I]+5;DB' /D!/!GT
M57S:SF?Z-4*)PZMJ=;@[QSIG7A#Y/&8B=!.?%7X:):G+XH(503Z02=4/S']8
M .O'T_ *\4/?%?1".N0?0)#)^O)R*M1?KX:B4 _%(.[@)79'OCN@4. N'&"%
M \9\X45^&G@L# K!\C!/B\"3B>^G3 RXPOLQPJ]AA6-_M3/1&L8[<N#+F>3H
MUAR#:@6/[GK-A%EKA$E7$W<N:;OTAU=.LP[*(-V)40^XLAZ$>S^) VWDT#<C
ML#_F9;&?.TW[I-%[VL,&'F"1]K-M6WN*A#+6WWUF\Y+A:IIO:10+(-0:"0J_
M)Q,5)HYO_:FW,AU?WD9/WFN9+S;[[:+,B[*<A['(DA !8V(9"1')($T\!BQR
M.R/\I9I>@2HVP7?AD5N;"[K-OR<2+_-\$28BR4._@ 'E11JE+, ^VFD0[H^A
M?F<GZ^X[-Y8+F#RYOD$W[>WH>A^"BU[SP5WO^]+5XU"K:U_2W@V\IE)MF1JG
M#O"MLAF!];NFV>9WK;#,E:/0\YIY]S!;,W2 MI4OO^C*EU?=RI??=>7+>[NJ
M>9V3=+WZLIT&]B"<QD7:/<0'<)0>XHBO'5+G>9NT2,,F^NQB/=???P,&/;7;
M;MJ_B<Y!=-&MNW0.YY11"^\UOP/CZO]D=BE$;/AGRP6^VW DS%L?9P^VGI15
M]<$0_<-1^Z#/?=M-X3"[>32=X7DQE$'?_K:;]O?M/S8Q#V[ '=G%DZD(F\(>
MMMY \8F_+\>WCA^-!DQXM%%^+SF8/<+Y^<+YH[P>RW)*00CC%/X%/0+S)L[0
M#6GTE8Y?:/UZX0SS)'W-2NQBU+(.N]5-&[A00T#K#/W%\PJMK>XT^F6_VR(2
M1@VWM6$PCLMQB6;GEW*RG+RLYO/J!K;L%<.M6]S:B2FA3$)/R" +>)CG.7.]
M7,*YB!/.HB >!#U*_.A_NB\B??R/:8U><^PG;"7'5NC%KN84WM=&L];C2(W[
MB'2G)E2_O+5_H6>^K& _WQ6ORSD8K=6\?G7-2B#%0>BC?6,>\<:81X> .B32
M$!)L3D&-B'M]ROIA#S@]G]"Y#)(>PZ+.%#W=W3@"!K3$G-VT'=QZ9&E\VW02
MM%<KW,$&WY]Y#OHRM]T4G^33'98XWF>)DR.73R>%]Z3PKB'</:@]/3&4.RQQ
MNL\29T?.4+XYA?=GC&PQ\9DT"\I^Z/=/[.NA6K',I2/)C\]5A@.0[M(H9Z,.
MQLRLT<\(2= Y@X%A"& )C[D=.:SE#%H%:A4Z!S6ZD<FM0/4;9CIN8PN6WM2[
MJ6[49;HMEVR.2C@HX_7"T9D;E[/9N.14_/U&@LH,ZA+F0: F!Y.LYG"5G$^<
M<06[.')FXV7M+&XJYVRSDHS^X[=-5\FW^IWXX+=3T+=9+5]+]5\[X2+UBBR*
M6!0'12A8G L,Z;$PA'/&/#;03X%49!UE.E)EN9/#X>^>P^&O9G"\L(P>.>>4
M1O%^7DYY.8-=PQUN-E?KM'UZH(:;8BGQ=]C?7,(0Y/:H0[N3OZ*B 4O[NILJ
M$\>>F\>^SV1:A''@Y5'NIW[FIFX@\V"H*>N1[IR])0)N/:<0-Z[(N6"WY[=P
M@LXQ'^/O#$3%O#$,XKYS_,)Y-QW?J@P[W;>Y1K:AP^?*.AVA%=+NZ>"&Y=3A
M><9*X"=@9=]<5YB:@\>8<*E&>(S1GJ$D,7Q=M5S@'9-R.<'K9G+*Q@O@$CE\
M3\/ITPBC$@J\5OU5FQ<^J+&3[14T<D_*R5WB*^Y>B[Q_:.YD[YSLG2>T=[R]
M HK>FHCBB:FL6ZY]%OG8HX;?G,USJ=1_28:$0GHR6@E^/^OHE8SS^5)V]<N>
MJG)6OR"G:BZ-W6,\_O@X4&]!O^HFJFYTX=JE.&T:MZVO%#N,L5Z"8=<;J$Z]
M,AGINAZA\PI,L>F4*NC 03LBK3L)5=DP^!ZE<H&>-JW 2$3E;RSK&C/II]M"
M#)1_UZ]U2$40!V &!9E@H1>GV!4J$6[A,5GX+!(/$D# ;#NZY5<@L<ER\K"V
M4C!L*VU-S;L82GV<J?#/7#ZH'NOM%57V3F'E.RWR7G%E[]@#RR=%]J3(KJ/<
M?>C]% N\TR+O%0STCCT:^,TILF\)L'2JU=C&X];WV/>26/!K@?J>JFJU4D9N
MACI4J\R07D'KMLH*5>F@NV6^F_^.P_Z-%.%W15OW^(J-QU*\O#6=L?6%=OE%
M#N28<M>+.2^ \;,,5, T#F68)&$JTG"=ZG<P-:TMWU 0$KB,0 XP6@W2UM20
M'+(IZ"AQW9$[I-MUC(B-5:\C=),B?@IL\A:MVYH%K,N[.<U9_ -O-7 SUIZP
M'+8ASK(BS>*P2$2>N &3OL2*HS JUKF\'T5UWH#'O++*+BC/J\W(.I$&M=S.
MV=JPDR%=$VZZ</[ K!KY!8C<&)?;SZ2N#;..(G/TDP?.XF.=O4SZ;A;X21AF
M(HR\) W#W(W"S(]8B!7!:_>Y-9U4<MBA3:<G.9/1FA/9TDM[-#>:]!2V0 J9
M\[*6K:6][8P.[>O/^BED,3<_-IOI6;M9N F"K4=%+F7(6)3*W'>#/$^DX-R5
M QVPU&Z^H;0SD$QM*&RU%?*1F<719K-XI+,ES1$K:[,=+1*X*3&^<-XLYUB(
M/6HBXU;<:CA$WCW<*EZNA6W5.>0";H.AL;$9RI#HQ1OF<L)*A/_:6,ZO*.2R
M>>H!>( (192+P.69ZX)R#C(W+/(DY2P.@T"F@^V,NN'-KY,;>%ATND5"=^.;
MFT4UZ() >R!;B/ARDTU;6V7LJU1&&E^7D=2[ 3_LP4O>J[@[NY(_XQL^5M;"
MVAU.?2\M9)KD49Z%:9RGH>0!BQ+ZY,OBD96#?7,0O&@#CD3'2=KN\F:=;-![
M.A#X-FDU^ )RKF*N[JI'=8+I"WM[5(,PB\+ B^*0IZ%P\S0HA,N%"Q(_+N)P
M7;[)H3RJ#\,(#B(Z/'>S[$#+K]WR^_FU@U!Z/(RB/,1><:A(R\B- ^'E6>&&
MQ=JS<O)K4T)[(S/EEQF,!<_6QGP><_WE5"B6]FZYJ!=LBCB0:[)[!(] TN5)
M'L"&R"C/"Y^!MN2GDF4>9X-M0[&8^"GR<JQL_6PE*>=!W4E[9=MZIW3;.RWR
M7OFVWK$GW)X" := P#K*W:=$_I0F=Z<J^+W2Y/QC3Y/[Y@(!J T5H#9H;Z\V
M+![+3RA +TTR1%E+0OBG2!.OD"&:@5P60@ZV4?EZ/0/;_81-F.6SK#%5B"T:
MB[+JU1_#M?5&G%"#C-K:Z^2UMW<G381DJ4P#X8>YEV9!GJ91P40&UK'@ZZIO
M+0_.3A[ #76RNZ]=$J3#/A5=L6',9N.<<W)6PP)JH[JHQF/RFCA V<O)C(CF
M!^5L14 JN')<%K+CF=D,((ZV!KT"*4<"(>(C+22NE[?M)>_9+:T,[*YX U1(
M^W#9#N1G/8:/<CZQ_;)>$H2@L2=YEG%@R%[F9X6?>DQX!0]YL+W7QJ[[TP=9
M%,MY [*8.&A'U'VS8>1\KN#$D9FY/>JG6AIM7ZZ7=UFN?S0#Z&&4%HE,_"R4
M0-G =HJ8^;&?9W$4>(%D?K1#Y^ ]Z'I?=U(V4--B%?+/R_J34R"N8)/"-]\I
MT'K0)?\=1O$&!F'7+-G>BASC!AD#=E*$A<^95X0\CV!1DYQE0TAXAU[P\"XX
ML-YJ=^7O=P %?! B-O""?1*.HU *$?BYS,."1P3FF*?22](@R(N!O,9#K^@Z
MUKR"PHIM;#>(M ;33WEF5G41+>H:T8=R;8ZJCZ"\5:?"$ OR;0D_GDU1&UK.
MYS"=%XBDS!!+60$"*A0$@CBHL)0/-M2 -[-)-5^ FD@"@8'*.6>HJIP3V@7P
MZ+)6.+]="=N@'?3JFBZ<2_4\I5-C46 ?_K.=_R .Z/:8GCEI2"?36MKJC9W^
MZD>N[Z6>%[ L3+,XS6/X)R^*((N\7.[0??/Q)'CD#POPSG[#WPV?DVKJ#^J@
M\O>#6SM51]QID?>JCO"/O3KBY* Z.:C64>X^]'Y*?[_3(N^5_NX?>_K[-^>@
M>C=U7DM.:H;C94/8:BICC@#2MRA-[W7_!NR0A\A5M8$DLU2F2(HT\UE> (V$
M&?-86+B)F\@HCE.W<+,!IX?G>YER>N!?QU*5OQY\+-X9?,S;Y(PR&&3]+(0V
M[Z2+#J84_)Z9BOX7;)&"J&+PWWT!,E1CC/=R7E:=WA5%G H1LS2,X+BG+LM]
M-RG [ PY@68\R\W<U["-+\)XP+ ]NPN8B96R,FU\:K1Y6QT.ZS=/Y0RW64(V
M1@8/HMR-HC2(9>@%11YX><(\GA<23!EOP(#YZK8M'-XV I5Y #R9()&9F[MQ
M[!<RS+T@%7!B>.CR/.5N,@2'_MR.S#WQ9"X0A;[_?^94((>31:$2OGN\#M@;
MF\WFU1=X]D*.;_?>O9_-"P:/3))';BR#@F=%$$H?VT[X0N1>Q%P_3Y-G>V3N
MT,HIN5A-SO_^PKD<*'9NI<^V>$EW/_2SS+;8,B?T?!8'B2\2-W2].,N9%P=^
MC.VO@T@.*Q"!=XSKOZ<GQP_6AF(:54Z[NGRE%&PI2B_K#BR8#NE4,[M,PB1&
M+_;*IRN*.'8+KTAY'H91DK(\$;[ORB+T6>:*H:S&8STT#Y4W]W:*&P.F (7/
M=BP9.\[RE(*QQ$O#0+K (J,@RF*6I2P)"^[), Z&RI!HM[_.L//V=/2CK$I)
M\B!(N)!9$:9AFD;,9VZ0^S)FD@D>K95S6SS:[Z;/Z'P.5)S=J4+E01TP>]5C
M^Z=Z[#LM\E[UV/ZQUV.?7.<GU_DZRMV'WD\)XW=:Y+T2QOUC3QC_YESG3YO;
MB25[;ABQ( M LY9 /"(7GI\(7F2YEPSE=GZ#2O:NN9TK,9 #Y'>F,@V3,/68
MS. _B<C]V/,YRUWN%Z'@0^!H/5??KKKT0=P*7NR.DO2!4SP[-9E/G^*9^,+%
M)$^>9S*4(DYSCS.?RQ ^!JE[_P0>:XN^LBS//&-%*EB!H@I$6@)T#59^"M9B
M43#AWC]%;@UU[YWH.>"S?&Z)GCSAJ9>D4G@!1\R=-(R!\7,WBZ*<N<E 6>H#
MK/F=8BON4&SEN'(]PS0O,A:PR,VCT ^"- ]SW\^!%X2!)\1!><!CIWO.=$3>
MN0%R<D"IJ#@U4<WEXD;*03Q^VAW\OA&8RLDX:G[08*?MTS04QG *J4X2S1<P
MMIK3G5-4!>&7*U;"@EG>:7C03MFBQ@E3UMBXP@J9PW! %QV/;^%E12$Q3545
M@2^& T<3N;BN8&J4?;JJ ]PC _5A$T]9)&6>R%"$?AAFL9\)!C)+R" LHHCS
M ?"/P]#LOJK%FHC%UMS3@9SE%@KM&A23SQ2_T"K($ET:K5IB87681&0.W(1R
M66ZNB?JK6MJ751P4<!4C:6GPL\ZV:)%>9I0'T:>.E@P;,GE0*W*O,LS@5(9Y
MI_:L>Y5A!L=>AGGR_YW\?^LH=Q]Z/^7CWVF1]VMQ?NSY^-^<_^_=M*?>K<N;
MG=IX<@?(H14\\#TW HLE]<-"LHR)+(7W^W&4\3C?H<#R"/,J#IA#^RQ29SV9
M>VF1%"GGH+0'J>=E",X61XR)@@W YSZ#/;Q'ZNR =Z85?7?*H7VDU%G?#81D
MGO1A^T+.PDS*-)9^('+NBM0=],5\9=L6#F[;@Z7.(K!7%+A9E$DO%*[+9"[B
M/'+S) F+=!CRZWD=F?NFSAY#?FPLLCA-@B3CG@@S$%%I)J,TYCQ)X:2D@^ZT
MY[ W]\Z/_8]_\V(PG3[:'8:>/#'3E2DOBH SZ:>A&\:P5P7+_(SY/O?B_#GM
MUE,G9@Z"RAYIAJ8?)$42>T$1^"P,TR"-(Y$#3Y6A[X$BLE9X?5O!XR//T(2#
M"OI_)GP6!6$>IYG@<'2QODZB$3E02K*3Z_?C376D!]5?#28=86)FL%?Y<7 J
M/[[3(N]5?AP<>_GQR3%[<LRNH]Q]Z/V4[7VG1=XKVSLX]FSO;\XQ^[2)F;Z;
M)&E4^)F;YJ&7<.9Z622\5(J8!4$^B,;V[>G6NR9F]A(H[I^5F8.!PSTWRF64
MA*+(TI#%B$?!,A[ +.\/EM?HSX<I]LSB4?S069E'!KR9 *OU_#R5TH_A!#'F
M1UG 8A[Z >;/#J0V[[]% UF9F(J)/ND@Z.=CJBS-8\[*C(0?Q3*7J9?YV(L/
M)):4L(9^$>6PF /5T8>A[GW=F&GZ_+,R,RD9* AY 6P%5CQ-BR2##[Z;)RP.
MXOLG$.ZRYG="X,S"H\_*Y &N8!SQ!%0LELD\*I) 2#\%2<I#.5!#_ "+>LK*
M?/JLS)X"L#8E\T$-@[W*XH)36=R=%GFOLKC@V,OB3BZ=DTMG'>7N0>_A*8'W
M+HO<+M>1LH>3<^;),OHM,V-+:O]=M(R&9NF(=OB*N5E][GUZNA/=/84X'/MO
M^FP=BSN?@%52U3/[-Y?^^?&[GZPEZ"R?LZ-7 EU7Y6(B50O!5[0M5]BI4]:O
M0;T=5S60$?*+E^.F)RJQCRC@@H%MP?(\#=W835DL_9Q)L)Z+2&;;,RF_<R18
M"#,8"Y@8<HBA2^!$'@_@KI"'8(/GG$=%YH8!XUX8<F^E5J##!_)J+.[.=:A9
MIF.M"IV SKIT"-ER<717?)CI;I_2'NO@/\@Z.*N2?=L!OL_,!S.[M]VTDMAM
MG^ER 4>']Z3#OJOQCGHY_"*OP*K3B<;()1]V30;#X=MN"A]M31Z90@;CUMMN
MVC]LW97+H9++=U^DCU9&D_(AU"I;C8UKE82+_9"YS6",_P$&H.W]12<Q"B[F
MXZ60=?,3Z 0DKN<2_=AEC7Z2'),W6B?'7$4\',$F[ IN97-+BCO BQ?E!.\@
M/POZ5J@ML%.#\"F+DF->R$Q26UD017@*9NTIV$&VWV?C!P.XVVZ*!X_!,=/W
M8 AUVTTK$=0'.^VOQJ#G<=CXC^B1(KKZ7=:2?$R6O'S8-1KT)FV[*?U:.>+*
MQ)Z2N5TSK-Q&/R2EX58.,_F=M4K]Q#FB@[>:*\8W-]2#I"3D9SFN9GBY@T[@
MSQ0S1DY8+.<D>\L%L36QY N'8X-KC-]IM[!Y=.T "\4:A_$MF%"W8.78/(YC
ME&^LXJ0X8N!X8/'<XE,_E\39!E5EBHZ^TF]X1<^@??JM6I1<KI2G2.FF;AI$
M+)!>*!.9,9<5K(!-+%@>A8.YA3W%>!/>R>*ZG"]N@8W?KF">Z!1+="&7.V7J
M.;:5<'CJ6'L:>F_EF$#P?[][^?O[-^]!-KV<2_;I$O[U76//C8%0\%0NKAO3
M>%'-C)FDOX&?%]6D>;N]\T.O>5-5"PQAZ'?<E&)QC3>[W^/)61GI\$-4FD-G
ML+;1QNE #+KS=EO)M%GY05]1UWH%V\4?,$FWKG4S]!E\<Y[C5^>L@('_X+#Q
M#1!:;S7A4==S<T^.49'YN5X^\H@,;-</3CC[HGZU%]JYUK/RZ;ZN<>ODC'^Z
MFE?+J3COV[T66]LVQ;]))M;N<V]:MAD]=##V\=H-;V=7^N!98<[U'#G"O[W]
M[?7/__WQW9MWO__JN>?_]=U/;^$D?OG/O[#!*0^=JL&3MOK-_SD_?__[NZ(<
MRY:44:0OOH>_O_>"[[___OS\IPV^EV-Q=FST</PBZUK*=S.)_K?IU2]8&E4/
M>31B&66>]+S<#?PP3D7JQZG$@*DK,LQS.8!' QZ#[80S'O$X9")A@J69+P(/
M9(;(HM!K/=3$.ITUFL0=O0[;7[O'6!_&Z^!Y%X[:HONI3MM'O\>4A]T-1Z8T
M;I_$'C-?<2H\M::Y(9'-I![VCKQ=:)=$A>19'B68X1,G>5)$ 4]\[%0JF$$N
MWGC2[<2'V$Y\>/O;FUU3'V#I5I/3*C-J8()8W82:,JJ^50%6>$>=I="$3AS
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MOP+O?][!RL[KZW*FBI?T=,T2P[0.6+ 4;NUN@8 M]36LHIFL0H.!7=/@ECL
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MUC6Y-T!SO9RR\6U=DC+5=";%ECP:$E!W(EB."273T6%[D.T[9Q#=(3/'GM9
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M6.JN"-4RM1E0;Q1LWK8@P]Y +6*D"KCB]I"\5<K-L":UB\+UC:G[R85&!1Q
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MV6X\6(,QR;I=4WO>Z)6;E\#(YHC^P##'ES)L,;/]"T*,Y-7UK9CK!&K$)#%
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M]W0SK_7&ZPQMHHXWKR^[B_>QN\1H%DN5SC[;T&O8VKLF'UO5]VB*H^TC6U;
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M7B.Z V6D$Q*8O0X-PM*[*7!9A#XCK#Y<%#,G#5&$JRTU\]*EM:9:YH\/JW@
MC2/6'IN^?H@"&!A< C>]RA$JB>K(%(Z#KCYOZE%:R*2A%-J5]-E.3-B>>EM%
M\-$*@MMA*&/R*C0X"URDSR"6,]R;U)E<_>73E?.+!'IZ69'<JH$ ?WGYZPLX
MCA>?+Q3A8)]SBA%A[O"B&E-GP8>L&!MDW[UB973] C^A^F,JOSNG&KS90&[
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MO+&*7%9T3BP0)G&N.*&^7W?<;2#*?H"1O]"E>*0F*B&%7W1 W]:[L6CG-$,
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MTZ*CSB=),UO,YTFN4/S"3FEQ+93;M"& 1RI.>ZP5M,"2P*A[K6GD4PZ[&"@
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M ,N:K-+A3D-$JX,=0AYYDN;!;*O5\K1+EY ?S7-8)'!."C045ATF0:3C=%V
M)P4XW><4KG5P]0Q-QLC*)DNH3F,GBVX)<D>$BI+*KCIQHZ0,@H5&8B??A9#_
M$9C&K_!N2BZ\*A@PE'1<VB==%55:H: EZ@5E:@U\T^PRHOOI4H9<@RU[:&S9
MJP9;UF#+%KX]W3W<'@=#[$S7#+-$OO*Q@/)^F*J^M^G=5,$<JI=SOG]_EQK
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M\<6SUW;Q&C>ID ;'TCYX41TI7P2O?X)'H5O5(!]?>UQE,7!Z9=!K>M*AGOY
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MC/51^WMQBI]=7^%!]R'YGU!+ P04    " !2/J]62+S#BCX)  !W+@  %P
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MZ.(T=K'M(T52%E&95"FJB?O7[U%'XJ9>FZ/=A@H&S//Q';]WD./8;)+)CS\
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MX$_LQ,RL^:N\X+2J[[UPOQ/]]']02P,$%     @ 4CZO5E<^_#-6"@  9X$
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M6QLU1O%U%P/4 _EC(B3^^']02P,$%     @ 4CZO5C[&BRX[,   (3,# !4
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MO^Y(*:-8P+JE=DF?O]L1MPE_*'^+\M>TD5^]JIHYPPFZ1>M7[-_/MY>[<NN
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M_,7AL6U;I(L@C),X?QFXF8#+)%Q:X%X)0&NN'_+:E',0JTH.J &3.^IX:K;
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M"I=0U9IRJ?PWI9J"FJ;D,G6>$@@:=UB U.LU.PE1=(##!02S1+^ _[#05MO
M^-_G/S7=#Z?CLT""MW1Q Z8.@S\V]QU['_TWHU =39/U>4W-EC,]ZE.5*N/E
M##UA,LB\R_G:1';J?_7?EF*%-(TY8#8U*X[AI=4I'J1&XA. "ZJ*P'^S2M6:
MM(RJ^$U-&&/8N&7*ANOU9\+B3R*QG3FTH,D'M$NSOEC924 8L':>7T4HWRY&
M5>NBS0T;J:B6Y^S:"6&/):]BR2@QF:L*SG2X+AR1HQO0)'9UA)B:_L66Q^"T
MR#(T\%*I$8O]!SOBI4%-HJX9;\*.M_-\,F(!#8U_T]DJ@>V01T!C36@4P&/&
M0-^\II]P&NH,@T-Z,3C;](M%'5=I,W!JLW>>LT0JH^E1<0IG5>Q]$V.C@88T
MC><1(Z2[3"*PPF"$>SFE\!:ZDRCWNGYG%?5&.9PYC#M9+KR/=G^9AGB+=OB^
M8I4PTPV?\2M0[E)B""C=/N=70 36454.G-VS?B%3UW?Q.<*!3Y>5:,50</^:
M7L7$?"1(G\@+V NPX,N[=V-H&#RH]@,/T%-S$X 0OA^? @D?'H7_@E*Z2DI6
M:;2*ME0K]M CCY]1G>0'?#2J5:9N,\4RCI:W:@,"'J>Z ESVKT(5*QB.)6Z>
MBE:W-NI'FJ=!$KZ?XVGH+_77NS!&:8C(51(Z?"=ZF3XC4CV7O4Q+PSVS_-3D
M'J_6:[KEH+8F@Y7L;IP=478WZFJ5=3/ER$6\"Q]15"3H>MVBYKP0-,9/HPDE
M_)R-6&. @\TW87=TTQ"JFAXG"^-Z5=7<@Z8BAW\6<8:J5"L?4?Z(HY;$/23K
M%JM;6[W8TG YLD$FP4^]3M?+M*YJ^[Y1/) XBH,L1F1%" [+OU+5_Q-3F_U*
MR8L,D5TN3_92,\&$_DTXKIIC#PZS)M@O#=V6&]C@(&Q"-M=O@#_&*697UYJ,
MI==?Z**:/,9/-R@+J>#!!IV\W 3 N=*(DOLXL>HEEP;?\<TR"9E:U;I^U'L:
MD$?V'YM#GND&I7Q^3%<I,4N9S#Y0C;M_:%%6-V;I[C"K'(W5O^=?PZ2(XG1#
M?WAD,6/9$_OS]1H-%L9N*F]2,LQ<^=)ZCU/C3.J <TL^\?DSYSK_:? 4YT%2
M/AN('XKJ>*]TIPQZD8QPAW@^X?+0J:CT1"3Q:W']#AG<84(GJW+"YNV @'#6
M<]71J%!6=1(J1+6TWQ2[.7"5A+#?K4: 8U7P6W,?I/O-Z=&I@IFQ6)M.VF N
MM_(^1I>+BZP#.Q' 0R_.U[[9W!]SPO; ,@W:INJPZ%C'ZG&E2?L,SN5<60@Z
M>%0UD?!P468D>QG !B<L5Z?P4:",KCG^X],Y6B_QN@I65PHT5>LHC\_&1=\Z
M+:,E9$\LM^>G8 OE[1*1[/*C0R0+F,,4=%.?RF!F+M(:W:*G(J,;*8)6FPR5
M2Z&^<)P$R)KE=EF1E<LY3+(ILC4>KWPG8Q]01Y4469FWDXQDMO$"Y-'V#3%@
M%D]3D!$G]YP*&GLS_MW)/YJ)ZC(-P<E>1-)L?$$29TFR=;LY5E*RFS%;L8YR
MNPOR=GV"?<&405?Q,XHNTSQ(-^S6>_F,DIR\? S^B;/3)" $S@&F6W*?%TR]
MY )6%^-;0GW1H56'ZR,X@;![4;FSS<C2<G#!I9VF_]+&C1AN"NW3RW^D*H $
M@W#%'@]NYG$XF/M]12(G*]<,4)0EX[((1A^N6U^F-QEFX0IO$4'4,.P [0P]
MHP0_L<$>7'9IE=G=N%$JXVAA-G;XPN,:0Q%B4-75_1BE*N>[DCT 7MG>"$7;
MM_MGB^=IL2W?/S+N)'=R,[IJ5\Y=7OAC;;+^1R=OC=GE\TH0_CMT$4WCEH9I
M'/4]3K-C-5W:7:G+J71/PQQ<KP%:24WJV B\5$92PN;AK(#0A8:K,,P*% W%
MZO<Y&5W3_?ATKAZ@RTV#U?7K9FWF<6:0%G!4'_#KO[/_/00$_?O_ E!+ P04
M    " !2/J]6H5 9W7J*   O0P@ %0   &=A;'0M,C R,S S,S%?;&%B+GAM
M;.R]:W/DN)DN^'TC]C]@>V?.M"-4W265[1E[SN2)+$G5UEHE:21U]\Y6G)B@
MDI!$.Y-0DTQ5R;]^ ?"2)(@K^8)$JNJ#W:KD>P&)YWGQXOX__]>7S1H]XRQ/
M2/H?WQW^\/8[A-,5B9/TX3^^V^9OHGR5)-_]K\7_^7_\S__KS9N?<(JSJ, Q
MNGM![S,2Q5D2/V!T=7UYGZPQ.GKWP[L?CG[XP^'O_ZWU^,T;IKY.TK__F?W?
M791C1-VF^9^_Y,E_?/=8%$]__O''SY\___#YW0\D>_CQZ.W;PQ__WX_G-ZM'
MO(G>)&E>1.D*?X>H_)]S_N,Y644%+W-+_<M=MJX-O/NQ\:648/]Z4XN]83^]
M.3QZ\^[PAR]Y_%U51/;8PDDM_J4G7[W3X9_^]*<?^=-&E!I*-*:;UZ9?#Z'R
M^V5DC:_Q/6+__?GZ3*G]IQ^9Q(\I+LZC.[RF+KEZ\?*$_^.[/-D\K7']VV.&
M[^5VUEG6F&%?YT_LZQS^D7V=_WMG^<<QQ7M@8+HE1;2&*2>WUR]KS\WX0E]
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M A497]D])EM;$>CMZ#T,SB]7*[)-B_PJ>F'+F-G8SFJ5;7'[!$\C^UV,*..
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MY]">&E]?SO:5%5ERMV7/*5/_QDRBY])F2,$2D!'*T F+0ET@'>])'5:AWB)
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M!E"TX-X"MOD9=!,H0XFA#514I;D1;"F:6L&>CYDX^!0E<7VC6MW1Y"N<Y3<
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MV;(S5<J&GAE&W'(PZ<Z^QPW53H6]#QQS[5. ?B=MA\J##U])'G W#K!4?GJ
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M&R.UNJ)5,OF;A_NT3.7*D\,>Q?N/&B:W'XTF[,X8_.4^?>-Z#@KBBWH+%SL
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M*>H-QO#DJ/PUT(P(%+6.&1((:B?,F$Z:9TX94U_-*F-JJ_GCY<[+Q!E3S_%
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M2H.%)>B+H"XKLZ!)5E;%-@03JH.(W'#%#J1&H?=>CI19^8 @D''6X&8-/FK
M:=/VQ\[#4$$@-[\ZQ:+,]+L HZU[H,@&TF'08&D-R44-26+3KL\&@#(?P@4
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MU:!LO2BS7K:VY#FQ],FPX;-@QK(,SXSS>)/BR>]Y\!RCL:4D3$OFE8*MN1?
M6DR5D.DO*I+V\R5XO4& U]^DB=O.4X\TY^% '')SAQ"..XI8*A7WH&+S,J6L
M=7>(>BV \;DU'>Q^=MP-!/*H^, 0E9<GG(LH*G/$@N0VB*/KM(YV_;0)/A1)
MFF!!.>X5<M*I. <3H_7'JW1\Y X409R"Z#+(4C0GS!=AN-ONRGVX^EW@GKO(
M-ZAU*]/ <2=2EEG%GV20>[E;-11;. T73K^==Q6A3"JN04,VQ::5XRMGZ>6:
M_A*91T+_+1O;*P*1!MB;R%QPR;1IS[Q,47HC>] ,0OJ/ZCC1QU6O0FBF[>M=
MDI G9C)+Q(L*"]7FWQ- "-!\]E1NP;EX_9:NO?0VK:OJ)XM=\02S^%^'GD _
M?&!!TX\:AM!>#5QJLAL[1AC2\?)V"56JZSS?R?E8%Y+G7P32?]^BRFS8KP@-
M+W=>J1*Q*V3)@O.\RXWJ6,9<3+9LUF@_H];3\MG9%IM-!C9HAE,=[Z[6=R!"
M$%A==P!!9.74A^^!:CCH;BF+PV=?U=*3,0>6I>[EOG1/UF6,_HE*G54'=&#X
M!)-*$[K/,IKX[*(R6C#FD0QB1[)[[7<R"5K<J^23],$%*24'<,?WYQ7E-9%8
M<D#MVE4]%L>"Q;9J,X'O.+3\'N=#2BMO/5]B+KKGO\NFY5,7S3<EGQHVD_*I
M=C.O?8HIOSF?:I,848K)J1PX01R3 Z9FQGD7LY1DU<^78\8GOU8?-*&H>X)B
M0([[6-\1U'<=B2U =;?I[?GYM5Z@"<3>\I.$YCB/&QM^^AXDN\.G[D:T+3U[
M;^2,]R7JJEJ<WBUN1O4N7C.OW$Q:?GU_XY'P\@Y8*_$9K5I767E4'I42W8*L
M[%X]GU-H,4PL9[=PW-/4I=9,/V=C]_*&UN Y$^;<7 )RZ$_>S<KEI=3T'^9\
MW-X30T;\ACH9%T"Q_,63:;B<=*/\I#<!M_?0MQ$?8<^^%5YI<O09*DV7,3/I
MEGJ4ZH.I-"#'S]O<2$[7N0[ W*H[I0IKI@H;.=AQ+%6X45:^6J^>43-,U>ZK
M;-<I8ADTC#'.9050M6<PH:R4BZKTFV[J-X!8+Z\)X4BQ*#:<G;N&.4 A 3^>
M=0%>0 *?L<IKWGHB2L$V-PRYL-:"F]A,4$W0;AACHJ]N%7+1>IFJ^P6D2.($
MEY:+MG$:8VEQX46Z!TE"UZH50KOM16K"*OB1$+&7";H#D44!5A187?</D4 *
M'D%!-<73/3,[0C4/6,+!^_0<B+XSM"$\<0>F4#H.T4;F>1UXT>21UJ6DUAX,
MQ-2.96)]83'(WL 4=EV#/&U)G]5*P]>*E8"W(?9U^@+RLC)@Q12I?SM8GO#!
MFO4)"\Q:WY"W$Y06L]M)A!1P=V%C]K*W7#1UQ*]3).2N7'+?P.*0E[7(_P:B
M3:F2!N!+$*<XX-X =NWWD?@&U>&U\?GAL:85I^':!ECP]XD#TH_IJSK&UR9:
M]K[ZX7)\H;1B8P^AQ@S]<^4.:7G%*++H$$R)9></LO,&7]Q%5E -Q^&@/OX9
MO>H$5'IF+X'8RVT4--(PU\W4;Z0'=K\Y[1,<,>3MWT7B[W9)-_VM>0]PD4;5
M6]S1/W?5E+SO#>H-J<F)_(8N^Y&V J2=3(6"1BQW9SK0[DR+ER!.JM+EK:R$
M^I3V+,CCD!>6Y%O3 I=,:Y==<IPJ](*?#!G]]'_;X9&4\"19FC0'Y,+4NF7
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MKW9%7@0IOGG!$VHV,ROR,[FEI?DYPB%'J<M-.@3I><5< Y.,GJ8=J*3U8_D
M8?;PUMW4="+"J;,T\W'"*<Y9BW/:OO%V0IV*BO2/,*:IU#J=5HC@;H4Z+:XF
MCW:*7)T"GCNV>*,Q3U%+%D]C1@:^1]U=X5TV:>B;C2_%X#<#7Z?PYY(UCB(
MSJ GBR=#IRT\.7YF/!\Z;>*Y,-?3]0M?P]STVWAVSJ%,7:[$-\ONL)1MN1]
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M!A;XW8D]'EVIWB,%VU3IY,)ZX44J\JI[D@"[1F*'?6_"B\_5^AQQ&M.'(C9
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M_L96C2X-);H#6ZE\(EC9-.3^*EAJ\-(.K HCF0H-/X_"NZO3X?#%!B#3;@J
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M+3$N:'1M4$L! A0#%     @ 4CZO5E^7N%7$!0  XQ0  !<
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7;%!+!08     "@ * *$"  "2?0(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
